

WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Wednesday, December 01, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L16	L14 AND L15	131
<input type="checkbox"/>	L15	blood OR Serum	481657
<input type="checkbox"/>	L14	S100b OR S100beta	200
<input type="checkbox"/>	L13	L11 AND S100b	29
<input type="checkbox"/>	L12	L11 AND S100beta	1
<input type="checkbox"/>	L11	(435/7.1,7.21,7.94.CCLS.)	11711
<input type="checkbox"/>	L10	Barnett.IN.	4368
<input type="checkbox"/>	L9	Barnett-G.IN.	24
<input type="checkbox"/>	L8	Barnett-Gene.IN.	1
<input type="checkbox"/>	L7	Mayberg.IN.	15
<input type="checkbox"/>	L6	Mayberg-M.IN.	4
<input type="checkbox"/>	L5	Mayberg-M.IN.	4
<input type="checkbox"/>	L4	Mayberg-Marc.IN.	4
<input type="checkbox"/>	L3	Janigro.IN.	10
<input type="checkbox"/>	L2	Janigro-D.IN.	3
<input type="checkbox"/>	L1	(Janigro-Damir.IN.)	4

END OF SEARCH HISTORY

WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Wednesday, December 01, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
<input type="checkbox"/>	L18	Mayberg-M-R.IN.	3
<input type="checkbox"/>	L17	Mayberg-Marc-R.IN.	4
<input type="checkbox"/>	L16	L14 AND L15	131
<input type="checkbox"/>	L15	blood OR Serum	481657
<input type="checkbox"/>	L14	S100b OR S100beta	200
<input type="checkbox"/>	L13	L11 AND S100b	29
<input type="checkbox"/>	L12	L11 AND S100beta	1
<input type="checkbox"/>	L11	(435/7.1,7.21,7.94.CCLS.)	11711
<input type="checkbox"/>	L10	Barnett.IN.	4368
<input type="checkbox"/>	L9	Barnett-G.IN.	24
<input type="checkbox"/>	L8	Barnett-Gene.IN.	1
<input type="checkbox"/>	L7	Mayberg.IN.	15
<input type="checkbox"/>	L6	Mayberg-M.IN.	4
<input type="checkbox"/>	L5	Mayberg-M.IN.	4
<input type="checkbox"/>	L4	Mayberg-Marc.IN.	4
<input type="checkbox"/>	L3	Janigro.IN.	10
<input type="checkbox"/>	L2	Janigro-D.IN.	3
<input type="checkbox"/>	L1	(Janigro-Damir.IN.)	4

END OF SEARCH HISTORY

Hit List

Search Forms

Search Results

Help

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

User Searches

Preferences

Logout

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20040009581 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 4

File: PGPB

Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040009581

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040009581 A1

TITLE: Markers of blood barrier disruption and methods of using same

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Janigro, Damir	Cleveland Heights	OH	US	

US-CL-CURRENT: 435/287.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20030170747 A1

L1: Entry 2 of 4

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170747

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170747 A1

TITLE: Peripheral marker of blood brain barrier permeability

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Janigro, Damir	St. James Parkway	OH	US	
Mayberg, Marc	Chagrin Falls	OH	US	
Barnett, Gene	Gates Mills	OH	US	

US-CL-CURRENT: 435/7.21; 435/7.9

ABSTRACT:

The present invention relates generally to a peripheral marker or markers of blood brain barrier ("BBB") integrity and methods of using same in the diagnosis, prognosis, and treatment of a variety of diseases. The peripheral marker(s) of the

present invention are particularly useful in the differential diagnosis of diseased states. The preferred embodiments of the present invention relate to methods, compositions, kits, and assays useful in determining the integrity or permeability of a blood brain barrier. The various embodiments of the present invention can be used to identify subjects at risk for developing a disease associated with increased permeability of the blood brain barrier, as well as to provide insight on the ability of an agent or agents to pass the blood brain barrier. Embodiments of the present invention preferably involve the use of subject derived blood samples to determine the occurrence and level of circulating proteins indicative of blood brain barrier permeability or integrity. The embodiments of the present invention also provides screening methods for diagnosis, prognosis, susceptibility, or degree of permeability of penetration of the blood brain barrier by detecting the presence of serum S-100.beta. either directly or through the use of antibodies. The present invention further provides for kits for carrying out the above described screening methods. Preferably, such kits will be used to screen patients for increased levels of S100.beta. protein alone or in combination with other markers of diseased states as a diagnostic and prognostic indicator of permeability of the BBB. Thus, the present invention provides a minimally invasive alternative to direct cerebrospinal fluid sampling to determine the permeability of the blood brain barrier.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 3. Document ID: US 20030054545 A1

L1: Entry 3 of 4

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054545

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030054545 A1

TITLE: Cell and tissue culture modeling device and apparatus and method of using same

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Janigro, Damir</u>	Cleveland Heights	OH	US	
McAllister, Mark S.	Saginaw	MI	US	

US-CL-CURRENT: 435/297.4; 210/321.8, 435/29, 435/32, 435/400

ABSTRACT:

A cell and tissue culture modeling device comprising a housing having an interior chamber, an inlet port in fluid communication with the internal chamber, an outlet port in fluid communication with the internal chamber, a plurality of hollow fibers disposed within the interior chamber and traversing the length of the housing between the inlet port and the outlet port. Each of the plurality of hollow fibers has an interior defining an intracapillary space and the interior chamber defines an extracapillary space unoccupied by the plurality of hollow fibers. To access the extracapillary space of the device, a portion of the housing is removable. The device can be used to conduct permeability, drug efficacy, and gene expression studies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

US-PAT-NO: 6667172

DOCUMENT-IDENTIFIER: US 6667172 B2

TITLE: Cell and tissue culture modeling device and apparatus and method of using same

DATE-ISSUED: December 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Janigro; Damir	Cleveland Heights	OH		
McAllister; Mark S.	Rocky River	OH		

US-CL-CURRENT: 435/297.4; 210/321.8, 359/398, 435/288.2, 435/29, 435/359, 435/400

ABSTRACT:

A cell and tissue culture modeling device comprising a housing having an interior chamber, an inlet port in fluid communication with the internal chamber, an outlet port in fluid communication with the internal chamber, a plurality of hollow fibers disposed within the interior chamber and traversing the length of the housing between the inlet port and the outlet port. Each of the plurality of hollow fibers has an interior defining an intracapillary space and the interior chamber defines an extracapillary space unoccupied by the plurality of hollow fibers. To access the extracapillary space of the device, a portion of the housing is removable. The device can be used to conduct permeability, drug efficacy, and gene expression studies.

33 Claims, 11 Drawing figures

Exemplary Claim Number: 1,9,14,23

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
(Janigro-Damir.IN.)	4

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: WO 2004078204 A1, US 20040009581 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 3

File: DWPI

Sep 16, 2004

DERWENT-ACC-NO: 2004-098607

DERWENT-WEEK: 200461

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Diagnosing of blood brain barrier integrity in a subject involves detecting elevated levels of transthyretin (TTR) protein in the blood sample derived from the subject

INVENTOR: JANIGRO, D

PRIORITY-DATA: 2002US-388371P (June 12, 2002), 2001US-0891023 (June 25, 2001), 2003US-0462222 (June 12, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2004078204 A1</u>	September 16, 2004	E	000	A61K039/00
<u>US 20040009581 A1</u>	January 15, 2004		015	C12M001/34

INT-CL (IPC): A61 K 39/00; A61 K 39/395; A61 K 47/00; C12 M 1/34; G01 N 33/00; G01 N 33/15; G01 N 33/48; G01 N 33/49

Full	Title	Citation	Front	Review	Classification	Date	Referen	Claims	KIMC	Drawn Des
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	-------------------------	------------------------	----------------------	---------------------------

☐ 2. Document ID: US 20030170747 A1

L2: Entry 2 of 3

File: DWPI

Sep 11, 2003

DERWENT-ACC-NO: 2004-069019

DERWENT-WEEK: 200410

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detection of blood brain barrier permeability for diagnosing e.g. neuronal distress, comprises detecting levels of S100 beta protein in blood samples and comparing the result to a control

INVENTOR: BARNETT, G; JANIGRO, D; MAYBERG, M

PRIORITY-DATA: 2001US-0891023 (June 25, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20030170747 A1</u>	September 11, 2003		018	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/542; G01 N 33/567

ABSTRACTED-PUB-NO: US20030170747A

BASIC-ABSTRACT:

NOVELTY - Diagnosis of blood brain barrier permeability comprising detecting levels of S100 beta protein in a blood sample of a subject, and comparing the result to S100 beta protein level of a control, is new. An increase in the level of S100 beta protein is indicative of blood brain barrier permeability.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of treating a patient comprising administering an agent which causes blood brain barrier opening, detecting elevated levels of S100 beta protein in the patient's blood, and administering a therapeutic agent.

USE - For diagnosis of blood brain barrier permeability useful in detecting e.g. neuronal distress (claimed). It is also useful for detecting neurological disorder, e.g. tumors, cancer, degenerative disorders, sensory and motor abnormalities, seizure, infection, immunological disorder, mental disorder, behavioral disorder, and localized central-nervous system (CNS) disease.

ADVANTAGE - The method provides a predictable and reliable monitoring of neurological status of a subject.

Full	Title	Citation	Front	Review	Classification	Date	Referen				Claims	KWMC	Drawn Des
------	-------	----------	-------	--------	----------------	------	---------	--	--	--	--------	------	-----------

☐ 3. Document ID: AU 2002341734 A1, US 20030054545 A1, WO 2003025206 A1, US 6667172 B2

L2: Entry 3 of 3

File: DWPI

Apr 1, 2003

DERWENT-ACC-NO: 2003-810758

DERWENT-WEEK: 200452

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Cell and tissue culture modeling device useful for gene expression studies, comprises housing, an inlet and outlet port, several hollow fibers having intracapillary, and extracapillary space unoccupied by fibers

INVENTOR: JANIGRO, D ; MCALLISTER, M S

PRIORITY-DATA: 2001US-0957063 (September 19, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002341734 A1</u>	April 1, 2003		000	C12Q001/02
<u>US 20030054545 A1</u>	March 20, 2003		021	C12M001/12
<u>WO 2003025206 A1</u>	March 27, 2003	E	000	C12Q001/02
<u>US 6667172 B2</u>	December 23, 2003		000	C12M001/34

INT-CL (IPC): C12 M 1/12; C12 M 1/34; C12 M 3/06; C12 Q 1/02

ABSTRACTED-PUB-NO: US20030054545A

BASIC-ABSTRACT:

NOVELTY - Cell and tissue culture modeling device comprising a housing with an interior chamber, an inlet and outlet port in fluid communication with the chamber, several hollow fibers disposed within the chamber and traversing the length of the

housing between the ports, the hollow fibers having an interior defining an intracapillary space, is new. The interior chamber defines an extracapillary space unoccupied by fibers.

DETAILED DESCRIPTION - A cell and tissue culture modeling device (10) (I) has a housing (15) having an interior chamber (57), an inlet port (20) and outlet port (25) in fluid communication with the internal chamber, several hollow fibers disposed within the interior chamber and traversing the length of the housing between the inlet port and the outlet port, each group of hollow fibers having an interior defining an intracapillary space, is new. The interior chamber defines an extracapillary space (67) unoccupied by several hollow fibers. At least a portion of the housing is removable to access the extracapillary space.

An INDEPENDENT CLAIM is also included for a cell and tissue culturing modeling apparatus (II) having at least one cell tissue culture modeling device including a housing having an interior chamber defining an extracapillary space, where at least a portion of the housing is removable to access the extracapillary space, an inlet port and outlet port in fluid communication with the internal chamber, with several hollow fibers disposed within the interior chamber and traversing the length of the housing between the inlet port and the outlet port. Each group of hollow fibers has an interior. The interior is defined as an intracapillary space, a pump system, a media reservoir, a first conduit interconnecting the media reservoir to the pump system, a second conduit interconnecting the pump system to the inlet port of the at least one device, and a third conduit interconnecting the outlet port of the at least one device to the media reservoir.

USE - (I) is useful for determining (M1) the permeability of an agent across a capillary wall which involves providing a cell culture model having several capillaries disposed within an interior chamber which defines an extracapillary space unoccupied by several capillaries, each of the capillaries including several pores that provide fluid communication between an intracapillary space and the extracapillary space, passing an agent having a known concentration through several intracapillary spaces, sampling the extracapillary space to provide an extracapillary space sample, and analyzing the extracapillary space sample to determine the permeability of the agent across each of the capillary walls. Several intracapillary spaces are inoculated with endothelial cells. The extracapillary space is inoculated with glial cells. The sampling step is accomplished by a microdialysis-driven sample probe. (M1) further comprises a second cell culture modeling device to allow for the simultaneous determination of permeability values of at least two agents in a single experiment. (I) is useful for determining (M2) the efficacy of a drug which involves providing a model that exhibits the properties of a functional blood brain barrier (BBB), the model having several intracapillary spaces and an extracapillary space accessible by an access panel, placing a tissue sample into the extracapillary space, passing an agent through the several intracapillary spaces, and analyzing the tissue sample for responsiveness to the agent. The tissue sample is a cancerous tissue sample, preferably, a brain tissue sample. The agent is a chemotherapeutic agent. (M2) further involves placing a neurochip in the extracapillary space before placing the brain tissue sample into the extracapillary space, the neurochip is capable of studying the electrophysiological activity of the brain tissue sample. The brain tissue sample is placed onto the surface of the neurochip. The brain tissue sample is an epileptic brain tissue sample. The agent is an anticonvulsant agent. Determining the efficacy of a drug further involves examining the tissue sample in the extracapillary space with a microscope. (I) is useful for determining (M3) gene expression over time in cells which involves providing a cell culture model having several hollow fibers disposed within an interior chamber which defines an extracapillary space unoccupied by several hollow fibers, each several hollow fibers includes an intracapillary space inoculated with a cell suspension, passing an agent through several intracapillary spaces, sampling at least one several intracapillary spaces by removing at least one several hollow fibers over time, removing cellular material from at least one several hollow fibers, and analyzing the gene expression of the cellular material. The cellular material is chosen from RNA, DNA, metabolites and protein. (All claimed.) (I) is useful as clinically predictive tool for the efficacy of chemotherapeutic agents in the treatment of primary central nervous

system malignancy. (I) is useful for stimulating the blood brain barrier in in vitro, to conduct a permeability study, for conducting gene expression studies and to determine the efficacy of a drug.

ADVANTAGE - The relative flatness of the device makes it modular and thus automation of simultaneous permeability determinations of compounds and multiplexing is possible.

DESCRIPTION OF DRAWING(S) - The drawing shows a side exploded view of a cell and tissue culture modeling device.

Cell and tissue culture modeling device 10

Housing 15

Internal chamber 57

Bottom panel 95

First end wall 30

Opposing second end wall 35

First side wall 40

Opposing second side wall 45

First and second end walls 30,35

First and second side walls 40,45

Inlet port 20

Extracapillary space 67

Outlet port 25

Access ports 50

Top panel. 55

Full	Title	Citation	Front	Review	Classification	Date	Referen	Claims	KMMC	Draw, Des
------	-------	----------	-------	--------	----------------	------	---------	--------	------	-----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Janigro-D.IN.	3

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. Document ID: US 20040009581 A1

Using default format because multiple data bases are involved.

L3: Entry 1 of 10

File: PGPB

Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040009581

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040009581 A1

TITLE: Markers of blood barrier disruption and methods of using same

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Janigro, Damir	Cleveland Heights	OH	US	

US-CL-CURRENT: 435/287.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 2. Document ID: US 20030170747 A1

L3: Entry 2 of 10

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170747

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170747 A1

TITLE: Peripheral marker of blood brain barrier permeability

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Janigro, Damir	St. James Parkway	OH	US	
Mayberg, Marc	Chagrin Falls	OH	US	
Barnett, Gene	Gates Mills	OH	US	

US-CL-CURRENT: 435/7.21; 435/7.9

ABSTRACT:

The present invention relates generally to a peripheral marker or markers of blood brain barrier ("BBB") integrity and methods of using same in the diagnosis, prognosis, and treatment of a variety of diseases. The peripheral marker(s) of the

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.4&ref=3&dbname=PGPB,USPT,USO...> 12/1/04

present invention are particularly useful in the differential diagnosis of diseased states. The preferred embodiments of the present invention relate to methods, compositions, kits, and assays useful in determining the integrity or permeability of a blood brain barrier. The various embodiments of the present invention can be used to identify subjects at risk for developing a disease associated with increased permeability of the blood brain barrier, as well as to provide insight on the ability of an agent or agents to pass the blood brain barrier. Embodiments of the present invention preferably involve the use of subject derived blood samples to determine the occurrence and level of circulating proteins indicative of blood brain barrier permeability or integrity. The embodiments of the present invention also provides screening methods for diagnosis, prognosis, susceptibility, or degree of permeability of penetration of the blood brain barrier by detecting the presence of serum S-100.beta. either directly or through the use of antibodies. The present invention further provides for kits for carrying out the above described screening methods. Preferably, such kits will be used to screen patients for increased levels of S100.beta. protein alone or in combination with other markers of diseased states as a diagnostic and prognostic indicator of permeability of the BBB. Thus, the present invention provides a minimally invasive alternative to direct cerebrospinal fluid sampling to determine the permeability of the blood brain barrier.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 3. Document ID: US 20030054545 A1

L3: Entry 3 of 10

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054545

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030054545 A1

TITLE: Cell and tissue culture modeling device and apparatus and method of using same

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Janigro, Damir</u>	Cleveland Heights	OH	US	
McAllister, Mark S.	Saginaw	MI	US	

US-CL-CURRENT: 435/297.4; 210/321.8, 435/29, 435/32, 435/400

ABSTRACT:

A cell and tissue culture modeling device comprising a housing having an interior chamber, an inlet port in fluid communication with the internal chamber, an outlet port in fluid communication with the internal chamber, a plurality of hollow fibers disposed within the interior chamber and traversing the length of the housing between the inlet port and the outlet port. Each of the plurality of hollow fibers has an interior defining an intracapillary space and the interior chamber defines an extracapillary space unoccupied by the plurality of hollow fibers. To access the extracapillary space of the device, a portion of the housing is removable. The device can be used to conduct permeability, drug efficacy, and gene expression studies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 4. Document ID: US 6667172 B2

L3: Entry 4 of 10

File: USPT

Dec 23, 2003

US-PAT-NO: 6667172

DOCUMENT-IDENTIFIER: US 6667172 B2

TITLE: Cell and tissue culture modeling device and apparatus and method of using same

DATE-ISSUED: December 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Janigro; Damir	Cleveland Heights	OH		
McAllister; Mark S.	Rocky River	OH		

US-CL-CURRENT: 435/297.4; 210/321.8, 359/398, 435/288.2, 435/29, 435/359, 435/400

ABSTRACT:

A cell and tissue culture modeling device comprising a housing having an interior chamber, an inlet port in fluid communication with the internal chamber, an outlet port in fluid communication with the internal chamber, a plurality of hollow fibers disposed within the interior chamber and traversing the length of the housing between the inlet port and the outlet port. Each of the plurality of hollow fibers has an interior defining an intracapillary space and the interior chamber defines an extracapillary space unoccupied by the plurality of hollow fibers. To access the extracapillary space of the device, a portion of the housing is removable. The device can be used to conduct permeability, drug efficacy, and gene expression studies.

33 Claims, 11 Drawing figures

Exemplary Claim Number: 1,9,14,23

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 5. Document ID: US 5425618 A

L3: Entry 5 of 10

File: USPT

Jun 20, 1995

US-PAT-NO: 5425618

DOCUMENT-IDENTIFIER: US 5425618 A

TITLE: Multistage pump provided with modular internal components made of wearproof materials

DATE-ISSUED: June 20, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Janigro; Aldo	Monza			IT
Valsecchi; Maurizio	Casarile			IT
De Bastiani; Fiorenzo	Seveso			IT

US-CL-CURRENT: 415/199.1; 415/200

ABSTRACT:

A multistage pump of the type including a jacket, a shaft which is coaxial to the jacket and connected to an electric motor, and active pumping stages rigidly coupled to the shaft; each stage is formed by an impeller with a front ring and by a distribution element facing the ring with the interposition of an annular supporting element shaped like an inverted bowl; the radial-vane impellers and their distribution elements are rigidly coupled to the jacket made of a highly wearproof material, and the impellers are mounted on the shaft and can move axially or float with a preset stroke with respect to the associated bowl-shaped element, whereas at least one annular supporting and sealing element for the impeller is interposed between the front ring of each impeller and the associated bowl-shaped element, is made of a material which is more wearproof than the impellers, and is suitable to withstand the axial thrusts of the various stages and prevent any fluid seepage during pump operation.

8 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 6. Document ID: EP 602576 A1

L3: Entry 6 of 10

File: EPAB

Jun 22, 1994

PUB-NO: EP000602576A1

DOCUMENT-IDENTIFIER: EP 602576 A1

TITLE: Multistage pump provided with modular internal components made of wearproof materials.

PUBN-DATE: June 22, 1994

INVENTOR-INFORMATION:

NAME

COUNTRY

JANIGRO, ALDO

IT

VALSECCHI, MAURIZIO

IT

DE, BASTIANI FIORENZO

IT

US-CL-CURRENT: 415/198.1

INT-CL (IPC): F04D 1/06; F04D 7/04; F04D 29/44

EUR-CL (EPC): F04D001/06; F04D007/04, F04D029/44

ABSTRACT:

A multistage pump of the type including a jacket (1), a shaft (2) which is coaxial to the jacket and connected to an electric motor, and active pumping stages rigidly coupled to the shaft; each stage is formed by an impeller (5) with a front ring and by a distribution element (6) facing the ring with the interposition of an annular supporting element (7) shaped like an inverted bowl; the radial-vane impellers and their distribution elements are rigidly coupled to the jacket made of a highly wearproof material, and the impellers are mounted on the shaft and can move axially or float with a preset stroke with respect to the associated bowl-shaped element, whereas at least one annular supporting and sealing element (8) for the impeller is interposed between the front ring of each impeller and the associated bowl-shaped element, is made of a material which is more wearproof than the impellers, and is suitable to withstand the axial thrusts of the various stages and prevent any fluid

seepage during pump operation.



Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 7. Document ID: WO 2004078204 A1, US 20040009581 A1

L3: Entry 7 of 10

File: DWPI

Sep 16, 2004

DERWENT-ACC-NO: 2004-098607

DERWENT-WEEK: 200461

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Diagnosing of blood brain barrier integrity in a subject involves detecting elevated levels of transthyretin (TTR) protein in the blood sample derived from the subject

INVENTOR: JANIGRO, D

PRIORITY-DATA: 2002US-388371P (June 12, 2002), 2001US-0891023 (June 25, 2001), 2003US-0462222 (June 12, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 2004078204 A1	September 16, 2004	E	000	A61K039/00
US 20040009581 A1	January 15, 2004		015	C12M001/34

INT-CL (IPC): A61 K 39/00; A61 K 39/395; A61 K 47/00; C12 M 1/34; G01 N 33/00; G01 N 33/15; G01 N 33/48; G01 N 33/49

ABSTRACTED-PUB-NO: US20040009581A

BASIC-ABSTRACT:

NOVELTY - A blood barrier integrity in a subject is diagnosed by detecting elevated levels of transthyretin (TTR) protein in the blood sample derived from a subject. The elevated levels of TTR protein indicate blood barrier permeability.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a kit for the diagnosis or prognosis of blood barrier integrity in a subject comprising a component for detecting the presence of TTR protein in a patient's blood sample.

USE - For diagnosing a blood brain barrier integrity in a subject.

ADVANTAGE - The inventive method provides diagnosis, prognosis, susceptibility, or degree of permeability of penetration of the blood brain barrier by simply detecting the presence of serum transthyretin either directly or through the use of antibodies.

DESCRIPTION OF DRAWING(S) - The drawing shows a diagrammatic representation of the different distribution between S-100 beta and transthyretin (TTR) in the brain.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 8. Document ID: US 20030170747 A1

DERWENT-ACC-NO: 2004-069019
 DERWENT-WEEK: 200410
 COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detection of blood brain barrier permeability for diagnosing e.g. neuronal distress, comprises detecting levels of S100 beta protein in blood samples and comparing the result to a control

INVENTOR: BARNETT, G; JANIGRO, D ; MAYBERG, M

PRIORITY-DATA: 2001US-0891023 (June 25, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030170747 A1	September 11, 2003		018	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/542; G01 N 33/567

ABSTRACTED-PUB-NO: US20030170747A
 BASIC-ABSTRACT:

NOVELTY - Diagnosis of blood brain barrier permeability comprising detecting levels of S100 beta protein in a blood sample of a subject, and comparing the result to S100 beta protein level of a control, is new. An increase in the level of S100 beta protein is indicative of blood brain barrier permeability.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of treating a patient comprising administering an agent which causes blood brain barrier opening, detecting elevated levels of S100 beta protein in the patient's blood, and administering a therapeutic agent.

USE - For diagnosis of blood brain barrier permeability useful in detecting e.g. neuronal distress (claimed). It is also useful for detecting neurological disorder, e.g. tumors, cancer, degenerative disorders, sensory and motor abnormalities, seizure, infection, immunological disorder, mental disorder, behavioral disorder, and localized central nervous system (CNS) disease.

ADVANTAGE - The method provides a predictable and reliable monitoring of neurological status of a subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 9. Document ID: AU 2002341734 A1, US 20030054545 A1, WO 2003025206 A1, US 6667172 B2

DERWENT-ACC-NO: 2003-810758
 DERWENT-WEEK: 200452
 COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Cell and tissue culture modeling device useful for gene expression studies, comprises housing, an inlet and outlet port, several hollow fibers having intracapillary, and extracapillary space unoccupied by fibers

INVENTOR: JANIGRO, D; MCALLISTER, M S

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002341734 A1</u>	April 1, 2003		000	C12Q001/02
<u>US 20030054545 A1</u>	March 20, 2003		021	C12M001/12
<u>WO 2003025206 A1</u>	March 27, 2003	E	000	C12Q001/02
<u>US 6667172 B2</u>	December 23, 2003		000	C12M001/34

INT-CL (IPC): C12 M 1/12; C12 M 1/34; C12 M 3/06; C12 Q 1/02

ABSTRACTED-PUB-NO: US20030054545A

BASIC-ABSTRACT:

NOVELTY - Cell and tissue culture modeling device comprising a housing with an interior chamber, an inlet and outlet port in fluid communication with the chamber, several hollow fibers disposed within the chamber and traversing the length of the housing between the ports, the hollow fibers having an interior defining an intracapillary space, is new. The interior chamber defines an extracapillary space unoccupied by fibers.

DETAILED DESCRIPTION - A cell and tissue culture modeling device (10) (I) has a housing (15) having an interior chamber (57), an inlet port (20) and outlet port (25) in fluid communication with the internal chamber, several hollow fibers disposed within the interior chamber and traversing the length of the housing between the inlet port and the outlet port, each group of hollow fibers having an interior defining an intracapillary space, is new. The interior chamber defines an extracapillary space (67) unoccupied by several hollow fibers. At least a portion of the housing is removable to access the extracapillary space.

An INDEPENDENT CLAIM is also included for a cell and tissue culturing modeling apparatus (II) having at least one cell tissue culture modeling device including a housing having an interior chamber defining an extracapillary space, where at least a portion of the housing is removable to access the extracapillary space, an inlet port and outlet port in fluid communication with the internal chamber, with several hollow fibers disposed within the interior chamber and traversing the length of the housing between the inlet port and the outlet port. Each group of hollow fibers has an interior. The interior is defined as an intracapillary space, a pump system, a media reservoir, a first conduit interconnecting the media reservoir to the pump system, a second conduit interconnecting the pump system to the inlet port of the at least one device, and a third conduit interconnecting the outlet port of the at least one device to the media reservoir.

USE - (I) is useful for determining (M1) the permeability of an agent across a capillary wall which involves providing a cell culture model having several capillaries disposed within an interior chamber which defines an extracapillary space unoccupied by several capillaries, each of the capillaries including several pores that provide fluid communication between an intracapillary space and the extracapillary space, passing an agent having a known concentration through several intracapillary spaces, sampling the extracapillary space to provide an extracapillary space sample, and analyzing the extracapillary space sample to determine the permeability of the agent across each of the capillary walls. Several intracapillary spaces are inoculated with endothelial cells. The extracapillary space is inoculated with glial cells. The sampling step is accomplished by a microdialysis-driven sample probe. (M1) further comprises a second cell culture modeling device to allow for the simultaneous determination of permeability values of at least two agents in a single experiment. (I) is useful for determining (M2) the efficacy of a drug which involves providing a model that exhibits the properties of a functional blood brain barrier (BBB), the model having several intracapillary spaces and an extracapillary space accessible by an access panel, placing a tissue sample into the extracapillary space, passing an agent through the several intracapillary spaces, and analyzing the tissue

sample for responsiveness to the agent. The tissue sample is a cancerous tissue sample, preferably, a brain tissue sample. The agent is a chemotherapeutic agent. (M2) further involves placing a neurochip in the extracapillary space before placing the brain tissue sample into the extracapillary space, the neurochip is capable of studying the electrophysiological activity of the brain tissue sample. The brain tissue sample is placed onto the surface of the neurochip. The brain tissue sample is an epileptic brain tissue sample. The agent is an anticonvulsant agent. Determining the efficacy of a drug further involves examining the tissue sample in the extracapillary space with a microscope. (I) is useful for determining (M3) gene expression over time in cells which involves providing a cell culture model having several hollow fibers disposed within an interior chamber which defines an extracapillary space unoccupied by several hollow fibers, each several hollow fibers includes an intracapillary space inoculated with a cell suspension, passing an agent through several intracapillary spaces, sampling at least one several intracapillary spaces by removing at least one several hollow fibers over time, removing cellular material from at least one several hollow fibers, and analyzing the gene expression of the cellular material. The cellular material is chosen from RNA, DNA, metabolites and protein. (All claimed.) (I) is useful as clinically predictive tool for the efficacy of chemotherapeutic agents in the treatment of primary central nervous system malignancy. (I) is useful for stimulating the blood brain barrier in in vitro, to conduct a permeability study, for conducting gene expression studies and to determine the efficacy of a drug.

ADVANTAGE - The relative flatness of the device makes it modular and thus automation of simultaneous permeability determinations of compounds and multiplexing is possible.

DESCRIPTION OF DRAWING(S) - The drawing shows a side exploded view of a cell and tissue culture modeling device.

Cell and tissue culture modeling device 10

Housing 15

Internal chamber 57

Bottom panel 95

First end wall 30

Opposing second end wall 35

First side wall 40

Opposing second side wall 45

First and second end walls 30,35

First and second side walls 40,45

Inlet port 20

Extracapillary space 67

Outlet port 25

Access ports 50

Top panel. 55

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	K00C	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

□ 10. Document ID: EP 602576 A1, ES 2072237 T3, US 5425618 A, ES 2072237 T1, IT 1256730 B, EP 602576 B1, DE 69313989 E

L3: Entry 10 of 10

File: DWPI

Jun 22, 1994

DERWENT-ACC-NO: 1994-193174

DERWENT-WEEK: 199806

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Multi-stage modular pump made of wear resistant materials - uses ceramic rotating parts to make high specific performance pumps

INVENTOR: DE BASTIANI, F; JANIGRO, A ; VALSECCHI, M

PRIORITY-DATA: 1992IT-MI02871 (December 16, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 602576 A1</u>	June 22, 1994	E	009	F04D001/06
<u>ES 2072237 T3</u>	December 16, 1997		000	F04D001/06
<u>US 5425618 A</u>	June 20, 1995		007	F01D001/02
<u>ES 2072237 T1</u>	July 16, 1995		000	F04D001/06
<u>IT 1256730 B</u>	December 15, 1995		000	F04C000/00
<u>EP 602576 B1</u>	September 17, 1997	E	008	F04D001/06
<u>DE 69313989 E</u>	October 23, 1997		000	F04D001/06

INT-CL (IPC): F01D 1/02; F04C 0/00; F04D 1/06; F04D 7/04; F04D 29/44

ABSTRACTED-PUB-NO: EP 602576A

BASIC-ABSTRACT:

The multi-stage pump has a tubular jacket(1) and a central shaft(2) connected to an electric motor drive. Each pump stage has an impeller(5) with a diffuser(6) and fixed supporting element(7) shaped like an inverted tray or bowl. The moving stage parts are made of highly wear resistant materials such as ceramics and the impellers are axially floating with respect to the supporting members(7).

At least one annular supporting and sealing member for the impellers is interposed between the front ring of each impeller and the supporting element(7). This member withstands the axial thrust of the various stages and limits fluid seepage during pump operation.

USE/ADVANTAGE - The high speed high specific fluid dynamic performance pump can be used to make reduced diameter submersible pumps and the like.

ABSTRACTED-PUB-NO:

EP 602576B EQUIVALENT-ABSTRACTS:

A multistage pump comprising a tubular body (1) having an internal surface, a shaft (2) mounted rotatably within said tubular body (1) and a plurality of pump stages mounted on said shaft within said tubular body (1), wherein each of said pump stages comprises an impeller (5) radially keyed to said shaft, a flow distribution element (6) facing said impeller (5), a bowl-shaped supporting element (7) interposed between said impeller (5) and said flow distribution element (6), and an annular supporting and sealing element (8) for said impeller, said impeller (5) being axially slideable on said shaft (2) and resting on said annular element (8) during operation of said pump for discharging axial thrust onto said tubular body and comparing a first part (5a) and a second disk-shaped part (5b), said first part (5a) being radially keyed to

said shaft (2) and said second disk-shaped part 5b) having formed thereon a plurality of vanes, said annular element (8) being anchored to said bowl-shaped supporting element (7), characterised in that said bowl-shaped supporting element (7) is rigidly anchored with a cylindrical part (7a) thereof to said internal surface of said tubular body (1), and said impeller (5), and flow distribution element (6) and said annular element (8) are made of ceramic materials.

US 5425618A

The pump includes a jacket with a shaft which is coaxial to the jacket and connected to an electric motor, and active pumping stages rigidly coupled to the shaft. Each stage is formed by an impeller with a front ring and by a distribution element facing the ring with the interposition of an annular supporting element shaped like an inverted bowl. The radial-vane impellers and their distribution elements are rigidly coupled to the jacket made of a highly wearproof material.

The impellers are mounted on the shaft and can move axially or float with a preset stroke with respect to the associated bowl-shaped element. At least one annular supporting and sealing element for the impeller is interposed between the front ring of each impeller and the associated bowl-shaped element, is made of a material which is more wearproof than the impellers. It is suitable to withstand the axial thrusts of the various stages and prevent any fluid seepage during pump operation.

ADVANTAGE - Allows very high nominal rotation rates and a significantly higher specific fluid-dynamics performance than obtainable with known pumps. Eliminates transmission of the axial thrusts of the various stages to the impeller supporting shaft and also the conventional thrust bearing.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Janigro.IN.	10

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20030170747 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 4

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170747

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170747 A1

TITLE: Peripheral marker of blood brain barrier permeability

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Janigro, Damir	St. James Parkway	OH	US	
<u>Mayberg, Marc</u>	Chagrin Falls	OH	US	
Barnett, Gene	Gates Mills	OH	US	

US-CL-CURRENT: 435/7.21; 435/7.9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 5779694 A

L4: Entry 2 of 4

File: USPT

Jul 14, 1998

US-PAT-NO: 5779694

DOCUMENT-IDENTIFIER: US 5779694 A

TITLE: Magnetic stereotactic system for treatment delivery

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Matthew A.	Seattle	WA		
<u>Mayberg; Marc</u>	Seattle	WA		
Grady; M. Sean	Seattle	WA		
Ritter; Rogers C.	Charlottesville	VA		
Gillies; George T.	Charlottesville	VA		

US-CL-CURRENT: 604/891.1; 600/12, 600/13, 604/158, 604/174

ABSTRACT:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.5&ref=4&dbname=PGPB,USPT,USO...> 12/1/04

A treatment delivery apparatus comprises a metallic object and a treatment carrier device which is connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. This electromagnet may be either a simple coil system attached to a robotic arm which moves the electromagnet adjacent the body part, or a multicoil electromagnet system surrounding the body part. In either case, the robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location. A computer controls either the robotic arm or multicoil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet means then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

13 Claims, 30 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: US 5707335 A

L4: Entry 3 of 4

File: USPT

Jan 13, 1998

US-PAT-NO: 5707335

DOCUMENT-IDENTIFIER: US 5707335 A

**** See image for Certificate of Correction ****

TITLE: Magnetic stereotactic system and treatment delivery

DATE-ISSUED: January 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Matthew A.	Seattle	WA		
<u>Mayberg; Marc</u>	Seattle	WA		
Grady; M. Sean	Seattle	WA		
Ritter; Rogers C.	Charlottesville	VA		
Gillies; George T.	Charlottesville	VA		

US-CL-CURRENT: 600/12; 604/890.1, 604/891.1, 604/95.01

ABSTRACT:

A treatment delivery apparatus comprises a metallic object and a treatment carrier device which is connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. This electromagnet may be either a simple coil system attached to a robotic arm which moves the electromagnet adjacent the body part, or a multicoil electromagnet system surrounding the body part. In either case, the robotically moved electromagnet or multicoil electromagnet system

moves the magnetic object within the body part to a desired location. A computer controls either the robotic arm or multicoil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet means then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

18 Claims, 30 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Notes	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-------	----------

☐ 4. Document ID: US 5125888 A

L4: Entry 4 of 4

File: USPT

Jun 30, 1992

US-PAT-NO: 5125888
DOCUMENT-IDENTIFIER: US 5125888 A

TITLE: Magnetic stereotactic system for treatment delivery

DATE-ISSUED: June 30, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Matthew A.	Seattle	WA		
Mayberg; Marc	Seattle	WA		
Grady; M. Sean	Seattle	WA		
Ritter; Rogers C.	Charlottesville	VA		
Gillies; George T.	Charlottesville	VA		

US-CL-CURRENT: 600/12; 604/890.1, 604/891.1

ABSTRACT:

A treatment delivery apparatus comprises a metallic object and a treatment carrier device which is connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. This electromagnet may be either a simple coil system attached to a robotic arm which moves the electromagnet adjacent the body part, or a multicoil electromagnet system surrounding the body part. In either case, the robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location. A computer controls either the robotic arm or multicoil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet means then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

37 Claims, 29 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Pub. No.	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	----------	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Mayberg-Marc.IN.	4

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20030170747 A1

Using default format because multiple data bases are involved.

L5: Entry 1 of 4

File: DWPI

Sep 11, 2003

DERWENT-ACC-NO: 2004-069019

DERWENT-WEEK: 200410

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detection of blood brain barrier permeability for diagnosing e.g. neuronal distress, comprises detecting levels of S100 beta protein in blood samples and comparing the result to a control

INVENTOR: BARNETT, G; JANIGRO, D ; MAYBERG, M

PRIORITY-DATA: 2001US-0891023 (June 25, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20030170747 A1</u>	September 11, 2003		018	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/542; G01 N 33/567

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 2. Document ID: US 5779694 A

L5: Entry 2 of 4

File: DWPI

Jul 14, 1998

DERWENT-ACC-NO: 1998-412893

DERWENT-WEEK: 200128

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Drug delivery for specific locations, e.g. the brain for Parkinson or epileptic conditions - has a magnet and drug carrier with semi-automatically controlled electromagnetic positioner and visualisation system

INVENTOR: GILLIES, G T; GRADY, M S ; HOWARD, M A ; MAYBERG, M ; RITTER, R C

PRIORITY-DATA: 1990US-0463340 (January 10, 1990), 1992US-0904032 (June 25, 1992), 1993US-0096214 (July 19, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 5779694 A</u>	July 14, 1998		016	A61M037/00

INT-CL (IPC): A61 K 9/22; A61 M 1/00; A61 M 37/00

ABSTRACTED-PUB-NO: US 5779694A

BASIC-ABSTRACT:

Drug delivery system has a magnet inserted into a body part, with a carrier taking the treatment to a specific location of the body part. The carrier is connected detachably to the magnet.

ADVANTAGE - Allows precise delivery, avoiding side effects from chemicals flooding the brain.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: US 5707335 A

L5: Entry 3 of 4

File: DWPI

Jan 13, 1998

DERWENT-ACC-NO: 1998-100189

DERWENT-WEEK: 200128

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Apparatus comprising magnetic delivery lead attached to one end of thin body - useful for, e.g. delivering localised treatment for Parkinson's disease or temporal lobe epilepsy

INVENTOR: GILLIES, G T; GRADY, M S ; HOWARD, M A ; MAYBERG, M ; RITTER, R C

PRIORITY-DATA: 1990US-0463340 (January 10, 1990), 1992US-0904032 (June 25, 1992), 1993US-0096214 (July 19, 1993), 1995US-0464279 (June 5, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 5707335 A</u>	January 13, 1998		015	A61N002/00

INT-CL (IPC): A61 N 2/00

ABSTRACTED-PUB-NO: US 5707335A

BASIC-ABSTRACT:

Apparatus has a magnetic delivery lead (121) attached to one end of a thin body (119). A treatment is associated with the body of the string. The treatment may be a gelatinous slurry of foetal neurons, genetically engineered cells, proteins or neurotrophic compounds. The treatment may be absorbed, embedded or coated on fibres of the string. An electromagnet external to a patient is used to position the lead and string within the patient's brain. The lead is heated to sever it from the string so it can be recovered.

USE - The apparatus may be used for localised treatment delivery especially for treating focal neurological disorders, e.g. Parkinson's disease or temporal lobe epilepsy.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 4. Document ID: US 5125888 A

L5: Entry 4 of 4

File: DWPI

Jun 30, 1992

DERWENT-ACC-NO: 1992-241755

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.6&ref=5&dbname=PGPB,USPT,USO...> 12/1/04

TITLE: Magnetic stereo-tactic system for treatment delivery - has magnetic object and treatment carrier connected by heat sensitive biodegradable connector to magnetic object, and external magnet

INVENTOR: GILLIES, G T; GRADY, M S ; HOWARD, M A ; MAYBERG, M ; RITTER, R C

PRIORITY-DATA: 1990US-0463340 (January 10, 1990)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5125888 A	June 30, 1992		017	A61N002/00

INT-CL (IPC): A61N 2/00

ABSTRACTED-PUB-NO: US 5125888A

BASIC-ABSTRACT:

The treatment delivery apparatus comprises a metallic object and a treatment carrier device connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. The robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location.

A computer controls the coil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

USE - For treating neurological disorders.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Summary	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	---------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Mayberg-M.IN.	4

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20030170747 A1

Using default format because multiple data bases are involved.

L6: Entry 1 of 4

File: DWPI

Sep 11, 2003

DERWENT-ACC-NO: 2004-069019

DERWENT-WEEK: 200410

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detection of blood brain barrier permeability for diagnosing e.g. neuronal distress, comprises detecting levels of S100 beta protein in blood samples and comparing the result to a control

INVENTOR: BARNETT, G; JANIGRO, D ; MAYBERG, M

PRIORITY-DATA: 2001US-0891023 (June 25, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20030170747 A1</u>	September 11, 2003		018	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/542; G01 N 33/567

FU	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Full Text	Claims	RPMC	Draw Des
--------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	--------------------------	---------------------------	------------------------	----------------------	--------------------------

☐ 2. Document ID: US 5779694 A

L6: Entry 2 of 4

File: DWPI

Jul 14, 1998

DERWENT-ACC-NO: 1998-412893

DERWENT-WEEK: 200128

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Drug delivery for specific locations, e.g. the brain for Parkinson or epileptic conditions - has a magnet and drug carrier with semi-automatically controlled electromagnetic positioner and visualisation system

INVENTOR: GILLIES, G T; GRADY, M S ; HOWARD, M A ; MAYBERG, M ; RITTER, R C

PRIORITY-DATA: 1990US-0463340 (January 10, 1990), 1992US-0904032 (June 25, 1992), 1993US-0096214 (July 19, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 5779694 A</u>	July 14, 1998		016	A61M037/00

INT-CL (IPC): A61 K 9/22; A61 M 1/00; A61 M 37/00

ABSTRACTED-PUB-NO: US 5779694A

BASIC-ABSTRACT:

Drug delivery system has a magnet inserted into a body part, with a carrier taking the treatment to a specific location of the body part. The carrier is connected detachably to the magnet.

ADVANTAGE - Allows precise delivery, avoiding side effects from chemicals flooding the brain.

→	FU	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
---	----	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: US 5707335 A

L6: Entry 3 of 4

File: DWPI

Jan 13, 1998

DERWENT-ACC-NO: 1998-100189

DERWENT-WEEK: 200128

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Apparatus comprising magnetic delivery lead attached to one end of thin body - useful for, e.g. delivering localised treatment for Parkinson's disease or temporal lobe epilepsy

INVENTOR: GILLIES, G T; GRADY, M S ; HOWARD, M A ; MAYBERG, M ; RITTER, R C

PRIORITY-DATA: 1990US-0463340 (January 10, 1990), 1992US-0904032 (June 25, 1992), 1993US-0096214 (July 19, 1993), 1995US-0464279 (June 5, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 5707335 A</u>	January 13, 1998		015	A61N002/00

INT-CL (IPC): A61 N 2/00

ABSTRACTED-PUB-NO: US 5707335A

BASIC-ABSTRACT:

Apparatus has a magnetic delivery lead (121) attached to one end of a thin body (119). A treatment is associated with the body of the string. The treatment may be a gelatinous slurry of foetal neurons, genetically engineered cells, proteins or neurotrophic compounds. The treatment may be absorbed, embedded or coated on fibres of the string. An electromagnet external to a patient is used to position the lead and string within the patient's brain. The lead is heated to sever it from the string so it can be recovered.

USE - The apparatus may be used for localised treatment delivery especially for treating focal neurological disorders, e.g. Parkinson's disease or temporal lobe epilepsy.

→	FU	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
---	----	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 4. Document ID: US 5125888 A

L6: Entry 4 of 4

File: DWPI

Jun 30, 1992

DERWENT-ACC-NO: 1992-241755

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.7&ref=6&dbname=PGPB,USPT,USO...> 12/1/04

TITLE: Magnetic stereo-tactic system for treatment delivery - has magnetic object and treatment carrier connected by heat sensitive biodegradable connector to magnetic object, and external magnet

INVENTOR: GILLIES, G T; GRADY, M S ; HOWARD, M A ; MAYBERG, M ; RITTER, R C

PRIORITY-DATA: 1990US-0463340 (January 10, 1990)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 5125888 A</u>	June 30, 1992		017	A61N002/00

INT-CL (IPC): A61N 2/00

ABSTRACTED-PUB-NO: US 5125888A

BASIC-ABSTRACT:

The treatment delivery apparatus comprises a metallic object and a treatment carrier device connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. The robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location.

A computer controls the coil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

USE - For treating neurological disorders.

 FU	Title	Citation	Front	Review	Classification	Date	Reference			Claims	K00C	Draw. Des.
--	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Mayberg-M.IN.	4

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 15 of 15 returned.

☐ 1. Document ID: US 20030170747 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 15

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170747

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170747 A1

TITLE: Peripheral marker of blood brain barrier permeability

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Janigro, Damir	St. James Parkway	OH	US	
Mayberg, Marc	Chagrin Falls	OH	US	
Barnett, Gene	Gates Mills	OH	US	

US-CL-CURRENT: 435/7.21; 435/7.9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20030149450 A1

L7: Entry 2 of 15

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030149450

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030149450 A1

TITLE: Brainstem and cerebellar modulation of cardiovascular response and disease

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mayberg, Marc R.	Chagrin Falls	OH	US	

US-CL-CURRENT: 607/3

ABSTRACT:

The present invention is directed to an apparatus and methods for modulating brainstem and cerebellar circuits controlling blood pressure or heart rate using a variety of techniques including but not limited to surface stimulation, depth

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.8&ref=7&dbname=PGPB,USPT,USO...> 12/1/04

electrode stimulation, and localized infusion of agents to these regions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 6326017 B1

L7: Entry 3 of 15

File: USPT

Dec 4, 2001

US-PAT-NO: 6326017

DOCUMENT-IDENTIFIER: US 6326017 B1

TITLE: Methods for the localized delivery of agents to blood vessels

DATE-ISSUED: December 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mayberg; Marc R.	Seattle	WA		

US-CL-CURRENT: 424/422; 424/423, 424/484, 424/486, 514/12, 514/423, 514/56,
604/890.1, 604/891.1

ABSTRACT:

Methods for the localized delivery of agents to blood vessels are disclosed. The methods of the present invention provide advantages over existing methods for treating, diagnosing, or preventing, vascular disorders. Localized delivery of agents permits the use of agents, such as heparin, for which systemic distribution may be undesirable. Suitable agents include antithrombotic and anti-intimal proliferation agents. An agent may be delivered to a blood vessel by a carrier, such as a polymer, which is adapted to restrict the release of the agent into tissue adjacent to the blood vessel. Alternatively, after applying a carrier to a blood vessel, the carrier may be covered with a barrier adapted to restrict the release of the agent into tissue adjacent to the blood vessel. The methods of the present invention may be applied to a variety of surgical and nonsurgical clinical settings.

10 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 4. Document ID: US 5779694 A

L7: Entry 4 of 15

File: USPT

Jul 14, 1998

US-PAT-NO: 5779694

DOCUMENT-IDENTIFIER: US 5779694 A

TITLE: Magnetic stereotactic system for treatment delivery

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Matthew A.	Seattle	WA		
Mayberg; Marc	Seattle	WA		
Grady; M. Sean	Seattle	WA		
Ritter; Rogers C.	Charlottesville	VA		
Gillies; George T.	Charlottesville	VA		

US-CL-CURRENT: 604/891.1; 600/12, 600/13, 604/158, 604/174

ABSTRACT:

A treatment delivery apparatus comprises a metallic object and a treatment carrier device which is connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. This electromagnet may be either a simple coil system attached to a robotic arm which moves the electromagnet adjacent the body part, or a multicoil electromagnet system surrounding the body part. In either case, the robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location. A computer controls either the robotic arm or multicoil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet means then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

13 Claims, 30 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 5. Document ID: US 5707335 A

L7: Entry 5 of 15

File: USPT

Jan 13, 1998

US-PAT-NO: 5707335

DOCUMENT-IDENTIFIER: US 5707335 A

**** See image for Certificate of Correction ****

TITLE: Magnetic stereotactic system and treatment delivery...

DATE-ISSUED: January 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Matthew A.	Seattle	WA		
Mayberg; Marc	Seattle	WA		
Grady; M. Sean	Seattle	WA		
Ritter; Rogers C.	Charlottesville	VA		
Gillies; George T.	Charlottesville	VA		

US-CL-CURRENT: 600/12; 604/890.1, 604/891.1, 604/95.01

ABSTRACT:

A treatment delivery apparatus comprises a metallic object and a treatment carrier device which is connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. This electromagnet may be either a simple coil system attached to a robotic arm which moves the electromagnet adjacent the body part, or a multicoil electromagnet system surrounding the body part. In either case, the robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location. A computer controls either the robotic arm or multicoil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet means then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

18 Claims, 30 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 6. Document ID: US 5125888 A

L7: Entry 6 of 15

File: USPT

Jun 30, 1992

US-PAT-NO: 5125888

DOCUMENT-IDENTIFIER: US 5125888 A

TITLE: Magnetic stereotactic system for treatment delivery

DATE-ISSUED: June 30, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Matthew A.	Seattle	WA		
Mayberg; Marc	Seattle	WA		
Grady; M. Sean	Seattle	WA		
Ritter; Rogers C.	Charlottesville	VA		
Gillies; George T.	Charlottesville	VA		

US-CL-CURRENT: 600/12; 604/890.1, 604/891.1

ABSTRACT:

A treatment delivery apparatus comprises a metallic object and a treatment carrier device which is connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. This electromagnet may be either a simple coil system attached to a robotic arm which moves the electromagnet adjacent

the body part, or a multicoil electromagnet system surrounding the body part. In either case, the robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location. A computer controls either the robotic arm or multicoil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet means then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

37 Claims, 29 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 7. Document ID: WO 2004069328 A2

L7: Entry 7 of 15

File: EPAB

Aug 19, 2004

PUB-NO: WO2004069328A2

DOCUMENT-IDENTIFIER: WO 2004069328 A2

TITLE: BRAINSTEM AND CEREBELLAR MODULATION OF CARDIOVASCULAR RESPONSE AND DISEASE

PUBN-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

MAYBERG, MARC R

US

INT-CL (IPC): A61 N 0/

EUR-CL (EPC): A61N001/08

ABSTRACT:

The present invention is directed to an apparatus and methods for modulating brainstem and cerebellar circuits controlling blood pressure or heart rate using a variety of techniques including but not limited to surface stimulation, depth electrode stimulation, and localized infusion of agents to these regions.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 8. Document ID: WO 9411022 A1

L7: Entry 8 of 15

File: EPAB

May 26, 1994

PUB-NO: WO009411022A1

DOCUMENT-IDENTIFIER: WO 9411022 A1

TITLE: USE OF TOPICALLY APPLIED FACTOR XIII FOR INHIBITING HEMORRHAGE

PUBN-DATE: May 26, 1994

INVENTOR-INFORMATION:

NAME

COUNTRY

MAYBERG, MARC R

US

EDWARDS, MARTIN WILLIAM

INT-CL (IPC): A61K 37/52

EUR-CL (EPC): A61K038/45

ABSTRACT:

The present invention provides methods for inhibiting delayed bleeding of wounds and post-operative hemorrhage through the topical application of factor XIII. The methods may be used at surgical sites, including intracranial sites, and in coagulopathic patients.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	WOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 9. Document ID: US 20030170747 A1

L7: Entry 9 of 15

File: DWPI

Sep 11, 2003

DERWENT-ACC-NO: 2004-069019

DERWENT-WEEK: 200410

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detection of blood brain barrier permeability for diagnosing e.g. neuronal distress, comprises detecting levels of S100 beta protein in blood samples and comparing the result to a control

INVENTOR: BARNETT, G; JANIGRO, D ; MAYBERG, M

PRIORITY-DATA: 2001US-0891023 (June 25, 2001)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

US 20030170747 A1

September 11, 2003

018

G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/542; G01 N 33/567

ABSTRACTED-PUB-NO: US20030170747A

BASIC-ABSTRACT:

NOVELTY - Diagnosis of blood brain barrier permeability comprising detecting levels of S100 beta protein in a blood sample of a subject, and comparing the result to S100 beta protein level of a control, is new. An increase in the level of S100 beta protein is indicative of blood brain barrier permeability.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of treating a patient comprising administering an agent which causes blood brain barrier opening, detecting elevated levels of S100 beta protein in the patient's blood, and administering a therapeutic agent.

USE - For diagnosis of blood brain barrier permeability useful in detecting e.g. neuronal distress (claimed). It is also useful for detecting neurological disorder, e.g. tumors, cancer, degenerative disorders, sensory and motor abnormalities, seizure, infection, immunological disorder, mental disorder, behavioral disorder, and

localized central nervous system (CNS) disease.

ADVANTAGE - The method provides a predictable and reliable monitoring of neurological status of a subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 10. Document ID: WO 2004069328 A2, US 20030149450 A1

L7: Entry 10 of 15

File: DWPI

Aug 19, 2004

DERWENT-ACC-NO: 2003-801636

DERWENT-WEEK: 200455

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Autonomic response modulating apparatus for treating cardiovascular disorders, has therapeutic delivery device that is positioned near site of hindbrain structure of vertebrate to modulate function of hindbrain

INVENTOR: MAYBERG, M R

PRIORITY-DATA: 2002US-353701P (February 1, 2002), 2003US-0357161 (February 3, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2004069328 A2</u>	August 19, 2004	E	000	A61N000/00
<u>US 20030149450 A1</u>	August 7, 2003		016	A61N001/18

INT-CL (IPC): A61 N 0/00; A61 N 1/18

ABSTRACTED-PUB-NO: US20030149450A

BASIC-ABSTRACT:

NOVELTY - The apparatus has a therapeutic delivery device (26) positioned near a site of a hindbrain structure of a vertebrate (44) to modulate a function of the hindbrain. A controller in communication with the therapeutic delivery device enables the device to deliver the therapy. A sensor is electrically connected to the controller to measure a cardiovascular state of the vertebrate.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of controlling a cardiovascular state of a patient.

USE - Used for modulating autonomic response in treating cardiovascular disorders.

ADVANTAGE - The therapeutic delivery device delivering the therapy and stimulating the cardiovascular response provides a more precise real-time adjustment of a patients cardiovascular state. Therefore the amount of pharmaceutical required, when compared with traditional therapeutic treatments of cardiovascular conditions is eliminated or reduced.

DESCRIPTION OF DRAWING(S) - The drawing shows a sagittal view of a brain with a therapeutic delivery device placed into it.

Cerebral cortex 20

Cerebellum 24

Therapeutic delivery device 26

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 11. Document ID: US 6326017 B1

L7: Entry 11 of 15

File: DWPI

Dec 4, 2001

DERWENT-ACC-NO: 2002-178583

DERWENT-WEEK: 200223

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for localized delivery of agents e.g. aspirin or heparin to blood vessels for treatment of vascular disorders without systemic effect, uses polymer matrix carrier e.g. polyvinylalcohol

INVENTOR: MAYBERG, M R

PRIORITY-DATA: 1989US-0416671 (October 2, 1989), 1991US-0780614 (October 23, 1991), 1993US-0042461 (April 5, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6326017 B1	December 4, 2001		006	A61F013/00

INT-CL (IPC): A61 F 13/00; A61 K 9/14

ABSTRACTED-PUB-NO: US 6326017B

BASIC-ABSTRACT:

NOVELTY - A method for localized delivery of agents to blood vessels for treatment of vascular disorders without systemic effect, comprises applying a polymer matrix carrier impregnated with agent to the blood vessel.

DETAILED DESCRIPTION - A method for treating vascular disorders comprises applying a polymer matrix, which is permeable to an agent for treatment of a vascular disorder and impregnated with the agent, directly in contact with an external surface of an artery or vein; and covering the polymer matrix with a barrier adapted to restrict the release of agent into tissue adjacent to the artery or vein, so that the agent diffuses from the polymer directly to the external surface of the artery or vein, producing a localized effect on the artery or vein without systemic effect.

ACTIVITY - Thrombolytic; anticoagulant.

11 Rats were anesthetized and the distal common, external and internal carotid arteries were exposed bilaterally in the rat's neck. A 2-French balloon embolectomy catheter was introduced into both external carotid arteries, inflated and advanced to produce consistent endothelial dequamation in the segment of the artery. Additional vessel wall injury was produced by passing a wire along the desquamated luminal surface. Heparin sulfate (600units, 0.03ml) was mixed with polyvinyl alcohol (PVA, 0.06ml) to produce a viscous gel, and immediately applied around the adventitial surface of the de-endothelialized distal left (treated) common carotid artery and surrounded by a Silastic shell to prevent release into adjacent tissue. PVA without heparin was similarly applied to the right (control) common carotid artery. 30 Minutes after application of the PVA, both common carotid arteries were occluded by microclips at the ends of the segment with injured endothelium. After 1 hour of occlusion, the systemic prothrombin time and partial thromboplastin time were

determined from arterial blood drawn from a femoral catheter. Microclips were removed and blood flow established for 5 minutes. Vessels were perfusion-fixed in situ. The common carotid arteries were removed.

Scanning electron microscopy was performed on the luminal surface of control and heparin/PVA-treated desquamated rat common carotid arteries. The control vessel showed an extensive thrombus that completely occluded the lumen. The treated vessel showed complete endothelial desquamation with exposed subendothelial collagen. The luminal surface of the treated vessel was coated with a monolayer of adherent platelets, but no fibrin formation or erythrocyte thrombus was present.

A significant (greater than 20%) intraluminal thrombus was present in all 10 control vessels, 4 of which were completely occluded, whereas significant thrombus was visible in only 1 of 10 treated vessels. The thrombus:lumen ratio was reduced from 60.2 plus or minus 25.8% in control vessels to 4.1 plus or minus 9.6% in treated vessels.

MECHANISM OF ACTION - None given in the source material.

USE - For treating vascular disorders (claimed), e.g. thrombosis, and for surgical clinical conditions (e.g. endarterectomy, large vessel and microvascular anastomosis, cerebral and systemic venous procedures, arteriovenous shunts, angioplasty, and free flaps) and nonsurgical clinical conditions (e.g. deep-vein thrombosis, cardiac valvular disease and arterial stenosis).

ADVANTAGE - The localized delivery reduces or eliminates side effects of an agent (e.g. heparin) that result from its systemic administration, and high concentrations of agent are provided at the site of action.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Indexing	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	----------	--------	------	----------

☐ 12. Document ID: US 5779694 A

L7: Entry 12 of 15

File: DWPI

Jul 14, 1998

DERWENT-ACC-NO: 1998-412893

DERWENT-WEEK: 200128

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Drug delivery for specific locations, e.g. the brain for Parkinson or epileptic conditions - has a magnet and drug carrier with semi-automatically controlled electromagnetic positioner and visualisation system

INVENTOR: GILLIES, G T; GRADY, M S ; HOWARD, M A ; MAYBERG, M ; RITTER, R C

PRIORITY-DATA: 1990US-0463340 (January 10, 1990), 1992US-0904032 (June 25, 1992), 1993US-0096214 (July 19, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 5779694 A</u>	July 14, 1998		016	A61M037/00

INT-CL (IPC): A61 K 9/22;

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20030149450 A1

Using default format because multiple data bases are involved.

L17: Entry 1 of 4

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030149450

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030149450 A1

TITLE: Brainstem and cerebellar modulation of cardiovascular response and disease

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mayberg, Marc R.	Chagrin Falls	OH	US	

US-CL-CURRENT: 607/3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 2. Document ID: US 6326017 B1

L17: Entry 2 of 4

File: USPT

Dec 4, 2001

US-PAT-NO: 6326017

DOCUMENT-IDENTIFIER: US 6326017 B1

TITLE: Methods for the localized delivery of agents to blood vessels

DATE-ISSUED: December 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mayberg, Marc R.	Seattle	WA		

US-CL-CURRENT: 424/422; 424/423, 424/484, 424/486, 514/12, 514/423, 514/56,
604/890.1, 604/891.1

ABSTRACT:

Methods for the localized delivery of agents to blood vessels are disclosed. The methods of the present invention provide advantages over existing methods for treating, diagnosing, or preventing, vascular disorders. Localized delivery of agents permits the use of agents, such as heparin, for which systemic distribution may be undesirable. Suitable agents include antithrombotic and anti-intimal proliferation agents. An agent may be delivered to a blood vessel by a carrier, such as a polymer,

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.20&ref=17&dbname=PGPB,USPT,US...> 12/1/04

which is adapted to restrict the release of the agent into tissue adjacent to the blood vessel. Alternatively, after applying a carrier to a blood vessel, the carrier may be covered with a barrier adapted to restrict the release of the agent into tissue adjacent to the blood vessel. The methods of the present invention may be applied to a variety of surgical and nonsurgical clinical settings.

10 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 3. Document ID: WO 2004069328 A2

L17: Entry 3 of 4

File: EPAB

Aug 19, 2004

PUB-NO: WO2004069328A2

DOCUMENT-IDENTIFIER: WO 2004069328 A2

TITLE: BRAINSTEM AND CEREBELLAR MODULATION OF CARDIOVASCULAR RESPONSE AND DISEASE

PUBN-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

MAYBERG, MARC R

US

INT-CL (IPC): A61 N 0/

EUR-CL (EPC): A61N001/08

ABSTRACT:

The present invention is directed to an apparatus and methods for modulating brainstem and cerebellar circuits controlling blood pressure or heart rate using a variety of techniques including but not limited to surface stimulation, depth electrode stimulation, and localized infusion of agents to these regions.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 4. Document ID: WO 9411022 A1

L17: Entry 4 of 4

File: EPAB

May 26, 1994

PUB-NO: WO009411022A1

DOCUMENT-IDENTIFIER: WO 9411022 A1

TITLE: USE OF TOPICALLY APPLIED FACTOR XIII FOR INHIBITING HEMORRHAGE

PUBN-DATE: May 26, 1994

INVENTOR-INFORMATION:

NAME

COUNTRY

MAYBERG, MARC R

US

EDWARDS, MARTIN WILLIAM

INT-CL (IPC): A61K 37/52
EUR-CL (EPC): A61K038/45

ABSTRACT:

The present invention provides methods for inhibiting delayed bleeding of wounds and post-operative hemorrhage through the topical application of factor XIII. The methods may be used at surgical sites, including intracranial sites, and in coagulopathic patients.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Mayberg-Marc-R.IN.	4

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: WO 2004069328 A2, US 20030149450 A1

Using default format because multiple data bases are involved.

L18: Entry 1 of 3

File: DWPI

Aug 19, 2004

DERWENT-ACC-NO: 2003-801636

DERWENT-WEEK: 200455

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Autonomic response modulating apparatus for treating cardiovascular disorders, has therapeutic delivery device that is positioned near site of hindbrain structure of vertebrate to modulate function of hindbrain

INVENTOR: MAYBERG, M R

PRIORITY-DATA: 2002US-353701P (February 1, 2002), 2003US-0357161 (February 3, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2004069328 A2</u>	August 19, 2004	E	000	A61N000/00
<u>US 20030149450 A1</u>	August 7, 2003		016	A61N001/18

INT-CL (IPC): A61 N 0/00; A61 N 1/18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 2. Document ID: US 6326017 B1

L18: Entry 2 of 3

File: DWPI

Dec 4, 2001

DERWENT-ACC-NO: 2002-178583

DERWENT-WEEK: 200223

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for localized delivery of agents e.g. aspirin or heparin to blood vessels for treatment of vascular disorders without systemic effect, uses polymer matrix carrier e.g. polyvinylalcohol

INVENTOR: MAYBERG, M R

PRIORITY-DATA: 1989US-0416671 (October 2, 1989), 1991US-0780614 (October 23, 1991), 1993US-0042461 (April 5, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6326017 B1</u>	December 4, 2001		006	A61F013/00

ABSTRACTED-PUB-NO: US 6326017B

BASIC-ABSTRACT:

NOVELTY - A method for localized delivery of agents to blood vessels for treatment of vascular disorders without systemic effect, comprises applying a polymer matrix carrier impregnated with agent to the blood vessel.

DETAILED DESCRIPTION - A method for treating vascular disorders comprises applying a polymer matrix, which is permeable to an agent for treatment of a vascular disorder and impregnated with the agent, directly in contact with an external surface of an artery or vein; and covering the polymer matrix with a barrier adapted to restrict the release of agent into tissue adjacent to the artery or vein, so that the agent diffuses from the polymer directly to the external surface of the artery or vein, producing a localized effect on the artery or vein without systemic effect.

ACTIVITY - Thrombolytic; anticoagulant.

11 Rats were anesthetized and the distal common, external and internal carotid arteries were exposed bilaterally in the rat's neck. A 2-French balloon embolectomy catheter was introduced into both external carotid arteries, inflated and advanced to produce consistent endothelial dequamation in the segment of the artery. Additional vessel wall injury was produced by passing a wire along the desquamated luminal surface. Heparin sulfate (600units, 0.03ml) was mixed with polyvinyl alcohol (PVA, 0.06ml) to produce a viscous gel, and immediately applied around the adventitial surface of the de-endothelialized distal left (treated) common carotid artery and surrounded by a Silastic shell to prevent release into adjacent tissue. PVA without heparin was similarly applied to the right (control) common carotid artery. 30 Minutes after application of the PVA, both common carotid arteries were occluded by microclips at the ends of the segment with injured endothelium. After 1 hour of occlusion, the systemic prothrombin time and partial thromboplastin time were determined from arterial blood drawn from a femoral catheter. Microclips were removed and blood flow established for 5 minutes. Vessels were perfusion-fixed in situ. The common carotid arteries were removed.

Scanning electron microscopy was performed on the luminal surface of control and heparin/PVA-treated desquamated rat common carotid arteries. The control vessel showed an extensive thrombus that completely occluded the lumen. The treated vessel showed complete endothelial desquamation with exposed subendothelial collagen. The luminal surface of the treated vessel was coated with a monolayer of adherent platelets, but no fibrin formation or erythrocyte thrombus was present.

A significant (greater than 20%) intraluminal thrombus was present in all 10 control vessels, 4 of which were completely occluded, whereas significant thrombus was visible in only 1 of 10 treated vessels. The thrombus:lumen ratio was reduced from 60.2 plus or minus 25.8% in control vessels to 4.1 plus or minus 9.6% in treated vessels.

MECHANISM OF ACTION - None given in the source material.

USE - For treating vascular disorders (claimed), e.g. thrombosis, and for surgical clinical conditions (e.g. endarterectomy, large vessel and microvascular anastomosis, cerebral and systemic venous procedures, arteriovenous shunts, angioplasty, and free flaps) and nonsurgical clinical conditions (e.g. deep-vein thrombosis, cardiac valvular disease and arterial stenosis).

ADVANTAGE - The localized delivery reduces or eliminates side effects of an agent (e.g. heparin) that result from its systemic administration, and high concentrations of agent are provided at the site of action.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

□ 3. Document ID: JP 2004231664 A, WO 9411022 A1, EP 669834 A1, JP 08505129 W, EP 669834 B1, DE 69326349 E, ES 2139729 T3, CA 2149209 C

L18: Entry 3 of 3

File: DWPI

Aug 19, 2004

DERWENT-ACC-NO: 1994-183158

DERWENT-WEEK: 200454

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Inhibition of haemorrhage by topical application of factor XIII - useful for preventing delayed bleeding in wounds and operation sites

INVENTOR: EDWARDS, M W; MAYBERG, M R

PRIORITY-DATA: 1992US-0975026 (November 12, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>JP 2004231664 A</u>	August 19, 2004		009	A61K038/43
<u>WO 9411022 A1</u>	May 26, 1994	E	020	A61K037/52
<u>EP 669834 A1</u>	September 6, 1995	E	000	A61K037/52
<u>JP 08505129 W</u>	June 4, 1996		018	A61K038/43
<u>EP 669834 B1</u>	September 8, 1999	E	000	A61K038/45
<u>DE 69326349 E</u>	October 14, 1999		000	A61K038/45
<u>ES 2139729 T3</u>	February 16, 2000		000	A61K038/45
<u>CA 2149209 C</u>	August 1, 2000	E	000	A61K038/45

INT-CL (IPC): A61 K 37/52; A61 K 38/43; A61 K 38/45; A61 P 7/04

ABSTRACTED-PUB-NO: EP 669834B

BASIC-ABSTRACT:

Inhibiting post-operative haemorrhage comprises topical application of a compsn contg factor XIII to a surgical site.

USE/ADVANTAGE - The method inhibits delayed bleeding of wounds and post-operative haemorrhage. The compsns are applied prior to closing the surgical opening and pref after the site has been treated to induce haemostasis by conventional methods. The method reduces the incidence of post-operative haemorrhage esp. in high-risk settings.

The concn of factor XIII in the vehicle is 0.1-100 mg/ml, pref 1.0-10 mg/ml.

ABSTRACTED-PUB-NO:

WO 9411022A EQUIVALENT-ABSTRACTS:

Inhibiting post-operative haemorrhage comprises topical application of a compsn contg factor XIII to a surgical site.

USE/ADVANTAGE - The method inhibits delayed bleeding of wounds and post-operative haemorrhage. The compsns are applied prior to closing the surgical opening and pref after the site has been treated to induce haemostasis by conventional methods. The method reduces the incidence of post-operative haemorrhage esp. in high-risk settings.

The concn of factor XIII in the vehicle is 0.1-100 mg/ml, pref 1.0-10 mg/ml.

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Mayberg-M-R.IN.	3

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 15 of 15 returned.

☐ 1. Document ID: US 20030170747 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 15

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170747

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170747 A1

TITLE: Peripheral marker of blood brain barrier permeability

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Janigro, Damir	St. James Parkway	OH	US	
<u>Mayberg</u> , Marc	Chagrin Falls	OH	US	
Barnett, Gene	Gates Mills	OH	US	

US-CL-CURRENT: 435/7.21; 435/7.9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 2. Document ID: US 20030149450 A1

L7: Entry 2 of 15

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030149450

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030149450 A1

TITLE: Brainstem and cerebellar modulation of cardiovascular response and disease

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Mayberg</u> , Marc R.	Chagrin Falls	OH	US	

US-CL-CURRENT: 607/3

ABSTRACT:

The present invention is directed to an apparatus and methods for modulating brainstem and cerebellar circuits controlling blood pressure or heart rate using a variety of techniques including but not limited to surface stimulation, depth

electrode stimulation, and localized infusion of agents to these regions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 6326017 B1

L7: Entry 3 of 15

File: USPT

Dec 4, 2001

US-PAT-NO: 6326017

DOCUMENT-IDENTIFIER: US 6326017 B1

TITLE: Methods for the localized delivery of agents to blood vessels

DATE-ISSUED: December 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mayberg; Marc R.	Seattle	WA		

US-CL-CURRENT: 424/422; 424/423, 424/484, 424/486, 514/12, 514/423, 514/56,
604/890.1, 604/891.1

ABSTRACT:

Methods for the localized delivery of agents to blood vessels are disclosed. The methods of the present invention provide advantages over existing methods for treating, diagnosing, or preventing, vascular disorders. Localized delivery of agents permits the use of agents, such as heparin, for which systemic distribution may be undesirable. Suitable agents include antithrombotic and anti-intimal proliferation agents. An agent may be delivered to a blood vessel by a carrier, such as a polymer, which is adapted to restrict the release of the agent into tissue adjacent to the blood vessel. Alternatively, after applying a carrier to a blood vessel, the carrier may be covered with a barrier adapted to restrict the release of the agent into tissue adjacent to the blood vessel. The methods of the present invention may be applied to a variety of surgical and nonsurgical clinical settings.

10 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 4. Document ID: US 5779694 A

L7: Entry 4 of 15

File: USPT

Jul 14, 1998

US-PAT-NO: 5779694

DOCUMENT-IDENTIFIER: US 5779694 A

TITLE: Magnetic stereotactic system for treatment delivery

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Matthew A.	Seattle	WA		
Mayberg; Marc	Seattle	WA		
Grady; M. Sean	Seattle	WA		
Ritter; Rogers C.	Charlottesville	VA		
Gillies; George T.	Charlottesville	VA		

US-CL-CURRENT: 604/891.1; 600/12, 600/13, 604/158, 604/174

ABSTRACT:

A treatment delivery apparatus comprises a metallic object and a treatment carrier device which is connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. This electromagnet may be either a simple coil system attached to a robotic arm which moves the electromagnet adjacent the body part, or a multicoil electromagnet system surrounding the body part. In either case, the robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location. A computer controls either the robotic arm or multicoil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet means then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

13 Claims, 30 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw. Des.

☐ 5. Document ID: US 5707335 A

L7: Entry 5 of 15

File: USPT

Jan 13, 1998

US-PAT-NO: 5707335

DOCUMENT-IDENTIFIER: US 5707335 A

**** See image for Certificate of Correction ****

TITLE: Magnetic stereotactic system and treatment delivery

DATE-ISSUED: January 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Matthew A.	Seattle	WA		
Mayberg; Marc	Seattle	WA		
Grady; M. Sean	Seattle	WA		
Ritter; Rogers C.	Charlottesville	VA		
Gillies; George T.	Charlottesville	VA		

US-CL-CURRENT: 600/12; 604/890.1, 604/891.1, 604/95.01

ABSTRACT:

A treatment delivery apparatus comprises a metallic object and a treatment carrier device which is connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. This electromagnet may be either a simple coil system attached to a robotic arm which moves the electromagnet adjacent the body part, or a multicoil electromagnet system surrounding the body part. In either case, the robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location. A computer controls either the robotic arm or multicoil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet means then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

18 Claims, 30 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 6. Document ID: US 5125888 A

L7: Entry 6 of 15

File: USPT

Jun 30, 1992

US-PAT-NO: 5125888
DOCUMENT-IDENTIFIER: US 5125888 A

TITLE: Magnetic stereotactic system for treatment delivery

DATE-ISSUED: June 30, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Matthew A.	Seattle	WA		
Mayberg; Marc	Seattle	WA		
Grady; M. Sean	Seattle	WA		
Ritter; Rogers C.	Charlottesville	VA		
Gillies; George T.	Charlottesville	VA		

US-CL-CURRENT: 600/12; 604/890.1, 604/891.1

ABSTRACT:

A treatment delivery apparatus comprises a metallic object and a treatment carrier device which is connected by a heat-sensitive biodegradable connector link to the magnetic object. This carrier device contains the treatment, i.e. the drug, to be transported. An electromagnet is positioned outside of the body part for producing a magnetic field which captures the magnetic object. This electromagnet may be either a simple coil system attached to a robotic arm which moves the electromagnet adjacent

the body part, or a multicoil electromagnet system surrounding the body part. In either case, the robotically moved electromagnet or multicoil electromagnet system moves the magnetic object within the body part to a desired location. A computer controls either the robotic arm or multicoil current magnitudes and directions. This computer also provides visualization for observing the location and movement of the magnetic object and carrier device. Upon reaching the desired location, the magnetic object is heated, which causes the heat-sensitive biodegradable connector link to melt, which separates the drug-containing carrier device from the magnetic object. The electromagnet means then moves the magnetic object back out of the body part. The treatment-containing carrier device remains in the desired location and the drug is delivered to the specific location.

37 Claims, 29 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 7. Document ID: WO 2004069328 A2

L7: Entry 7 of 15

File: EPAB

Aug 19, 2004

PUB-NO: WO2004069328A2

DOCUMENT-IDENTIFIER: WO 2004069328 A2

TITLE: BRAINSTEM AND CEREBELLAR MODULATION OF CARDIOVASCULAR RESPONSE AND DISEASE

PUBN-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

MAYBERG, MARC R

US

INT-CL (IPC): A61 N 0/

EUR-CL (EPC): A61N001/08

ABSTRACT:

The present invention is directed to an apparatus and methods for modulating brainstem and cerebellar circuits controlling blood pressure or heart rate using a variety of techniques including but not limited to surface stimulation, depth electrode stimulation, and localized infusion of agents to these regions.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 8. Document ID: WO 9411022 A1

L7: Entry 8 of 15

File: EPAB

May 26, 1994

PUB-NO: WO009411022A1

DOCUMENT-IDENTIFIER: WO 9411022 A1

TITLE: USE OF TOPICALLY APPLIED FACTOR XIII FOR INHIBITING HEMORRHAGE

PUBN-DATE: May 26, 1994

INVENTOR-INFORMATION:

NAME

MAYBERG, MARC R

EDWARDS, MARTIN WILLIAM

COUNTRY

US

INT-CL (IPC): A61K 37/52

EUR-CL (EPC): A61K038/45

ABSTRACT:

The present invention provides methods for inhibiting delayed bleeding of wounds and post-operative hemorrhage through the topical application of factor XIII. The methods may be used at surgical sites, including intracranial sites, and in coagulopathic patients.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 9. Document ID: US 20030170747 A1

L7: Entry 9 of 15

File: DWPI

Sep 11, 2003

DERWENT-ACC-NO: 2004-069019

DERWENT-WEEK: 200410

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detection of blood brain barrier permeability for diagnosing e.g. neuronal distress, comprises detecting levels of S100 beta protein in blood samples and comparing the result to a control

INVENTOR: BARNETT, G; JANIGRO, D ; MAYBERG, M

PRIORITY-DATA: 2001US-0891023 (June 25, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20030170747 A1</u>	September 11, 2003		018	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/542; G01 N 33/567

ABSTRACTED-PUB-NO: US20030170747A

BASIC-ABSTRACT:

NOVELTY - Diagnosis of blood brain barrier permeability comprising detecting levels of S100 beta protein in a blood sample of a subject, and comparing the result to S100 beta protein level of a control, is new. An increase in the level of S100 beta protein is indicative of blood brain barrier permeability.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of treating a patient comprising administering an agent which causes blood brain barrier opening, detecting elevated levels of S100 beta protein in the patient's blood, and administering a therapeutic agent.

USE - For diagnosis of blood brain barrier permeability useful in detecting e.g. neuronal distress (claimed). It is also useful for detecting neurological disorder, e.g. tumors, cancer, degenerative disorders, sensory and motor abnormalities, seizure, infection, immunological disorder, mental disorder, behavioral disorder, and

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.8&ref=7&dbname=PGPB,USPT,USO...> 12/1/04

localized central nervous system (CNS) disease.

ADVANTAGE - The method provides a predictable and reliable monitoring of neurological status of a subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	RMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 10. Document ID: WO 2004069328 A2, US 20030149450 A1

L7: Entry 10 of 15

File: DWPI

Aug 19, 2004

DERWENT-ACC-NO: 2003-801636

DERWENT-WEEK: 200455

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Autonomic response modulating apparatus for treating cardiovascular disorders, has therapeutic delivery device that is positioned near site of hindbrain structure of vertebrate to modulate function of hindbrain

INVENTOR: MAYBERG, M R

PRIORITY-DATA: 2002US-353701P (February 1, 2002), 2003US-0357161 (February 3, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2004069328 A2</u>	August 19, 2004	E	000	A61N000/00
<u>US 20030149450 A1</u>	August 7, 2003		016	A61N001/18

INT-CL (IPC): A61 N 0/00; A61 N 1/18

ABSTRACTED-PUB-NO: US20030149450A

BASIC-ABSTRACT:

NOVELTY - The apparatus has a therapeutic delivery device (26) positioned near a site of a hindbrain structure of a vertebrate (44) to modulate a function of the hindbrain. A controller in communication with the therapeutic delivery device enables the device to deliver the therapy. A sensor is electrically connected to the controller to measure a cardiovascular state of the vertebrate.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of controlling a cardiovascular state of a patient.

USE - Used for modulating autonomic response in treating cardiovascular disorders.

ADVANTAGE - The therapeutic delivery device delivering the therapy and stimulating the cardiovascular response provides a more precise real-time adjustment of a patients cardiovascular state. Therefore the amount of pharmaceutical required, when compared with traditional therapeutic treatments of cardiovascular conditions is eliminated or reduced.

DESCRIPTION OF DRAWING(S) - The drawing shows a sagittal view of a brain with a therapeutic delivery device placed into it.

Cerebral cortex 20

Cerebellum 24

Therapeutic delivery device 26

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	------------

☐ 11. Document ID: US 6326017 B1

L7: Entry 11 of 15

File: DWPI

Dec 4, 2001

DERWENT-ACC-NO: 2002-178583

DERWENT-WEEK: 200223

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for localized delivery of agents e.g. aspirin or heparin to blood vessels for treatment of vascular disorders without systemic effect, uses polymer matrix carrier e.g. polyvinylalcohol

INVENTOR: MAYBERG, M R

PRIORITY-DATA: 1989US-0416671 (October 2, 1989), 1991US-0780614 (October 23, 1991), 1993US-0042461 (April 5, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6326017 B1</u>	December 4, 2001		006	A61F013/00

INT-CL (IPC): A61 F 13/00; A61 K 9/14

ABSTRACTED-PUB-NO: US 6326017B

BASIC-ABSTRACT:

NOVELTY - A method for localized delivery of agents to blood vessels for treatment of vascular disorders without systemic effect, comprises applying a polymer matrix carrier impregnated with agent to the blood vessel.

DETAILED DESCRIPTION - A method for treating vascular disorders comprises applying a polymer matrix, which is permeable to an agent for treatment of a vascular disorder and impregnated with the agent, directly in contact with an external surface of an artery or vein; and covering the polymer matrix with a barrier adapted to restrict the release of agent into tissue adjacent to the artery or vein, so that the agent diffuses from the polymer directly to the external surface of the artery or vein, producing a localized effect on the artery or vein without systemic effect.

ACTIVITY - Thrombolytic; anticoagulant.

11 Rats were anesthetized and the distal common, external and internal carotid arteries were exposed bilaterally in the rat's neck. A 2-French balloon embolectomy catheter was introduced into both external carotid arteries, inflated and advanced to produce consistent endothelial dequamation in the segment of the artery. Additional vessel wall injury was produced by passing a wire along the desquamated luminal surface. Heparin sulfate (600units, 0.03ml) was mixed with polyvinyl alcohol (PVA, 0.06ml) to produce a viscous gel, and immediately applied around the adventitial surface of the de-endothelialized distal left (treated) common carotid artery and surrounded by a Silastic shell to prevent release into adjacent tissue. PVA without heparin was similarly applied to the right (control) common carotid artery. 30 Minutes after application of the PVA, both common carotid arteries were occluded by microclips at the ends of the segment with injured endothelium. After 1 hour of occlusion, the systemic prothrombin time and partial thromboplastin time were

determined from arterial blood drawn from a femoral catheter. Microclips were removed and blood flow established for 5 minutes. Vessels were perfusion-fixed in situ. The common carotid arteries were removed.

Scanning electron microscopy was performed on the luminal surface of control and heparin/PVA-treated desquamated rat common carotid arteries. The control vessel showed an extensive thrombus that completely occluded the lumen. The treated vessel showed complete endothelial desquamation with exposed subendothelial collagen. The luminal surface of the treated vessel was coated with a monolayer of adherent platelets, but no fibrin formation or erythrocyte thrombus was present.

A significant (greater than 20%) intraluminal thrombus was present in all 10 control vessels, 4 of which were completely occluded, whereas significant thrombus was visible in only 1 of 10 treated vessels. The thrombus:lumen ratio was reduced from 60.2 plus or minus 25.8% in control vessels to 4.1 plus or minus 9.6% in treated vessels.

MECHANISM OF ACTION - None given in the source material.

USE - For treating vascular disorders (claimed), e.g. thrombosis, and for surgical clinical conditions (e.g. endarterectomy, large vessel and microvascular anastomosis, cerebral and systemic venous procedures, arteriovenous shunts, angioplasty, and free flaps) and nonsurgical clinical conditions (e.g. deep-vein thrombosis, cardiac valvular disease and arterial stenosis).

ADVANTAGE - The localized delivery reduces or eliminates side effects of an agent (e.g. heparin) that result from its systemic administration, and high concentrations of agent are provided at the site of action.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Summary	Claims	KOMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	---------	--------	------	------------

☐ 12. Document ID: US 5779694 A

L7: Entry 12 of 15

File: DWPI

Jul 14, 1998

DERWENT-ACC-NO: 1998-412893

DERWENT-WEEK: 200128

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Drug delivery for specific locations, e.g. the brain for Parkinson or epileptic conditions - has a magnet and drug carrier with semi-automatically controlled electromagnetic positioner and visualisation system

INVENTOR: GILLIES, G T; GRADY, M S ; HOWARD, M A ; MAYBERG, M ; RITTER, R C

PRIORITY-DATA: 1990US-0463340 (January 10, 1990), 1992US-0904032 (June 25, 1992), 1993US-0096214 (July 19, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 5779694 A</u>	July 14, 1998		016	A61M037/00

INT-CL (IPC): A61 K 9/22;

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 20030170747 A1

Using default format because multiple data bases are involved.

L8: Entry 1 of 1

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170747

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170747 A1

TITLE: Peripheral marker of blood brain barrier permeability

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Janigro, Damir	St. James Parkway	OH	US	
Mayberg, Marc	Chagrin Falls	OH	US	
Barnett, Gene	Gates Mills	OH	US	

US-CL-CURRENT: 435/7.21; 435/7.9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Terms	Documents
Barnett-Gene.IN.	1

Display Format:

[Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 24 of 24 returned.

☐ 1. Document ID: US 6708215 B1

Using default format because multiple data bases are involved.

L9: Entry 1 of 24

File: DWPI

Mar 16, 2004

DERWENT-ACC-NO: 2004-302896

DERWENT-WEEK: 200428

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Outbound customer interaction facilitation method on computer system, involves initiating communication from service provider to user based on trigger event detected related to user activity with respect to retrieved resource

INVENTOR: BARNETT, G ; HINGORANI, S

PRIORITY-DATA: 2000US-0632095 (August 2, 2000), 1998US-0008523 (January 16, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6708215 B1	March 16, 2004		015	G06F013/00

INT-CL (IPC): G06 F 13/00

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 2. Document ID: US 20030170747 A1

L9: Entry 2 of 24

File: DWPI

Sep 11, 2003

DERWENT-ACC-NO: 2004-069019

DERWENT-WEEK: 200410

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detection of blood brain barrier permeability for diagnosing e.g. neuronal distress, comprises detecting levels of S100 beta protein in blood samples and comparing the result to a control

INVENTOR: BARNETT, G ; JANIGRO, D ; MAYBERG, M

PRIORITY-DATA: 2001US-0891023 (June 25, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030170747 A1	September 11, 2003		018	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/542; G01 N 33/567

ABSTRACTED-PUB-NO: US20030170747A

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.10&ref=9&dbname=PGPB,USPT,USO...> 12/1/04

BASIC-ABSTRACT:

NOVELTY - Diagnosis of blood brain barrier permeability comprising detecting levels of S100 beta protein in a blood sample of a subject, and comparing the result to S100 beta protein level of a control, is new. An increase in the level of S100 beta protein is indicative of blood brain barrier permeability.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of treating a patient comprising administering an agent which causes blood brain barrier opening, detecting elevated levels of S100 beta protein in the patient's blood, and administering a therapeutic agent.

USE - For diagnosis of blood brain barrier permeability useful in detecting e.g. neuronal distress (claimed). It is also useful for detecting neurological disorder, e.g. tumors, cancer, degenerative disorders, sensory and motor abnormalities, seizure, infection, immunological disorder, mental disorder, behavioral disorder, and localized central nervous system (CNS) disease.

ADVANTAGE - The method provides a predictable and reliable monitoring of neurological status of a subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 3. Document ID: EP 1472465 A1, WO 2003067102 A1, AU 2003202079 A1

L9: Entry 3 of 24

File: DWPI

Nov 3, 2004

DERWENT-ACC-NO: 2003-646329

DERWENT-WEEK: 200472

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Shearable fastener, for securing electrical conductors to electrical connectors in form of bolt, has several weakened portions on the shank that shear on application of sufficient torque

INVENTOR: BARNETT, G

PRIORITY-DATA: 2002GB-0002710 (February 6, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 1472465 A1</u>	November 3, 2004	E	000	F16B031/02
<u>WO 2003067102 A1</u>	August 14, 2003	E	016	F16B031/02
<u>AU 2003202079 A1</u>	September 2, 2003		000	F16B031/02

INT-CL (IPC): F16 B 31/02; F16 B 39/286; F16 B 39/2866; F16 B 39/30; F16 B 39/300;
H01 R 4/30; H01 R 4/300

ABSTRACTED-PUB-NO: WO2003067102A

BASIC-ABSTRACT:

NOVELTY - Shearable fastener includes a threaded shank (10) that engages with a threaded bore and a head portion (12) that engages with a drive tool. The shank is formed with a series of axially separated weakenings defining a series of shear planes. Weakenings are formed so that the applied torque necessary to cause the shank to shear increases progressively from shear plane furthest from the head portion to the shear plane nearest the head portion.

DETAILED DESCRIPTION - The weakenings comprise holes, grooves or slits formed in the

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.10&ref=9&dbname=PGPB,USPT,USO...> 12/1/04

shank. The radius at the bottom of the holes, grooves or slits is varied to produce or contribute to the increase in shear torque.

USE - For securing electrical conductors to electrical connectors.

ADVANTAGE - Allows single type of shearable fastener to be used where different lengths are required.

DESCRIPTION OF DRAWING(S) - The drawing shows shearing of the shearable fastener following continued application of torque to the fastener

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 4. Document ID: AU 2002222265 A1, WO 200253325 A1, EP 1353781 A1

L9: Entry 4 of 24

File: DWPI

Jul 16, 2002

DERWENT-ACC-NO: 2002-537936

DERWENT-WEEK: 200427

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Driving tool for shearing fasteners such as bolts in electrical connectors for connecting electrical cables using sockets formed for drive tool and bolt

INVENTOR: BARNETT, G; HOLLICK, D J

PRIORITY-DATA: 2001GB-0000393 (January 6, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002222265 A1</u>	July 16, 2002		000	B25B023/14
<u>WO 200253325 A1</u>	July 11, 2002	E	016	B25B023/14
<u>EP 1353781 A1</u>	October 22, 2003	E	000	B25B023/14

INT-CL (IPC):

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 24 of 24 returned.

☐ 1. Document ID: US 6708215 B1

Using default format because multiple data bases are involved.

L9: Entry 1 of 24

File: DWPI

Mar 16, 2004

DERWENT-ACC-NO: 2004-302896

DERWENT-WEEK: 200428

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Outbound customer interaction facilitation method on computer system, involves initiating communication from service provider to user based on trigger event detected related to user activity with respect to retrieved resource

INVENTOR: BARNETT, G ; HINGORANI, S

PRIORITY-DATA: 2000US-0632095 (August 2, 2000), 1998US-0008523 (January 16, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6708215 B1</u>	March 16, 2004		015	G06F013/00

INT-CL (IPC): G06 F 13/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	------	----------

☐ 2. Document ID: US 20030170747 A1

L9: Entry 2 of 24

File: DWPI

Sep 11, 2003

DERWENT-ACC-NO: 2004-069019

DERWENT-WEEK: 200410

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Detection of blood brain barrier permeability for diagnosing e.g. neuronal distress, comprises detecting levels of S100 beta protein in blood samples and comparing the result to a control

INVENTOR: BARNETT, G ; JANIGRO, D ; MAYBERG, M

PRIORITY-DATA: 2001US-0891023 (June 25, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20030170747 A1</u>	September 11, 2003		018	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/542; G01 N 33/567

ABSTRACTED-PUB-NO: US20030170747A

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.10&ref=9&dbname=PGPB,USPT,USO...> 12/1/04

BASIC-ABSTRACT:

NOVELTY - Diagnosis of blood brain barrier permeability comprising detecting levels of S100 beta protein in a blood sample of a subject, and comparing the result to S100 beta protein level of a control, is new. An increase in the level of S100 beta protein is indicative of blood brain barrier permeability.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a method of treating a patient comprising administering an agent which causes blood brain barrier opening, detecting elevated levels of S100 beta protein in the patient's blood, and administering a therapeutic agent.

USE - For diagnosis of blood brain barrier permeability useful in detecting e.g. neuronal distress (claimed). It is also useful for detecting neurological disorder, e.g. tumors, cancer, degenerative disorders, sensory and motor abnormalities, seizure, infection, immunological disorder, mental disorder, behavioral disorder, and localized central nervous system (CNS) disease.

ADVANTAGE - The method provides a predictable and reliable monitoring of neurological status of a subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	-----	----------

☐ 3. Document ID: EP 1472465 A1, WO 2003067102 A1, AU 2003202079 A1

L9: Entry 3 of 24

File: DWPI

Nov 3, 2004

DERWENT-ACC-NO: 2003-646329

DERWENT-WEEK: 200472

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Shearable fastener, for securing electrical conductors to electrical connectors in form of bolt, has several weakened portions on the shank that shear on application of sufficient torque

INVENTOR: BARNETT, G

PRIORITY-DATA: 2002GB-0002710 (February 6, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 1472465 A1</u>	November 3, 2004	E	000	F16B031/02
<u>WO 2003067102 A1</u>	August 14, 2003	E	016	F16B031/02
<u>AU 2003202079 A1</u>	September 2, 2003		000	F16B031/02

INT-CL (IPC): F16 B 31/02; F16 B 39/286; F16 B 39/2866; F16 B 39/30; F16 B 39/300;
H01 R 4/30; H01 R 4/300

ABSTRACTED-PUB-NO: WO2003067102A

BASIC-ABSTRACT:

NOVELTY - Shearable fastener includes a threaded shank (10) that engages with a threaded bore and a head portion (12) that engages with a drive tool. The shank is formed with a series of axially separated weakenings defining a series of shear planes. Weakenings are formed so that the applied torque necessary to cause the shank to shear increases progressively from shear plane furthest from the head portion to the shear plane nearest the head portion.

DETAILED DESCRIPTION - The weakenings comprise holes, grooves or slits formed in the

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.10&ref=9&dbname=PGPB,USPT,USO...> 12/1/04

shank. The radius at the bottom of the holes, grooves or slits is varied to produce or contribute to the increase in shear torque.

USE - For securing electrical conductors to electrical connectors.

ADVANTAGE - Allows single type of shearable fastener to be used where different lengths are required.

DESCRIPTION OF DRAWING(S) - The drawing shows shearing of the shearable fastener following continued application of torque to the fastener

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	------	----------

☐ 4. Document ID: AU 2002222265 A1, WO 200253325 A1, EP 1353781 A1

L9: Entry 4 of 24

File: DWPI

Jul 16, 2002

DERWENT-ACC-NO: 2002-537936

DERWENT-WEEK: 200427

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Driving tool for shearing fasteners such as bolts in electrical connectors for connecting electrical cables using sockets formed for drive tool and bolt

INVENTOR: BARNETT, G ; HOLLICK, D J

PRIORITY-DATA: 2001GB-0000393 (January 6, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2002222265 A1</u>	July 16, 2002		000	B25B023/14
<u>WO 200253325 A1</u>	July 11, 2002	E	016	B25B023/14
<u>EP 1353781 A1</u>	October 22, 2003	E	000	B25B023/14

INT-CL (IPC): B25 B 23/14

ABSTRACTED-PUB-NO: WO 200253325A

BASIC-ABSTRACT:

NOVELTY - A drive unit comprises upper and lower parts (11,12) and a socket (13) for a half-inch square drive tool formed at the upper part, while a lower socket (14) can receive a bolt head. The retaining assembly comprises a cylindrical body (23) with a flange (24) and extending through a friction disc (22) and a friction washer (25). The drive unit is connected to a bolt in an electrical connector and is rotated by a drive tool fitted into the socket (13).

USE - Mechanical and electrical connection of electrical cables to electrical connectors.

DESCRIPTION OF DRAWING(S) - The drawing shows the drive unit

Sockets 13,14

Body 23

Friction disc 22

Friction washer 25

□ 5. Document ID: WO 200218803 A1, AU 200179969 A, EP 1334281 A1

L9: Entry 5 of 24

File: DWPI

Mar 7, 2002

DERWENT-ACC-NO: 2002-269585

DERWENT-WEEK: 200464

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: A shearable bolt for mechanical and electrical connection of electrical cables to connectors includes a threaded shank connected by a narrow neck to a hexagonal head, and a central hexagonal blind bore filled with a tough material

INVENTOR: BARNETT, G ; HOLLICK, D J

PRIORITY-DATA: 2000GB-0021277 (August 31, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 200218803 A1</u>	March 7, 2002	E	017	F16B031/02
<u>AU 200179969 A</u>	March 13, 2002		000	F16B031/02
<u>EP 1334281 A1</u>	August 13, 2003	E	000	F16B031/02

INT-CL (IPC): F16 B 31/02

ABSTRACTED-PUB-NO: WO 200218803A

BASIC-ABSTRACT:

NOVELTY - A shearable bolt (10) has an externally threaded shank (11) connected by a narrow neck (12) to a hexagonal head (13). A central, hexagonal blind bore (14) extends through the head, past the neck and a short distance into the shank. The bore is filled with a plug (15) of tough elastomeric or soft material. When a torque applied to the head exceeds a shearing torque, the neck yields quite suddenly, but torsion of the plug retards acceleration and restrains further movement.

USE - The shearable bolt is used for mechanical and electrical connection of electrical cables to connectors.

ADVANTAGE - The shearable bolt avoids damage to muscles and other tissues of a person's arm, or impact with nearby obstructions at the point of sudden yielding of the neck. Risk of injury to the user is reduced.

DESCRIPTION OF DRAWING(S) - The figure shows a side view, in section, of a shearable bolt.

Shearable bolt 10

Threaded shank 11

Narrow neck 12

Hexagonal head 13

Central, hexagonal blind bore 14

Tough elastomeric or soft material 15

☐ 6. Document ID: US 20030050884 A1, WO 200173654 A1, AU 200149407 A

L9: Entry 6 of 24

File: DWPI

Mar 13, 2003

DERWENT-ACC-NO: 2001-626288

DERWENT-WEEK: 200321

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Transaction security management method for financial assets, involves establishing business platform and producing selling agreements using receivables record for each business entity

INVENTOR: BARNETT, G

PRIORITY-DATA: 2000US-191901P (March 24, 2000), 2002US-0239773 (September 24, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030050884 A1	March 13, 2003		000	G06F017/60
WO 200173654 A1	October 4, 2001	E	041	G06F017/60
AU 200149407 A	October 8, 2001		000	G06F017/60

INT-CL (IPC): G06 F 17/60

ABSTRACTED-PUB-NO: WO 200173654A

BASIC-ABSTRACT:

NOVELTY - A business entity is chartered to acquire or finance receivables of members belonging to a group of competing independent buyer/obligator companies. Offers are extended from business entity to holders of receivables. Receivable record representing payment details is output by the entity. Based on the record, business platform is established and agreement for selling companies is produced. The selling is initiated using the receivables.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for computer system.

USE - For managing transaction and financial assets security in financial applications and other business services.

ADVANTAGE - Enables finance companies to finance for assets more efficiently by offering aggregated loans, independently. Improves financial debt management, due to co-operative consultations between entities and obligor companies.

DESCRIPTION OF DRAWING(S) - The figure shows the block diagram of parties and cash flows in a transaction.

☐ 7. Document ID: US 6699062 B1, GB 2356296 A, WO 200135495 A1, AU 200111633 A, BR 200015452 A, EP 1228553 A1, EP 1228553 B1, GB 2356296 B, AU 760318 B, DE 60002753 E, ES 2197122 T3

L9: Entry 7 of 24

File: DWPI

Mar 2, 2004

DERWENT-ACC-NO: 2001-411456
DERWENT-WEEK: 200417
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Insulation piercing fastener for electrical conductor has cylindrical shank that has diametrically opposed interruptions in wall of axial bore

INVENTOR: BARNETT, G ; HOLLICK, D J ; KIRKMAN, M D

PRIORITY-DATA: 1999GB-0026519 (November 10, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6699062 B1</u>	March 2, 2004		000	H01R011/20
<u>GB 2356296 A</u>	May 16, 2001		016	H01R004/24
<u>WO 200135495 A1</u>	May 17, 2001	E	000	H01R004/24
<u>AU 200111633 A</u>	June 6, 2001		000	H01R004/24
<u>BR 200015452 A</u>	July 9, 2002		000	H01R004/24
<u>EP 1228553 A1</u>	August 7, 2002	E	000	H01R004/24
<u>EP 1228553 B1</u>	May 14, 2003	E	000	H01R004/24
<u>GB 2356296 B</u>	May 28, 2003		000	H01R004/24
<u>AU 760318 B</u>	May 15, 2003		000	H01R004/24
<u>DE 60002753 E</u>	June 18, 2003		000	H01R004/24
<u>ES 2197122 T3</u>	January 1, 2004		000	H01R004/24

INT-CL (IPC): H01 R 4/24; H01 R 4/26; H01 R 11/20

ABSTRACTED-PUB-NO: GB 2356296A

BASIC-ABSTRACT:

NOVELTY - The bore (2) is extended for full length of cylindrical and external threaded shank. The bore has hexagonal cross section at upper end and circular cross section at lower end. The diametrically opposed interruptions are formed in the wall of the bore. The diameter of shank is set as 6-30 mm. The width and depth of interruption is set as 0.5-5 mm and 0.5-20 mm respectively.

DETAILED DESCRIPTION - The shank is made to contact the connector. An INDEPENDENT CLAIM is also included for electrical connector.

USE - For establishing connection between conductor and fastener.

ADVANTAGE - Enables efficient usage in conductors having solid cover, and plastic insulation and conductors having stranded cores and mineral oil impregnated paper insulation. Maintains excellent electrical contact state by increasing contact area between tip of fastener and conductor. Simplifies manufacture of shank.

DESCRIPTION OF DRAWING(S) - The figure shows the perspective and schematic view of fastener.

Bore 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	MMCC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	------	----------

☐ 8. Document ID: ES 2204499 T3, WO 200046878 A1, AU 200023066 A, EP 1161778 A1, CN 1339185 A, US 6402544 B1, ZA 200106957 A, AU 755568 B, EP 1161778 B1, DE 60004333 E

DERWENT-ACC-NO: 2000-579004

DERWENT-WEEK: 200431

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Electrical connector for connecting service cable to line main cable, shears spindle at position between shroud opening and engagement tip of connecting bolt to withdraw cap and residual portion of spindle

INVENTOR: BARNETT, G

PRIORITY-DATA: 1999GB-0002358 (February 4, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>ES 2204499 T3</u>	May 1, 2004		000	H01R004/24
<u>WO 200046878 A1</u>	August 10, 2000	E	017	H01R004/24
<u>AU 200023066 A</u>	August 25, 2000		000	
<u>EP 1161778 A1</u>	December 12, 2001	E	000	H01R004/24
<u>CN 1339185 A</u>	March 6, 2002		000	H01R004/24
<u>US 6402544 B1</u>	June 11, 2002		000	H01R004/24
<u>ZA 200106957 A</u>	October 30, 2002		024	H01R000/00
<u>AU 755568 B</u>	December 19, 2002		000	H01R004/24
<u>EP 1161778 B1</u>	August 6, 2003	E	000	H01R004/24
<u>DE 60004333 E</u>	September 11, 2003		000	H01R004/24

INT-CL (IPC): H01 R 0/00; H01 R 4/24

ABSTRACTED-PUB-NO: US 6402544B

BASIC-ABSTRACT:

NOVELTY - Connector (1) with insulating plastic shroud (12), has threaded bore (4) to engage bolt (5) connected to conductor (3) in socket. Drive spindle (7) extending via shroud opening to rotary insulator cap (10) shears at position between opening and contact point of spindle and bolt, when preset torque is applied to spindle to withdraw cap and residual portion (8) from opening which is closed after withdrawal.

DETAILED DESCRIPTION - The plastic shroud is formed with number of leaves which are resiliently deformed by the drive spindle, which relax to cover the opening of the threaded bore when the drive spindle shears and is removed with the cap. The connector is made of electrically conducting material like aluminum or brass and the cap is made of an insulating material.

USE - For connecting service cable to existing line main cables.

ADVANTAGE - Reduces the risk of exposure of an operator to electrically live surfaces during the fitting of the connector, even to an electrically live conductor. After installation, the insulated mechanism bulk can be removed without exposing live metalwork, thus reducing the volume of encapsulant required without compromising the safety of installer. Also it is simple to use, and of compact design.

DESCRIPTION OF DRAWING(S) - The figure shows the fragmentary side view in section of an electrical connector.

Connector 1

Conductor 3

Threaded bore 4

Bolt 5

Drive spindle 7

Residual portion 8

Rotary insulator cap 10

Insulating plastic shroud 12

ABSTRACTED-PUB-NO:

WO 200046878A EQUIVALENT-ABSTRACTS:

NOVELTY - Connector (1) with insulating plastic shroud (12), has threaded bore (4) to engage bolt (5) connected to conductor (3) in socket. Drive spindle (7) extending via shroud opening to rotary insulator cap (10) shears at position between opening and contact point of spindle and bolt, when preset torque is applied to spindle to withdraw cap and residual portion (8) from opening which is closed after withdrawal.

DETAILED DESCRIPTION - The plastic shroud is formed with number of leaves which are resiliently deformed by the drive spindle, which relax to cover the opening of the threaded bore when the drive spindle shears and is removed with the cap. The connector is made of electrically conducting material like aluminum or brass and the cap is made of an insulating material.

USE - For connecting service cable to existing line main cables.

ADVANTAGE - Reduces the risk of exposure of an operator to electrically live surfaces during the fitting of the connector, even to an electrically live conductor. After installation, the insulated mechanism bulk can be removed without exposing live metalwork, thus reducing the volume of encapsulant required without compromising the safety of installer. Also it is simple to use, and of compact design.

DESCRIPTION OF DRAWING(S) - The figure shows the fragmentary side view in section of an electrical connector.

Connector 1

Conductor 3

Threaded bore 4

Bolt 5

Drive spindle 7

Residual portion 8

Rotary insulator cap 10

Insulating plastic shroud 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	KUMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	------	------------

☐ 9. Document ID: GB 2346490 B, GB 2346490 A

L9: Entry 9 of 24

File: DWPI

Oct 9, 2002

DERWENT-ACC-NO: 2000-551337
DERWENT-WEEK: 200267
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Electrical connector for live electrical connector uses socket for electrical conductor with body with electrically insulating shroud and threaded bore for engaging bolt which engages with conductor inserted into socket

INVENTOR: BARNETT, G

PRIORITY-DATA: 1999GB-0000235 (February 4, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>GB 2346490 B</u>	October 9, 2002		000	H01R004/70
<u>GB 2346490 A</u>	August 9, 2000		015	H01R004/70

INT-CL (IPC): H01 R 4/24; H01 R 4/36; H01 R 4/70

ABSTRACTED-PUB-NO: GB 2346490A
BASIC-ABSTRACT:

NOVELTY - Connector has a body with a socket for an electrical conductor, an electrically insulating shroud and a threaded bore for engaging a connecting bolt (5) which engages with the conductor in the socket using a drive member engaged with the bolt and extending through an opening in the insulating shroud to a rotatable electrically insulating cap. The drive shears when a preset torque is applied to it.

USE - As a connector for a live electrical connector.

ADVANTAGE - Provides for satisfactory insulation during and after installation and associated mechanisms are minimal size decreasing encapsulation costs.

DESCRIPTION OF DRAWING(S) - The drawing shows a fragmentary side view in section of the electrical connector in the first stage of use.

the bolt engaging in the threaded bore 5
ABSTRACTED-PUB-NO:

GB 2346490B EQUIVALENT-ABSTRACTS:

NOVELTY - Connector has a body with a socket for an electrical conductor, an electrically insulating shroud and a threaded bore for engaging a connecting bolt (5) which engages with the conductor in the socket using a drive member engaged with the bolt and extending through an opening in the insulating shroud to a rotatable electrically insulating cap. The drive shears when a preset torque is applied to it.

USE - As a connector for a live electrical connector.

ADVANTAGE - Provides for satisfactory insulation during and after installation and associated mechanisms are minimal size decreasing encapsulation costs.

DESCRIPTION OF DRAWING(S) - The drawing shows a fragmentary side view in section of the electrical connector in the first stage of use.

the bolt engaging in the threaded bore 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	RMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	-----	----------

☐ 10. Document ID: US 5859964 A

L9: Entry 10 of 24

File: DWPI

Jan 12, 1999

DERWENT-ACC-NO: 1999-120240

DERWENT-WEEK: 199910

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Processing tool fault detection system in semiconductor wafer fabrication - provides sample of process parameter signals acquired during operation of processing tool to model and receives generated prediction error based on which fault in processing tool is detected

INVENTOR: BARNETT, G ; CHENG, Y ; GREIG, R M ; WANG, Q

PRIORITY-DATA: 1996US-0736919 (October 25, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5859964 A	January 12, 1999		027	G06F011/00

INT-CL (IPC): G06 F 11/00

ABSTRACTED-PUB-NO: US 5859964A

BASIC-ABSTRACT:

The system includes a receiving unit which receives process event signals (16) generated by a processing tool of process equipment. The process event signals comprise one event from group comprising wafer start, wafer ends, new lot, new recipe and alarm. The data acquisition device acquires sample of process parameter signals (18) during operation of the processing tool. The model (60a) uses reference database (58) to generate prediction error in response to acquired sample of process parameter signals. The model also receives recipe identifier specified via user input and generates corresponding prediction error.

The model is chosen from group containing universal process model, a principal component analysis model and neural network. A data viewer (64) displays the acquired sample. A report browser (62) displays prediction error. A fault detector (50) is provided in communication with the model (60a) for receiving sample from the data acquisition device and process event signals. The fault detector provides sample to the model and receive prediction error generated by the model based on which fault in process tool is detected.

ADVANTAGE - Avoids wafer scrap and improves mean time between failures. Uses process event information in combination with process parameter signal samples to perform improved fault detection. Facilitates modular selection of models for particular fabrication process.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	RWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	------	----------

☐ 11. Document ID: WO 9737379 A1

L9: Entry 11 of 24

File: DWPI

Oct 9, 1997

DERWENT-ACC-NO: 1997-503359

DERWENT-WEEK: 199746

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: In-situ sensor for measuring deposition of etching chamber walls - has laser source and detector located external to etch chamber, with detector sensing intensity of laser beam reflected from inner wall of etching chamber

INVENTOR: BARNETT, G ; TOPRAE, A J

PRIORITY-DATA: 1996US-0627861 (April 3, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9737379 A1</u>	October 9, 1997	E	017	H01L021/66

INT-CL (IPC): H01 L 21/66

ABSTRACTED-PUB-NO: WO 9737379A

BASIC-ABSTRACT:

The sensor comprises a laser source (122) positioned external to the etching chamber (110) for directing a laser beam (126) toward and through an etching chamber window to a point (130) at an inner wall (114) of the etching chamber. A laser detector (124) is positioned external to the etching chamber and directed toward the etching chamber window to the point at the inner wall of the etching chamber for detecting an intensity of the laser beam reflected from the interior surface of the etching chamber. A recorder (160) is coupled to the laser detector for recording the intensity of the reflected laser beam (131) over time.

A chopper (140) is positioned between the laser source and the etching chamber along the directed beam for interrupting the laser beam at regular interval. The system may also include a semi-transparent mirror (142) that is positioned between the laser source and the etch chamber along the directed beam axis for deflecting a portion of the energy of the laser beam a controlled reflection angle (144) so that a deflected beam (146) is deflected to a calibration detector (150).

USE - In integrated circuit manufacture.

ADVANTAGE - Mis-processing of semiconductor wafers due to substandard excitation of plasma in etch chamber as result of deposits on chamber walls is avoided. Wafer contamination due to particulates is prevented. Stop etch problems are avoided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Publications	Claims	RWMD	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------------	--------	------	----------

☐ 12. Document ID: WO 9501585 A1, US 5653063 A, AU 9470039 A, GB 2289135 A, EP 706675 A1, JP 09502537 W

L9: Entry 12 of 24

File: DWPI

Jan 12, 1995

DERWENT-ACC-NO: 1995-061111

DERWENT-WEEK: 199737

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Photographic booth for use in public locations - has housing for photographic equipment plus chamber having folding seat and arcuate door, for access of user, controlled in response to detected passage of door

INVENTOR: BARNETT, G ; TEMPLE, A

PRIORITY-DATA: 1994GB-0007172 (April 12, 1994), 1993GB-0013454 (June 30, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9501585 A1	January 12, 1995	E	016	G03B017/53
US 5653063 A	August 5, 1997		008	G03B017/53
AU 9470039 A	January 24, 1995		000	G03B017/53
GB 2289135 A	November 8, 1995		015	G03B017/53
EP 706675 A1	April 17, 1996	E	016	G03B017/53
JP 09502537 W	March 11, 1997		017	G03B017/53

INT-CL (IPC): G03 B 17/53

ABSTRACTED-PUB-NO: US 5653063A

BASIC-ABSTRACT:

The booth (2) includes an upright housing (2) for photographic equipment abutting a circular chamber (4). The chamber has an opening on the opposite side to the housing. A ramp adjacent the opening leads up to the floor of the chamber and an arcuate door (6) is provided to open and close the opening.

A seat is provided within the chamber which may be folded down to enable users to be seated during photography. Four circumferentially spaced detectors determine the position of the trailing edge of the door and are used to control the speed and direction of the motor which is initially energised by insertion of a coin. A photodetector may be mounted on the door edge to stop its movement on detection of obstructions.

USE/ADVANTAGE - Is designed for taking passport-type photographs. Used folded seat enables access to wheelchairs and arcuate door provides more privacy.

ABSTRACTED-PUB-NO:

WO 9501585A EQUIVALENT-ABSTRACTS:

A photographic booth comprising:

a chamber to be occupied by a user and defining an opening on one side thereof providing access to the user;

a photographic apparatus mounted on a side opposite said opening and directed into the chamber; and

a seat located between the apparatus and the opening for use by the user.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	-----	----------

☐ 13. Document ID: GB 2279462 A, US 5653063 A, WO 9501586 A1, AU 9470776 A, EP 657041 A1

L9: Entry 13 of 24

File: DWPI

Jan 4, 1995

DERWENT-ACC-NO: 1995-054321

DERWENT-WEEK: 199737

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Photographic booth for able-bodied or disabled users - includes rotary doors, screens, blinds or shutters for access, security or background use, with motorised drive

INVENTOR: TEMPLE, A; BARNETT, G

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.10&ref=9&dbname=PGPB,USPT,USO...> 12/1/04

PRIORITY-DATA: 1993GB-0013454 (June 30, 1993), 1994GB-0007172 (April 12, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
GB 2279462 A	January 4, 1995		010	G03B017/53
US 5653063 A	August 5, 1997		008	G03B017/53
WO 9501586 A1	January 12, 1995	E	012	G03B017/53
AU 9470776 A	January 24, 1995		000	G03B017/53
EP 657041 A1	June 14, 1995	E	010	G03B017/53

INT-CL (IPC): G03 B 17/53

ABSTRACTED-PUB-NO: GB 2279462A
BASIC-ABSTRACT:

The booth is accessible by wheelchair users. Activation of the door is via compressed air and a spring housed in the roof. The door foot rests in a nylon brush enclosed channel.

Being secure as when inoperative, the doors rotate, concealing both the photographic equipment and the cash box. Should the occupant violate the integrity of either photographic equipment or coin box, the booth will lock and alarm will sound.

USE - Photo-booth which affords easy access for both able-bodied and disabled users by way of motorised doors.
ABSTRACTED-PUB-NO:

US 5653063A EQUIVALENT-ABSTRACTS:

A photographic booth comprising:

a chamber to be occupied by a user and defining an opening on one side thereof providing access to the user;

a photographic apparatus mounted on a side opposite said opening and directed into the chamber; and

a seat located between the apparatus and the opening for use by the user.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no		Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----	--	--------	------	------------

☐ 14. Document ID: US 4960592 A

L9: Entry 14 of 24

File: DWPI

Oct 2, 1990

DERWENT-ACC-NO: 1990-319790
DERWENT-WEEK: 199042
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Anhydrous skin treatment compsn. - comprising 10-90 per cent lanolin and 90-100 per cent lanolin oil is hypoallergenic and is useful for treating dry skin

INVENTOR: BARNETT, G ; HAGEN, R

PRIORITY-DATA: 1989US-0338673 (April 17, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 4960592 A	October 2, 1990		000	

INT-CL (IPC): A61K 7/48; A61K 35/36

ABSTRACTED-PUB-NO: US 4960592A
BASIC-ABSTRACT:

Anhydrous skin treatment compsn. comprises (by wt.) 10-90 % of lanolin (I), and 90-10 % of lanolin oil (II).

Pref. compsns. comprise (by wt.) 50-90 % esp. ca 75% (I); and 50-10 % esp. ca 25% (II). The pref. compsns. are hypoallergenic.

(II) (ca 25%) was added to (I) (ca 75%) at e.g. 50 deg.C, and the blend was cooled to room temp.

ADVANTAGE - The anhydrous, lanolin-based skin treatment, emollient compsn. is aesthetically acceptable, is hypoallergenic, and is useful for the treatment of dry skin.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no		Claims	MMCC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--	--------	------	----------

☐ 15. Document ID: DE 3941524 A, DE 3941524 C2, FR 2640647 A, GB 2229194 A, GB 2229194 B, IT 1238351 B, JP 02217431 A, US 4964920 A

L9: Entry 15 of 24

File: DWPI

Jun 21, 1990

DERWENT-ACC-NO: 1990-194598
DERWENT-WEEK: 199026
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Soln. for removing masking coating of tin, lead, or tin-lead alloy - from copper base using aq. soln. of nitric acid, iron nitrate and anthranile acid to reduce degree of attack on copper

INVENTOR: BARNETT, G ; JACKSON, B

PRIORITY-DATA: 1988GB-0029253 (December 15, 1988), 1989GB-0028313 (December 14, 1989), 1989US-0451054 (December 15, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 3941524 A	June 21, 1990		000	
DE 3941524 C2	October 7, 1993		006	C23F001/44
FR 2640647 A	June 22, 1990		000	
GB 2229194 A	September 19, 1990		000	
GB 2229194 B	May 5, 1993		000	C23F001/18
IT 1238351 B	July 13, 1993		000	C22B000/00
JP 02217431 A	August 30, 1990		000	
US 4964920 A	October 23, 1990		000	

INT-CL (IPC): C09K 13/06; C22B 15/14; C23F 1/18; C23F 1/44; C23F 4/00; C23G 1/10; C23G 5/00; H05K 3/26

ABSTRACTED-PUB-NO: DE 3941524A

BASIC-ABSTRACT:

Compsn. used to remove a coating of Sn, Pb or Sn-Pb alloy from a Cu substrate contains nitric acid, iron nitrate and anthranile acid.

USE/ADVANTAGE - To remove a masking layer applied to a Cu substrate prior to preferentially etching. The substrate is pref. a conductor plate. The addn. of anthranile acid reduces the deg. of attack on the Cu substrate.

ABSTRACTED-PUB-NO:

DE 3941524C EQUIVALENT-ABSTRACTS:

A layer of a metal from the gp. Sn, Pb and Sn/Pb alloy is removed from a Cu, or Cu alloy substrate, partic. the solder film is removed from a circuit board, by an aq. soln. of 100-300 ml/l HNO₃ measured as 69 wt.% aq. HNO₃ soln., 30-140 g/l Fe (III) nitrate, in the form of (Fe(NO₃)₃·9H₂O), and 1-30 g/l anthranilic acid. A tenside may be added.

ADVANTAGE - Removes solder without damaging the substrate.

GB 2229194B

A composition for removing a layer of a metal which is tin, lead, tin/copper or a tin/lead alloy from a copper substrate, the composition comprising an aqueous solution of nitric acid, ferric nitrate and anthranilic acid.

US 4964920A

Selective etchant compsn. for removing layers of Sn, Pb or Sn/Pb alloy from a copper substrate comprises an aq. soln. contg.

HNO₃ (69wt.%; 100-300 cm³, diluted to 1 dm³) and Fe(NO₃)₃ · 9H₂O (about 30-140 g/dm³) as etchants; and also anthranilic acid (about 1-30 g/dm³) to inhibit the dissolution of Cu, and pref. surfactants, e.g., cocoamine and ethoxylated fatty alcohols (each about 0.1-5.0 g/dm³). USE - The prods. remove solder from printed board circuits without damage to the copper circuitry.

(5pp)

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	COMM	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	------	----------

☐ 16. Document ID: GB 2198705 A, GB 2198705 B

L9: Entry 16 of 24

File: DWPI

Jun 22, 1988

DERWENT-ACC-NO: 1988-169721

DERWENT-WEEK: 198825

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Display-sales package of window type - has ends of flap forming wings which distort and hook behind board when flap is pushed through slit

INVENTOR: BARNETT, G

PRIORITY-DATA: 1986GB-0027011 (November 12, 1986), 1987GB-0026501 (November 12, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
GB 2198705 A	June 22, 1988		009	

INT-CL (IPC): B65D 33/14; B65D 73/00

ABSTRACTED-PUB-NO: GB 2198705A
BASIC-ABSTRACT:

The display-sales package has a transparent bag (10) to which is secured a saddle header (11). The rear side of this has a flap (17) cut from it, remaining attached e.g. along the fold line of the header, although with slits (18,19,21) or weaknesses.

The ends of the flap form wings (20). When the flap is pushed through a slit with skew ends in a mounting board, the wings distort and then revert to hook behind the board, thus holding the package. The latter can be removed by pulling, which tears off the flap. The front side of the header pref. has an Euro-hole (13).

USE - Bag or package with transparent window and suspension device attached to upper edge.

ABSTRACTED-PUB-NO:

GB 2198705B EQUIVALENT-ABSTRACTS:

A package comprising a bag or envelope to hold one or more objects for sale, and a suspension device for the bag comprises a folded sheet or card having two portions connected by a fold line remote from the bag or envelope, the portions being stapled or otherwise attached to the bag, wherein a flap is cut from one portion but remains attached to the card along a weakened part of the fold line, the flap extending beyond each end of said weakened part and thereby having wings to allow the flap to be inserted through a slit in a mounting board, to be then retained by the wings, and to be subsequently removed from the board by tearing along said weakened part.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	-----	------------

☐ 17. Document ID: GB 2192583 A, GB 2192583 B

L9: Entry 17 of 24

File: DWPI

Jan 20, 1988

DERWENT-ACC-NO: 1988-016298

DERWENT-WEEK: 198803

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Sheet with several gift cards - has weakness lines between cards, with fold lines incorporated for compactness

INVENTOR: BARNETT, G

PRIORITY-DATA: 1986GB-0014996 (June 19, 1986), 1987GB-0014417 (June 19, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>GB 2192583 A</u>	January 20, 1988		000	
<u>GB 2192583 B</u>	March 14, 1990		000	

INT-CL (IPC): B42D 15/02

ABSTRACTED-PUB-NO: GB 2192583A
BASIC-ABSTRACT:

The sheet is formed with lines of weakness in grid fashion so that individual cards can be manually detached and folded. The complete sheet has a foldability, using some of the lines, enabling one side of the folded sheet to display faces only of individual cards. The sheet folded in this manner may be transparently packaged for display and sale purposes.

When the sheet is so folded, the face of at least one card may overlies the back of another card whose face is then presented alongside the face of the one card. The sheet will normally be printed on one side only but at least a portion of the sheet may be folded to triple the initial thickness and this will enable any initially-spaced faces of the cards to be brought close together.

ADVANTAGE - The cards are arranged so that a variety can be visible to the buyer in a larger than usual package.

ABSTRACTED-PUB-NO:

GB 2192583B EQUIVALENT-ABSTRACTS:

A multi-card sheet comprising a plurality of cards each with portions separated by a fold line and a face on one said portion, wherein the sheet has the faces all on one side and is formed with lines of weakness in grid fashion so that individual cards can be manually detached and folded, the complete sheet having a foldability, using some of said lines, enabling one side of the folded sheet to display faces only of individual cards.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	------	----------

☐ 18. Document ID: WO 8300487 A, AU 8287399 A, DE 3248945 T, JP 58501232 W, JP 92038762 B, US 4481306 A

L9: Entry 18 of 24

File: DWPI

Feb 17, 1983

DERWENT-ACC-NO: 1983-20000K

DERWENT-WEEK: 198308

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Radiation grafted fluoro:polymer useful in permselective membranes - mfd. by grafting (non) functional monomers onto per:halogenated fluorine-contg. polymeric substrate

INVENTOR: BARNETT, G ; MARKUS, M

PRIORITY-DATA: 1981AU-0000111 (August 7, 1981)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 8300487 A</u>	February 17, 1983	E	022	
<u>AU 8287399 A</u>	February 22, 1983		000	
<u>DE 3248945 T</u>	November 3, 1983		000	
<u>JP 58501232 W</u>	July 28, 1983		000	
<u>JP 92038762 B</u>	June 25, 1992		007	C08F259/08
<u>US 4481306 A</u>	November 6, 1984		000	

INT-CL (IPC): B01J 1/00; B01J 39/18; B01J 39/20; C08F 2/54; C08F 8/00; C08F 214/18; C08F 216/16; C08F 259/08; C08F 261/06; C08J 5/22; C08J 7/18; C08L 51/00; C25B 1/46; C25B 13/08

ABSTRACTED-PUB-NO: WO 8300487A

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.10&ref=9&dbname=PGPB,USPT,USO...> 12/1/04

BASIC-ABSTRACT:

Process for prodn. of a cation exchange resin comprises radiation grafting with copolymerisation onto a perhalogenated fluorine-contg. polymeric skeletal substrate at least one functional monomer chosen from $\text{CF}_2=\text{CF}(\text{CF}_2)_n\text{A}$ (I) and $\text{CF}_2=\text{CF}-\text{O}-(\text{CFX}-\text{CFX})_m\text{A}$ (II) in which A is carboxyl, 1-6C alkoxy-carbonyl, hydroxy-1-6 C alkoxy-carbonyl, CN, hydroxysulphonyl, fluorosulphonyl or a gp. $-\text{CONR}_1\text{R}_2$ in which R1 and R2 are independently chosen from H and 1-6 C alkyl, one X is F and the other X is Cl, F or CF_3 , $n=0-12$, and $m=1-3$; together with at least one non-functional linking monomer chosen from cpds. $\text{CF}_2=\text{CFY}$ (III) in which Y is Cl, F or CF_3 .

Pref. the backbone polymer is a (co)polymer of a fluorinated ethylene such as tetrafluoroethylene, or chlorotrifluoroethylene homopolymers or a copolymer of tetrafluoroethylene with 3.5-12.5 wt.% hexafluoropropylene. The functional monomers (I) and (II) are e.g. pentafluorobutenoic acid (IV) 1-6C alkyl pentafluorobutenoates and trifluorovinylsulphony fluoride. The non-functional monomer (III) is pref. TFE or chlorotrifluoroethylene. Pref. the mol. ratio functional monomer to non-functional monomer is in the range 9:1-1:20, esp. 4:1 to 1:4 and partic. 2:1 to 1:2.

The polymers are esp. useful in the prodn. of permselective membranes in electrolytic cells such as those used in the mfr. of alkali metal hydroxide solns. and chlorine.
ABSTRACTED-PUB-NO:

US 4481306A EQUIVALENT-ABSTRACTS:

Prepn. of a cation exchange resin comprises radiation grafting with copolymerisation onto a perhalogenated F-contg. hydrocarbon polymeric skeleton, a functional monomer of formula:

$\text{CF}_2=\text{CF}(\text{CF}_2)_n\text{A}$ or

$\text{CF}_2=\text{CF}-\text{O}-(\text{CFX}-\text{CFX})_m\text{A}$

together with a non-functional linking monomer of formula:

$\text{CF}_2=\text{CFY}$

in the presence of a pooymerisation inhibitor and a chain transfer agent. Mol. ratio of functional monomer to nonfunctional linking monomer is 9:1-1:20. At least 40.7% grafting is accomplished.

In the formulae, A is carboxy or 1-6C alkoxy-carbonyl; one X is F and the other X is Cl, F or CF_3 ; n is 0-12; m is 1-3; and y is Cl, F or CF_3 .

USE/ADVANTAGE - For moulding into membranes. Useful as permselective membranes in (chlor-alkali) electrolysis cells, and as separators and solid electrolytes in fuel cells and batteries. The resin has enhanced wettability. (6pp)

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	KOMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	-------	----------

☐ 19. Document ID: WO 8300157 A, AU 8285876 A, DD 209639 A, EP 82166 A, IT 1212529 B, JP 58501038 W, JP 91004627 B, NO 8300666 A, US 4506035 A, ZA 8204471 A

L9: Entry 19 of 24

File: DWPI

Jan 20, 1983

DERWENT-ACC-NO: 1983-12150K

DERWENT-WEEK: 198305

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Hydrophilic fluoro:polymeric porous diaphragm for chlor:alkali cell - made by co-grafting a mixt. of functional and non-functional monomers onto a fluorine contg.

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.10&ref=9&dbname=PGPB,USPT,USO...> 12/1/04

polymeric substrate

INVENTOR: BARNETT, G ; MARKUS, M V

PRIORITY-DATA: 1981AU-0009455 (June 26, 1981)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 8300157 A	January 20, 1983	E	035	
AU 8285876 A	February 2, 1983		000	
DD 209639 A	May 16, 1984		000	
EP 82166 A	June 29, 1983	E	000	
IT 1212529 B	November 30, 1989		000	
JP 58501038 W	June 30, 1983		000	
JP 91004627 B	January 23, 1991		000	
NO 8300666 A	April 25, 1983		000	
US 4506035 A	March 19, 1985		000	
ZA 8204471 A	March 1, 1983		000	

INT-CL (IPC): C05B 13/08; C08F 8/00; C08F 259/08; C08J 5/20; C08J 7/18; C08J 9/36; C25B 13/08

ABSTRACTED-PUB-NO: WO 8300157A

BASIC-ABSTRACT:

A hydrophilic fluoropolymeric microporous diaphragm comprises a fluorine-contg. polymeric substrate to which has been radiation co-grafted a mixt. of monomers comprising (A) at least one functional monomer chosen from cpds. $\text{CF}_2=\text{CF}(\text{CF}_2)_n\text{A}$ (I) and $\text{CF}_2=\text{CF}-\text{O}-(\text{CFX}-\text{CFX})_m\text{A}$ (II) in which A is carboxyl, alkoxycarbonyl, hydroxyalkoxy, carbonyl, cyano, hydroxysulphonyl, fluorosulphonyl or $-\text{CO}-\text{NR}_1\text{R}_2$ in which R_1 and R_2 (same or different) are H or 1-6C alkyl, one of X is F and the other is Cl, F or CF_3 , $n=1-12$, $m=1-3$, and unsatd. dicarboxylic acids or derivs. contg. the gp. (III) $-\text{C}(\text{R}_3)(\text{COOH})-\text{C}(\text{R}_4)(\text{COOH})-$, in which R_3 and R_4 (same or different) are H, F, Cl, 1-6C alkyl or halogenated 1-6C alkyl, or R_3 and R_4 together form a double bond; and (B) at least one non-functional monomer chosen from aliphatic vinyl monomers $\text{CY}_2=\text{CZ}$ (IV) and aromatic vinyl monomers of formula (V) in which Y is H or F, Z is H, F or Cl, and W is H, 1-6C alkyl, 2-6C alkenyl, halogenated 1-6C alkyl or halogenated 2-6C alkenyl; and in which the mol. ratio co-grafted monomer (A) to (B) is 2:1 to 1:20, esp. 2:1 to 1:3.

The diaphragms are rendered hydrophilic by the grafting treatment and thus have improved wettability and performance when used as electrode sepg. membranes in chlor-alkali cells used for the electrolysis of alkali metal chloride solns.

ABSTRACTED-PUB-NO:

US 4506035A EQUIVALENT-ABSTRACTS:

Hydrophilic microporous diaphragm comprises a fluorocarbon polymer on which is grafted by radiation a mixt. of one or more monomers of formula $\text{CF}_2=\text{CF}(\text{CF}_2)_n\text{A}$; at least one monomer of formula $\text{CF}_2=\text{CF}-\text{O}-(\text{CFX}-\text{CFX})_m\text{A}$; one or more unsatd. dicarboxylic acids having a functional gp. of formula $-\text{C}(\text{R})(\text{C}\sim\text{OH})-\text{C}(\text{R}')(\text{COOH})-$; one or more monomers of formula $\text{CY}_2=\text{CZ}$ or formula (I); such that the molar ratio of grafted functional monomer to nonfunctional monomer is 0.05-2.0. In the formulae A is COOH , alkoxycarbonyl, hydroxyalkoxy, CO, CN, SO_3H , SO_2F or opt. substd. CONH_2 ; one X is F and the other is Cl, F or CF_3 ; n is 1-12; m is 1-3; R and R' are each H, F, Cl, or opt. halogenated 1-6C alkyl, or together denote an extra C to C bond; Y is H or F; Z is H, F or Cl; and W is H or opt. halogenated 1-6C alkyl or alkenyl.

USE - The prods. have improved wetting properties for use in chlorine-alkali cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	-----	------------

☐ 20. Document ID: WO 8201882 A, DE 3173537 G, EP 65547 A, EP 65547 B, JP 57501858 W, JP 90061498 B, US 4602045 A, ZA 8108207 A

L9: Entry 20 of 24

File: DWPI

Jun 10, 1982

DERWENT-ACC-NO: 1982-50214E

DERWENT-WEEK: 198224

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Radiation graft copolymerisation of fluorinated carboxylic acid - to fluoro-polymeric permselective membrane, used in chlor:alkali electrolysis cells

INVENTOR: BARNETT, G ; MARKUS, M

PRIORITY-DATA: 1980AU-0006668 (November 27, 1980)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 8201882 A</u>	June 10, 1982	E	018	
<u>DE 3173537 G</u>	February 27, 1986		000	
<u>EP 65547 A</u>	December 1, 1982	E	000	
<u>EP 65547 B</u>	January 15, 1986	E	000	
<u>JP 57501858 W</u>	October 14, 1982		000	
<u>JP 90061498 B</u>	December 20, 1990		000	
<u>US 4602045 A</u>	July 22, 1986		000	
<u>ZA 8108207 A</u>	September 10, 1982		000	

INT-CL (IPC): C08F 2/54; C08F 14/18; C08F 214/26; C08F 259/08; C08J 5/22; C08J 7/18; C25B 1/46; C25B 13/08; H01M 2/16

ABSTRACTED-PUB-NO: EP 65547B

BASIC-ABSTRACT:

A fluoropolymeric permselective membrane is irradiated with high energy radiation to generate free radical sites in it and treated with a monomer material comprising a fluorinated carboxylic acid or its deriv. to effect graft copolymerisation.

Pref. perfluoro-but-3-enoic acid or its Me or Et ester is used as the monomer material; and a membrane derived from a copolymer of tetrafluoro-ethylene and perfluoro-vinyl sulphonyl fluoride.

The membrane may contain sulphonate, carboxylate or phosphonate cation exchange gps. Gamma- or X-rays or electron beams can be used for the irradiation. The wt. increase in the membrane after graft copolymerisation is suitably less than 12, pref. 3-5, %.

The membrane is also used in batteries and fuel cells. The process improves the resistance of the membrane to back-migration of hydroxyl ions when it is used in a chloralkali electrolysis cell. The treatment can be applied to the whole depth of the membrane; and the modified is not subject to leaching problems.

ABSTRACTED-PUB-NO:

US 4602045A EQUIVALENT-ABSTRACTS:

A process for treating a fluoropolymeric permselective membrane to improve its resistance to back-migration of hydroxyl ions when it is used in a chlor-alkali electrolysis cell, which process comprises irradiating the same membrane with high energy radiation to generate free radical sites therein and treating the said membrane with a monomer material comprising a fluorinated carboxylic acid or an alkyl ester thereof containing from 1 to 6 carbon atoms so that the said monomeric material graft copolymerises with the fluoropolymer to form a copolymeric component therein. (7pp)

Preformed permselective membrane derived from a copolymer of TFE and perfluorovinyl sulphonyl fluoride is contacted with perfluorobutenoic acid or (m)ethyl perfluorobut-3-enotae as monomer and simultaneously irradiated with high energy radiation to graft copolymerise the monomer onto the membrane. Pref gamma, x-ray or electron beam irradiation is used and the membrane undergoes a wt. increase of 3-5 wt.%.

USE/ADVANTAGE - The membrane aquires improved resistance to back migration of OH ions when used in a chloralkali electrolysis cell, enabling high current efficiency to be obtd. The membrane can also be used e.g. as a separator or solid electrolyte in batteries, fuel cells and other electrolysis cells. (6pp)

WO 8201882A

Full	Title	Citation	Front	Review	Classification	Date	Reference	no		Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--	--------	------	----------

☐ 21. Document ID: US 4159318 A

L9: Entry 21 of 24

File: DWPI

Jun 26, 1979

DERWENT-ACC-NO: 1979-52464B

DERWENT-WEEK: 197928

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Oil-free make-up contg. inorganic pigments - in aq. vehicle thickened with clay and hydroxyethyl cellulose

INVENTOR: BARNETT, G ; GERSHAW, N ; MAUSNER, J J

PRIORITY-DATA: 1977US-0815306 (July 13, 1977)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 4159318 A	June 26, 1979		000	

INT-CL (IPC): A61K 7/02

ABSTRACTED-PUB-NO: US 4159318A

BASIC-ABSTRACT:

A stable oil-free make-up compsn. contains 0.1-1.25 wt.% hydrous Mg al silicate a bactericidal preservative, a chelating agent, 0.1 wt.% allantoin, 0.30 wt.% triethanolamine 0.5-5.0 wt.% ethoxylated methyl glucoside, 20.00 wt.% propylene glycol, 0.05 wt.% dioctyl Na sulphosuccinate, 0.3-1.45 wt.% hydroxyethyl cellulose 0.05-2.5 wt.% Na polynaphthalene sulphonate, water insoluble pigment, (esp. an iron oxide), 0.05 wt.% perfume, 0.01 wt.% camphor, 0.01 wt.% menthol, balance water.

The compsn. is emollient and lubricating, but free of oil, and is not prone to colour streaking.

☐ 22. Document ID: US 4148875 A

L9: Entry 22 of 24

File: DWPI

Apr 10, 1979

DERWENT-ACC-NO: 1979-33253B

DERWENT-WEEK: 197917

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Gel toner compsn. for skin - contains protein encapsulated by hectorite clay and polar cpd.

INVENTOR: BARNETT, G ; GERSHAW, N ; MAUSNER, J J

PRIORITY-DATA: 1977US-0781844 (March 28, 1977), 1975US-0611435 (September 5, 1975)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 4148875 A	April 10, 1979		000	

INT-CL (IPC): A61K 31/78; B01J 13/00

ABSTRACTED-PUB-NO: US 4148875A

BASIC-ABSTRACT:

An aqs. gel toner for use on the skin consists of a carrier and an encapsulated base. The carrier comprises an emulsifier, a dispersing agent, a nonionic surfactant, a hymequant, a gel-forming amt. of hectorite clay, a peptiser for the clay, and water. The encapsulated base comprises milk protein, hectorite clay a cpd. with polar gps. in sufficient amt. to form insoluble particles greater than colloidal size on reaction with the clay and water.

The compsn. is non-oily, easily washed off, and contains protein encapsulated so that it is protected from degradation and loss of activity.

☐ 23. Document ID: US 4136166 A

L9: Entry 23 of 24

File: DWPI

Jan 23, 1979

DERWENT-ACC-NO: 1979-09908B

DERWENT-WEEK: 200400

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Skin lightening cosmetic compsn. - contg. stabilised hydroquinone in moisturising base, and a sunscreensing agent

INVENTOR: BARNETT, G ; GERSHAW, N ; MAUSNER, J J

PRIORITY-DATA: 1977US-0788440 (April 18, 1977)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC

INT-CL (IPC): A61K 7/13

ABSTRACTED-PUB-NO: US 4136166A

BASIC-ABSTRACT:

Skin lightening cosmetic compsn. consists of (all pts. by wt.): Phase (A) cetyl alcohol (0.25-8), polyoxyethylene (40) stearate (I) (0.25-5), polyoxyethylene(2)-cetyl ether (II) (0.25-5), white mineral oil (2-35), preservative, stearic acid (0.25-5), and amyl p-dimethylaminobenzoate (0.25-5); Phase (b) propylene glycol (1-15), preservative, hydroxyethylcellulose (0.25-3.5), Mg Al silicate (0.25-3.5), di-Na EDTA (0.05-1), 20% aq. citric acid (0.1-1), hydroquinone (0.1-4), and H₂O (qs 100); and Phase (c) Na₂SO₃ (0.05-2.5), Na₂S₂O₅ (0.05-2.5), and H₂O (qs 100).

Compsn. is effective in bleaching skin (e.g., dark or blotchy patches in elderly people), but is mild in action. The compsn. also contains a sunscreening agent so that the user may be exposed to sun after applying the compsn.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	K00C	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	------	----------

☐ 24. Document ID: US 4129645 A

L9: Entry 24 of 24

File: DWPI

Dec 12, 1978

DERWENT-ACC-NO: 1978-93142A

DERWENT-WEEK: 197851

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Ultraviolet sunscreen compsn. contg. skin moisturising base - and suncreening agent encapsulated in hectorite clay for use when sunbathing

INVENTOR: BARNETT, G ; GERSHAW, N ; MAUSNER, J J

PRIORITY-DATA: 1977US-0788885 (April 19, 1977), 1975US-0611435 (September 5, 1975)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 4129645 A	December 12, 1978		000	

INT-CL (IPC): A61K 7/44

ABSTRACTED-PUB-NO: US 4129645A

BASIC-ABSTRACT:

A UV sunscreen comprises (A) an oil phase of emulsifier, emollient and nonionic surfactant; (B) a water phase of (by-wt.) 0.1-7.5 pts. hectorite clay (I); 0.1-7.5 pts. peptiser (II) for (II); 1-15 pts. humectant (III); 0.1 pts. hydrolysed animal fatty protein complex and water, and (C) an encapsulated active base.

(C) comprises (by wt.) 0.1-10 pts. (I); 0.1-3 pts. organic cpd. (IV) with polar gps.; 0.5-2 pts. (II), suncreening agent (V) and water. (IV) can react with (I) giving water-insoluble particles of above colloidal size when added to an aq. colloidal soln. of (I) and Na₄P₂O₇ and is a simple organic cpd. with ≥ 1 polar gp. and which is sparingly soluble in water at ordinary temp., or is an organic hydrophilic colloid. Pref. (IV) is hydroxyethylcellulose.

Full	Title	Citation	Front	Review	Classification	Date	Reference	no	Claims	K00C	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----	--------	------	----------

Terms	Documents
Barnett-G.IN.	24

Display Format: [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 20040204359 A1

Using default format because multiple data bases are involved.

L12: Entry 1 of 1

File: PGPB

Oct 14, 2004

PGPUB-DOCUMENT-NUMBER: 20040204359

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040204359 A1

TITLE: Methods and compositions in treating pain and painful disorders using
16386,15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145,
59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620

PUBLICATION-DATE: October 14, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Silos-Santiago, Inmaculada	Del Mar	CA	US	
Karicheti, Venkateswarlu	Chapel Hill	NC	US	
Eliasof, Scott D.	Lexington	MA	US	

US-CL-CURRENT: 514/12; 424/143.1, 435/7.1

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [Claims](#) [RDMC](#) [Draw Desc](#)

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Terms	Documents
L11 AND S100beta	1

Display Format: [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 29 of 29 returned.

☐ 1. Document ID: US 20040209307 A1

Using default format because multiple data bases are involved.

L13: Entry 1 of 29

File: PGPB

Oct 21, 2004

PGPUB-DOCUMENT-NUMBER: 20040209307

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040209307 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: October 21, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars	Escondido	CA	US	
Dahlen, Jeffrey	San Diego	CA	US	
Kirchick, Howard	San Diego	CA	US	
Buechler, Kenneth F.	San Diego	CA	US	

US-CL-CURRENT: 435/7.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 2. Document ID: US 20040175754 A1

L13: Entry 2 of 29

File: PGPB

Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175754

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040175754 A1

TITLE: Diagnosis and monitoring of inflammation, ischemia and appendicitis

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bar-Or, David	Englewood	CO	US	
Bar-Or, Raphael	Denver	CO	US	
Winkler, James V.	Denver	CO	US	
Yukl, Richard L.	Denver	CO	US	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The invention provides methods and kits for diagnosing and monitoring inflammation and/or ischemia in an animal. The methods comprise determining the quantity of a post-translationally modified protein, other than phosphorylated tau, present in a body fluid from an animal.

The invention also provides an improved method and kits for diagnosing appendicitis in an animal. The method comprises determining the quantities of orthohydroxyhippuric acid and of a marker of general inflammation, such as a post-translationally modified protein, present in one or more body fluids of the animal.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NAME	Drawg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------

☐ 3. Document ID: US 20030203404 A1

L13: Entry 3 of 29

File: PGPB

Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203404

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030203404 A1

TITLE: Bioluminescence resonance energy transfer(bret) system with broad spectral resolution between donor and acceptor emission wavelengths and its use

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Joly, Erik	Blainville		CA	

US-CL-CURRENT: 435/7.1; 435/287.2, 435/320.1, 435/325, 435/69.1, 435/8

ABSTRACT:

The present invention provides a bioluminescence resonance energy transfer (BRET) detection system characterised by a broad spectral resolution between donor and acceptor emission wavelengths. The broad spectral resolution between the emission wavelength of the bioluminescent donor protein and the fluorescent acceptor molecule results in an increased signal-to-base ratio and dynamic range in comparison with a basic BRET system.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NAME	Drawg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------

☐ 4. Document ID: US 20030199000 A1

L13: Entry 4 of 29

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199000

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199000 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars E.	Escondido	CA	US	
Dahlen, Jeffery	San Diego	CA	US	
Kirchick, Howard J.	San Diego	CA	US	
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	

US-CL-CURRENT: 435/7.1; 435/287.2

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 5. Document ID: US 20030157554 A1

L13: Entry 5 of 29

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157554

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030157554 A1

TITLE: Protein-protein complexes and methods of using same

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Giot, Loic	Madison	CT	US	
Eisen, Andrew	Rockville	MD	US	
Lewin, David A.	New Haven	CT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/23

ABSTRACT:

The invention provides complexes of at least two polypeptides, and methods of using the same. Purified complexes of two polypeptides are provided, including chimeric complexes, and chimeric polypeptides and complexes thereof are also provided, as are nucleic acids encoding chimeric polypeptides and vectors and cells containing the same. Also provided are methods of identifying agents that disrupt polypeptide complexes, methods of identifying complex or polypeptide in a sample, and for removing the same, methods of determining altered expression of a polypeptide in a subject, and methods of treating/preventing disorders involving altered levels of

complex or polypeptide.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 6. Document ID: US 20030139358 A1

L13: Entry 6 of 29

File: PGPB

Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030139358

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030139358 A1

TITLE: Novel human proteins, polynucleotides encoding them and methods of using the same

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Spytek, Kimberly A.	New Haven	CT	US	
Padigaru, Muralidhara	Branford	CT	US	
Majumder, Kumud	Stamford	CT	US	
MacDougall, John R.	Hamden	CT	US	
Stone, David J.	Guilford	CT	US	
Gangolli, Esha A.	Madison	CT	US	
Spaderna, Steven K.	Berlin	CT	US	
Smithson, Glenda	Branford	CT	US	

US-CL-CURRENT: 514/44; 435/183, 435/320.1, 435/6, 435/69.1, 435/7.1, 514/12, 536/23.2

ABSTRACT:

The invention provides polypeptides, designated herein as POLYX polypeptides, as well as polynucleotides encoding POLYX polypeptides, and antibodies that immunospecifically-bind to POLYX polypeptide or polynucleotide, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which the POLYX polypeptide, polynucleotide, and antibody are used in the detection, prevention, and treatment of a broad range of pathological states.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 7. Document ID: US 20030130827 A1

L13: Entry 7 of 29

File: PGPB

Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030130827

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030130827 A1

TITLE: Protein design automation for protein libraries

PUBLICATION-DATE: July 10, 2003

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.16&ref=13&dbname=PGPB,USPT,US...> 12/1/04

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bentzien, Joerg	White Plains	NY	US	
Dahiyat, Bassil I.	Altadena	CA	US	
Desjarlais, John R.	Pasadena	CA	US	
Hayes, Robert J.	Pasadena	CA	US	
Vielmetter, Jost	Altadena	CA	US	

US-CL-CURRENT: 703/11; 435/7.1

ABSTRACT:

The invention relates to the use of protein design automation (PDA.TM.) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 8. Document ID: US 20030119064 A1

L13: Entry 8 of 29

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119064

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030119064 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars E.	Escondido	CA	US	
Dahlen, Jeffrey R.	San Diego	CA	US	
Kirchick, Howard J.	San Diego	CA	US	
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

☐ 9. Document ID: US 20030104445 A1

L13: Entry 9 of 29

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104445

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104445 A1

TITLE: RNA dependent RNA polymerase mediated protein evolution

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hayes, Robert J.	Pasadena	CA	US	
Aguinaldo, Anna-Marie	Altadena	CA	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.1, 435/91.2, 530/350, 536/23.2

ABSTRACT:

The invention relates to the use of RNA dependent RNA polymerase to generate libraries of proteins, and to methods of making and methods and compositions utilizing the libraries.

☐ 10. Document ID: US 20030064416 A1

L13: Entry 10 of 29

File: PGPB

Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030064416

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030064416 A1

TITLE: Process for differential diagnosis of Alzheimer's dementia in patients exhibiting mild cognitive impairment

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Takahashi, Miyoko	North York		CA	

US-CL-CURRENT: 435/7.21

ABSTRACT:

A method for determining those patients suffering from mild cognitive impairment (MCI) who have a likelihood of progressing to Alzheimer's disease (AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 11. Document ID: US 20020160425 A1

L13: Entry 11 of 29

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160425
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160425 A1

TITLE: Process for differential diagnosis of Alzheimer's dementia and device therefor

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Takahashi, Miyoko	North York		CA	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 12. Document ID: US 20020160423 A1

L13: Entry 12 of 29

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160423
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160423 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1536 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 13. Document ID: US 20020160422 A1

L13: Entry 13 of 29

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160422

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020160422 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence

and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------

☐ 14. Document ID: US 20020160421 A1

L13: Entry 14 of 29

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160421
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160421 A1

TITLE: Method for monitoring and validating stress induction of disease state

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Stanton, Eric B.	Burlington		CA	

US-CL-CURRENT: 435/7.1; 435/6, 702/19, 702/20

ABSTRACT:

The present invention provides a biochemically-based methodology for ascertaining the presence and/or verifying the historical release of biopolymers, which have been shown to be indicative of a disease state or are predictive of the development of said disease state.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------

☐ 15. Document ID: US 20020160420 A1

L13: Entry 15 of 29

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160420
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160420 A1

TITLE: Process for diagnosis of physiological conditions by characterization of proteomic materials

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

ABSTRACT:

The present invention discloses the use of proteomic investigation as a diagnostic tool; and particularly teaches the use of proteomic investigative techniques and methodology to determine a proteomic basis for the development and progression of abnormal physiological conditions and the development and characterization of risk assessment, diagnostic and therapeutic means and methodologies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 16. Document ID: US 20020160419 A1

L13: Entry 16 of 29

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160419

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020160419 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 17. Document ID: US 20020160418 A1

L13: Entry 17 of 29

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160418

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160418 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1949 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------

☐ 18. Document ID: US 20020160417 A1

L13: Entry 18 of 29

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160417
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160417 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Stanton, Eric B.	Burlington		CA	
Thatcher, Brad	Toronto		CA	
Vrees, Tammy	Oakville		CA	
Yantha, Jason	Toronto		CA	
Marshall, John	Toronto		CA	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 19. Document ID: US 6780606 B1

L13: Entry 19 of 29

File: USPT

Aug 24, 2004

US-PAT-NO: 6780606

DOCUMENT-IDENTIFIER: US 6780606 B1

TITLE: Method for diagnosing and distinguishing stroke and diagnostic devices for use therein

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA

US-CL-CURRENT: 435/7.92; 422/50, 422/60, 422/61, 424/184.1, 424/9.1, 435/7.2, 435/7.21, 436/501, 436/514, 436/518, 436/524

ABSTRACT:

A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.

30 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------

☐ 20. Document ID: US 6756476 B2

L13: Entry 20 of 29

File: USPT

Jun 29, 2004

US-PAT-NO: 6756476

DOCUMENT-IDENTIFIER: US 6756476 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons

DATE-ISSUED: June 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 530/300; 435/7.1, 435/7.2, 436/173, 436/174, 436/501, 436/63, 436/86, 436/89, 530/387.9, 530/388.25, 530/391.3, 530/412

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	WMD	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------

☐ 21. Document ID: US 6670136 B2

L13: Entry 21 of 29

File: USPT

Dec 30, 2003

US-PAT-NO: 6670136

DOCUMENT-IDENTIFIER: US 6670136 B2

TITLE: Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schmidt; Ann Marie	Franklin Lakes	NJ		
Stern; David	Great Neck	NY		

US-CL-CURRENT: 435/7.1; 530/324, 530/350, 530/388.1, 530/389.1

ABSTRACT:

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.16&ref=13&dbname=PGPB,USPT,US...> 12/1/04

inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction measured in step (b) with the amount measured between the peptide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

2 Claims, 27 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 27

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------

☐ 22. Document ID: US 6638504 B1

L13: Entry 22 of 29

File: USPT

Oct 28, 2003

US-PAT-NO: 6638504

DOCUMENT-IDENTIFIER: US 6638504 B1

**** See image for Certificate of Correction ****

TITLE: Methods for treating cancer

DATE-ISSUED: October 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lukanidin; Eugene	Copenhagen			DK

US-CL-CURRENT: 424/130.1; 435/4, 435/7.1

ABSTRACT:

The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.

5 Claims, 46 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------

☐ 23. Document ID: US 6627457 B2

L13: Entry 23 of 29

File: USPT

Sep 30, 2003

US-PAT-NO: 6627457

DOCUMENT-IDENTIFIER: US 6627457 B2

**** See image for Certificate of Correction ****

TITLE: Methods for detecting pregnancy

DATE-ISSUED: September 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pandian; Murugan R.	Mission Viejo	CA		
Lu; Julie Y.	Mission Viejo	CA		

US-CL-CURRENT: 436/501; 435/7.1, 435/7.8, 436/510, 436/536, 436/542, 436/65, 436/804,
436/818, 436/824, 530/387.5, 530/388.24, 530/389.2

ABSTRACT:

Methods for detecting pregnancy in a woman comprise screening a biological sample of the woman for pregnancy markers. The methods of the invention include chemiluminescent assays for the pregnancy markers. The methods of the invention also comprise utilizing at least two capture antibodies that specifically bind different epitopes of the pregnancy marker in one assay. The methods of the invention permit detection of pregnancy within about 7 days after ovulation or implantation.

37 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------

☐ 24. Document ID: US 6461828 B1

L13: Entry 24 of 29

File: USPT

Oct 8, 2002

US-PAT-NO: 6461828

DOCUMENT-IDENTIFIER: US 6461828 B1

TITLE: Conjunctive analysis of biological marker expression for diagnosing organ failure

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stanton; Eric B.	Burlington			CA
Jackowski; George	Kettleby			CA

US-CL-CURRENT: 435/7.92; 422/60, 422/61, 435/7.93, 435/7.94, 435/969, 435/970,

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.16&ref=13&dbname=PGPB,USPT,US...> 12/1/04

435/973, 435/975, 436/514, 436/518, 436/528, 436/530, 436/807, 436/808, 436/810

ABSTRACT:

A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.

5 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------

☐ 25. Document ID: US 6451547 B1

L13: Entry 25 of 29

File: USPT

Sep 17, 2002

US-PAT-NO: 6451547

DOCUMENT-IDENTIFIER: US 6451547 B1

TITLE: Process for differential diagnosis of Alzheimer's dementia and device therefor

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Takahashi; Miyoko	North York			CA

US-CL-CURRENT: 435/7.4; 435/7.1, 435/7.9, 435/7.92, 435/7.93, 435/7.94, 435/7.95, 530/387.2, 530/388.1, 530/388.25, 530/388.26, 530/389.1, 530/389.3, 530/391.1

ABSTRACT:

A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

13 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------

☐ 26. Document ID: US 6235489 B1

US-PAT-NO: 6235489

DOCUMENT-IDENTIFIER: US 6235489 B1

TITLE: Method for diagnosing and distinguishing stroke and diagnostic devices for use therein

DATE-ISSUED: May 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA

US-CL-CURRENT: 435/7.92; 422/55, 422/56, 422/58, 422/60, 422/61, 424/9.1, 435/13, 435/4, 435/5, 435/6, 435/7.1, 435/7.21, 435/7.4, 435/7.9, 435/7.94, 435/7.95, 435/9, 435/969, 435/970, 435/973, 435/975, 436/161, 436/164, 436/514, 436/528, 436/530, 436/531, 436/807, 436/808, 436/810, 436/811

ABSTRACT:

A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.

19 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------

☐ 27. Document ID: US 6140058 A

L13: Entry 27 of 29

File: USPT

Oct 31, 2000

US-PAT-NO: 6140058

DOCUMENT-IDENTIFIER: US 6140058 A

TITLE: Activation of p53 protein

DATE-ISSUED: October 31, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lane; David Philip	St. Andrews			GB
Hupp; Theodore Robert	Dundee			GB

US-CL-CURRENT: 435/7.1; 424/155.1, 424/174.1, 435/7.23, 530/350, 530/358

ABSTRACT:

A class of mutant forms of p53 protein, such as His273 and Lys285, which are defective in conversion from the latent to the activated state by casein kinase II, but with the ability to be activated for specific DNA binding by the action of ligands such as monoclonal antibody PAb421 and heat shock protein DnaK. Activation of these mutants, which are found at high levels in certain types of tumour, can potentially lead to selective growth arrest and induction of apoptosis in the tumor cells. p53 can be constitutively activated also by deletion of the C-terminal 30 amino acids. p53 activated in this way, or by ligand binding, can be administered for the purposes of tumour or cell growth suppression.

17 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------

☐ 28. Document ID: US 5989827 A

L13: Entry 28 of 29

File: USPT

Nov 23, 1999

US-PAT-NO: 5989827

DOCUMENT-IDENTIFIER: US 5989827 A

TITLE: Use of nuclear magnetic resonance to design ligands to target biomolecules

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fesik; Stephen W.	Gurnee	IL		
Hajduk; Philip J.	Palatine	IL		
Olejniczak; Edward T.	Grayslake	IL		

US-CL-CURRENT: 435/7.1; 436/173, 436/501

ABSTRACT:

The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional $^{15}\text{N}/^1\text{H}$ NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional $^{15}\text{N}/^1\text{H}$ NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.

8 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------

US-PAT-NO: 5891643

DOCUMENT-IDENTIFIER: US 5891643 A

**** See image for Certificate of Correction ****

TITLE: Use of nuclear magnetic resonance to design ligands to target biomolecules

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fesik; Stephen W.	Gurnee	IL		
Hajduk; Philip J.	Palatine	IL		
Olejniczak; Edward T.	Grayslake	IL		

US-CL-CURRENT: 435/7.1; 436/173, 436/501

ABSTRACT:

The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional ¹⁵N/¹H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional ¹⁵N/¹H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.

8 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Index	Claims	KWIC	Drwg
------	-------	----------	-------	--------	----------------	------	-----------	----------	-------	--------	------	------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L11 AND S100b	29

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 100 of 131 returned.

☐ 1. Document ID: US 20040224423 A1

Using default format because multiple data bases are involved.

L16: Entry 1 of 131

File: PGPB

Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040224423

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040224423 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2056 daltons

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: [436/518](#); [530/326](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20040209307 A1

L16: Entry 2 of 131

File: PGPB

Oct 21, 2004

PGPUB-DOCUMENT-NUMBER: 20040209307

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040209307 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: October 21, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars	Escondido	CA	US	
Dahlen, Jeffrey	San Diego	CA	US	
Kirchick, Howard	San Diego	CA	US	
Buechler, Kenneth F.	San Diego	CA	US	

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20040204359 A1

L16: Entry 3 of 131

File: PGPB

Oct 14, 2004

PGPUB-DOCUMENT-NUMBER: 20040204359

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040204359 A1

TITLE: Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620

PUBLICATION-DATE: October 14, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Silos-Santiago, Inmaculada	Del Mar	CA	US	
Karicheti, Venkateswarlu	Chapel Hill	NC	US	
Eliasof, Scott D.	Lexington	MA	US	

US-CL-CURRENT: 514/12; 424/143.1, 435/7.1

ABSTRACT:

The present invention relates to methods for the diagnosis and treatment of pain or painful disorders. Specifically, the present invention identifies the differential expression of 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 and 32620 genes in tissues relating to pain sensation, relative to their expression in normal, or non-painful disease states, and/or in response to manipulations relevant to pain. The present invention describes methods for the diagnostic evaluation and prognosis of various pain disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating pain or painful disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of pain and painful disorders.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20040198950 A1

L16: Entry 4 of 131

File: PGPB

Oct 7, 2004

PGPUB-DOCUMENT-NUMBER: 20040198950
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040198950 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons

PUBLICATION-DATE: October 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/326; 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20040175754 A1

L16: Entry 5 of 131

File: PGPB

Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175754
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040175754 A1

TITLE: Diagnosis and monitoring of inflammation, ischemia and appendicitis

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bar-Or, David	Englewood	CO	US	
Bar-Or, Raphael	Denver	CO	US	
Winkler, James V.	Denver	CO	US	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The invention provides methods and kits for diagnosing and monitoring inflammation and/or ischemia in an animal. The methods comprise determining the quantity of a post-translationally modified protein, other than phosphorylated tau, present in a body fluid from an animal.

The invention also provides an improved method and kits for diagnosing appendicitis in an animal. The method comprises determining the quantities of orthohydroxyhippuric acid and of a marker of general inflammation, such as a post-translationally modified protein, present in one or more body fluids of the animal.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	K00C	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20040121372 A1

L16: Entry 6 of 131

File: PGPB

Jun 24, 2004

PGPUB-DOCUMENT-NUMBER: 20040121372

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040121372 A1

TITLE: Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof

PUBLICATION-DATE: June 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schmidt, Ann Marie	Franklin Lakes	NJ	US	
Stern, David	Great Neck	NY	US	

US-CL-CURRENT: 435/6; 435/252.3, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction measured in step (b) with the amount measured between the peptide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide,, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20040106168 A1

L16: Entry 7 of 131

File: PGPB

Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040106168

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040106168 A1

TITLE: System and method for neuronal network analysis

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Evans, Daron G.	Dallas	TX	US	

US-CL-CURRENT: 435/40.5; 435/283.1, 435/29

ABSTRACT:

The present invention provides a system and method for testing the neuronal effects of a compound. The system (100) includes a microelectrode array (102), a data capture unit (106) communicably coupled to the microelectrode array (102), a processor (108) communicably coupled to the data capture unit (106) and one or more input/output devices (110) communicably coupled to the processor (108). The microelectrode array (102) is capable of supporting genetically modified neuronal cells (104) and measuring neuronal activity. The method (400) determines the effects of a sample on genetically modified neuronal cells by growing a culture of genetically modified neuronal cells on a microelectrode array (402) and exposing a portion of the genetically modified neuronal cells to a sample (404). The effects of the sample on the genetically modified neuronal cells exposed to the sample are measured to determine the effects of the sample on the genetically modified neuronal cells (406).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 8. Document ID: US 20040086617 A1

L16: Entry 8 of 131

File: PGPB

May 6, 2004

PGPUB-DOCUMENT-NUMBER: 20040086617

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040086617 A1

TITLE: Additive for infant milk formulas

PUBLICATION-DATE: May 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Gazzolo, Diego
Michetti, Fabrizio

Genova
Roma

IT
IT

US-CL-CURRENT: 426/580

ABSTRACT:

Disclosed is the use of the protein S100B as an infant milk formula supplement.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 9. Document ID: US 20040082542 A1

L16: Entry 9 of 131

File: PGPB

Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040082542
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040082542 A1

TITLE: Azole derivatives and fused bicyclic azole derivatives as therapeutic agents

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mjalli, Adnan M.M.	Jamestown	NC	US	
Andrews, Robert C.	Jamestown	NC	US	
Gopalaswamy, Ramesh	Jamestown	NC	US	
Hari, Anitha	High Point	NC	US	
Avor, Kwasi S.	High Point	NC	US	
Qabajaj, Ghassan	High Point	NC	US	
Guo, Xiao-Chuan	High Point	NC	US	
Gupta, Suparna	Greensboro	NC	US	
Jones, David R.	Asheboro	NC	US	
Chen, Xin	High Point	NC	US	

US-CL-CURRENT: 514/63; 514/264.1, 514/266.2, 514/266.23, 514/310, 514/314, 514/365,
514/374, 514/400, 544/279, 544/284, 546/148, 548/110, 548/190, 548/222, 548/326.5

ABSTRACT:

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, .beta.-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

□ 10. Document ID: US 20040072997 A1

L16: Entry 10 of 131

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072997
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20040072997 A1

TITLE: Therapeutic polypeptides, nucleic acids encoding same, and methods of use

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Alsobrook, John P. II	Madison	CT	US	
Anderson, David W.	Branford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	
Edinger, Shlomit R.	New Haven	CT	US	
Ellerman, Karen	Branford	CT	US	
Furtak, Katarzyna	Ansonia	CT	US	
Gangolli, Esha A.	Cambridge	MA	US	
Gerlach, Valerie	Branford	CT	US	
Gilbert, Jennifer A.	Madison	CT	US	
Gunther, Erik	Branford	CT	US	
Gorman, Linda	Branford	CT	US	
Guo, Xiaojia (Sasha)	Branford	CT	US	
Ji, Weizhen	Branford	CT	US	
Li, Li	Branford	CT	US	
Miller, Charles E.	Guilford	CT	US	
Padigar, Muralidhara	Branford	CT	US	
Patturajan, Meera	Branford	CT	US	
Rastelli, Luca	Guilford	CT	US	
MacDougall, John R.	Hamden	CT	US	
Mishra, Vishnu	Gainesville	FL	US	
Smithson, Glennnda	Guilford	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Stone, David J.	Guilford	CT	US	
Shenoy, Suresh G.	Branford	CT	US	
Taupier, Raymond J. JR.	East Haven	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Zhong, Mei	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Millet, Isabelle	Milford	CT	US	
Kekuda, Ramesh	Norwalk	CT	US	
Grosse, William M.	Branford	CT	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/388.22, 536/23.5

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 11. Document ID: US 20040072749 A1

L16: Entry 11 of 131

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072749

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040072749 A1

TITLE: Composition for the elimination of autoreactive b-cells

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zochoer, Marcel	Munchen		DE	
Bauerle, Patrick	Gauting		DE	
Dreier, Torsten	Munchen		DE	

US-CL-CURRENT: 514/12

ABSTRACT:

The present invention relates to a composition for the selective elimination of autoreactive B-cells comprising at least one (poly)peptide construct consisting of at least two domains wherein one of said domains comprises an autoreactive antigen or (a) fragments(s) thereof specifically recognized by the Ig receptors of said autoreactive B-cells and wherein one of said domains comprises an effector molecule capable of interacting with and/or of activating NK-cells, T-cells, macrophages, monocytes and/or granulocytes and/or capable of activating the complement system.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 12. Document ID: US 20040072744 A1

L16: Entry 12 of 131

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072744

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040072744 A1

TITLE: Synthetic peptide as treatment for down's syndrome and schizophrenia

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lipps, Binie V.	Bellaire	TX	US	
Lipps, Frederick W.	Bellaire	TX	US	

US-CL-CURRENT: 514/12; 514/14, 514/15

ABSTRACT:

Adesh is a synthetic peptide consisting of at least the first four amino acids from the N-terminal of the sequence N L G E H P V C D S T D T W V (SEQ. ID. NO.: 1) and no more than 25 amino acids total. The synthetic peptide mimics the biological properties of nerve growth factor (NGF) consisting of 116 amino acids and is advocated to treat Down Syndrome (DS) and schizophrenia. It is believed that these neuro-degenerative diseases are linked with inadequate neurotrophic factors.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 13. Document ID: US 20040072160 A1

L16: Entry 13 of 131

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072160

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040072160 A1

TITLE: Molecular toxicology modeling

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mendrick, Donna	Gaithersburg	MD	US	
Porter, Mark	Gaithersburg	MD	US	
Johnson, Kory	Gaithersburg	MD	US	
Higgs, Brandon	Gaithersburg	MD	US	
Castle, Arthur	Gaithersburg	MD	US	
Elashoff, Michael	Gaithersburg	MD	US	

US-CL-CURRENT: 435/6; 435/91.2, 436/84

ABSTRACT:

The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 14. Document ID: US 20040019921 A1

L16: Entry 14 of 131

File: PGPB

Jan 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040019921

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040019921 A1

TITLE: Non-human mammal with disrupted or modified MIF gene, and uses thereof

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fingerle-Rowson, Gunter R.	Long Beach	NY	US	
Delaney, Patrick R.			US	

US-CL-CURRENT: 800/18

ABSTRACT:

The present invention demonstrates transgenic mammals, particularly transgenic mice, having a genomic disruption or mutation affecting the MIF gene. The invention is also directed to use of the transgenic mice in developing therapies to inflammatory or neoplastic disorders involving MIF cellular activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 15. Document ID: US 20040005577 A1

L16: Entry 15 of 131

File: PGPB

Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005577

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040005577 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and

antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 16. Document ID: US 20040002584 A1

L16: Entry 16 of 131

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002584

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002584 A1

TITLE: Proteins, polynucleotides encoding them and methods of using the same

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pena, Carol E. A.	New Haven	CT	US	
Shimkets, Richard A.	Guilford	CT	US	
Li, Li	Branford	CT	US	
Shenoy, Suresh G.	Branford	CT	US	
Kekuda, Ramesh	Norwalk	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Guo, Xiaojia (Sasha)	Branford	CT	US	
Gusev, Vladimir Y.	Madison	CT	US	
Casman, Stacie J.	North Haven	CT	US	
Boldog, Ferenc L.	North Haven	CT	US	
Furtak, Katarzyna	Ansonia	CT	US	
Tchernev, Velizar T.	Branford	CT	US	
Patturajan, Meera	Branford	CT	US	
Gangolli, Esha A.	Madison	CT	US	
Padigaru, Muralidhara	Branford	CT	US	
Liu, Xiaohong	Branford	CT	US	
Baumgartner, Jason C.	New Haven	CT	US	
Gerlach, Valerie	Branford	CT	US	
Spaderna, Steven K.	Berlin	CT	US	
Zerhusen, Bryan D.	Branford	CT	US	

US-CL-CURRENT: 530/350

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMD	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 17. Document ID: US 20040002120 A1

L16: Entry 17 of 131

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002120

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040002120 A1

TITLE: Therapeutic polypeptides, nucleic acids encoding same, and methods of use

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kekuda, Ramesh	Danbury	CT	US	
Tchernev, Velizar T.	Branford	CT	US	
Liu, Xiaohong	Branford	CT	US	
Spytek, Kimberly A.	New Haven	CT	US	
Patturajan, Meera	Branford	CT	US	
Burgess, Catherine E.	Wethersfield	CT	US	
Vernet, Corine A.M.	Branford	CT	US	
Li, Li	Branford	CT	US	
Gorman, Linda	Branford	CT	US	
Malyankar, Uriel M.	Branford	CT	US	
Boldog, Ferenc L.	North Haven	CT	US	
Guo, Xiaojia (Sasha)	Branford	CT	US	
Shenoy, Suresh G.	Branford	CT	US	
Padigar, Muralidhara	Branford	CT	US	
Taupier, Raymond J. JR.	East Haven	CT	US	
Miller, Charles E.	Guilford	CT	US	
Casman, Stacie J.	North Haven	CT	US	
Pena, Carol E. A.	New Haven	CT	US	
Gangolli, Esha A.	Madison	CT	US	
Gusev, Vladimir Y.	Madison	CT	US	
Smithson, Glennda	Guilford	CT	US	
Zerhusen, Bryan D.	Branford	CT	US	
Gerlach, Valerie	Branford	CT	US	
Pochart, Pascale F-J	Madison	CT	US	
Fernandes, Elma R.	Branford	CT	US	
Shinkets, Richard A.	Guilford	CT	US	
Rastelli, Luca	Guilford	CT	US	

Spaderna, Steven K.	Berlin	CT	US
LaRoche, William J.	Madison	CT	US
Zhong, Mei	Branford	CT	US
Khramtsov, Nikolai V.	Branford	CT	US
Voss, Edward Z.	Wallingford	CT	US
Herrmann, John L.	Guilford	CT	US

US-CL-CURRENT: 435/7.2; 435/320.1, 435/325, 435/69.1, 514/12, 530/350, 536/23.5

ABSTRACT:

Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 18. Document ID: US 20030219718 A1

L16: Entry 18 of 131

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219718

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030219718 A1

TITLE: Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Weber, David J.	Towson	MD	US	
Markowitz, Joseph	Baltimore	MD	US	
Carrier, France	Silver Spring	MD	US	
MacKerell, Alexander D.	Baltimore	MD	US	

US-CL-CURRENT: 435/4; 514/211.11, 514/404, 514/471, 514/635, 514/679

ABSTRACT:

Compounds that bind S100 and inhibit the S100-p53 protein-protein interaction and activate the tumor suppressor activity of p53, and thus which have an antineoplastic effect are disclosed, as well as methods for identifying these compounds, compositions comprising the same, and methods of using the same to treat cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 19. Document ID: US 20030207393 A1

L16: Entry 19 of 131

File: PGPB

Nov 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030207393
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030207393 A1

TITLE: Cbp86, a sperm specific protein

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Herr, John C.	Charlottesville	VA	US	
Buer, Sen	Lilburn	GA	US	
Mandal, Arabinda	Charlottesville	VA	US	
Wolkowicz, Michael	Charlottesville	VA	US	
Naaby-Hansen, Soren	London		GB	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 530/388.1, 536/23.5

ABSTRACT:

The present invention relates to acidic (pI 4.0) 86 kDA isoforms of a novel, polymorphic, testis-specific protein designated calcium binding protein 86 (CBP86). This protein is tyrosine phosphorylated during in vitro capacitation and bound calcium.sup.45 on 2-D gels, the latter effect abolished by dephosphorylation with alkaline phosphatase. CBP86 localizes to the principal piece of the human sperm flagellum in association with the fibrous sheath and is the first demonstration of a sperm protein that both oligomerizes and gains calcium binding capacity in a tyrosine phosphorylation dependent manner during capacitation.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 20. Document ID: US 20030203404 A1

L16: Entry 20 of 131

File: PGPB

Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203404
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030203404 A1

TITLE: Bioluminescence resonance energy transfer(bret) system with broad spectral resolution between donor and acceptor emission wavelengths and its use

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Joly, Erik	Blainville		CA	

US-CL-CURRENT: 435/7.1; 435/287.2, 435/320.1, 435/325, 435/69.1, 435/8

ABSTRACT:

The present invention provides a bioluminescence resonance energy transfer (BRET) detection system characterised by a broad spectral resolution between donor and acceptor emission wavelengths. The broad spectral resolution between the emission wavelength of the bioluminescent donor protein and the fluorescent acceptor molecule results in an increased signal-to-base ratio and dynamic range in comparison with a basic BRET system.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 21. Document ID: US 20030199000 A1

L16: Entry 21 of 131

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199000

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199000 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars E.	Escondido	CA	US	
Dahlen, Jeffery	San Diego	CA	US	
Kirchick, Howard J.	San Diego	CA	US	
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	

US-CL-CURRENT: 435/7.1; 435/287.2

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 22. Document ID: US 20030198970 A1

L16: Entry 22 of 131

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198970

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030198970 A1

TITLE: Genostics

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roberts, Gareth Wyn	Cambs		GB	

US-CL-CURRENT: 435/6; 536/24.3

ABSTRACT:

People vary enormously in their response to disease and the also in their response to therapeutic interventions aimed at ameliorating the disease process and progression. However, the provision of medical care and medical management is centered around observations and protocols developed in clinical trials on groups or cohorts of patients. This group data is used to derive a standardised method of treatment which is subsequently applied on an individual basis. There is considerable evidence that a significant factor underlying the individual variability in response to disease, therapy and prognosis lies in a person's genetic make-up. There have been numerous examples relating that polymorphisms within a given gene can alter the functionality of the protein encoded by that gene thus leading to a variable physiological response. In order to bring about the integration of genomics into medical practice and enable design and building of a technology platform which will enable the everyday practice of molecular medicine a way must be invented for the DNA sequence data to be aligned with the identification of genes central to the induction, development, progression and outcome of disease or physiological states of interest. According to the invention, the number of genes and their configurations (mutations and polymorphisms) needed to be identified in order to provide critical clinical information concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome. The identification of the identity of the core group of genes enables the invention of a design for genetic profiling technologies which comprises of the identification of the core group of genes and their sequence variants required to provide a broad base of clinical prognostic information--`genostics`. The "GenosticTM" profiling of patients and persons will radically enhance the ability of clinicians, healthcare professionals and other parties to plan and manage healthcare provision and the targeting of appropriate healthcare resources to those deemed most in need. The use of our invention could also lead to a host of new applications for such profiling technologies, such as identification of persons with particular work or environment related risk, selection of applicants for employment, training or specific opportunities or for the enhancing the planning and organisation of health services, education services and social services.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 23. Document ID: US 20030194704 A1

L16: Entry 23 of 131

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194704

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030194704 A1

TITLE: Human genome-derived single exon nucleic acid probes useful for gene expression analysis two

PUBLICATION-DATE: October 16, 2003

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.19&ref=16&dbname=PGPB,USPT,US...> 12/1/04

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Penn, Sharron Gaynor	San Mateo	CA	US	
Rank, David Russell	Fremont	CA	US	
Hanzel, David Kagen	Palo Alto	CA	US	

US-CL-CURRENT: 435/6; 536/24.3

ABSTRACT:

Methods and apparatus for predicting, confirming and displaying functional regions from genomic sequence data are used to identify 13,700 unique human genome-derived single exon probes useful for gene expression analysis, particularly gene expression analysis by microarray. Also presented are genome-derived single exon microarrays that include such probes, peptides encoded by the exons, and antibodies thereto.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	----------

☐ 24. Document ID: US 20030176437 A1

L16: Entry 24 of 131

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030176437

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030176437 A1

TITLE: Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Watterson, D.M.	Chicago	IL	US	
Sawkar, Anu R.	La Jolla	CA	US	
Lukas, Thomas J.	Evanston	IL	US	
Mirzoeva, Salida	Chicago	IL	US	
Van Eldik, Linda J.	Chicago	IL	US	
Hibert, Marcel	Eschau	IL	FR	
Velentza, Anastasia	Chicago	IL	US	
Zasadzki, Magdalena	Arlington Heights		US	
Haiech, Jacques	Strasbourg		FR	
Bourguignon, Jean-Jacques	Illkirch Graffenstaden		FR	

US-CL-CURRENT: 514/252.02; 544/224, 544/238

ABSTRACT:

A novel class of pyridazine compositions and related methods of use.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	----------

☐ 25. Document ID: US 20030175895 A1

L16: Entry 25 of 131

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175895
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175895 A1

TITLE: Chemokine

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lesslauer, Werner	Riehen		CH	
Utans-Schneitz, Ulrike	Basle		CH	

US-CL-CURRENT: 435/69.5; 435/252.3, 435/325, 530/351, 536/23.5

ABSTRACT:

The present invention relates to the discovery of novel genes and proteins, which function in pathways involved in brain pathogenesis. In particular, the novel genes and proteins relate to inflammatory tissue responses caused by brain injuries such trauma, ischemia or autoimmune-inflammation or other diseases or processes related to neuroinflammation. The compounds disclosed in the present invention are useful as therapeutics, diagnostics and in screening assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 26. Document ID: US 20030157554 A1

L16: Entry 26 of 131

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157554
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030157554 A1

TITLE: Protein-protein complexes and methods of using same

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Giot, Loic	Madison	CT	US	
Eisen, Andrew	Rockville	MD	US	
Lewin, David A.	New Haven	CT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/23

ABSTRACT:

The invention provides complexes of at least two polypeptides, and methods of using the same. Purified complexes of two polypeptides are provided, including chimeric complexes, and chimeric polypeptides and complexes thereof are also provided, as are nucleic acids encoding chimeric polypeptides and vectors and cells containing the same. Also provided are methods of identifying agents that disrupt polypeptide complexes, methods of identifying complex or polypeptide in a sample, and for removing the same, methods of determining altered expression of a polypeptide in a subject, and methods of treating/preventing disorders involving altered levels of complex or polypeptide.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 27. Document ID: US 20030152570 A1

L16: Entry 27 of 131

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152570

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030152570 A1

TITLE: Method for retarding or precluding alzheimer's dementia

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettelby		CA	
Furesz, Shirley	Cambridge		CA	

US-CL-CURRENT: 424/140.1

ABSTRACT:

A method for treating a condition related to the development of Alzheimer's disease (AD) is disclosed. The method involves the removal of circulating autoantibodies of a biochemical marker or markers, specifically human glial fibrillary acidic protein (GFAP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), from the sera of a patient in an amount effective to reduce or eliminate phagocytosis of astrocytic cells. The invention further includes a process of immune system modulation effective for autoantibody removal.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 28. Document ID: US 20030143539 A1

L16: Entry 28 of 131

File: PGPB

Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143539

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030143539 A1

TITLE: Gene expression profiling of primary breast carcinomas using arrays of candidate genes

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bertucci, Francois	Marseille		FR	
Houlgatte, Remi	Marseille		FR	
Birnbaum, Daniel	Marseille		FR	
Nguyen, Catherine	Marseille		FR	
Viens, Patrice	Marseille		FR	
Fert, Vincent	Allauch		FR	

US-CL-CURRENT: 435/6; 536/23.1

ABSTRACT:

A polynucleotide library useful in the molecular characterization of a carcinoma, the library including a pool of polynucleotide sequences or subsequences thereof wherein the sequences or subsequences are overexpressed in tumor cells, further wherein the sequences or subsequences correspond substantially to any of the polynucleotide sequences set forth in any of SEQ ID NOS: 1-468 or the complement thereof.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 29. Document ID: US 20030139358 A1

L16: Entry 29 of 131

File: PGPB

Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030139358

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030139358 A1

TITLE: Novel human proteins, polynucleotides encoding them and methods of using the same

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Spytek, Kimberly A.	New Haven	CT	US	
Padigar, Muralidhara	Branford	CT	US	
Majumder, Kumud	Stamford	CT	US	
MacDougall, John R.	Hamden	CT	US	
Stone, David J.	Guilford	CT	US	
Gangolli, Esha A.	Madison	CT	US	
Spaderna, Steven K.	Berlin	CT	US	
Smithson, Glennda	Branford	CT	US	

US-CL-CURRENT: 514/44; 435/183, 435/320.1, 435/6, 435/69.1, 435/7.1, 514/12, 536/23.2

ABSTRACT:

The invention provides polypeptides, designated herein as POLYX polypeptides, as well as polynucleotides encoding POLYX polypeptides, and antibodies that

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.19&ref=16&dbname=PGPB,USPT,US...> 12/1/04

immunospecifically-bind to POLYX polypeptide or polynucleotide, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which the POLYX polypeptide, polynucleotide, and antibody are used in the detection, prevention, and treatment of a broad range of pathological states.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 30. Document ID: US 20030130827 A1

L16: Entry 30 of 131

File: PGPB

Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030130827

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030130827 A1

TITLE: Protein design automation for protein libraries

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bentzien, Joerg	White Plains	NY	US	
Dahiyat, Bassil I.	Altadena	CA	US	
Desjarlais, John R.	Pasadena	CA	US	
Hayes, Robert J.	Pasadena	CA	US	
Vielmetter, Jost	Altadena	CA	US	

US-CL-CURRENT: 703/11; 435/7.1

ABSTRACT:

The invention relates to the use of protein design automation (PDA.TM.) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 31. Document ID: US 20030129134 A1

L16: Entry 31 of 131

File: PGPB

Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129134

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030129134 A1

TITLE: Method of monitoring neuroprotective treatment

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chenard, Bertrand L.	Waterford	CT	US	

Friedman, David L.	Madison	CT	US
Kimmel, Lida	Chester	CT	US
Nelms, Linda F.	Gales Ferry	CT	US
Silber, B. Michael	Madison	CT	US
Soares, Holly D.	Noank	CT	US
Frost White, Walter JR.	Ledyard	CT	US

US-CL-CURRENT: 424/9.3; 435/7.92

ABSTRACT:

Methods for monitoring and evaluating the efficacy of neuroprotective treatment of a patient suffering from neurological damage by measuring the amount of at least one biomarker in a biological sample taken from the patient during or after treatment.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 32. Document ID: US 20030125246 A9

L16: Entry 32 of 131

File: PGPB

Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030125246

PGPUB-FILING-TYPE: corrected

DOCUMENT-IDENTIFIER: US 20030125246 A9

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.1

ABSTRACT:

The present invention relates to novel respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "respiratory system antigens," and the use of such respiratory system antigens for detecting disorders of the respiratory system, particularly the presence of cancer of respiratory system tissues and cancer metastases. More specifically, isolated respiratory system associated nucleic acid molecules are provided encoding novel respiratory system associated polypeptides. Novel respiratory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human respiratory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the respiratory system, including cancer of respiratory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the

production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 33. Document ID: US 20030119074 A1

L16: Entry 33 of 131

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119074

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030119074 A1

TITLE: Diagnosis and treatment of dementia utilizing thrombospondin

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Zhang, Rulin	Toronto		CA	

US-CL-CURRENT: 435/7.9

ABSTRACT:

A method for diagnosing various forms of dementia, including MCI, and Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically thrombospondin, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to thrombospondin, or alternatively an autoantibody to a thrombospondin antibody.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 34. Document ID: US 20030119064 A1

L16: Entry 34 of 131

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119064

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030119064 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars E.	Escondido	CA	US	
Dahlen, Jeffrey R.	San Diego	CA	US	
Kirchick, Howard J.	San Diego	CA	US	
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 35. Document ID: US 20030104635 A1

L16: Entry 35 of 131

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104635

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104635 A1

TITLE: Screening methods

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jakobsen, Bent Karsten	Wantage		GB	

US-CL-CURRENT: 436/518; 435/7.9

ABSTRACT:

The present invention provides methods for sequentially screening for compounds with the potential to interfere with low affinity receptor-ligand contacts using an interfacial optical assay, such as surface plasmon resonance (SPR). The method comprises contacting a candidate compound with an immobilized receptor, contacting the receptor, which may or may not have the candidate compound bound to it, with the ligand and detecting by interfacial optical assay whether or not the ligand or ligand-compound complex has bound to the receptor or receptor-compound complex. If the ligand binds, the method shows that the compound does not inhibit the receptor-ligand interaction. If the ligand does not bind, the method shows that the compound inhibits the receptor-ligand interaction. The method is particularly useful for screening for inhibitors of the interaction between MHC/peptide complex and T cell receptor, MHC/peptide complex and CD8 coreceptor or MHC/peptide complex and CD4 coreceptor.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 36. Document ID: US 20030104445 A1

L16: Entry 36 of 131

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104445
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030104445 A1

TITLE: RNA dependent RNA polymerase mediated protein evolution

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hayes, Robert J.	Pasadena	CA	US	
Aguinaldo, Anna-Marie	Altadena	CA	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.1, 435/91.2,
530/350, 536/23.2

ABSTRACT:

The invention relates to the use of RNA dependent RNA polymerase to generate libraries of proteins, and to methods of making and methods and compositions utilizing the libraries.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 37. Document ID: US 20030100503 A1

L16: Entry 37 of 131

File: PGPB

May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100503
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030100503 A1

TITLE: Neurogenic compositions and methods

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lukanidin, Eugene	Copenhagen		DK	
Bock, Elisabeth Marianne	Charlottenlund		DK	
Berezin, Vladimir	Copenhagen N.		DK	

US-CL-CURRENT: 514/12; 530/350

ABSTRACT:

The present invention has found that the Mts1 protein is expressed in white matter astrocytes in the spinal cord. Such expression is significantly increased following sciatic nerve injury or dorsal root injury, particularly in astrocytes surrounding

dorsal funiculus containing the central processes of the injured primary sensory neurons. The present invention has further demonstrated that Mts1 proteins administered extracellularly promote neurite outgrowth from neuronal cells. Based on these surprising findings, the present invention provides compositions and methods that are useful for the treatment of various neurological conditions characterized by death, degeneration or injury of neuronal cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 38. Document ID: US 20030100038 A1

L16: Entry 38 of 131

File: PGPB

May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100038
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030100038 A1

TITLE: Diagnostic assay for stroke

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hochstrasser, Denis Francois	Geneva		CH	
Sanchez, Jean-Charles	Geneva		CH	
Zimmerman, Catherine Gabrielle	Geneva		CH	

US-CL-CURRENT: 435/7.92

ABSTRACT:

Heart and brain fatty acid binding proteins (H-FABP, B-FABP) are markers for stroke. The invention provides a diagnostic assay for either of these markers, preferably by ELISA using anti-H-FABP or B-FABP antibody. Since H-FABP is also a marker for acute myocardial infarction (AMI), to distinguish stroke from AMI requires an assay specific to AMI, e.g. using troponin-I or creatine kinase-MB as a marker, also to be carried out.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 39. Document ID: US 20030092089 A1

L16: Entry 39 of 131

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092089
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092089 A1

TITLE: Method for diagnosing multiple sclerosis and an assay therefore

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moscarello, Mario Anthony	Toronto		CA	
Chamczuk, Andrea	Toronto		CA	

US-CL-CURRENT: 435/7.92

ABSTRACT:

This invention is directed toward a serum/plasma assay for the diagnosis and subsequent monitoring of patients with multiple sclerosis (MS). Assay performance characteristics indicate that the assay is accurate and repeatable. Using blood from patients with clinically definite multiple sclerosis, a clinical sensitivity of 77% and a specificity of 95% has been achieved through the measurement of circulating myelin basic protein autoantibodies. The assay provides a simple, rapid, and minimally invasive tool for the diagnosis and monitoring of progression of MS.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 40. Document ID: US 20030064416 A1

L16: Entry 40 of 131

File: PGPB

Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030064416
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030064416 A1

TITLE: Process for differential diagnosis of Alzheimer's dementia in patients exhibiting mild cognitive impairment

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Takahashi, Miyoko	North York		CA	

US-CL-CURRENT: 435/7.21

ABSTRACT:

A method for determining those patients suffering from mild cognitive impairment (MCI) who have a likelihood of progressing to Alzheimer's disease (AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 41. Document ID: US 20030054414 A1

L16: Entry 41 of 131

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054414
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054414 A1

TITLE: Diagnosis and treatment of early pre-type-1 diabetes utilizing glial fibrillary acidic protein

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Li, Xiaomao	Toronto		CA	

US-CL-CURRENT: 435/7.9; 436/514, 530/387.2

ABSTRACT:

This invention relates to the treatment and diagnosis of Type-1 Diabetes (T1D); particularly to the use of glial fibrillary acidic protein (GFAP) as a mediator of the disease; and most particularly to GFAP binding proteins useful for prediabetes screening and/or staging.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 42. Document ID: US 20030040602 A1

L16: Entry 42 of 131

File: PGPB

Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040602
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030040602 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1406 daltons

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular

sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 43. Document ID: US 20030032663 A1

L16: Entry 43 of 131

File: PGPB

Feb 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030032663

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030032663 A1

TITLE: Benzimidazole derivatives as therapeutic agents

PUBLICATION-DATE: February 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
M. Mjalli, Adnan M.	Jamestown	NC	US	
Gopalaswamy, Ramesh	Jamestown	NC	US	

US-CL-CURRENT: 514/394; 548/304.4

ABSTRACT:

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, .beta.-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 44. Document ID: US 20030032181 A1

L16: Entry 44 of 131

File: PGPB

Feb 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030032181

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030032181 A1

TITLE: Production of radial glial cells

PUBLICATION-DATE: February 13, 2003

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.19&ref=16&dbname=PGPB,USPT,US...> 12/1/04

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Weiss, Samuel	Calgary		CA	
Gregg, Christopher	Calgary		CA	

US-CL-CURRENT: 435/368

ABSTRACT:

The present invention relates to a method of producing radial glial cells from neural stem cells, particularly by contacting neural stem cells with epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2) and/or TGF.alpha.. Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) can optionally be added to enhance the effect of EGF, FGF-1 or TGF.alpha.. Also provided are methods of producing radial glial cells from ependymal cells, as well as methods of proliferating ependymal cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 45. Document ID: US 20030031681 A1

L16: Entry 45 of 131

File: PGPB

Feb 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030031681

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030031681 A1

TITLE: Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector

PUBLICATION-DATE: February 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
McCart, J. Andrea	Toronto	PA	CA	
Bartlett, David L.	Pittsburgh	MD	US	
Moss, Bernard	Bethesda		US	

US-CL-CURRENT: 424/186.1; 435/235.1, 435/456

ABSTRACT:

A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 46. Document ID: US 20030027234 A1

L16: Entry 46 of 131

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027234

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027234 A1

TITLE: Methods for detecting Down's syndrome

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pandian, Murugan R.	Mission Viejo	CA	US	
Lu, Julie Y.	Mission Viejo	CA	US	

US-CL-CURRENT: 435/7.93

ABSTRACT:

Methods for detecting Down's syndrome in a fetus of a pregnant woman include screening serum samples obtained from the pregnant woman for abnormal levels of invasive trophoblast antigen. In particular, serum levels of invasive trophoblast antigen are compared to a standard. The methods can also be practiced using at least one additional marker.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 47. Document ID: US 20030022381 A1

L16: Entry 47 of 131

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022381
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022381 A1

TITLE: Methods for detecting pregnancy

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pandian, Murugan R.	Mission Viejo	CA	US	
Lu, Julie Y.	Mission Viejo	CA	US	

US-CL-CURRENT: 436/65; 422/52, 422/61, 436/172, 436/56, 436/814, 436/906

ABSTRACT:

Methods for detecting pregnancy in a woman comprise screening a biological sample of the woman for pregnancy markers. The methods of the invention include chemiluminescent assays for the pregnancy markers. The methods of the invention also comprise utilizing at least two capture antibodies that specifically bind different epitopes of the pregnancy marker in one assay. The methods of the invention permit detection of pregnancy within about 7 days after ovulation or implantation.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 48. Document ID: US 20030013845 A1

L16: Entry 48 of 131

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030013845

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030013845 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	K00C	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 49. Document ID: US 20030008398 A1

L16: Entry 49 of 131

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008398

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008398 A1

TITLE: Self-enhancing, pharmacologically controllable expression systems

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mueller, Rolf	Marburg		DE	
Sedlacek, Hans-Harald	Marburg		DE	

ABSTRACT:

Self-enhancing, pharmacologically controllable expression systems The invention relates to a nucleic acid construct which constitutes a self-enhancing expression system and which comprises the following components:

at least one first structural gene that encodes an active compound;

at least one second structural gene that encodes a transcription factor protein; and

at least one activation sequence comprised of at least one sequence that binds the transcription factor protein and at least one promoter sequence;

wherein each activation sequence activates the expression of a structural gene and the expression of the transcription factor protein; and to the use of the nucleic acid construct for preparing a drug for treating diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 50. Document ID: US 20030004307 A1

L16: Entry 50 of 131

File: PGPB

Jan 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030004307

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030004307 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons

PUBLICATION-DATE: January 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

☐ 51. Document ID: US 20020193432 A1

L16: Entry 51 of 131

File: PGPB

Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020193432
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20020193432 A1

TITLE: Carboxamide derivatives as therapeutic agents

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mjalli, Adnan M. M.	Jamestown	NC	US	
Andrews, Robert C.	Jamestown	NC	US	
Gopalaswamy, Ramesh	Jamestown	NC	US	
Wysong, Chris	Winston-Salem	NC	US	

US-CL-CURRENT: 514/478; 514/617, 514/626, 560/159, 564/161

ABSTRACT:

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, .beta.-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

☐ 52. Document ID: US 20020192217 A1

L16: Entry 52 of 131

File: PGPB

Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020192217
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20020192217 A1

TITLE: Methods for regulation of immune responses to conditions involving mediator-induced pathology

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Calandra, Thierry	Lausanne		CH	
Roger, Thierry	Lausanne		CH	
Glauser, Michel P.	Lausanne		CH	

US-CL-CURRENT: 424/145.1; 514/44

ABSTRACT:

The present invention relates to methods for inhibiting the release and/or biological activity of the cytokine macrophage migration inhibitory factor (MIF). In particular, the invention relates to the uses of such methods for the treatment of various conditions involving mediator-induced diseases or pathology, which include, but are not limited to sepsis, severe sepsis, septic shock, inflammation, graft versus host disease, and/or autoimmune diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 53. Document ID: US 20020172676 A1

L16: Entry 53 of 131

File: PGPB

Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020172676

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020172676 A1

TITLE: Method of treatment of alzheimer's disease and device therefor

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Furesz, Shirley	Cambridge		CA	

US-CL-CURRENT: 424/140.1; 604/5.02

ABSTRACT:

A method and device for treating Alzheimer's disease (AD) is disclosed. The method involves the removal of circulating autoantibodies of a biochemical marker or markers, specifically human glial fibrillary acidic protein (GFAP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), in bodily fluid, preferably blood or a blood product. The invention further includes a device or process of immune system modulation effective for autoantibody removal.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 54. Document ID: US 20020169278 A1

L16: Entry 54 of 131

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169278
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169278 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of
1690 daltons

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/300; 435/69.3

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 55. Document ID: US 20020161188 A1

L16: Entry 55 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161188
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161188 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of
1020 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/328

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 56. Document ID: US 20020161187 A1

L16: Entry 56 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161187
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161187 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 57. Document ID: US 20020161186 A1

L16: Entry 57 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161186
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161186 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 58. Document ID: US 20020161185 A1

L16: Entry 58 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161185
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161185 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 59. Document ID: US 20020161184 A1

L16: Entry 59 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161184

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020161184 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 60. Document ID: US 20020161183 A1

L16: Entry 60 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161183
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161183 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 61. Document ID: US 20020161182 A1

L16: Entry 61 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161182
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161182 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 62. Document ID: US 20020161181 A1

L16: Entry 62 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161181

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020161181 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 63. Document ID: US 20020161180 A1

L16: Entry 63 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161180
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161180 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1896 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 64. Document ID: US 20020161179 A1

L16: Entry 64 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161179
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161179 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 65. Document ID: US 20020161177 A1

L16: Entry 65 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161177

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020161177 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2937 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 530/324

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 66. Document ID: US 20020160958 A1

L16: Entry 66 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160958
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160958 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1521 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 514/14; 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWAC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 67. Document ID: US 20020160533 A1

L16: Entry 67 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160533
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160533 A1

TITLE: Biopolymer marker indicative of disease state having a molecular of weight of 1525 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 436/518; 422/61, 436/173, 436/56

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.19&ref=16&dbname=PGPB,USPT,US...> 12/1/04

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMD	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 68. Document ID: US 20020160532 A1

L16: Entry 68 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160532

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020160532 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1998 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 436/518

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMD	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 69. Document ID: US 20020160531 A1

L16: Entry 69 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160531
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160531 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 436/518; 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 70. Document ID: US 20020160529 A1

L16: Entry 70 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160529
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160529 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Vrees, Tammy	Oakville		CA	
Yantha, Jason	Toronto		CA	
Marshall, John	Toronto		CA	

US-CL-CURRENT: 436/518; 422/61, 436/173, 436/56

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 71. Document ID: US 20020160528 A1

L16: Entry 71 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160528

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020160528 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 436/518; 422/61, 436/173, 436/56

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 72. Document ID: US 20020160434 A1

L16: Entry 72 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160434
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160434 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1777 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 435/7.92; 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 73. Document ID: US 20020160425 A1

L16: Entry 73 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160425
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160425 A1

TITLE: Process for differential diagnosis of Alzheimer's dementia and device therefor

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Takahashi, Miyoko	North York		CA	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.19&ref=16&dbname=PGPB,USPT,US...> 12/1/04

directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 74. Document ID: US 20020160423 A1

L16: Entry 74 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160423
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160423 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1536 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 75. Document ID: US 20020160422 A1

L16: Entry 75 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160422
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160422 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 76. Document ID: US 20020160421 A1

L16: Entry 76 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160421

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020160421 A1

TITLE: Method for monitoring and validating stress induction of disease state

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Stanton, Eric B.	Burlington		CA	

US-CL-CURRENT: 435/7.1; 435/6, 702/19, 702/20

ABSTRACT:

The present invention provides a biochemically-based methodology for ascertaining the presence and/or verifying the historical release of biopolymers, which have been shown to be indicative of a disease state or are predictive of the development of said disease state.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 77. Document ID: US 20020160420 A1

L16: Entry 77 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160420
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160420 A1

TITLE: Process for diagnosis of physiological conditions by characterization of proteomic materials

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 435/7.1; 435/7.5, 436/518, 702/19

ABSTRACT:

The present invention discloses the use of proteomic investigation as a diagnostic tool; and particularly teaches the use of proteomic investigative techniques and methodology to determine a proteomic basis for the development and progression of abnormal physiological conditions and the development and characterization of risk assessment, diagnostic and therapeutic means and methodologies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 78. Document ID: US 20020160419 A1

L16: Entry 78 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160419
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160419 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 79. Document ID: US 20020160418 A1

L16: Entry 79 of 131

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160418

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020160418 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1949 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Thatcher, Brad	Toronto		CA	
Marshall, John	Toronto		CA	
Yantha, Jason	Toronto		CA	
Vrees, Tammy	Oakville		CA	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 80. Document ID: US 20020160417 A1

PGPUB-DOCUMENT-NUMBER: 20020160417
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160417 A1

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackowski, George	Kettleby		CA	
Stanton, Eric B.	Burlington		CA	
Thatcher, Brad	Toronto		CA	
Vrees, Tammy	Oakville		CA	
Yantha, Jason	Toronto		CA	
Marshall, John	Toronto		CA	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 81. Document ID: US 20020151049 A1

L16: Entry 81 of 131

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151049
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020151049 A1

TITLE: Self-enhancing, pharmacologically controllable expression systems

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mueller, Rolf	Marburg		DE	
Sedlacek, Hans-Harald	Marburg		DE	

US-CL-CURRENT: 435/320.1; 514/44

ABSTRACT:

The invention relates to a nucleic acid construct which constitutes a self-enhancing expression system and which comprises the following components:

at least one first structural gene that encodes an active compound;

at least one second structural gene that encodes a transcription factor protein; and

at least one activation sequence comprised of at least one sequence that binds the transcription factor protein and at least one promoter sequence;

wherein each activation sequence activates the expression of a structural gene and the expression of the transcription factor protein; and to the use of the nucleic acid construct for preparing a drug for treating diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 82. Document ID: US 20020137699 A1

L16: Entry 82 of 131

File: PGPB

Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020137699

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020137699 A1

TITLE: EXPRESSION SYSTEMS COMPRISING CHIMERIC PROMOTERS WITH BINDING SITES FOR RECOMBINANT TRANSCRIPTION FACTORS

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
MUELLER, ROLF	MARBURG		DE	
NETTELBECK, DIRK	MARBURG		DE	
SEDLACEK, HANS-HARALD	MARBURG		DE	

US-CL-CURRENT: 514/44; 435/320.1, 435/455, 536/23.1, 536/23.2, 800/21

ABSTRACT:

Expression systems comprising chimeric promoters with binding sites for recombinant transcription factors The present invention relates to a nucleic acid construct which comprises the following components:

Component a): at least one promoter

Component b): a nucleic acid sequence encoding at least one recombinant transactivator whose transcription is activated by component a) and which comprises:

component b1): a nucleic acid sequence encoding a DNA-binding domain

component b2): a nucleic acid sequence encoding a transactivation domain comprising glutamine, serine and threonine

Component c): at least one a nucleic acid sequence sequence for binding the expression product of component b)

Component d): at least one promoter which comprises the CDE-CHR element or the E2FBS-CHR element and whose 5' end is bound, i.e., linked, to the 3' end of component c)

Component e): at least one effector gene whose transcription is activated by the expression product of component b) binding to component c);

to its preparation and its use; to vectors comprising the nucleic acid construct, cells comprising these vectors, and to the use of the nucleic acid construct for the preparation of a medicament.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 83. Document ID: US 20020106726 A1

L16: Entry 83 of 131

File: PGPB

Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106726

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020106726 A1

TITLE: Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schmidt, Ann Marie	Franklin Lakes	NJ	US	
Stern, David	Great Neck	NY	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction measured in step (b) with the amount measured between the peptide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound/thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 84. Document ID: US 20020099010 A1

L16: Entry 84 of 131

File: PGPB

Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020099010

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020099010 A1

TITLE: Neurogenic compositions and methods

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lukanidin, Eugene	Copenhagen		DK	
Bock, Elisabeth Marianne	Charlottenlund		DK	
Berezin, Vladimir	Copenhagen N.		DK	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/368, 435/69.1

ABSTRACT:

The present invention has found that the Mts1 protein is expressed in white matter astrocytes in the spinal cord. Such expression is significantly increased following sciatic nerve injury or dorsal root injury, particularly in astrocytes surrounding dorsal funiculus containing the central processes of the injured primary sensory neurons. The present invention has further demonstrated that Mts1 proteins administered extracellularly promote neurite outgrowth from neuronal cells. Based on these surprising findings, the present invention provides compositions and methods that are useful for the treatment of various neurological conditions characterized by death, degeneration or injury of neuronal cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KOMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 85. Document ID: US 20020086821 A1

L16: Entry 85 of 131

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086821

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086821 A1

TITLE: Nucleic acids, proteins, and antibodies

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	
Barash, Steven C.	Rockville	MD	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.1

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ghkli3.19&ref=16&dbname=PGPB,USPT,US...> 12/1/04

ABSTRACT:

The present invention relates to novel respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "respiratory system antigens," and the use of such respiratory system antigens for detecting disorders of the respiratory system, particularly the presence of cancer of respiratory system tissues and cancer metastases. More specifically, isolated respiratory system associated nucleic acid molecules are provided encoding novel respiratory system associated polypeptides. Novel respiratory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human respiratory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the respiratory system, including cancer of respiratory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 86. Document ID: US 20020048763 A1

L16: Entry 86 of 131

File: PGPB

Apr 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020048763

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020048763 A1

TITLE: Human genome-derived single exon nucleic acid probes useful for gene expression analysis

PUBLICATION-DATE: April 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Penn, Sharron Gaynor	San Mateo	CA	US	
Rank, David Russell	Fremont	CA	US	
Chen, Wensheng	Mountain View	CA	US	
Hanzel, David Kagen	Palo Alto	CA	US	

US-CL-CURRENT: 435/6; 536/24.3

ABSTRACT:

Methods and apparatus for predicting, confirming and displaying functional regions from genomic sequence data are used to identify 16,834 unique human genome-derived single exon probes useful for gene expression analysis, particularly gene expression analysis by microarray. Also presented are genome-derived single exon microarrays that include such probes, peptides encoded by the exons, and antibodies thereto.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 87. Document ID: US 20020006957 A1

L16: Entry 87 of 131

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006957

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006957 A1

TITLE: Method for the synthesis of compounds of formula I and their uses thereof

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mjalli, Adnan M.M.	Jamestown	NC	US	
Gopalaswamy, Ramesh	Greensboro	NC	US	
Avor, Kwasi S.	High Point	NC	US	
Wysong, Christopher L.	Winston-Salem	NC	US	
Patron, Andrew	San Diego	CA	US	

US-CL-CURRENT: 514/510; 514/514, 568/24, 568/48

ABSTRACT:

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, .beta.-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 88. Document ID: US 20010041349 A1

L16: Entry 88 of 131

File: PGPB

Nov 15, 2001

PGPUB-DOCUMENT-NUMBER: 20010041349

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010041349 A1

TITLE: Protein expression system arrays and use in biological screening

PUBLICATION-DATE: November 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Patron, Andrew	San Diego	CA	US	
Sawafta, Reyad	Greensboro	NC	US	

US-CL-CURRENT: 435/7.92; 435/6, 702/19

ABSTRACT:

The present invention relates to the generation of an array of protein expression systems for parallel in vitro screening of small molecule libraries, protein or peptide libraries, or other protein-binding components. In an aspect, the invention provides a spatially defined array of protein expression systems comprising: (a) a substrate; (b) a binding surface which covers some or all of the substrate surface; and (c) a plurality of discrete protein expression systems arranged in discrete positions on portions of said substrate covered by said binding surface. Also described are method of using the array for the rapid identification of compounds of able to interact with proteins expressed by any given array.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 89. Document ID: US 20010011126 A1

L16: Entry 89 of 131

File: PGPB

Aug 2, 2001

PGPUB-DOCUMENT-NUMBER: 20010011126

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010011126 A1

TITLE: NEUROGENIC COMPOSITIONS AND METHODS

PUBLICATION-DATE: August 2, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BOCK, ELISABETH MARIANNE	CHARLOTTENLUND		DK	
BEREZIN, VLADIMIR	COPENHAGEN		DK	
LUKANIDIN, EUGENE	COPENHAGEN		DK	

US-CL-CURRENT: 530/324; 530/350

ABSTRACT:

The present invention has found that the Mts1 protein is expressed in white matter astrocytes in the spinal cord. Such expression is significantly increased following sciatic nerve injury or dorsal root injury, particularly in astrocytes surrounding dorsal funiculus containing the central processes of the injured primary sensory neurons. The present invention has further demonstrated that Mts1 proteins administered extracellularly promote neurite outgrowth from neuronal cells. Based on these surprising findings, the present invention provides compositions and methods that are useful for the treatment of various neurological conditions characterized by death, degeneration or injury of neuronal cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 90. Document ID: US 20010007657 A1

PGPUB-DOCUMENT-NUMBER: 20010007657
 PGPUB-FILING-TYPE: new-utility
 DOCUMENT-IDENTIFIER: US 20010007657 A1

TITLE: Compositions and methods for manipulating glial progenitor cells and treating neurological deficits

PUBLICATION-DATE: July 12, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Reid, James Steven	Berkeley	CA	US	
Fallon, James H.	Irvine	CA	US	

US-CL-CURRENT: 424/93.7

ABSTRACT:

The invention provides compositions and methods for attracting glial and neuronal progenitor cells and their progeny to desired sites within the central nervous system tissue. These compositions and methods can also be used to induce directed differentiation of these cells. By providing various ways to generate new glial and neuronal cells from endogenous progenitor cells, the invention also provides methods for inducing regeneration of tissues and neurological function, and, indeed, generating new phenotypes and capabilities. Thus, the invention features methods and compositions for ameliorating neurological deficits, including inherited disorders, trauma, infections and the like.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 91. Document ID: US 6780606 B1

L16: Entry 91 of 131

File: USPT

Aug 24, 2004

US-PAT-NO: 6780606
 DOCUMENT-IDENTIFIER: US 6780606 B1

TITLE: Method for diagnosing and distinguishing stroke and diagnostic devices for use therein

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA

US-CL-CURRENT: 435/7.92; 422/50, 422/60, 422/61, 424/184.1, 424/9.1, 435/7.2, 435/7.21, 436/501, 436/514, 436/518, 436/524

ABSTRACT:

A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected

markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.

30 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 92. Document ID: US 6759518 B1

L16: Entry 92 of 131

File: USPT

Jul 6, 2004

US-PAT-NO: 6759518

DOCUMENT-IDENTIFIER: US 6759518 B1

TITLE: Single-chain multiple antigen-binding molecule, its preparation and use

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kontermann; Roland	Ebsdorfergrund			DE
Sedlacek; Hans-Harald	Marburg			DE
Mueller; Rolf	Marburg			DE

US-CL-CURRENT: 530/387.3; 435/320.1, 530/387.7, 536/23.1

ABSTRACT:

The present invention relates to a single-chain, multiple antigen-binding molecule with diverse variable domains of a heavy and of a light chain of an immunoglobulin, which are connected in the form of a VH-VL construct, which are in turn connected together via a peptide, and to the preparation and use thereof as pharmaceutical or diagnostic aid.

19 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 93. Document ID: US 6756476 B2

L16: Entry 93 of 131

File: USPT

Jun 29, 2004

US-PAT-NO: 6756476

DOCUMENT-IDENTIFIER: US 6756476 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.19&ref=16&dbname=PGPB,USPT,US...> 12/1/04

DATE-ISSUED: June 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 530/300; 435/7.1, 435/7.2, 436/173, 436/174, 436/501, 436/63, 436/86, 436/89, 530/387.9, 530/388.25, 530/391.3, 530/412

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Drawn Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 94. Document ID: US 6703366 B2

L16: Entry 94 of 131

File: USPT

Mar 9, 2004

US-PAT-NO: 6703366

DOCUMENT-IDENTIFIER: US 6703366 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1,896 daltons

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby, Ontario		L0G 1J0	CA
Thatcher; Brad	Toronto, Ontario		M8Y 3Y4	CA
Marshall; John	Toronto, Ontario		M6R 2V3	CA
Yantha; Jason	Toronto, Ontario		M4Y 2W4	CA
Vrees; Tammy	Oakville, Ontario		L6L 3C5	CA

US-CL-CURRENT: 514/13; 436/173, 436/174, 436/501, 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 95. Document ID: US 6693080 B2

L16: Entry 95 of 131

File: USPT

Feb 17, 2004

US-PAT-NO: 6693080
DOCUMENT-IDENTIFIER: US 6693080 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1521 daltons

DATE-ISSUED: February 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/14; 436/173, 436/174, 436/501, 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 96. Document ID: US 6677303 B2

L16: Entry 96 of 131

File: USPT

Jan 13, 2004

US-PAT-NO: 6677303

DOCUMENT-IDENTIFIER: US 6677303 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons

DATE-ISSUED: January 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/2; 436/173, 436/174, 436/501, 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 97. Document ID: US 6670147 B1

L16: Entry 97 of 131

File: USPT

Dec 30, 2003

US-PAT-NO: 6670147

DOCUMENT-IDENTIFIER: US 6670147 B1

TITLE: Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Heidtmann; Hans Heinrich	Marburg			DE
Mueller; Rolf	Marburg			DE

US-CL-CURRENT: 435/69.1; 435/252.3, 435/325, 435/70.1, 530/350, 536/23.1

ABSTRACT:

The invention relates to a nucleic acid construct for expressing an active substance which is activated by an enzyme which is released from mammalian cells, which construct comprises the following components: a) at least one promoter element, b) at least one DNA sequence which encodes an active compound (protein B), c) a least one DNA sequence which encodes an amino acid sequence (part structure C) which can be cleaved specifically by an enzyme which is released from a mammalian cell, and d) at least one DNA sequence which encodes a peptide or protein (part structure D) which is bound to the active compound (protein B) by way of the cleavable amino acid sequence (part structure C) and inhibits the activity of the active compound (protein B), and also to the use of the nucleic acid construct for preparing a drug for treating diseases.

7 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	K00C	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 98. Document ID: US 6670136 B2

L16: Entry 98 of 131

File: USPT

Dec 30, 2003

US-PAT-NO: 6670136

DOCUMENT-IDENTIFIER: US 6670136 B2

TITLE: Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schmidt; Ann Marie	Franklin Lakes	NJ		
Stern; David	Great Neck	NY		

US-CL-CURRENT: 435/7.1; 530/324, 530/350, 530/388.1, 530/389.1

ABSTRACT:

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction measured in step (b) with the amount measured between the peptide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting

inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

2 Claims, 27 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 27

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 99. Document ID: US 6638504 B1

L16: Entry 99 of 131

File: USPT

Oct 28, 2003

US-PAT-NO: 6638504

DOCUMENT-IDENTIFIER: US 6638504 B1

**** See image for Certificate of Correction ****

TITLE: Methods for treating cancer

DATE-ISSUED: October 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lukanidin; Eugene	Copenhagen			DK

US-CL-CURRENT: 424/130.1; 435/4, 435/7.1

ABSTRACT:

The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as tseful model systems for in vitro and in vivo anti-metastasis drug screening.

5 Claims, 46 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 100. Document ID: US 6627608 B2

L16: Entry 100 of 131

File: USPT

Sep 30, 2003

US-PAT-NO: 6627608

DOCUMENT-IDENTIFIER: US 6627608 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ghkli3.19&ref=16&dbname=PGPB,USPT,US...> 12/1/04

1206 daltons

DATE-ISSUED: September 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/14; 436/173, 436/174, 436/501, 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 5

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L14 AND L15	131

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 101 through 131 of 131 returned.

☐ 101. Document ID: US 6627607 B2

Using default format because multiple data bases are involved.

L16: Entry 101 of 131

File: USPT

Sep 30, 2003

US-PAT-NO: 6627607

DOCUMENT-IDENTIFIER: US 6627607 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons

DATE-ISSUED: September 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/13; 436/173, 436/174, 436/501, 530/326

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	Draw-Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	----------

☐ 102. Document ID: US 6627606 B2

L16: Entry 102 of 131

File: USPT

Sep 30, 2003

US-PAT-NO: 6627606

DOCUMENT-IDENTIFIER: US 6627606 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons

DATE-ISSUED: September 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/13; 436/173, 436/174, 436/501, 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 103. Document ID: US 6627457 B2

L16: Entry 103 of 131

File: USPT

Sep 30, 2003

US-PAT-NO: 6627457

DOCUMENT-IDENTIFIER: US 6627457 B2

**** See image for Certificate of Correction ****

TITLE: Methods for detecting pregnancy

DATE-ISSUED: September 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pandian; Murugan R.	Mission Viejo	CA		
Lu; Julie Y.	Mission Viejo	CA		

US-CL-CURRENT: 436/501; 435/7.1, 435/7.8, 436/510, 436/536, 436/542, 436/65, 436/804, 436/818, 436/824, 530/387.5, 530/388.24, 530/389.2

ABSTRACT:

Methods for detecting pregnancy in a woman comprise screening a biological sample of the woman for pregnancy markers. The methods of the invention include chemiluminescent assays for the pregnancy markers. The methods of the invention also comprise utilizing at least two capture antibodies that specifically bind different epitopes of the pregnancy marker in one assay. The methods of the invention permit detection of pregnancy within about 7 days after ovulation or implantation.

37 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 104. Document ID: US 6620787 B2

L16: Entry 104 of 131

File: USPT

Sep 16, 2003

US-PAT-NO: 6620787

DOCUMENT-IDENTIFIER: US 6620787 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons

DATE-ISSUED: September 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettelby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/12; 436/173, 436/174, 436/501, 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 105. Document ID: US 6620786 B2

L16: Entry 105 of 131

File: USPT

Sep 16, 2003

US-PAT-NO: 6620786

DOCUMENT-IDENTIFIER: US 6620786 B2

TITLE: Biopolymer marker indicative of disease state having molecular weight of 2937 daltons

DATE-ISSUED: September 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA

Marshall; John	Toronto	CA
Yantha; Jason	Toronto	CA
Vrees; Tammy	Oakville	CA

US-CL-CURRENT: 514/12; 436/173, 436/174, 436/501, 530/324

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures

Exemplary Claim Number: 5

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 106. Document ID: US 6617308 B2

L16: Entry 106 of 131

File: USPT

Sep 9, 2003

US-PAT-NO: 6617308

DOCUMENT-IDENTIFIER: US 6617308 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons

DATE-ISSUED: September 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/13; 436/173, 436/174, 436/501, 530/326

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 107. Document ID: US 6613801 B2

L16: Entry 107 of 131

File: USPT

Sep 2, 2003

US-PAT-NO: 6613801

DOCUMENT-IDENTIFIER: US 6613801 B2

TITLE: Method for the synthesis of compounds of formula I and their uses thereof

DATE-ISSUED: September 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mjalli; Adnan M. M.	Jamestown	NC		
Gopalaswamy; Ramesh	Greensboro	NC		
Avor; Kwasi S.	High Point	NC		
Wysong; Christopher L.	Winston-Salem	NC		
Patron; Andrew	San Diego	CA		

US-CL-CURRENT: 514/514; 514/516, 564/155

ABSTRACT:

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, .beta.-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

27 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 108. Document ID: US 6602855 B2

L16: Entry 108 of 131

File: USPT

Aug 5, 2003

US-PAT-NO: 6602855

DOCUMENT-IDENTIFIER: US 6602855 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons

DATE-ISSUED: August 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/14; 436/173, 436/174, 436/501, 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 3 Drawing figures
Exemplary Claim Number: 5
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Drawings	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	----------	--------	-----	----------

☐ 109. Document ID: US 6599877 B2

L16: Entry 109 of 131

File: USPT

Jul 29, 2003

US-PAT-NO: 6599877

DOCUMENT-IDENTIFIER: US 6599877 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/2; 436/173, 436/174, 436/501, 530/328

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 5
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 110. Document ID: US 6593298 B2

L16: Entry 110 of 131

File: USPT

Jul 15, 2003

US-PAT-NO: 6593298

DOCUMENT-IDENTIFIER: US 6593298 B2

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Thatcher; Brad	Toronto			CA
Marshall; John	Toronto			CA
Yantha; Jason	Toronto			CA
Vrees; Tammy	Oakville			CA

US-CL-CURRENT: 514/14; 436/173, 436/174, 436/501, 530/327

ABSTRACT:

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

9 Claims, 4 Drawing figures
Exemplary Claim Number: 5
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 111. Document ID: US 6555340 B1

L16: Entry 111 of 131

File: USPT

Apr 29, 2003

US-PAT-NO: 6555340

DOCUMENT-IDENTIFIER: US 6555340 B1

TITLE: Nucleic acid encoding bovine extracellular rage binding protein (en-rage)

DATE-ISSUED: April 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schmidt; Ann Marie	Franklin Lakes	NJ		
Stern; David	Great Neck	NY		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 536/23.5

ABSTRACT:

The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

14 Claims, 36 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 27

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 112. Document ID: US 6537794 B1

L16: Entry 112 of 131

File: USPT

Mar 25, 2003

US-PAT-NO: 6537794

DOCUMENT-IDENTIFIER: US 6537794 B1

TITLE: Chemokine

DATE-ISSUED: March 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lesslauer; Werner	Riehen			CH
Utans-Schneitz; Ulrike	Basel			CH

US-CL-CURRENT: 435/252.3; 435/252.33, 435/254.11, 435/320.1, 435/325, 435/69.1

ABSTRACT:

The present invention relates to the discovery of novel genes and proteins, which function in pathways involved in brain pathogenesis. In particular, the novel genes and proteins relate to inflammatory tissue responses caused by brain injuries such as trauma, ischemia or autoimmune-inflammation or other diseases or processes related to neuroinflammation. The compounds disclosed in the present invention are useful as therapeutics, diagnostics and in screening assays.

4 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 113. Document ID: US 6482618 B2

L16: Entry 113 of 131

File: USPT

Nov 19, 2002

US-PAT-NO: 6482618
DOCUMENT-IDENTIFIER: US 6482618 B2

TITLE: Self-enhancing, pharmacologically controllable expression systems

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mueller; Rolf	Marburg			DE
Sedlacek; Hans-Harald	Marburg			DE

US-CL-CURRENT: 435/91.41; 435/320.1, 435/325, 536/23.4, 536/24.1

ABSTRACT:

The invention relates to a nucleic acid construct which constitutes a self-enhancing expression system and which comprises the following components: at least one first structural gene that encodes an active compound; at least one second structural gene that encodes a transcription factor protein; and at least one activation sequence comprised of at least one sequence that binds the transcription factor protein and at least one promoter sequence;

wherein each activation sequence activates the expression of a structural gene and the expression of the transcription factor protein; and to the use of the nucleic acid construct for preparing a drug for treating diseases.

17 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 114. Document ID: US 6465246 B1

L16: Entry 114 of 131

File: USPT

Oct 15, 2002

US-PAT-NO: 6465246

DOCUMENT-IDENTIFIER: US 6465246 B1

TITLE: Oncogene- or virus-controlled expression systems

DATE-ISSUED: October 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mueller; Rolf	Marburg			DE
Sedlacek; Hans-Harald	Marburg			DE

US-CL-CURRENT: 435/320.1; 435/325, 435/375, 435/69.1, 435/69.7, 435/91.1, 435/91.4,
530/352, 530/358, 536/23.1, 536/23.4 , 536/23.5, 536/23.72

ABSTRACT:

Nucleic acid constructs for expressing an effector gene, with the nucleic acid construct comprising a promoter I (component a) which controls the expression of a transcription factor gene (component b), a transcription factor gene (component b), a promoter II (component c) to which the gene product of the transcription factor gene binds and which controls the expression of an effector gene (component d), and effector gene (component d), wherein the activity of the gene product of the transcription factor gene depends on one or more cellular regulatory proteins which bind to this gene product and affect its activity, and isolated cells containing the nucleic acid constructs, can be used for preparing a drug for treating diseases and in methods of treating diseases.

2 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 115. Document ID: US 6461828 B1

L16: Entry 115 of 131

File: USPT

Oct 8, 2002

US-PAT-NO: 6461828

DOCUMENT-IDENTIFIER: US 6461828 B1

TITLE: Conjunctive analysis of biological marker expression for diagnosing organ failure

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stanton; Eric B.	Burlington			CA
Jackowski; George	Kettleby			CA

US-CL-CURRENT: 435/7.92; 422/60, 422/61, 435/7.93, 435/7.94, 435/969, 435/970,
435/973, 435/975, 436/514, 436/518, 436/528, 436/530, 436/807, 436/808, 436/810

ABSTRACT:

A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 116. Document ID: US 6451547 B1

L16: Entry 116 of 131

File: USPT

Sep 17, 2002

US-PAT-NO: 6451547

DOCUMENT-IDENTIFIER: US 6451547 B1

TITLE: Process for differential diagnosis of Alzheimer's dementia and device therefor

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA
Takahashi; Miyoko	North York			CA

US-CL-CURRENT: 435/7.4; 435/7.1, 435/7.9, 435/7.92, 435/7.93, 435/7.94, 435/7.95,
530/387.2, 530/388.1, 530/388.25, 530/388.26, 530/389.1, 530/389.3, 530/391.1

ABSTRACT:

A method for diagnosing Alzheimer's disease(AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.

13 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 117. Document ID: US 6383785 B1

L16: Entry 117 of 131

File: USPT

May 7, 2002

US-PAT-NO: 6383785

DOCUMENT-IDENTIFIER: US 6383785 B1

TITLE: Self-enhancing, pharmacologically controllable expression systems

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mueller; Rolf	Marburg			DE
Sedlacek; Hans-Harald	Marburg			DE

US-CL-CURRENT: 435/91.41; 435/320.1, 435/325, 536/23.4, 536/24.1

ABSTRACT:

The invention relates to a nucleic acid construct which constitutes a self-enhancing expression system and which comprises the following components:

at least one first structural gene that encodes an active compound;

at least one second structural gene that encodes a transcription factor protein; and

at least one activation sequence comprised of at least one sequence that binds the transcription factor protein and at least one promoter sequence;

wherein each activation sequence activates the expression of a structural gene and the expression of the transcription factor protein; and to the use of the nucleic acid construct for preparing a drug for treating diseases.

12 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 118. Document ID: US 6380170 B1

L16: Entry 118 of 131

File: USPT

Apr 30, 2002

US-PAT-NO: 6380170

DOCUMENT-IDENTIFIER: US 6380170 B1

TITLE: Nucleic acid construct for the cell cycle regulated expression of structural genes

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Muller; Rolf	Marburg			DE
Liu; Ningshu	Marburg			DE
Zwicker; Jork	Marburg			DE
Sedlacek; Hans-Harald	Marburg			DE

US-CL-CURRENT: 514/44; 424/93.2, 435/320.1, 435/325, 435/455, 536/23.1, 536/24.1

ABSTRACT:

The invention refers to a nucleic acid construct comprising at least one activator sequence, at least one chimeric promoter module comprising a nucleotide sequence which binds a protein of the E2F family and a protein of the CDF-1 family, and at least one gene, wherein said chimeric promoter module promotes expression of the gene in the cell cycle later than the B-myb promoter but earlier than the cdc25C promoter. The invention also concerns the purification and identification of CDF-1 protein, and use of this protein to develop new control systems.

16 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 119. Document ID: US 6358732 B1

L16: Entry 119 of 131

File: USPT

Mar 19, 2002

US-PAT-NO: 6358732

DOCUMENT-IDENTIFIER: US 6358732 B1

TITLE: DNA for expression under control of a cell cycle-dependent promoter

DATE-ISSUED: March 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sedlacek; Hans-Harald	Marburg			DE
Muller; Rolf	Marburg			DE

US-CL-CURRENT: 435/320.1; 424/93.2, 435/375, 435/455, 514/44, 536/23.1, 536/23.5, 536/24.1

ABSTRACT:

A DNA sequence is disclosed for the genetic therapy of diseases of the central nervous system. The essential components for the DNA sequence are the activator sequence, the promoter module, and the active substance coding gene. The activator sequence is specifically activated in activated endothelial or glial cells. Activation is cell cycle-regulated by the promoter module. The active substance represents an inhibitor of the nerve growth factor, a dopamine metabolism enzyme, and/or a nerve cell protection factor. The disclosed DNA sequence is inserted into a viral or non-viral vector, supplemented with a ligand with affinity for the target cells.

16 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 120. Document ID: US 6265562 B1

US-PAT-NO: 6265562

DOCUMENT-IDENTIFIER: US 6265562 B1

TITLE: Nucleic acid constructs whose activity is affected by inhibitors of cyclin-dependent kinases and uses thereof

DATE-ISSUED: July 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Eilers; Martin	Marburg			DE
Buerger; Andrea	Marburg			DE
Sedlacek; Hans-Harald	Marburg			DE

US-CL-CURRENT: 536/23.4; 536/23.1, 536/23.5

ABSTRACT:

The present application discloses nucleic acid constructs comprising nucleic acids which encode a protein which inhibits the cellular protein p27 and thereby relieves the inhibition of the proliferation of the cell which is brought about by p27, fragments and variants thereof, some of which possess a dominant interfering character.

28 Claims, 25 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 25

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 121. Document ID: US 6235489 B1

L16: Entry 121 of 131

File: USPT

May 22, 2001

US-PAT-NO: 6235489

DOCUMENT-IDENTIFIER: US 6235489 B1

TITLE: Method for diagnosing and distinguishing stroke and diagnostic devices for use therein

DATE-ISSUED: May 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jackowski; George	Kettleby			CA

US-CL-CURRENT: 435/7.92; 422/55, 422/56, 422/58, 422/60, 422/61, 424/9.1, 435/13, 435/4, 435/5, 435/6, 435/7.1, 435/7.21, 435/7.4, 435/7.9, 435/7.94, 435/7.95, 435/9, 435/969, 435/970, 435/973, 435/975, 436/161, 436/164, 436/514, 436/528, 436/530, 436/531, 436/807, 436/808, 436/810, 436/811

ABSTRACT:

A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.

19 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 122. Document ID: US 6080575 A

L16: Entry 122 of 131

File: USPT

Jun 27, 2000

US-PAT-NO: 6080575

DOCUMENT-IDENTIFIER: US 6080575 A

TITLE: Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use

DATE-ISSUED: June 27, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Heidtmann; Hans Heinrich	Marburg			DE
Mueller; Rolf	Marburg			DE
Sedlacek; Hans-Harald	Marburg			DE

US-CL-CURRENT: 435/320.1; 435/456, 435/464, 536/23.1

ABSTRACT:

The invention relates to a nucleic acid construct for expressing an active substance which is activated by an enzyme which is released from mammalian cells, which construct comprises the following components: a) at least one promoter element, b) at least one DNA sequence which encodes an active compound (protein B) c) a least one DNA sequence which encodes an amino acid sequence (part structure C) which can be cleaved specifically by an enzyme which is released from a mammalian cell, and d) at least one DNA sequence which encodes a peptide or protein (part structure D) which is bound to the active compound (protein B) by way of the cleavable amino acid sequence (part structure C) and inhibits the activity of the active compound (protein B), and also to the use of the nucleic acid construct for preparing a drug for treating diseases.

22 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 123. Document ID: US 6057426 A

L16: Entry 123 of 131

File: USPT

May 2, 2000

US-PAT-NO: 6057426

DOCUMENT-IDENTIFIER: US 6057426 A

TITLE: Chemokine

DATE-ISSUED: May 2, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lesslauer; Werner	Riehen			CH
Utans-Schneitz; Ulrike	Basel			CH

US-CL-CURRENT: 530/351; 424/85.1, 430/140, 530/402, 530/408, 530/409, 530/410,
530/810, 530/812

ABSTRACT:

The present invention relates to the discovery of novel genes and proteins, which function in pathways involved in brain pathogenesis. In particular, the novel genes and proteins relate to inflammatory tissue responses caused by brain injuries such trauma, ischemia or autoimmune-inflammation or other diseases or processes related to neuroinflammation. The compounds disclosed in the present invention are useful as therapeutics, diagnostics and in screening assays.

7 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-----	----------

☐ 124. Document ID: US 5990080 A

L16: Entry 124 of 131

File: USPT

Nov 23, 1999

US-PAT-NO: 5990080

DOCUMENT-IDENTIFIER: US 5990080 A

TITLE: Use of protein S-100-b in medicines containing the protein S-100b

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Haglid; Kenneth G.	Hov.ang.s			SE

US-CL-CURRENT: 514/2; 424/400, 514/12, 530/300, 530/324

ABSTRACT:

The present invention concerns the use of the protein S-100b in medicines for the stimulation of growth and survival of damaged neurons. The invention includes as well

a medicine containing the S-100b protein in an aqueous solution which may contain also other biocompatible substances.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 125. Document ID: US 5989827 A

L16: Entry 125 of 131

File: USPT

Nov 23, 1999

US-PAT-NO: 5989827
DOCUMENT-IDENTIFIER: US 5989827 A

TITLE: Use of nuclear magnetic resonance to design ligands to target biomolecules

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fesik; Stephen W.	Gurnee	IL		
Hajduk; Philip J.	Palatine	IL		
Olejniczak; Edward T.	Grayslake	IL		

US-CL-CURRENT: 435/7.1; 436/173, 436/501

ABSTRACT:

The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional $^{15}\text{N}/^1\text{H}$ NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional $^{15}\text{N}/^1\text{H}$ NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.

8 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 126. Document ID: US 5891643 A

L16: Entry 126 of 131

File: USPT

Apr 6, 1999

US-PAT-NO: 5891643
DOCUMENT-IDENTIFIER: US 5891643 A

**** See image for Certificate of Correction ****

TITLE: Use of nuclear magnetic resonance to design ligands to target biomolecules

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fesik; Stephen W.	Gurnee	IL		
Hajduk; Philip J.	Palatine	IL		
Olejniczak; Edward T.	Grayslake	IL		

US-CL-CURRENT: 435/7.1; 436/173, 436/501

ABSTRACT:

The present invention provides a process of designing compounds which bind to a specific target molecule. The process includes the steps of a) identifying a first ligand to the target molecule using two-dimensional ¹⁵N/¹H NMR correlation spectroscopy; b) identifying a second ligand to the target molecule using two-dimensional ¹⁵N/¹H NMR correlation spectroscopy; c) forming a ternary complex by binding the first and second ligands to the target molecule; d) determining the three dimensional structure of the ternary complex and thus the spatial orientation of the first and second ligands on the target molecule; and e) linking the first and second ligands to form the drug, wherein the spatial orientation of step (d) is maintained.

8 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KOMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 127. Document ID: US 5801184 A

L16: Entry 127 of 131

File: USPT

Sep 1, 1998

US-PAT-NO: 5801184

DOCUMENT-IDENTIFIER: US 5801184 A

TITLE: Carbon monoxide dependent guanylyl cyclase modifiers and methods of use

DATE-ISSUED: September 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Glasky; Alvin J.	Tustin	CA	92680	
Rathbone; Michel P.	Hamilton, Ontario			CA

US-CL-CURRENT: 514/310; 514/263.38, 544/265, 544/276

ABSTRACT:

Disclosed herein are methods directed generally to the control of neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for

specific naturally occurring molecules such as neurotrophic factors through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, and cellular disorders.

16 Claims, 39 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 128. Document ID: US 5627047 A

L16: Entry 128 of 131

File: USPT

May 6, 1997

US-PAT-NO: 5627047

DOCUMENT-IDENTIFIER: US 5627047 A

TITLE: Astrocyte-specific transcription of human genes

DATE-ISSUED: May 6, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brenner; Michael	Gaithersburg	MD		
Besnard; Francois	Rockville	MD		
Nakatani; Yoshihiro	Bethesda	MD		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/354, 435/368, 435/69.7, 536/23.4, 536/23.5, 536/24.1

ABSTRACT:

Three unique control DNA sequences of the glial fibrillary acidic (gfa) protein gene have been identified upstream of its basal promoter that are capable of regulating astrocyte-specific transcription of the human gene for glial fibrillary acidic protein (GFAP). One or more of those three regions alone or together with the SV40 early promoter and SV40 enhancer control expression of endogenous or heterologous protein in astrocytes. Transgenic animals expressing amyloid protein can be prepared and used as a model for evaluating Alzheimer's disease. Many heterologous proteins can be expressed in the astrocytes so as to take advantage of the growing list of astrocyte functions. Such proteins include hormones, growth factors, and their receptors. Examples include basic fibroblast growth factor (bFGF), acidic FGF (aFGF), platelet derived growth factor (PDGF), insulin like growth factors 1 and 2 (IGF-1, IGF-2), epidermal growth factor (EGF), transforming growth factors .beta.-1 and .beta.-2 (TGF.beta.1, TGF.beta.2), and S100.beta.; other examples totalled proteins encoded by oncogenes like myc, fos, and erb-a, ion channels, like the calcium channel and the potassium channel, and metabolic enzymes, especially ones involved in processing drugs or neurotransmitters; e.g., glutamine synthetase. Additionally, in each case, a dominant dysfunctional protein, an antisense RNA, or a ribozyme, all of which can inhibit the function or production of the protein, can be expressed in astrocytes.

37 Claims, 7 Drawing figures
Exemplary Claim Number: 1,28
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 129. Document ID: US 5447939 A

L16: Entry 129 of 131

File: USPT

Sep 5, 1995

US-PAT-NO: 5447939

DOCUMENT-IDENTIFIER: US 5447939 A

TITLE: Carbon monoxide dependent guanylyl cyclase modifiers and methods of use

DATE-ISSUED: September 5, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Glasky; Alvin J.	Tustin	CA	92680	
Rathbone; Michael P.	Hamilton, Ontario			CA

US-CL-CURRENT: 514/310; 514/263.37, 514/263.38, 544/265, 544/276

ABSTRACT:

Disclosed herein are methods directed generally to the control of neural activity and to the treatment of neural disorders. More particularly, the present invention is directed to methods for the modification of mammalian neural activity through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative and neurological disorders.

39 Claims, 39 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 130. Document ID: US 5274550 A

L16: Entry 130 of 131

File: USPT

Dec 28, 1993

US-PAT-NO: 5274550

DOCUMENT-IDENTIFIER: US 5274550 A

TITLE: Blood alcohol level determining device

DATE-ISSUED: December 28, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Greenlee; Robert J.	Wausau	WI	54401	

US-CL-CURRENT: 73/23.3

ABSTRACT:

A blood alcohol level determining device for calculating the blood alcohol level of a person, the blood alcohol level determining device comprising: first memory structure for storing characteristic information regarding the person; second memory structure for storing characteristic information regarding an alcoholic beverage; human interface structure for receiving, from a human operator of the device, information regarding the characteristics of the person and the characteristics of an alcoholic beverage, the interface structure communicating with the first and second memory structure; clock structure for measuring time; and structure communicating with the clock structure, with the first memory structure, and with the second memory structure, for calculating a blood alcohol level for the person based on the characteristics of the alcoholic beverage, the characteristics of the person, and time measured by the clock structure.

14 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 131. Document ID: WO 9801471 A1, AU 9735633 A, NO 9806218 A, NZ 333408 A, EP 931094 A1, HU 9902836 A2, AU 715797 B, BR 9710175 A, JP 2000515854 W

L16: Entry 131 of 131

File: DWPI

Jan 15, 1998

DERWENT-ACC-NO: 1998-100999

DERWENT-WEEK: 200423

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Peptide(s) from human brain protein S100beta fragments useful in S100 assay - by producing antibodies directed to the peptide(s), useful e.g. for diagnosis and monitoring of cerebral dysfunction and melanoma cancer

INVENTOR: BRUNDELL, J; NYBERG, L

PRIORITY-DATA: 1996SE-0002677 (July 5, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9801471 A1</u>	January 15, 1998	E	029	C07K014/435
<u>AU 9735633 A</u>	February 2, 1998		000	C07K014/435
<u>NO 9806218 A</u>	December 30, 1998		000	C07K014/435
<u>NZ 333408 A</u>	May 28, 1999		000	C07K014/435
<u>EP 931094 A1</u>	July 28, 1999	E	000	C07K014/435
<u>HU 9902836 A2</u>	December 28, 1999		000	C07K014/435
<u>AU 715797 B</u>	February 10, 2000		000	C07K014/435
<u>BR 9710175 A</u>	January 11, 2000		000	C07K014/435
<u>JP 2000515854 W</u>	November 28, 2000		031	C07K014/47

INT-CL (IPC): C07 K 14/435; C07 K 14/47; C07 K 16/18; C12 P 21/08; G01 N 33/53; G01 N 33/543; G01 N 33/553; G01 N 33/577

ABSTRACTED-PUB-NO: EP 931094A

BASIC-ABSTRACT:

A new peptide consisting of at least 1 sub-fragment of the human brain protein S100B beta subunit (S100 beta) comprises 6-38 amino acids and shows at least 90 % homology, whilst retaining identical immunological properties, with sequence (I) and/or sequence (II). SELEKAMVALIDVFHQYSGREGDKHKLKKSELKELINN (I) TACHEFFEHE (II). Also claimed is a monoclonal antibody or fragment specifically binding to the peptide. Also claimed are peptides (III)-(V) derived from sequence (I), peptide (VI) derived from sequence (II) and specifically binding monoclonal antibodies/fragments: REGDKHKLKK (III) DKHKLKKSEL (IV) KLKKSELKEL (V) EFFEHE (VI)

USE - The peptides can be used to elicit antibodies (claimed), and the peptides and monoclonal antibodies/fragments used in immunological assay methods (claimed). The monoclonal antibodies/fragments are especially useful for assaying for human S100 beta ; a sample is immunologically reacted firstly with antibodies/fragments binding with peptide derived from sequence (I) and coupled to a carrier (e.g. a magnetic particle), and secondly with antibodies/fragments binding with peptide derived from sequence (II) and containing a detection means (e.g. emission of luminescence), then washed, and the amount of S100 beta detected (claimed). Kits for this method and for assaying human S100 beta polypeptide in a sample using claimed peptides or antibodies are provided (claimed). Determining the presence of brain protein S100B allows diagnosis and monitoring of patients with cerebral dysfunction and melanoma cancer.

ADVANTAGE - The antibodies provide a method with high sensitivity (e.g. detection limit 0.01 μ g) and the use of epitopes at a distance from each other means that different antibodies do not interfere with each other when binding to the analyte, often a problem with immunological assays. E.g. in an assay of S100 beta in serum from 577 melanoma patients at various stages of cancer progression, geometric means for Clinical Stage I and Clinical Stage II were 0.12 μ g/l and 0.33 μ g/l respectively ($p < 0.001$), and of 136 patients with various stages of melanoma only 25 had S100 beta below 0.08 compared with 93/100 blood donors.

ABSTRACTED-PUB-NO:

WO 9801471A EQUIVALENT-ABSTRACTS:

A new peptide consisting of at least 1 sub-fragment of the human brain protein S100B beta subunit (S100 beta) comprises 6-38 amino acids and shows at least 90 % homology, whilst retaining identical immunological properties, with sequence (I) and/or sequence (II). SELEKAMVALIDVFHQYSGREGDKHKLKKSELKELINN (I) TACHEFFEHE (II). Also claimed is a monoclonal antibody or fragment specifically binding to the peptide. Also claimed are peptides (III)-(V) derived from sequence (I), peptide (VI) derived from sequence (II) and specifically binding monoclonal antibodies/fragments: REGDKHKLKK (III) DKHKLKKSEL (IV) KLKKSELKEL (V) EFFEHE (VI)

USE - The peptides can be used to elicit antibodies (claimed), and the peptides and monoclonal antibodies/fragments used in immunological assay methods (claimed). The monoclonal antibodies/fragments are especially useful for assaying for human S100 beta ; a sample is immunologically reacted firstly with antibodies/fragments binding with peptide derived from sequence (I) and coupled to a carrier (e.g. a magnetic particle), and secondly with antibodies/fragments binding with peptide derived from sequence (II) and containing a detection means (e.g. emission of luminescence), then washed, and the amount of S100 beta detected (claimed). Kits for this method and for assaying human S100 beta polypeptide in a sample using claimed peptides or antibodies are provided (claimed). Determining the presence of brain protein S100B allows diagnosis and monitoring of patients with cerebral dysfunction and melanoma cancer.

ADVANTAGE - The antibodies provide a method with high sensitivity (e.g. detection limit 0.01 μ g) and the use of epitopes at a distance from each other means that different antibodies do not interfere with each other when binding to the analyte, often a problem with immunological assays. E.g. in an assay of S100 beta in serum from 577 melanoma patients at various stages of cancer progression, geometric means for Clinical Stage I and Clinical Stage II were 0.12 μ g/l and 0.33 μ g/l respectively ($p < 0.001$), and of 136 patients with various stages of melanoma only 25 had S100 beta below 0.08 compared with 93/100 blood donors.

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------


Terms	Documents
L14 AND L15	131

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for S100b AND serum Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Items 1 - 96 of 96

One page

1: Tort AB, Portela LV, Rockenbach IC, Monte TL, Pereira ML, Souza DO, Rieder CR, Jardim LB. Related Articles, Links

S100B and NSE serum concentrations in Machado Joseph disease.
Clin Chim Acta. 2005 Jan;351(1-2):143-8.
PMID: 15563883 [PubMed - in process]

2: Margis R, Zanatto VC, Tramontina F, Vinade E, Lhullier F, Portela LV, Souza DO, Dalmaz C, Kapczinski F, Goncalves CA. Related Articles, Links

Changes in S100B cerebrospinal fluid levels of rats subjected to predator stress.
Brain Res. 2004 Dec 3;1028(2):213-8.
PMID: 15527746 [PubMed - in process]

3: Dietrich Mde O, Souza DO, Portela LV. Related Articles, Links

Serum S100B Protein: What Does It Mean During Exercise?
Clin J Sport Med. 2004 Nov;14(6):368. No abstract available.
PMID: 15523213 [PubMed - in process]

4: Stalnaeke BM, Tegner Y, Sojka P. Related Articles, Links

Serum S100B Protein: What Does It Mean During Exercise?: Response.
Clin J Sport Med. 2004 Nov;14(6):368-9. No abstract available.
PMID: 15523212 [PubMed - in process]

5: Brvar M, Mozina M, Osredkar J, Suput D, Bunc M. Related Articles, Links

Prognostic value of S100B protein in carbon monoxide-poisoned rats.
Crit Care Med. 2004 Oct;32(10):2128-30.
PMID: 15483424 [PubMed - in process]

6: Lim ET, Petzold A, Leary SM, Altmann DR, Keir G, Thompson EJ, Miller DH, Thompson AJ, Giovannoni G. Related Articles, Links

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
J Negat Results Biomed. 2004 Oct 13;3(1):4.
PMID: 15482599 [PubMed - as supplied by publisher]


















7: Hovsepyan MR, Haas MJ, Boyajyan AS, Guevorkyan AA, Mamikonyan AA, Myers SE, Mooradian AD. Related Articles, Links











Astrocytic and neuronal biochemical markers in the sera of subjects with diabetes mellitus.
Neurosci Lett. 2004 Oct 21;369(3):224-7.
PMID: 15464269 [PubMed - in process]

8: Unden J, Beilner J, Reinstrup P, Romner B. Related Articles, Links




















Serial S100B levels before, during and after cerebral herniation.
Br J Neurosurg. 2004 Jun;18(3):277-80.
PMID: 15327232 [PubMed - indexed for MEDLINE]

9: Hetzel G, Moeller O, Evers S, Erfurth A, Ponath G, Arolt V, Rothermundt M. Related Articles, Links

-  The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment.
Psychopharmacology (Berl). 2004 Aug 14; [Epub ahead of print]
PMID: 15316717 [PubMed - as supplied by publisher]
-  **10:** Kogel D, Peters M, Konig HG, Hashemi SM, Bui NT, Arolt V, Rothermundt M, Prehn JH. [Related Articles, Links](#)
-  S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury.
Neuroscience. 2004;127(4):913-20.
PMID: 15312903 [PubMed - indexed for MEDLINE]
-  **11:** Foerch C, Otto B, Singer OC, Neumann-Haefelin T, Yan B, Berkefeld J, Steinmetz H, Sitzer M. [Related Articles, Links](#)
-  Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion.
Stroke. 2004 Sep;35(9):2160-4. Epub 2004 Aug 05.
PMID: 15297628 [PubMed - in process]
-  **12:** Fujii EY, Kozuki M, Mu J, Ino Y, Ushioda N, Tomimatsu T, Fukuda H, Kanzaki T, Nakayama M, Murata Y. [Related Articles, Links](#)
-  Correlation of neuron-specific enolase and S100B with histological cerebral damage in fetal sheep after severe asphyxia.
Brain Res. 2004 Aug 20;1018(1):136-40.
PMID: 15262215 [PubMed - indexed for MEDLINE]
-  **13:** Hayakata T, Shiozaki T, Tasaki O, Ikegawa H, Inoue Y, Toshiyuki F, Hosotubo H, Kieko F, Yamashita T, Tanaka H, Shimazu T, Sugimoto H. [Related Articles, Links](#)
-  Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury.
Shock. 2004 Aug;22(2):102-7.
PMID: 15257081 [PubMed - in process]
-  **14:** Harpio R, Einarsson R. [Related Articles, Links](#)
-  S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
Clin Biochem. 2004 Jul;37(7):512-8.
PMID: 15234232 [PubMed - in process]
-  **15:** Pelsters MM, Hanhoff T, Van der Voort D, Arts B, Peters M, Ponds R, Honig A, Rudzinski W, Spener F, de Kruijk JR, Twijnstra A, Hermens WT, Menheere PP, Glatz JF. [Related Articles, Links](#)
-  Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility.
Clin Chem. 2004 Sep;50(9):1568-75. Epub 2004 Jun 24.
PMID: 15217991 [PubMed - indexed for MEDLINE]
-  **16:** Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M. [Related Articles, Links](#)
-  Effects of head and extracranial injuries on serum protein S100B levels in trauma patients.
J Trauma. 2004 Jun;56(6):1229-34; discussion 1234.
PMID: 15211130 [PubMed - indexed for MEDLINE]
-  **17:** Brvar M, Mozina H, Osredkar J, Mozina M, Noc M, Brucan A, Bunc M. [Related Articles, Links](#)
-  S100B protein in carbon monoxide poisoning: a pilot study.
Resuscitation. 2004 Jun;61(3):357-60.
PMID: 15172716 [PubMed - indexed for MEDLINE]


-  **18:** [Kleindienst A, Harvey HB, Rice AC, Muller C, Hamm RJ, Gaub MR, Bullock MR](#) [Related Articles, Links](#)
Intraventricular infusion of the neurotrophic protein S100B improves cognitive recovery after fluid percussion injury in the rat.
 J Neurotrauma. 2004 May;21(5):541-7.
 PMID: 15165362 [PubMed - indexed for MEDLINE]
-  **19:** [Lardner D, Davidson A, McKenzie L, Cochrane A](#) [Related Articles, Links](#)
Delayed rises in serum S100B levels and adverse neurological outcome in infants and children undergoing cardiopulmonary bypass.
 Paediatr Anaesth. 2004 Jun;14(6):495-500.
 PMID: 15153214 [PubMed - indexed for MEDLINE]
-  **20:** [Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, van Geel W, de Reus H, Biert J, Verbeek MM](#) [Related Articles, Links](#)
Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury.
 Neurology. 2004 Apr 27;62(8):1303-10.
 PMID: 15111666 [PubMed - indexed for MEDLINE]
-  **21:** [Banfalvi T, Gergye M, Beczassy E, Gilde K, Otto S](#) [Related Articles, Links](#)
[Role of S100B protein in neoplasms and other diseases]
 Magy Onkol. 2004;48(1):71-4. Epub 2004 Apr 23. Review. Hungarian.
 PMID: 15105899 [PubMed - indexed for MEDLINE]
-  **22:** [Sorci G, Riuzzi F, Agnietti AL, Marchetti C, Donato R](#) [Related Articles, Links](#)
S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner.
 J Cell Physiol. 2004 May;199(2):274-83.
 PMID: 15040010 [PubMed - indexed for MEDLINE]
-  **23:** [Scaccianoce S, Del Bianco P, Pannitteri G, Passarelli F](#) [Related Articles, Links](#)
Relationship between stress and circulating levels of S100B protein.
 Brain Res. 2004 Apr 9;1004(1-2):208-11.
 PMID: 15033438 [PubMed - indexed for MEDLINE]
-  **24:** [Park ES, Park CI, Choi KS, Choi IH, Shin JS](#) [Related Articles, Links](#)
Over-expression of S100B protein in children with cerebral palsy or delayed development.
 Brain Dev. 2004 Apr;26(3):190-6.
 PMID: 15030908 [PubMed - indexed for MEDLINE]
-  **25:** [Snyder-Ramos SA, Gruhlke T, Bauer H, Bauer M, Luntz AP, Motsch J, Martin E, Vahl CF, Missler U, Wiesmann M, Bottiger BW](#) [Related Articles, Links](#)
Cerebral and extracerebral release of protein S100B in cardiac surgical patients.
 Anaesthesia. 2004 Apr;59(4):344-9.
 PMID: 15023104 [PubMed - indexed for MEDLINE]
-  **26:** [Unden J, Christensson B, Bellner J, Alling C, Romner B](#) [Related Articles, Links](#)
Serum S100B levels in patients with cerebral and extracerebral infectious disease.
 Scand J Infect Dis. 2004;36(1):10-3.
 PMID: 15000552 [PubMed - indexed for MEDLINE]
-  **27:** [Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V](#) [Related Articles, Links](#)

S100B serum levels and long-term improvement of negative symptoms in

-  patients with schizophrenia.
Neuropsychopharmacology. 2004 May;29(5):1004-11.
PMID: 14997170 [PubMed - indexed for MEDLINE]
-  **28:** Valencia JV, Mone M, Zhang J, Weetall M, Buxton FP, Hughes TE. [Related Articles](#), [Links](#)
-  Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA.
Diabetes. 2004 Mar;53(3):743-51.
PMID: 14988260 [PubMed - indexed for MEDLINE]
-  **29:** Timar J, Udvarhelyi N, Banfalvi T, Gilde K, Orosz Z. [Related Articles](#), [Links](#)
-  Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies.
Histopathology. 2004 Feb;44(2):180-4.
PMID: 14764062 [PubMed - indexed for MEDLINE]
-  **30:** Schmidt AP, Tort AB, Amaral OB, Schmidt AP, Walz R, Vettorazzi-Stuckzynski J, Martins-Costa SH, Ramos JG, Souza DO, Portela LV. [Related Articles](#), [Links](#)
-  Serum S100B in pregnancy-related hypertensive disorders: a case-control study.
Clin Chem. 2004 Feb;50(2):435-8. No abstract available.
PMID: 14752015 [PubMed - indexed for MEDLINE]
-  **31:** Di Legge S, Di Piero V, Di Stani F, Perna R, Gattuso R, Reale MG, Benedetti Valentini F, Lenzi GL. [Related Articles](#), [Links](#)
-  Carotid endarterectomy and gliofibrillar S100b protein release.
Neurol Sci. 2003 Dec;24(5):351-6.
PMID: 14716532 [PubMed - indexed for MEDLINE]
-  **32:** Dietrich MO, Tort AB, Schaf DV, Farina M, Goncalves CA, Souza DO, Portela LV. [Related Articles](#), [Links](#)
-  Increase in serum S100B protein level after a swimming race.
Can J Appl Physiol. 2003 Oct;28(5):710-6.
PMID: 14710522 [PubMed - indexed for MEDLINE]
-  **33:** Dietrich DE, Hauser U, Peters M, Zhang Y, Wiesmann M, Hasselmann M, Rudolf S, Jungling O, Kirchner H, Munte TF, Arolt V, Emrich HM, Johannes S, Rothermundt M. [Related Articles](#), [Links](#)
-  Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression.
Neurosci Lett. 2004 Jan 2;354(1):69-73.
PMID: 14698484 [PubMed - indexed for MEDLINE]
-  **34:** Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T. [Related Articles](#), [Links](#)
-  Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker.
Melanoma Res. 2003 Dec;13(6):587-93.
PMID: 14646622 [PubMed - in process]
-  **35:** Tort AB, Dietrich MO, Goncalves CA, Souza DO, Portela LV. [Related Articles](#), [Links](#)
-  Influence of anticoagulants on the measurement of S100B protein in blood.
Clin Biochem. 2003 Nov;36(8):629-32.
PMID: 14636878 [PubMed - indexed for MEDLINE]
-  **36:** Portela LV, Tort AB, Walz R, Bianchin M, Trevisol-Bittencourt PC, Wille PR, Cardoso RC, Ishida MM, vonWangenheim A, Grisard EC, Steindel M, Goncalves CA, Souza DO. [Related Articles](#), [Links](#)
-  Interictal serum S100B levels in chronic neurocysticercosis and idiopathic epilepsy.

Acta Neurol Scand. 2003 Dec;108(6):424-7. Erratum in: Acta Neurol Scand. 2004 Jan;109(1):84.

PMID: 14616295 [PubMed - indexed for MEDLINE]


-  **37:** [Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC.](#) Related Articles, Links



Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study.

Mol Cell Proteomics. 2004 Jan;3(1):66-72. Epub 2003 Oct 26.

PMID: 14581522 [PubMed - indexed for MEDLINE]

-  **38:** [Anderson RE, Winnerkvist A, Hansson LO, Nilsson O, Rosengren L, Settergren G, Vaage J.](#) Related Articles, Links



Biochemical markers of cerebrospinal ischemia after repair of aneurysms of the descending and thoracoabdominal aorta.

J Cardiothorac Vasc Anesth. 2003 Oct;17(5):598-603.

PMID: 14579213 [PubMed - indexed for MEDLINE]

-  **39:** [Tort AB, Dietrich MO, Goncalves CA, Souza DO, Portela LV.](#) Related Articles, Links



Influence of anticoagulants on the measurement of S100B protein in blood.

Clin Biochem. 2003 Oct;36(7):519-22.

PMID: 14563444 [PubMed - indexed for MEDLINE]

-  **40:** [Herrmann M, Ehrenreich H.](#) Related Articles, Links



Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring.

Restor Neurol Neurosci. 2003;21(3-4):177-90. Review.

PMID: 14530580 [PubMed - indexed for MEDLINE]


-  **41:** [Jonsson H.](#) Related Articles, Links



S100B and cardiac surgery: possibilities and limitations.

Restor Neurol Neurosci. 2003;21(3-4):151-7. Review.

PMID: 14530577 [PubMed - indexed for MEDLINE]

-  **42:** [Abdul-Khaliq H, Schubert S, Stoltenburg-Didinger G, Huebler M, Troitzsch D, Wehsack A, Boettcher W, Schwaller B, Crausaz M, Celio M, Schroter ML, Blasig IE, Hetzer R, Lange PE.](#) Related Articles, Links



Release patterns of astrocytic and neuronal biochemical markers in serum during and after experimental settings of cardiac surgery.

Restor Neurol Neurosci. 2003;21(3-4):141-50.

PMID: 14530576 [PubMed - indexed for MEDLINE]

-  **43:** [Petzold A, Keir G, Lim D, Smith M, Thompson EJ.](#) Related Articles, Links



Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern.

Brain Res Bull. 2003 Aug 15;61(3):281-5.

PMID: 12909298 [PubMed - indexed for MEDLINE]


-  **44:** [Kleine TO, Benes L, Zofel P.](#) Related Articles, Links



Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients.

Brain Res Bull. 2003 Aug 15;61(3):265-79.

PMID: 12909297 [PubMed - indexed for MEDLINE]


-  **45:** [Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, Kirchner H, Rothermundt M.](#) Related Articles, Links



S100B and response to treatment in major depression: a pilot study.

Eur Neuropsychopharmacol. 2003 Aug;13(4):235-9.

PMID: 12888182 [PubMed - indexed for MEDLINE]

-  **46:** [Schroeter ML, Abdul-Khaliq H, Fruhauf S, Hohne R, Schick G.](#) Related Articles, Links

Diefenbacher A, Blasig IE.



Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia.

Schizophr Res. 2003 Aug 1;62(3):231-6.

PMID: 12837519 [PubMed - indexed for MEDLINE]



47: Sorci G, Riuzzi F, Agneletti AL, Marchetti C, Donato R.

[Related Articles](#), [Links](#)



S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner.

Mol Cell Biol. 2003 Jul;23(14):4870-81.

PMID: 12832473 [PubMed - indexed for MEDLINE]



48: de Baar M, Diephuis JC, Moons KG, Holtkamp J, Hijman R, Kalkman CJ.

[Related Articles](#), [Links](#)



The effect of zero-balanced ultrafiltration during cardiopulmonary bypass on S100b release and cognitive function.

Perfusion. 2003 Mar;18(1):9-14.

PMID: 12705644 [PubMed - indexed for MEDLINE]



49: Kay A, Petzold A, Kerr M, Keir G, Thompson E, Nicoll J.

[Related Articles](#), [Links](#)



Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: correlation with injury severity and clinical outcome.

Stroke. 2003 Mar;34(3):637-42. Epub 2003 Feb 13.

PMID: 12624284 [PubMed - indexed for MEDLINE]



50: Foerch C, du Mesnil de Rochemont R, Singer O, Neumann-Haefelin T, Buchkremer M, Zanella FE, Steinmetz H, Sitzer M.

[Related Articles](#), [Links](#)



S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion.

J Neurol Neurosurg Psychiatry. 2003 Mar;74(3):322-5.

PMID: 12588916 [PubMed - indexed for MEDLINE]



51: Hamberg AP, Korse CM, Bonfrer JM, de Gast GC.

[Related Articles](#), [Links](#)



Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.

Melanoma Res. 2003 Feb;13(1):45-9.

PMID: 12569284 [PubMed - indexed for MEDLINE]



52: Banfalvi T, Boldizsar M, Gergye M, Gilde K, Kremmer T, Otto S.

[Related Articles](#), [Links](#)



Comparison of prognostic significance of serum 5-S-Cysteinyl-dopa, LDH and S-100B protein in Stage III-IV malignant melanoma.

Pathol Oncol Res. 2002;8(3):183-7. Epub 2003 Jan 06.

PMID: 12515998 [PubMed - indexed for MEDLINE]



53: Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Kochanek PM.

[Related Articles](#), [Links](#)



Serum S100B concentrations are increased after closed head injury in children: a preliminary study.

J Neurotrauma. 2002 Nov;19(11):1405-9.

PMID: 12490005 [PubMed - indexed for MEDLINE]



54: Petzold A, Green AJ, Keir G, Fairley S, Kitchen N, Smith M, Thompson EJ.

[Related Articles](#), [Links](#)



Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study.

Crit Care Med. 2002 Dec;30(12):2705-10.

PMID: 12483062 [PubMed - indexed for MEDLINE]



55: Guidi B, Diociaiuti A, Capizzi R, Forni F, Scribano D, Vultaggio P.

[Related Articles](#), [Links](#)

Zappacosta B, Amerio PL.



Increased S100B serum levels in diffuse dermatitis.

Melanoma Res. 2002 Dec;12(6):633. No abstract available.
PMID: 12459654 [PubMed - indexed for MEDLINE]

56: Anderson RE.

Related Articles, Links



No correlation between serum concentrations of S100B and cognitive function.

Acta Anaesthesiol Scand. 2002 Oct;46(9):1179. No abstract available.
PMID: 12366525 [PubMed - indexed for MEDLINE]

57: Schroeter ML, Abdul-Khalik H, Diefenbacher A, Blasig IE.

Related Articles, Links



S100B is increased in mood disorders and may be reduced by antidepressive treatment.

Neuroreport. 2002 Sep 16;13(13):1675-8.
PMID: 12352625 [PubMed - indexed for MEDLINE]

58: Bokesch PM, Appachi E, Cavaglia M, Mossad E, Mee RB.

Related Articles, Links



A glial-derived protein, S100B, in neonates and infants with congenital heart disease: evidence for preexisting neurologic injury.

Anesth Analg. 2002 Oct;95(4):889-92, table of contents.
PMID: 12351263 [PubMed - indexed for MEDLINE]

59: Goncalves D, Karl J, Leite M, Rotta L, Salbego C, Rocha E, Wofchuk S, Goncalves CA.

Related Articles, Links



High glutamate decreases S100B secretion stimulated by serum deprivation in astrocytes.

Neuroreport. 2002 Aug 27;13(12):1533-5.
PMID: 12218700 [PubMed - indexed for MEDLINE]

60: Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T.

Related Articles, Links



Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.

Melanoma Res. 2002 Jun;12(3):255-62.
PMID: 12140382 [PubMed - indexed for MEDLINE]

61: Tokuno S, Hinokiyama K, Tokuno K, Lowbeer C, Hansson LO, Valen G.

Related Articles, Links



Spontaneous ischemic events in the brain and heart adapt the hearts of severely atherosclerotic mice to ischemia.

Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):995-1001.
PMID: 12067910 [PubMed - indexed for MEDLINE]

62: Portela LV, Tort AB, Schaf DV, Ribeiro L, Nora DB, Walz R, Rotta LN, Silva CT, Busnello JV, Kapczinski F, Goncalves CA, Souza DO.

Related Articles, Links



The serum S100B concentration is age dependent.

Clin Chem. 2002 Jun;48(6 Pt 1):950-2. No abstract available.
PMID: 12029017 [PubMed - indexed for MEDLINE]

63: Svenmarker S, Sandstrom E, Karlsson T, Aberg T.

Related Articles, Links































Is there an association between release of protein S100B during cardiopulmonary bypass and memory disturbances?











Scand Cardiovasc J. 2002 Mar;36(2):117-22.
PMID: 12028876 [PubMed - indexed for MEDLINE]

64: Machado-Vieira R, Lara DR, Portela LV, Goncalves CA, Soares JC, Kapczinski F, Souza DO.


Related Articles, Links

-  Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study.
Eur Neuropsychopharmacol. 2002 Jun;12(3):269-72.
PMID: 12007679 [PubMed - indexed for MEDLINE]
-  **65:** Djukanovic D, Hofmann U, Sucker A, Schadendorf D. [Related Articles, Links](#)
-  Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing.
Br J Dermatol. 2001 Dec;145(6):1030-1. No abstract available.
PMID: 11899133 [PubMed - indexed for MEDLINE]
-  **66:** Herrmann M. [Related Articles, Links](#)
-  High serum S100B levels for trauma patients without head injuries.
Neurosurgery. 2001 Nov;49(5):1272-3. No abstract available.
PMID: 11865807 [PubMed - indexed for MEDLINE]
-  **67:** Raabe A. [Related Articles, Links](#)
-  High serum S100B levels for trauma patients without head injuries.
Neurosurgery. 2001 Dec;49(6):1491-2; author reply 1492-3. No abstract available.
PMID: 11859839 [PubMed - indexed for MEDLINE]
-  **68:** Romner B, Ingebrigtsen T. [Related Articles, Links](#)
-  High serum S100B levels for trauma patients without head injuries.
Neurosurgery. 2001 Dec;49(6):1490; author reply 1492-3. No abstract available.
PMID: 11859838 [PubMed - indexed for MEDLINE]
-  **69:** Rothoerl RD, Woertgen C. [Related Articles, Links](#)
-  High serum S100B levels for trauma patients without head injuries.
Neurosurgery. 2001 Dec;49(6):1490-1; author reply 1492-3. No abstract available.
PMID: 11859837 [PubMed - indexed for MEDLINE]
-  **70:** Connolly ES Jr, Winfree CJ, Rampersad A, Sharma R, Mack WJ, Mocco J, Solomon RA, Todd G, Quest DO, Stern Y, Heyer EJ. [Related Articles, Links](#)
-  Serum S100B protein levels are correlated with subclinical neurocognitive declines after carotid endarterectomy.
Neurosurgery. 2001 Nov;49(5):1076-82; discussion 1082-3.
PMID: 11846900 [PubMed - indexed for MEDLINE]
-  **71:** Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, Kochanek PM. [Related Articles, Links](#)
-  Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children.
Pediatrics. 2002 Feb;109(2):E31.
PMID: 11826241 [PubMed - indexed for MEDLINE]
-  **72:** Portela LV, Brenol JC, Walz R, Bianchin M, Tort AB, Canabarro UP, Beheregaray S, Marasca JA, Xavier RM, Neto EC, Goncalves CA, Souza DO. [Related Articles, Links](#)
-  Serum S100B levels in patients with lupus erythematosus: preliminary observation.
Clin Diagn Lab Immunol. 2002 Jan;9(1):164-6.
PMID: 11777848 [PubMed - indexed for MEDLINE]
-  **73:** Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, Lejeune F; EORTC Melanoma Group. [Related Articles, Links](#)
-  On the release and half-life of S100B protein in the peripheral blood of melanoma patients.
Int J Cancer. 2001 Nov15;94(4):586-90.
PMID: 11745448 [PubMed - indexed for MEDLINE]


-  **74:** [Potapov EV, Loebe M, Abdul-Khaliq H, Koster A, Stein J, Sodian R, Kopitz M, Hausmann H, Noon GP, DeBakey ME, Hetzer R](#) [Related Articles, Links](#)
Postoperative course of S-100B protein and neuron-specific enolase in patients after implantation of continuous and pulsatile flow LVADs.
J Heart Lung Transplant. 2001 Dec;20(12):1310-6.
 PMID: 11744415 [PubMed - indexed for MEDLINE]
-  **75:** [Schmidt M, Scheunert T, Steinbach G, Schürmer U, Marx T, Freitag N, Reinelt H](#) [Related Articles, Links](#)
Hypertension as a risk factor for cerebral injury during cardiopulmonary bypass. Protein S100B and transcranial Doppler findings.
Anaesthesia. 2001 Aug;56(8):733-8.
 PMID: 11493235 [PubMed - indexed for MEDLINE]
-  **76:** [Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J](#) [Related Articles, Links](#)
Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources.
Ann Thorac Surg. 2001 May;71(5):1512-7.
 PMID: 11383792 [PubMed - indexed for MEDLINE]
-  **77:** [Anderson RE, Hansson LO, Nilsson O, Djilai-Merzoug R, Settergren G](#) [Related Articles, Links](#)
High serum S100B levels for trauma patients without head injuries.
Neurosurgery. 2001 Jun;48(6):1255-8; discussion 1258-60.
 PMID: 11383727 [PubMed - indexed for MEDLINE]
-  **78:** [Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LV, Goncalves CA, Fonseca M, Hauck S, Souza DO](#) [Related Articles, Links](#)
Increased serum S100B protein in schizophrenia: a study in medication-free patients.
J Psychiatr Res. 2001 Jan-Feb;35(1):11-4.
 PMID: 11287051 [PubMed - indexed for MEDLINE]
-  **79:** [van Passel R, Schlooz WA, Lamers KJ, Lemmens WA, Rotteveel JJ](#) [Related Articles, Links](#)
S100B protein, glia and Gilles de la Tourette syndrome.
Eur J Paediatr Neurol. 2001;5(1):15-9.
 PMID: 11277359 [PubMed - indexed for MEDLINE]
-  **80:** [Pinto SS, Gottfried C, Mendez A, Goncalves D, Karl J, Goncalves CA, Wofchuk S, Rodnight R](#) [Related Articles, Links](#)
Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology.
FEBS Lett. 2000 Dec 15;486(3):203-7.
 PMID: 11119704 [PubMed - indexed for MEDLINE]
-  **81:** [Morozov GV, Asanova LM, Lavrova TN, Davydov DM, Poletaev AB, Morozov SG](#) [Related Articles, Links](#)
[The humoral immunity characteristics of women with neurotic depressions]
Zh Nevrol Psikhiatr Im S S Korsakova. 2000;100(9):39-44. Russian.
 PMID: 11026135 [PubMed - indexed for MEDLINE]
-  **82:** [Poletaev AB, Morozov SG, Gnedenko BB, Zlunikin VM, Korzhenevsky DA](#) [Related Articles, Links](#)
Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders.
Autoimmunity. 2000;32(1):33-8.
 PMID: 10958173 [PubMed - indexed for MEDLINE]


-  **83:** Walz R, Portela LV, Tort AB, Neto EC, Fernandes LN, Goncalves CA, Souza DO. [Related Articles](#), [Links](#)
Serum S100B levels in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.
 Neurology. 2000 May 23;54(10):2021-2. No abstract available.
 PMID: 10822451 [PubMed - indexed for MEDLINE]
-  **84:** Stigbrand T, Nyberg L, Ullen A, Haglid K, Sandstrom E, Brundell J. [Related Articles](#), [Links](#)
A new specific method for measuring S-100B in serum.
 Int J Biol Markers. 2000 Jan-Mar;15(1):33-40.
 PMID: 10763138 [PubMed - indexed for MEDLINE]
-  **85:** Brouard M, Quillien V, Ollivier I, Lesimple T, Adamski H, Chevrant-Breton J. [Related Articles](#), [Links](#)
[Serum S100B protein and stage of cutaneous melanoma: a prospective study]
 Ann Dermatol Venereol. 2000 Jan;127(1):56-9. French.
 PMID: 10717564 [PubMed - indexed for MEDLINE]
-  **86:** Muller F, Ngo S, Rebiffe M, Oury JF, Uzan S, Satge D. [Related Articles](#), [Links](#)
Maternal serum s100b protein is ineffective for Down syndrome screening.
 Prenat Diagn. 1999 Nov;19(11):1086. No abstract available.
 PMID: 10589070 [PubMed - indexed for MEDLINE]
-  **87:** Bhattacharya K, Westaby S, Pillai R, Standing SJ, Johnsson P, Taggart DP. [Related Articles](#), [Links](#)
Serum S100B and hypothermic circulatory arrest in adults.
 Ann Thorac Surg. 1999 Oct;68(4):1225-9.
 PMID: 10543483 [PubMed - indexed for MEDLINE]
-  **88:** Ashraf S, Bhattacharya K, Tian Y, Watterson K. [Related Articles](#), [Links](#)
Cytokine and S100B levels in paediatric patients undergoing corrective cardiac surgery with or without total circulatory arrest.
 Eur J Cardiothorac Surg. 1999 Jul;16(1):32-7.
 PMID: 10456399 [PubMed - indexed for MEDLINE]
-  **89:** Takahashi M, Chameczuk A, Hong Y, Jackowski G. [Related Articles](#), [Links](#)
Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody.
 Clin Chem. 1999 Aug;45(8 Pt 1):1307-11. No abstract available.
 PMID: 10430807 [PubMed - indexed for MEDLINE]
-  **90:** Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E. [Related Articles](#), [Links](#)
Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients.
 Melanoma Res. 1999 Apr;9(2):155-61.
 PMID: 10380938 [PubMed - indexed for MEDLINE]
-  **91:** Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E. [Related Articles](#), [Links](#)
Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
 Br J Dermatol. 1999 Jun;140(6):1065-71.
 PMID: 10354072 [PubMed - indexed for MEDLINE]
-  **92:** Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E. [Related Articles](#), [Links](#)


S100B protein detection in serum is a significant prognostic factor in


 metastatic melanoma.
Oncology. 1999;56(4):338-44.
PMID: 10343200 [PubMed - indexed for MEDLINE]


 **93:** [Levy R, Shohat L, Solomon B.](#) [Related Articles, Links](#)


 Specificity of an anti-aluminium monoclonal antibody toward free and protein-bound aluminium.
J Inorg Biochem. 1998 Feb 15;69(3):159-63.
PMID: 9629674 [PubMed - indexed for MEDLINE]


 **94:** [Karnell R, von Schoultz E, Hansson LO, Nilsson B, Arstrand K, Kagedal B.](#) [Related Articles, Links](#)

 S100B protein, 5-S-cysteinyl-dopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Melanoma Res. 1997 Oct;7(5):393-9.
PMID: 9429222 [PubMed - indexed for MEDLINE]

 **95:** [Nishi M, Whitaker-Azmitia PM, Azmitia EC.](#) [Related Articles, Links](#)

 Enhanced synaptophysin immunoreactivity in rat hippocampal culture by 5-HT 1A agonist, S100b, and corticosteroid receptor agonists.
Synapse. 1996 May;23(1):1-9.
PMID: 8723130 [PubMed - indexed for MEDLINE]


 **96:** [Usui A, Kato K, Murase M, Hotta T, Tanaka M, Takeuchi E, Abe T.](#) [Related Articles, Links](#)

 Neural tissue-related proteins (NSE, G0 alpha, 28-kDa calbindin-D, S100b and CK-BB) in serum and cerebrospinal fluid after cardiac arrest.
J Neurol Sci. 1994 May;123(1-2):134-9.
PMID: 8064306 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** Sort **Send to** **Text**

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 23 2004 06:26:50



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for S100b AND blood Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Items 1 - 127 of 127

One page

☐ 1: Tort AB, Portela LV, Rockenbach IC, Monte TL, Pereira ML, Souza DO, Rieder CR, Jardim LB. Related Articles, Links



S100B and NSE serum concentrations in Machado Joseph disease.
Clin Chim Acta. 2005 Jan;351(1-2):143-8.
PMID: 15563883 [PubMed - in process]

☐ 2: Wunderlich MT, Wallesch CW, Goertler M. Related Articles, Links



Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke.
J Neurol Sci. 2004 Dec 15;227(1):49-53.
PMID: 15546591 [PubMed - in process]

☐ 3: Brvar M, Mozina M, Osredkar J, Suput D, Bunc M. Related Articles, Links



Prognostic value of S100B protein in carbon monoxide-poisoned rats.
Crit Care Med. 2004 Oct;32(10):2128-30.
PMID: 15483424 [PubMed - in process]

☐ 4: Hovsepyan MR, Haas MJ, Boyajyan AS, Guevorkyan AA, Mamikonyan AA, Myers SE, Mooradian AD. Related Articles, Links



Astrocytic and neuronal biochemical markers in the sera of subjects with diabetes mellitus.
Neurosci Lett. 2004 Oct 21;369(3):224-7.
PMID: 15464269 [PubMed - in process]

☐ 5: Leite M, Frizzo JK, Nardin P, de Almeida LM, Tramontina F, Gottfried C, Goncalves CA. Related Articles, Links



Beta-hydroxy-butyrate alters the extracellular content of S100B in astrocyte cultures.
Brain Res Bull. 2004 Aug 30;64(2):139-43.
PMID: 15342101 [PubMed - in process]

☐ 6: Unden J, Bellner J, Reinstrup P, Romner B. Related Articles, Links



Serial S100B levels before, during and after cerebral herniation.
Br J Neurosurg. 2004 Jun;18(3):277-80.
PMID: 15327232 [PubMed - indexed for MEDLINE]

☐ 7: Foerch C, Otto B, Singer OC, Neumann-Haefelin T, Yan B, Berkefeld J, Steinmetz H, Sitzer M. Related Articles, Links



Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion.
Stroke. 2004 Sep;35(9):2160-4. Epub 2004 Aug 05.
PMID: 15297628 [PubMed - in process]


☐ 8: Fujii EY, Kozuki M, Mu J, Ino Y, Ushioda N, Tomimatsu T, Fukuda H, Kanzaki T, Nakayama M, Murata Y. Related Articles, Links




Correlation of neuron-specific enolase and S100B with histological cerebral damage in fetal sheep after severe asphyxia.
Brain Res. 2004 Aug 20;1018(1):136-40.

PMID: 15262215 [PubMed - indexed for MEDLINE]


- 9: [Chen Y, Yan SS, Colgan J, Zhang HP, Luban J, Schmidt AM, Stern D, Herold KC](#) [Related Articles, Links](#)

 **Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products.**
J Immunol. 2004 Jul 15;173(2):1399-405.
PMID: 15240736 [PubMed - indexed for MEDLINE]


- 10: [Pelsers MM, Hanhoff T, Van der Voort D, Arts B, Peeters M, Ponds R, Honig A, Rudzinski W, Spener F, de Kruijk JR, Twijnstra A, Hermens WT, Menheere PP, Glatz JF](#) [Related Articles, Links](#)

 **Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility.**
Clin Chem. 2004 Sep;50(9):1568-75. Epub 2004 Jun 24.
PMID: 15217991 [PubMed - indexed for MEDLINE]


- 11: [Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M](#) [Related Articles, Links](#)

 **Effects of head and extracranial injuries on serum protein S100B levels in trauma patients.**
J Trauma. 2004 Jun;56(6):1229-34; discussion 1234.
PMID: 15211130 [PubMed - indexed for MEDLINE]


- 12: [Nygren De Boussard C, Fredman P, Lundin A, Andersson K, Edman G, Borg J](#) [Related Articles, Links](#)

 **S100 in mild traumatic brain injury.**
Brain Inj. 2004 Jul;18(7):671-83.
PMID: 15204328 [PubMed - indexed for MEDLINE]


- 13: [Brvar M, Mozina H, Osredkar J, Mozina M, Noc M, Brucan A, Bunc M](#) [Related Articles, Links](#)

 **S100B protein in carbon monoxide poisoning: a pilot study.**
Resuscitation. 2004 Jun;61(3):357-60.
PMID: 15172716 [PubMed - indexed for MEDLINE]


- 14: [Kleindienst A, Harvey HB, Rice AC, Muller C, Hamm RJ, Gaab MR, Bullock MR](#) [Related Articles, Links](#)

 **Intraventricular infusion of the neurotrophic protein S100B improves cognitive recovery after fluid percussion injury in the rat.**
J Neurotrauma. 2004 May;21(5):541-7.
PMID: 15165362 [PubMed - indexed for MEDLINE]


- 15: [Lardner D, Davidson A, McKenzie I, Cochrane A](#) [Related Articles, Links](#)

 **Delayed rises in serum S100B levels and adverse neurological outcome in infants and children undergoing cardiopulmonary bypass.**
Paediatr Anaesth. 2004 Jun;14(6):495-500.
PMID: 15153214 [PubMed - indexed for MEDLINE]

- 16: [Valencia JV, Mone M, Koehne C, Rediske J, Hughes TE](#) [Related Articles, Links](#)


 **Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products.**
Diabetologia. 2004 May;47(5):844-52. Epub 2004 May 01.
PMID: 15127201 [PubMed - in process]

- 17: [Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, van Geel W, de Reus H, Biert J, Verbeek MM](#) [Related Articles, Links](#)


 **Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury.**


Neurology. 2004 Apr 27;62(8):1303-10.
PMID: 15111666 [PubMed - indexed for MEDLINE]


-  **18:** [Banfalvi T, Gergye M, Beczassy E, Gilde K, Otto S.](#) [Related Articles, Links](#)


 **[Role of S100B protein in neoplasms and other diseases]**
Magy Onkol. 2004;48(1):71-4. Epub 2004 Apr 23. Review. Hungarian.
PMID: 15105899 [PubMed - indexed for MEDLINE]


-  **19:** [Alston RP.](#) [Related Articles, Links](#)

 **A response to 'A pilot study of evaluation of cerebral function by S100B protein and near-infrared spectroscopy during cold and warm cardiopulmonary bypass in infants and children undergoing open-heart surgery'** Shaaban Ali M, Harmer M, Elliott M, Lloyd Thomas A and Kirkham F, Anaesthesia 2003; 59: 20-6.
Anaesthesia. 2004 May;59(5):519-20; author reply 520. No abstract available.
PMID: 15096264 [PubMed - indexed for MEDLINE]


-  **20:** [Soderlund J, Nilsson C, Lore K, Castanos-Velez E, Ekman M, Heiden T, Biberfeld G, Andersson J, Biberfeld P.](#) [Related Articles, Links](#)


 **Dichotomy between CD1a+ and CD83+ dendritic cells in lymph nodes during SIV infection of macaques.**
J Med Primatol. 2004 Feb;33(1):16-24.
PMID: 15061728 [PubMed - indexed for MEDLINE]


-  **21:** [Han RQ, Li SR, Wang BG, Wang EZ, Liu W, Wang S, Zhao JZ.](#) [Related Articles, Links](#)


 **[The effect of isoflurane induced hypotension on intraoperative cerebral vasospasm in intracranial aneurysm surgery]**
Zhonghua Yi Xue Za Zhi. 2004 Feb 17;84(4):286-9. Chinese.
PMID: 15059509 [PubMed - indexed for MEDLINE]


-  **22:** [Scaccianoce S, Del Bianco P, Pannitteri G, Passarelli F.](#) [Related Articles, Links](#)

 **Relationship between stress and circulating levels of S100B protein.**
Brain Res. 2004 Apr 9;1004(1-2):208-11.
PMID: 15033438 [PubMed - indexed for MEDLINE]


-  **23:** [Park ES, Park CI, Choi KS, Choi IH, Shin JS.](#) [Related Articles, Links](#)

 **Over-expression of S100B protein in children with cerebral palsy or delayed development.**
Brain Dev. 2004 Apr;26(3):190-6.
PMID: 15030908 [PubMed - indexed for MEDLINE]


-  **24:** [Snyder-Ramos SA, Gruhlke T, Bauer H, Bauer M, Luntz AP, Motsch J, Martin E, Vahl CF, Missler U, Wiesmann M, Bottiger BW.](#) [Related Articles, Links](#)

 **Cerebral and extracerebral release of protein S100B in cardiac surgical patients.**
Anaesthesia. 2004 Apr;59(4):344-9.
PMID: 15023104 [PubMed - indexed for MEDLINE]


-  **25:** [Unden J, Christensson B, Bellner J, Alling C, Romner B.](#) [Related Articles, Links](#)


 **Serum S100B levels in patients with cerebral and extracerebral infectious disease.**
Scand J Infect Dis. 2004;36(1):10-3.
PMID: 15000552 [PubMed - indexed for MEDLINE]


-  **26:** [Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V.](#) [Related Articles, Links](#)


 **S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia.**

Neuropsychopharmacology. 2004 May;29(5):1004-11.
PMID: 14997170 [PubMed - indexed for MEDLINE]


-  **27:** Gazzolo D, Masetti P, Kornacka M, Abella R, Bruschetti P, Michetti F. [Related Articles, Links](#)


 **Phentolamine administration increases blood S100B protein levels in pediatric open-heart surgery patients.**
Acta Paediatr. 2003 Dec;92(12):1427-32.
PMID: 14971794 [PubMed - indexed for MEDLINE]


-  **28:** Schmidt AP, Tort AB, Amaral OB, Schmidt AP, Walz R, Vettorazzi-Stuckzynski J, Martins-Costa SH, Ramos JG, Souza DO, Portela LV. [Related Articles, Links](#)


 **Serum S100B in pregnancy-related hypertensive disorders: a case-control study.**
Clin Chem. 2004 Feb;50(2):435-8. No abstract available.
PMID: 14752015 [PubMed - indexed for MEDLINE]


-  **29:** Venkataraman R, Song M, Lynas R, Kellum JA. [Related Articles, Links](#)


 **Hemoadsorption to improve organ recovery from brain-dead organ donors: a novel therapy for a novel indication?**
Blood Purif. 2004;22(1):143-9. Review.
PMID: 14732823 [PubMed - indexed for MEDLINE]


-  **30:** Di Legge S, Di Piero V, Di Stani F, Perna R, Gattuso R, Reale MG, Benedetti Valentini F, Lenzi GL. [Related Articles, Links](#)


 **Carotid endarterectomy and gliofibrillar S100b protein release.**
Neurol Sci. 2003 Dec;24(5):351-6.
PMID: 14716532 [PubMed - indexed for MEDLINE]


-  **31:** Dietrich MO, Tort AB, Schaf DV, Farina M, Goncalves CA, Souza DO, Portela LV. [Related Articles, Links](#)


 **Increase in serum S100B protein level after a swimming race.**
Can J Appl Physiol. 2003 Oct;28(5):710-6.
PMID: 14710522 [PubMed - indexed for MEDLINE]


-  **32:** Dietrich DE, Hauser U, Peters M, Zhang Y, Wiesmann M, Hasselmann M, Rudolf S, Jungling O, Kirchner H, Munte TF, Arolt V, Emrich HM, Johannes S, Rothermundt M. [Related Articles, Links](#)


 **Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression.**
Neurosci Lett. 2004 Jan 2;354(1):69-73.
PMID: 14698484 [PubMed - indexed for MEDLINE]


-  **33:** Pelinka LE, Harada N, Szalay L, Jafarmadar M, Redl H, Bahrami S. [Related Articles, Links](#)

 **Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats.**
Shock. 2004 Jan;21(1):72-6.
PMID: 14676687 [PubMed - in process]

-  **34:** Tort AB, Dietrich MO, Goncalves CA, Souza DO, Portela LV. [Related Articles, Links](#)


 **Influence of anticoagulants on the measurement of S100B protein in blood.**
Clin Biochem. 2003 Nov;36(8):629-32.
PMID: 14636878 [PubMed - indexed for MEDLINE]


-  **35:** Portela LV, Tort AB, Walz R, Bianchin M, Trevisol-Bittencourt PC, Wille PR, Cardoso RC, Ishida MM, vonWangenheim A, Grisard EC, Steindel M, Goncalves CA, Souza DO. [Related Articles, Links](#)

 **Interictal serum S100B levels in chronic neurocysticercosis and idiopathic epilepsy.**

Acta Neurol Scand. 2003 Dec;108(6):424-7. Erratum in: Acta Neurol Scand. 2004 Jan;109(1):84.


PMID: 14616295 [PubMed - indexed for MEDLINE]


-  **36:** Baydas G, Reiter RJ, Yasar A, Tuzcu M, Akdemir I, Nedzvetskii VS. [Related Articles, Links](#)

 Melatonin reduces glial reactivity in the hippocampus, cortex, and cerebellum of streptozotocin-induced diabetic rats.

Free Radic Biol Med. 2003 Oct 1;35(7):797-804.


PMID: 14583344 [PubMed - indexed for MEDLINE]


-  **37:** Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC. [Related Articles, Links](#)

 Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study.

Mol Cell Proteomics. 2004 Jan;3(1):66-72. Epub 2003 Oct 26.

PMID: 14581522 [PubMed - indexed for MEDLINE]


-  **38:** Anderson RE, Winnerkvist A, Hansson LO, Nilsson O, Rosengren L, Settergren G, Vaage J. [Related Articles, Links](#)

 Biochemical markers of cerebrospinal ischemia after repair of aneurysms of the descending and thoracoabdominal aorta.

J Cardiothorac Vasc Anesth. 2003 Oct;17(5):598-603.

PMID: 14579213 [PubMed - indexed for MEDLINE]


-  **39:** Tort AB, Dietrich MO, Goncalves CA, Souza DO, Portela LV. [Related Articles, Links](#)

 Influence of anticoagulants on the measurement of S100B protein in blood.

Clin Biochem. 2003 Oct;36(7):519-22.

PMID: 14563444 [PubMed - indexed for MEDLINE]

-  **40:** Herrmann M, Ehrenreich H. [Related Articles, Links](#)

 Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring.

Restor Neurol Neurosci. 2003;21(3-4):177-90. Review.


PMID: 14530580 [PubMed - indexed for MEDLINE]


-  **41:** Jonsson H. [Related Articles, Links](#)

 S100B and cardiac surgery: possibilities and limitations.

Restor Neurol Neurosci. 2003;21(3-4):151-7. Review.


PMID: 14530577 [PubMed - indexed for MEDLINE]


-  **42:** Abdul-Khalig H, Schubert S, Stolttenburg-Didinger G, Huebler M, Troitzsch D, Wehsack A, Boettcher W, Schwaller B, Crausaz M, Celio M, Schroter ML, Blasig IE, Hetzer R, Lange PE. [Related Articles, Links](#)

 Release patterns of astrocytic and neuronal biochemical markers in serum during and after experimental settings of cardiac surgery.

Restor Neurol Neurosci. 2003;21(3-4):141-50.

PMID: 14530576 [PubMed - indexed for MEDLINE]


-  **43:** Pelinka LE, Szalay L, Jafarmadar M, Schmidhammer R, Redl H, Bahrami S. [Related Articles, Links](#)

 Circulating S100B is increased after bilateral femur fracture without brain injury in the rat.

Br J Anaesth. 2003 Oct;91(4):595-7.


PMID: 14504167 [PubMed - indexed for MEDLINE]


-  **44:** Michetti F, Gazzolo D. [Related Articles, Links](#)


 S100B testing in pregnancy.


Clin Chim Acta. 2003 Sep;335(1-2):1-7. Review.


PMID: 12927678 [PubMed - indexed for MEDLINE]


 **45:** [Petzold A, Keir G, Lim D, Smith M, Thompson EJ.](#) [Related Articles, Links](#)


 **Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern.**
Brain Res Bull. 2003 Aug 15;61(3):281-5.
PMID: 12909298 [PubMed - indexed for MEDLINE]


 **46:** [Kleine TO, Benes L, Zofel P.](#) [Related Articles, Links](#)


 **Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients.**
Brain Res Bull. 2003 Aug 15;61(3):265-79.
PMID: 12909297 [PubMed - indexed for MEDLINE]


 **47:** [Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, Kirchner H, Rothermundt M.](#) [Related Articles, Links](#)


 **S100B and response to treatment in major depression: a pilot study.**
Eur Neuropsychopharmacol. 2003 Aug;13(4):235-9.
PMID: 12888182 [PubMed - indexed for MEDLINE]


 **48:** [Shanmugam N, Kim YS, Lanting L, Natarajan R.](#) [Related Articles, Links](#)


 **Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products.**
J Biol Chem. 2003 Sep 12;278(37):34834-44. Epub 2003 Jun 30.
PMID: 12837757 [PubMed - indexed for MEDLINE]


 **49:** [Schroeter ML, Abdul-Khaliq H, Fruhauf S, Hohne R, Schick G, Diefenbacher A, Blasig IE.](#) [Related Articles, Links](#)


 **Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia.**
Schizophr Res. 2003 Aug 1;62(3):231-6.
PMID: 12837519 [PubMed - indexed for MEDLINE]


 **50:** [Gazzolo D, Kornacka M, Bruschettini M, Lituania M, Giovannini L, Serra G, Majewska U, Michetti F.](#) [Related Articles, Links](#)


 **Maternal glucocorticoid supplementation and S100B protein concentrations in cord blood and urine of preterm infants.**
Clin Chem. 2003 Jul;49(7):1215-8. No abstract available.
PMID: 12816930 [PubMed - indexed for MEDLINE]


 **51:** [Gazzolo D, Michetti F, Bruschettini M, Marchese N, Lituania M, Mangraviti S, Pedrazzi E, Bruschettini P.](#) [Related Articles, Links](#)

 **Pediatric concentrations of S100B protein in blood: age- and sex-related changes.**
Clin Chem. 2003 Jun;49(6 Pt 1):967-70. No abstract available.
PMID: 12765999 [PubMed - indexed for MEDLINE]

 **52:** [Lindberg L, Forsell C, Jogi P, Olsson AK.](#) [Related Articles, Links](#)

 **Effects of dexamethasone on clinical course, C-reactive protein, S100B protein and von Willebrand factor antigen after paediatric cardiac surgery.**
Br J Anaesth. 2003 Jun;90(6):728-32.
PMID: 12765886 [PubMed - indexed for MEDLINE]

 **53:** [de Baar M, Diephuis JC, Moons KG, Holtkamp J, Hijman R, Kalkman CJ.](#) [Related Articles, Links](#)

 **The effect of zero-balanced ultrafiltration during cardiopulmonary bypass on S100b release and cognitive function.**
Perfusion. 2003 Mar;18(1):9-14.
PMID: 12705644 [PubMed - indexed for MEDLINE]

 **54:** [Moroz OV, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB.](#) [Related Articles, Links](#)

Multiple structural states of S100A12: A key to its functional diversity.



Microsc Res Tech. 2003 Apr 15;60(6):581-92. Review.
PMID: 12645006 [PubMed - indexed for MEDLINE]



55: [Foerch C, du Mesnil de Rochemont R, Singer O, Neumann-Haefelin T, Buchkremer M, Zanella FE, Steinmetz H, Sitzer M.](#)

[Related Articles, Links](#)



S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion.

J Neurol Neurosurg Psychiatry. 2003 Mar;74(3):322-5.
PMID: 12588916 [PubMed - indexed for MEDLINE]



56: [Hamberg AP, Korse CM, Bonfrer JM, de Gast GC.](#)

[Related Articles, Links](#)



Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.

Melanoma Res. 2003 Feb;13(1):45-9.
PMID: 12569284 [PubMed - indexed for MEDLINE]



57: [Gazzolo D, Masetti P, Vinesi P, Meli M, Abella R, Marcelletti C, Michetti F.](#)

[Related Articles, Links](#)



S100B blood levels correlate with rewarming time and cerebral Doppler in pediatric open heart surgery.

J Card Surg. 2002 Jul-Aug;17(4):279-84.
PMID: 12546072 [PubMed - indexed for MEDLINE]



58: [Johnsson P, Backstrom M, Bergh C, Jonsson H, Luhrs C, Ailing C.](#)

[Related Articles, Links](#)



Increased S100B in blood after cardiac surgery is a powerful predictor of late mortality.

Ann Thorac Surg. 2003 Jan;75(1):162-8.
PMID: 12537211 [PubMed - indexed for MEDLINE]



59: [Gazzolo D, Monego G, Corvino V, Bruschettini M, Bruschettini P, Zelano G, Michetti F.](#)

[Related Articles, Links](#)



Human milk contains S100B protein.

Biochim Biophys Acta. 2003 Jan 20;1619(2):209-12.
PMID: 12527118 [PubMed - indexed for MEDLINE]



60: [Banfalvi T, Boldizsar M, Gergye M, Gilde K, Kremmer T, Otto S.](#)

[Related Articles, Links](#)



Comparison of prognostic significance of serum 5-S-Cysteinyl-dopa, LDH and S-100B protein in Stage III-IV malignant melanoma.

Pathol Oncol Res. 2002;8(3):183-7. Epub 2003 Jan 06.
PMID: 12515998 [PubMed - indexed for MEDLINE]



61: [Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Kochanek PM.](#)

[Related Articles, Links](#)



Serum S100B concentrations are increased after closed head injury in children: a preliminary study.

J Neurotrauma. 2002 Nov;19(11):1405-9.
PMID: 12490005 [PubMed - indexed for MEDLINE]



62: [Petzold A, Green AJ, Keir G, Fairley S, Kitchen N, Smith M, Thompson EJ.](#)

[Related Articles, Links](#)



Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study.

Crit Care Med. 2002 Dec;30(12):2705-10.
PMID: 12483062 [PubMed - indexed for MEDLINE]



63: [Guidi B, Diociaiuti A, Capizzi R, Forni F, Scribano D, Vultaggio P, Zappacosta B, Amerio PL.](#)

[Related Articles, Links](#)



Increased S100B serum levels in diffuse dermatitis.

Melanoma Res. 2002 Dec;12(6):633. No abstract available.
PMID: 12459654 [PubMed - indexed for MEDLINE]

 **64:** [Michetti F, Gazzolo D.](#)


[Related Articles](#), [Links](#)



S100B protein in biological fluids: a tool for perinatal medicine.

Clin Chem. 2002 Dec;48(12):2097-104. Review.

PMID: 12446464 [PubMed - indexed for MEDLINE]

 **65:** [Gazzolo D, Visser GH, Lituanica M, Sari R, Bruschetti M, Michetti F, Bruschetti PL.](#)

[Related Articles](#), [Links](#)



S100B protein cord blood levels and development of fetal behavioral states: a study in normal and small-for-dates fetuses.

J Matern Fetal Neonatal Med. 2002 Jun;11(6):378-84.

PMID: 12389652 [PubMed - indexed for MEDLINE]

 **66:** [Tsoporis JN, Marks A, Van Eldik LJ, O'Hanlon D, Parker TG.](#)

[Related Articles](#), [Links](#)



Regulation of the S100B gene by alpha 1-adrenergic stimulation in cardiac myocytes.

Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H193-203. Epub 2002 Sep 05.

PMID: 12388300 [PubMed - indexed for MEDLINE]

 **67:** [Anderson RE.](#)

[Related Articles](#), [Links](#)



No correlation between serum concentrations of S100B and cognitive function.

Acta Anaesthesiol Scand. 2002 Oct;46(9):1179. No abstract available.

PMID: 12366525 [PubMed - indexed for MEDLINE]

 **68:** [Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE.](#)


[Related Articles](#), [Links](#)



S100B is increased in mood disorders and may be reduced by antidepressive treatment.

Neuroreport. 2002 Sep 16;13(13):1675-8.

PMID: 12352625 [PubMed - indexed for MEDLINE]

 **69:** [Bokesch PM, Appachi E, Cavaglia M, Mossad E, Mee RB.](#)


[Related Articles](#), [Links](#)



A glial-derived protein, S100B, in neonates and infants with congenital heart disease: evidence for preexisting neurologic injury.

Anesth Analg. 2002 Oct;95(4):889-92, table of contents.

PMID: 12351263 [PubMed - indexed for MEDLINE]

 **70:** [Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T.](#)

[Related Articles](#), [Links](#)



Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.

Melanoma Res. 2002 Jun;12(3):255-62.

PMID: 12140382 [PubMed - indexed for MEDLINE]

 **71:** [Sherstnev VV, Gruden' MA, Skvortsova VI, Tabolin VA.](#)


[Related Articles](#), [Links](#)



[Neurotrophic factors and autoantibodies to them as molecular predictors of cerebral dysfunctions]

Vestn Ross Akad Med Nauk. 2002;(6):48-52. Russian.

PMID: 12116762 [PubMed - indexed for MEDLINE]

 **72:** [Gazzolo D, Di Iorio R, Marinoni E, Masetti P, Serra G, Giovannini L, Michetti F.](#)


[Related Articles](#), [Links](#)



S100B protein is increased in asphyxiated term infants developing intraventricular hemorrhage.

Crit Care Med. 2002 Jun;30(6):1356-60.

PMID: 12072694 [PubMed - indexed for MEDLINE]

 **73:** [Tokuno S, Hinokiyama K, Tokuno K, Lowbeer C, Hansson LO, Valen G.](#)


[Related Articles](#), [Links](#)



Spontaneous ischemic events in the brain and heart adapt the hearts of severely atherosclerotic mice to ischemia.

Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):995-1001.

PMID: 12067910 [PubMed - indexed for MEDLINE]



74: [Portela LV, Tort AB, Schaf DV, Ribeiro L, Nora DB, Walz R, Rotta LN, Silva CT, Busnello JV, Kapczinski F, Goncalves CA, Souza DO.](#)


[Related Articles, Links](#)



The serum S100B concentration is age dependent.

Clin Chem. 2002 Jun;48(6 Pt 1):950-2. No abstract available.

PMID: 12029017 [PubMed - indexed for MEDLINE]



75: [Svenmarker S, Sandstrom E, Karlsson T, Aberg T.](#)


[Related Articles, Links](#)



Is there an association between release of protein S100B during cardiopulmonary bypass and memory disturbances?

Scand Cardiovasc J. 2002 Mar;36(2):117-22.

PMID: 12028876 [PubMed - indexed for MEDLINE]



76: [Machado-Vieira R, Lara DR, Portela LV, Goncalves CA, Soares JC, Kapczinski F, Souza DO.](#)


[Related Articles, Links](#)



Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study.

Eur Neuropsychopharmacol. 2002 Jun;12(3):269-72.

PMID: 12007679 [PubMed - indexed for MEDLINE]



77: [Gazzolo D, Masetti P, Meli M, Grutzfeld D, Michetti F.](#)


[Related Articles, Links](#)



Elevated S100B protein as an early indicator of intracranial haemorrhage in infants subjected to extracorporeal membrane oxygenation.

Acta Paediatr. 2002;91(2):218-21.

PMID: 11952012 [PubMed - indexed for MEDLINE]



78: [Gazzolo D, Bruschetti M, Di Iorio R, Marinoni E, Lituania M, Marras M, Sarli R, Bruschetti PL, Michetti F.](#)


[Related Articles, Links](#)



Maternal nitric oxide supplementation decreases cord blood S100B in intrauterine growth-retarded fetuses.

Clin Chem. 2002;48(4):647-50. No abstract available.

PMID: 11901065 [PubMed - indexed for MEDLINE]



79: [Djukanovic D, Hofmann U, Sucker A, Schadendorf D.](#)

[Related Articles, Links](#)



Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing.

Br J Dermatol. 2001 Dec;145(6):1030-1. No abstract available.

PMID: 11899133 [PubMed - indexed for MEDLINE]



80: [Herrmann M.](#)


[Related Articles, Links](#)



High serum S100B levels for trauma patients without head injuries.

Neurosurgery. 2001 Nov;49(5):1272-3. No abstract available.

PMID: 11865807 [PubMed - indexed for MEDLINE]



81: [Raabe A.](#)


[Related Articles, Links](#)



High serum S100B levels for trauma patients without head injuries.

Neurosurgery. 2001 Dec;49(6):1491-2; author reply 1492-3. No abstract available.

PMID: 11859839 [PubMed - indexed for MEDLINE]



82: [Romner B, Ingebrigtsen T.](#)




















[Related Articles, Links](#)



High serum S100B levels for trauma patients without head injuries.

Neurosurgery. 2001 Dec;49(6):1490; author reply 1492-3. No abstract available.

PMID: 11859838 [PubMed - indexed for MEDLINE]

-  **83:** [Rothoerl RD, Woertgen C.](#) [Related Articles, Links](#)
-  **High serum S100B levels for trauma patients without head injuries.**
Neurosurgery. 2001 Dec;49(6):1490-1; author reply 1492-3. No abstract available.
PMID: 11859837 [PubMed - indexed for MEDLINE]
-  **84:** [Connolly ES Jr, Winfree CJ, Rampersad A, Sharma R, Mack WJ, Mocco J, Solomon RA, Todd G, Quest DO, Stern Y, Heyer EJ.](#) [Related Articles, Links](#)
-  **Serum S100B protein levels are correlated with subclinical neurocognitive declines after carotid endarterectomy.**
Neurosurgery. 2001 Nov;49(5):1076-82; discussion 1082-3.
PMID: 11846900 [PubMed - indexed for MEDLINE]
-  **85:** [Gazzolo D, Marinoni E, di Iorio R, Lituania M, Bruschettini PL, Michetti F.](#) [Related Articles, Links](#)
-  **Circulating S100beta protein is increased in intrauterine growth-retarded fetuses.**
Pediatr Res. 2002 Feb;51(2):215-9.
PMID: 11809917 [PubMed - indexed for MEDLINE]
-  **86:** [Portela LV, Brenol JC, Walz R, Bianchin M, Tort AB, Canabarro UP, Beheregaray S, Marasca JA, Xavier RM, Neto EC, Goncalves CA, Souza DO.](#) [Related Articles, Links](#)
-  **Serum S100B levels in patients with lupus erythematosus: preliminary observation.**
Clin Diagn Lab Immunol. 2002 Jan;9(1):164-6.
PMID: 11777848 [PubMed - indexed for MEDLINE]
-  **87:** [Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, Lejeune F; EORTC Melanoma Group.](#) [Related Articles, Links](#)
-  **On the release and half-life of S100B protein in the peripheral blood of melanoma patients.**
Int J Cancer. 2001 Nov15;94(4):586-90.
PMID: 11745448 [PubMed - indexed for MEDLINE]
-  **88:** [Potapov EV, Loebe M, Abdul-Khaliq H, Koster A, Stein J, Sodian R, Kopitz M, Hausmann H, Noon GP, DeBaakey ME, Hetzer R.](#) [Related Articles, Links](#)
-  **Postoperative course of S-100B protein and neuron-specific enolase in patients after implantation of continuous and pulsatile flow LVADs.**
J Heart Lung Transplant. 2001 Dec;20(12):1310-6.
PMID: 11744415 [PubMed - indexed for MEDLINE]
-  **89:** [Manev H, Manev R.](#) [Related Articles, Links](#)
-  **S100B: an old neurotrophic factor with putative new roles in psychiatric illnesses.**
J Psychiatr Res. 2001 Nov-Dec;35(6):347-50. No abstract available.
PMID: 11684142 [PubMed - indexed for MEDLINE]
-  **90:** [Jackson RG, Sales KM, Samra GS, Strunin L.](#) [Related Articles, Links](#)
-  **Extra cranial sources of S100B.**
Br J Anaesth. 2001 Apr;86(4):601. No abstract available.
PMID: 11573650 [PubMed - indexed for MEDLINE]
-  **91:** [Schmidt M, Scheunert T, Steinbach G, Schirmer U, Marx T, Freitag N, Reinelt H.](#) [Related Articles, Links](#)
-  **Hypertension as a risk factor for cerebral injury during cardiopulmonary bypass. Protein S100B and transcranial Doppler findings.**
Anaesthesia. 2001 Aug;56(8):733-8.
PMID: 11493235 [PubMed - indexed for MEDLINE]
-  **92:** [Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J.](#) [Related Articles, Links](#)

Wiesmann M, Rudolf S, Wandinger KP, Kirchner H.



Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology.

Mol Psychiatry. 2001 Jul;6(4):445-9.

PMID: 11443531 [PubMed - indexed for MEDLINE]

☐ **93:** Donato R.

[Related Articles, Links](#)



S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles.

Int J Biochem Cell Biol. 2001 Jul;33(7):637-68. Review.

PMID: 11390274 [PubMed - indexed for MEDLINE]

☐ **94:** Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J.

[Related Articles, Links](#)



Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources.

Ann Thorac Surg. 2001 May;71(5):1512-7.

PMID: 11383792 [PubMed - indexed for MEDLINE]

☐ **95:** Jonsson H, Johnsson P, Birch-Jensen M, Alling C, Westaby S, Blomquist S.

[Related Articles, Links](#)



S100B as a predictor of size and outcome of stroke after cardiac surgery.

Ann Thorac Surg. 2001 May;71(5):1433-7.

PMID: 11383778 [PubMed - indexed for MEDLINE]

☐ **96:** Anderson RE, Hansson LO, Nilsson O, Djlai-Merzoug R, Settergren G.

[Related Articles, Links](#)



High serum S100B levels for trauma patients without head injuries.

Neurosurgery. 2001 Jun;48(6):1255-8; discussion 1258-60.

PMID: 11383727 [PubMed - indexed for MEDLINE]

☐ **97:** Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LV, Goncalves CA, Fonseca M, Hauck S, Souza DO.

[Related Articles, Links](#)



Increased serum S100B protein in schizophrenia: a study in medication-free patients.

J Psychiatr Res. 2001 Jan-Feb;35(1):11-4.

PMID: 11287051 [PubMed - indexed for MEDLINE]

☐ **98:** van Passel R, Schlooz WA, Lamers KJ, Lemmens WA, Rotteveel JJ.

[Related Articles, Links](#)



S100B protein, glia and Gilles de la Tourette syndrome.

Eur J Paediatr Neurol. 2001;5(1):15-9.

PMID: 11277359 [PubMed - indexed for MEDLINE]

☐ **99:** Matheis G, Scholz M, Gerber J, Abdel-Rahman U, Wimmer-Greinecker G, Moritz A.

[Related Articles, Links](#)



Leukocyte filtration in the early reperfusion phase on cardiopulmonary bypass reduces myocardial injury.

Perfusion. 2001 Jan;16(1):43-9.

PMID: 11192307 [PubMed - indexed for MEDLINE]

☐ **100:** Jonsson H, Johnsson P, Hoglund P, Alling C, Blomquist S.

[Related Articles, Links](#)



Elimination of S100B and renal function after cardiac surgery.

J Cardiothorac Vasc Anesth. 2000 Dec;14(6):698-701.

PMID: 11139112 [PubMed - indexed for MEDLINE]


☐ **101:** Morozov GV, Asanova LM, Lavrova TN, Davydov DM, Poletaev AB, Morozov SG.

[Related Articles, Links](#)



[The humoral immunity characteristics of women with neurotic depressions]

Zh Nevrol Psikhiatr Im S S Korsakova. 2000;100(9):39-44. Russian.
PMID: 11026135 [PubMed - indexed for MEDLINE]


-  **102:** Huttunen HJ, Kuja-Panula J, Sorci G, Agnietti AL, Donato R, Rauvala H. [Related Articles, Links](#)



Coregulation of neurite outgrowth and cell survival by amphotericin and S100 proteins through receptor for advanced glycation end products (RAGE) activation.

J Biol Chem. 2000 Dec 22;275(51):40096-105.

PMID: 11007787 [PubMed - indexed for MEDLINE]


-  **103:** Poletaev AB, Morozov SG, Gnedenko BB, Zlunikin VM, Korzhenevsky DA. [Related Articles, Links](#)



Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders.

Autoimmunity. 2000;32(1):33-8.

PMID: 10958173 [PubMed - indexed for MEDLINE]


-  **104:** Gazzolo D, Vinesi P, Marinoni E, Di Iorio R, Marras M, Lituania M, Bruschettini P, Michetti F. [Related Articles, Links](#)



S100B protein concentrations in cord blood: correlations with gestational age in term and preterm deliveries.

Clin Chem. 2000 Jul;46(7):998-1000. No abstract available.

PMID: 10894846 [PubMed - indexed for MEDLINE]


-  **105:** Ziagarova GG, Olinevich VB. [Related Articles, Links](#)



[Use of S100b protein for optimization of cornea regeneration after surgery]

Izv Akad Nauk Ser Biol. 2000 Jan-Feb;(1):27-32. Russian.

PMID: 10881424 [PubMed - indexed for MEDLINE]


-  **106:** Walz R, Portela LV, Tort AB, Neto EC, Fernandes LN, Goncalves CA, Souza DO. [Related Articles, Links](#)



Serum S100B levels in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.

Neurology. 2000 May 23;54(10):2021-2. No abstract available.

PMID: 10822451 [PubMed - indexed for MEDLINE]


-  **107:** Stigbrand T, Nyberg L, Ullen A, Haglid K, Sandstrom E, Brundell J. [Related Articles, Links](#)



A new specific method for measuring S-100B in serum.

Int J Biol Markers. 2000 Jan-Mar;15(1):33-40.

PMID: 10763138 [PubMed - indexed for MEDLINE]


-  **108:** Brouard M, Quillien V, Ollivier I, Lesimple T, Adamski H, Chevrant-Breton J. [Related Articles, Links](#)



[Serum S100B protein and stage of cutaneous melanoma: a prospective study]

Ann Dermatol Venereol. 2000 Jan;127(1):56-9. French.

PMID: 10717564 [PubMed - indexed for MEDLINE]


-  **109:** Muller F, Ngo S, Rebiffe M, Oury JF, Uzan S, Satge D. [Related Articles, Links](#)



Maternal serum s100b protein is ineffective for Down syndrome screening.

Prenat Diagn. 1999 Nov;19(11):1086. No abstract available.

PMID: 10589070 [PubMed - indexed for MEDLINE]

-  **110:** Bhattacharya K, Westaby S, Pillai R, Standing SJ, Johnsson P, Taggart DP. [Related Articles, Links](#)




Serum S100B and hypothermic circulatory arrest in adults.

Ann Thorac Surg. 1999 Oct;68(4):1225-9.
PMID: 10543483 [PubMed - indexed for MEDLINE]

-  **111:** Ashraf S, Bhattacharya K, Tian Y, Watterson K. [Related Articles, Links](#)



Cytokine and S100B levels in paediatric patients undergoing corrective cardiac surgery with or without total circulatory arrest.
Eur J Cardiothorac Surg. 1999 Jul;16(1):32-7.
PMID: 10456399 [PubMed - indexed for MEDLINE]

-  **112:** Babin-Ebell J, Misoph M, Mullges W, Neukam K, Reese J, Elert O. [Related Articles, Links](#)



Intraoperative embolus formation during cardiopulmonary bypass affects the release of S100B.
Thorac Cardiovasc Surg. 1999 Jun;47(3):166-9.
PMID: 10443518 [PubMed - indexed for MEDLINE]

-  **113:** Takahashi M, Chamczuk A, Hong Y, Jackowski G. [Related Articles, Links](#)




Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody.
Clin Chem. 1999 Aug;45(8 Pt 1):1307-11. No abstract available.
PMID: 10430807 [PubMed - indexed for MEDLINE]

-  **114:** Anderson RE, Hansson LO, Vaage J. [Related Articles, Links](#)




Release of S100B during coronary artery bypass grafting is reduced by off-pump surgery.
Ann Thorac Surg. 1999 Jun;67(6):1721-5.
PMID: 10391281 [PubMed - indexed for MEDLINE]

-  **115:** Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E. [Related Articles, Links](#)




Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients.
Melanoma Res. 1999 Apr;9(2):155-61.
PMID: 10380938 [PubMed - indexed for MEDLINE]

-  **116:** Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E. [Related Articles, Links](#)




Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
Br J Dermatol. 1999 Jun;140(6):1065-71.
PMID: 10354072 [PubMed - indexed for MEDLINE]

-  **117:** Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E. [Related Articles, Links](#)




S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.
Oncology. 1999;56(4):338-44.
PMID: 10343200 [PubMed - indexed for MEDLINE]

-  **118:** Camby I, Nagy N, Lopes MB, Schafer BW, Maurage CA, Ruchoux MM, Murmann P, Pochet R, Heizmann CW, Brothi J, Salmon I, Kiss R, Decaestecker C. [Related Articles, Links](#)



Supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas are characterized by a differential expression of S100 proteins.
Brain Pathol. 1999 Jan;9(1):1-19.
PMID: 9989446 [PubMed - indexed for MEDLINE]

-  **119:** Yang YH, Kim IK, Oh SH, Kim CK, Kim JY. [Related Articles, Links](#)



Rapid prenatal diagnosis of trisomy 21 by polymerase chain reaction-associated analysis of small tandem repeats and S100B in chromosome 21. Fetal Diagn Ther. 1998 Nov-Dec;13(6):361-6.
PMID: 9933820 [PubMed - indexed for MEDLINE]

120: [Schmidt S.](#)

[Related Articles, Links](#)



[S100B: pathogenetic and pathophysiologic significance in neurology] Nervenarzt. 1998 Aug;69(8):639-46. Review. German.
PMID: 9757414 [PubMed - indexed for MEDLINE]

121: [Shrestha P, Muramatsu Y, Kudeken W, Mori M, Takai Y, Ilg EC, Schafer BW, Heizmann CW.](#)

[Related Articles, Links](#)



Localization of Ca(2+)-binding S100 proteins in epithelial tumours of the skin. Virchows Arch. 1998 Jan;432(1):53-9.
PMID: 9463588 [PubMed - indexed for MEDLINE]

122: [Karnell R, von Schoultz E, Hansson L-O, Nilsson B, Arstrand K, Kagedal B.](#)

[Related Articles, Links](#)



S100B protein, 5-S-cysteinyl-dopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res. 1997 Oct;7(5):393-9.
PMID: 9429222 [PubMed - indexed for MEDLINE]

123: [Steinman RM, Pack M, Inaba K.](#)

[Related Articles, Links](#)



Dendritic cells in the T-cell areas of lymphoid organs. Immunol Rev. 1997 Apr;156:25-37. Review.
PMID: 9176697 [PubMed - indexed for MEDLINE]

124: [Usui A, Kato K, Murase M, Hotta T, Tanaka M, Takeuchi E, Abe T.](#)

[Related Articles, Links](#)



Neural tissue-related proteins (NSE, G0 alpha, 28-kDa calbindin-D, S100b and CK-BB) in serum and cerebrospinal fluid after cardiac arrest. J Neurol Sci. 1994 May;123(1-2):134-9.
PMID: 8064306 [PubMed - indexed for MEDLINE]

125: [von Eggeling F, Freytag M, Fahsold R, Horsthemke B, Claussen U.](#)

[Related Articles, Links](#)



Rapid detection of trisomy 21 by quantitative PCR. Hum Genet. 1993 Jul;91(6):567-70.
PMID: 8340111 [PubMed - indexed for MEDLINE]

126: [Crete N, Delabar JM, Rahmani Z, Yaspo ML, Kraus J, Marks A, Sinet PM, Creau-Goldberg N.](#)

[Related Articles, Links](#)



Partial physical map of human chromosome 21 from fibroblast and lymphocyte DNA. Hum Genet. 1993 Apr;91(3):245-53.
PMID: 8478008 [PubMed - indexed for MEDLINE]


127: [Shimizu A, Sakai Y, Ohno K, Masaki S, Kuwano R, Takahashi Y, Miyashita N, Watanabe T.](#)

[Related Articles, Links](#)



A molecular genetic linkage map of mouse chromosome 10, including the Myb, S100b, Pah, Sl, and Ifg genes. Biochem Genet. 1992 Oct;30(9-10):529-35.
PMID: 1359872 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for S100beta AND blood Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 150 of 150

One page.

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Fujii EY, Kozuki M, Mu J, Ino Y, Ushioda N, Tomimatsu T, Fukuda H, Kanzaki T, Nakayama M, Murata Y. Related Articles, Links

Correlation of neuron-specific enolase and S100B with histological cerebral damage in fetal sheep after severe asphyxia.
Brain Res. 2004 Aug 20;1018(1):136-40.
PMID: 15262215 [PubMed - indexed for MEDLINE]

2: Fazio V, Bhudia SK, Marchi N, Aumayr B, Janigro D. Related Articles, Links

Peripheral detection of S100beta during cardiothoracic surgery: what are we really measuring?
Ann Thorac Surg. 2004 Jul;78(1):46-52; discussion 52-3.
PMID: 15223400 [PubMed - in process]

3: Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M. Related Articles, Links

Effects of head and extracranial injuries on serum protein S100B levels in trauma patients.
J Trauma. 2004 Jun;56(6):1229-34; discussion 1234.
PMID: 15211130 [PubMed - indexed for MEDLINE]

4: Schmidt H, Sorensen BS, Nexø E, von der Maase H. Related Articles, Links

S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma.
Melanoma Res. 2004 Jun;14(3):211-5.
PMID: 15179191 [PubMed - in process]

5: Brvar M, Mozina H, Osredkar J, Mozina M, Noc M, Brucan A, Bunc M. Related Articles, Links

S100B protein in carbon monoxide poisoning: a pilot study.
Resuscitation. 2004 Jun;61(3):357-60.
PMID: 15172716 [PubMed - indexed for MEDLINE]

6: Kleindienst A, Harvey HB, Rice AC, Muller C, Hamm RJ, Gaab MR, Bullock MR. Related Articles, Links

Intraventricular infusion of the neurotrophic protein S100B improves cognitive recovery after fluid percussion injury in the rat.
J Neurotrauma. 2004 May;21(5):541-7.
PMID: 15165362 [PubMed - indexed for MEDLINE]


7: Durgut K, Hosgor K, Gormus N, Ozergin U, Solak H. Related Articles, Links


The cerebroprotective effects of pentoxifylline and aprotinin during cardiopulmonary bypass in dogs.
Perfusion. 2004 Mar;19(2):101-6.
PMID: 15162924 [PubMed - in process]

8: Husain S. Related Articles, Links

Clinical and radiological predictors of recanalisation: time to define a rapid scoring system.
J Neurol Neurosurg Psychiatry. 2004 Jun;75(6):811-2. No abstract available.


PMID: 15145990 [PubMed - indexed for MEDLINE]


-  **9:** Hasselblatt M, Mooren FC, von Ahsen N, Keyvani K, Fromme A, Schwarze-Eicker K, Senner V, Paulus W. [Related Articles, Links](#)


 **Serum S100beta increases in marathon runners reflect extracranial release rather than glial damage.**


Neurology. 2004 May 11;62(9):1634-6.

PMID: 15136701 [PubMed - indexed for MEDLINE]

-  **10:** Banfalvi T, Gergye M, Beczassy E, Gilde K, Otto S. [Related Articles, Links](#)


 **[Role of S100B protein in neoplasms and other diseases]**
Magy Onkol. 2004;48(1):71-4. Epub 2004 Apr 23. Review. Hungarian.
PMID: 15105899 [PubMed - indexed for MEDLINE]


-  **11:** Oki A, Ohtake H, Okada Y, Kawada T, Takaba T. [Related Articles, Links](#)

 **Simultaneous monitoring of somatosensory evoked potentials and regional cerebral oxygen saturation combined with serial measurement of plasma levels of cerebral specific proteins for the early diagnosis of postoperative brain damage in cardiovascular surgery.**

J Artif Organs. 2004;7(1):13-8.


PMID: 15083339 [PubMed - indexed for MEDLINE]

-  **12:** Soderlund J, Nilsson C, Lore K, Castanos-Velez E, Ekman M, Heiden T, Biberfeld G, Andersson J, Biberfeld P. [Related Articles, Links](#)

 **Dichotomy between CD1a+ and CD83+ dendritic cells in lymph nodes during SIV infection of macaques.**

J Med Primatol. 2004 Feb;33(1):16-24.


PMID: 15061728 [PubMed - indexed for MEDLINE]


-  **13:** Scaccianoce S, Del Bianco P, Pannitteri G, Passarelli F. [Related Articles, Links](#)

 **Relationship between stress and circulating levels of S100B protein.**

Brain Res. 2004 Apr 9;1004(1-2):208-11.


PMID: 15033438 [PubMed - indexed for MEDLINE]


-  **14:** Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. [Related Articles, Links](#)

 **Peripheral markers of blood-brain barrier damage.**

Clin Chim Acta. 2004 Apr;342(1-2):1-12.


PMID: 15026262 [PubMed - in process]


-  **15:** Snyder-Ramos SA, Gruhlke T, Bauer H, Bauer M, Luntz AP, Motsch J, Martin E, Vahl CF, Missler U, Wiesmann M, Bottiger BW. [Related Articles, Links](#)

 **Cerebral and extracerebral release of protein S100B in cardiac surgical patients.**

Anaesthesia. 2004 Apr;59(4):344-9.


PMID: 15023104 [PubMed - indexed for MEDLINE]


-  **16:** Stolz E, Gerriets T, Kluge A, Klovekom WP, Kaps M, Bachmann G. [Related Articles, Links](#)

 **Diffusion-weighted magnetic resonance imaging and neurobiochemical markers after aortic valve replacement: implications for future neuroprotective trials?**

Stroke. 2004 Apr;35(4):888-92. Epub 2004 Feb 19.


PMID: 14976326 [PubMed - indexed for MEDLINE]

-  **17:** Gazzolo D, Masetti P, Kornacka M, Abella R, Bruschetti P, Michetti F. [Related Articles, Links](#)

 **Phentolamine administration increases blood S100B protein levels in pediatric open-heart surgery patients.**

Acta Paediatr. 2003 Dec;92(12):1427-32.

PMID: 14971794 [PubMed - indexed for MEDLINE]


-  **18:** [Fayol L, Baud O, Monier A, Pellerin L, Magistretti P, Evrard P, Verney C.](#) [Related Articles, Links](#)



Immunocytochemical expression of monocarboxylate transporters in the human visual cortex at midgestation.

Brain Res Dev Brain Res. 2004 Jan 31;148(1):69-76.

PMID: 14757520 [PubMed - indexed for MEDLINE]


-  **19:** [Schmidt AP, Tort AB, Amaral OB, Schmidt AP, Walz R, Vettorazzi-Stuckzynski J, Martins-Costa SH, Ramos JG, Souza DO, Portela LV.](#) [Related Articles, Links](#)



Serum S100B in pregnancy-related hypertensive disorders: a case-control study.

Clin Chem. 2004 Feb;50(2):435-8. No abstract available.

PMID: 14752015 [PubMed - indexed for MEDLINE]


-  **20:** [Kawakami N, Lassmann S, Li Z, Odoardi F, Ritter T, Ziemssen T, Klinkert WE, Ellwart JW, Bradl M, Krivacic K, Lassmann H, Ransohoff RM, Volk HD, Wekerle H, Linington C, Flugel A.](#) [Related Articles, Links](#)



The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis.

J Exp Med. 2004 Jan 19;199(2):185-97.

PMID: 14734524 [PubMed - indexed for MEDLINE]


-  **21:** [Di Legge S, Di Piero V, Di Stani F, Perna R, Gattuso R, Reale MG, Benedetti Valentini F, Lenzi GL.](#) [Related Articles, Links](#)



Carotid endarterectomy and gliofibrillar S100b protein release.

Neurol Sci. 2003 Dec;24(5):351-6.

PMID: 14716532 [PubMed - indexed for MEDLINE]


-  **22:** [Dietrich MO, Tort AB, Schaf DV, Farina M, Goncalves CA, Souza DO, Portela LV.](#) [Related Articles, Links](#)



Increase in serum S100B protein level after a swimming race.

Can J Appl Physiol. 2003 Oct;28(5):710-6.

PMID: 14710522 [PubMed - indexed for MEDLINE]


-  **23:** [Dietrich DE, Hauser U, Peters M, Zhang Y, Wiesmann M, Hasselmann M, Rudolf S, Jungling O, Kirchner H, Munte TF, Arolt V, Emrich HM, Johannes S, Rothermundt M.](#) [Related Articles, Links](#)



Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression.

Neurosci Lett. 2004 Jan 2;354(1):69-73.

PMID: 14698484 [PubMed - indexed for MEDLINE]


-  **24:** [Shaaban Ali M, Harmer M, Elliott M, Thomas AL, Kirkham F.](#) [Related Articles, Links](#)



A pilot study of evaluation of cerebral function by S100beta protein and near-infrared spectroscopy during cold and warm cardiopulmonary bypass in infants and children undergoing open-heart surgery.

Anaesthesia. 2004 Jan;59(1):20-6.

PMID: 14687094 [PubMed - indexed for MEDLINE]


-  **25:** [Schulpis KH, Kariyannis C, Papassotiriou I.](#) [Related Articles, Links](#)






















Serum levels of neural protein S-100B in phenylketonuria.


Clin Biochem. 2004 Jan;37(1):76-9.

PMID: 14675567 [PubMed - indexed for MEDLINE]

-  **26:** [Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT.](#) [Related Articles, Links](#)

Novel diagnostic test for acute stroke.


-  Stroke. 2004 Jan;35(1):57-63. Epub 2003 Dec 11.
PMID: 14671250 [PubMed - indexed for MEDLINE]
-  **27:** Sussmuth SD, Tumani H, Ecker D, Ludolph AC. [Related Articles, Links](#)
-  Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum.
Neurosci Lett. 2003 Dec 15;353(1):57-60.
PMID: 14642437 [PubMed - indexed for MEDLINE]
-  **28:** Tort AB, Dietrich MO, Goncalves CA, Souza DO, Portela LV. [Related Articles, Links](#)
-  Influence of anticoagulants on the measurement of S100B protein in blood.
Clin Biochem. 2003 Nov;36(8):629-32.
PMID: 14636878 [PubMed - indexed for MEDLINE]
-  **29:** Portela LV, Tort AB, Walz R, Bianchini M, Trevisol-Bittencourt PC, Wille PR, Cardoso RC, Ishida MM, vonWangenheim A, Grisard EC, Steindel M, Goncalves CA, Souza DO. [Related Articles, Links](#)
-  Interictal serum S100B levels in chronic neurocysticercosis and idiopathic epilepsy.
Acta Neurol Scand. 2003 Dec;108(6):424-7. Erratum in: Acta Neurol Scand. 2004 Jan;109(1):84.
PMID: 14616295 [PubMed - indexed for MEDLINE]
-  **30:** Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC. [Related Articles, Links](#)
-  Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study.
Mol Cell Proteomics. 2004 Jan;3(1):66-72. Epub 2003 Oct 26.
PMID: 14581522 [PubMed - indexed for MEDLINE]
-  **31:** Anderson RE, Winnerkvist A, Hansson LO, Nilsson O, Rosengren L, Settergren G, Vaage J. [Related Articles, Links](#)
-  Biochemical markers of cerebrospinal ischemia after repair of aneurysms of the descending and thoracoabdominal aorta.
J Cardiothorac Vasc Anesth. 2003 Oct;17(5):598-603.
PMID: 14579213 [PubMed - indexed for MEDLINE]
-  **32:** Jonsson H. [Related Articles, Links](#)
-  S100B and cardiac surgery: possibilities and limitations.
Restor Neurol Neurosci. 2003;21(3-4):151-7. Review.
PMID: 14530577 [PubMed - indexed for MEDLINE]
-  **33:** Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, Kanner A, Ayumar B, Albensi B, Cavaglia M, Janigro D. [Related Articles, Links](#)
-  Peripheral markers of brain damage and blood-brain barrier dysfunction.
Restor Neurol Neurosci. 2003;21(3-4):109-21. Review.
PMID: 14530574 [PubMed - indexed for MEDLINE]
-  **34:** Herrmann M, Johnsson P, Romner B. [Related Articles, Links](#)
-  Molecular markers of brain damage: current state and future perspectives.
Restor Neurol Neurosci. 2003;21(3-4):75-7. No abstract available. Erratum in: Restor Neurol Neurosci. 2004;22(1):55.
PMID: 14530571 [PubMed - indexed for MEDLINE]
-  **35:** Pelinka LE, Szalay L, Jafarmadar M, Schmidhammer R, Redl H, Bahrami S. [Related Articles, Links](#)
-  Circulating S100B is increased after bilateral femur fracture without brain injury in the rat.
Br J Anaesth. 2003 Oct;91(4):595-7.
PMID: 14504167 [PubMed - indexed for MEDLINE]

 **36:** Michetti F, Gazzolo D.

[Related Articles](#), [Links](#)




S100B testing in pregnancy.
Clin Chim Acta. 2003 Sep;335(1-2):1-7. Review.
PMID: 12927678 [PubMed - indexed for MEDLINE]

 **37:** Wang K, Walz W.

[Related Articles](#), [Links](#)




Unusual topographical pattern of proximal astrogliosis around a cortical devascularizing lesion.
J Neurosci Res. 2003 Aug 15;73(4):497-506.
PMID: 12898534 [PubMed - indexed for MEDLINE]

 **38:** Zhou FC, Sari Y, Powrozek T, Goodlett CR, Li TK.

[Related Articles](#), [Links](#)




Moderate alcohol exposure compromises neural tube midline development in prenatal brain.
Brain Res Dev Brain Res. 2003 Aug 12;144(1):43-55.
PMID: 12888216 [PubMed - indexed for MEDLINE]

 **39:** Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, Kirchner H, Rothermundt M.

[Related Articles](#), [Links](#)



S100B and response to treatment in major depression: a pilot study.
Eur Neuropsychopharmacol. 2003 Aug;13(4):235-9.
PMID: 12888182 [PubMed - indexed for MEDLINE]

 **40:** Vaquero J, Jordano Q, Lee WM, Blei AT; US Acute Liver Failure Study Group.

[Related Articles](#), [Links](#)




Serum protein S-100b in acute liver failure: Results of the US Acute Liver Failure Study group.
Liver Transpl. 2003 Aug;9(8):887-8. No abstract available.
PMID: 12884207 [PubMed - indexed for MEDLINE]

 **41:** Malberg JE, Duman RS.

[Related Articles](#), [Links](#)




Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment.
Neuropsychopharmacology. 2003 Sep;28(9):1562-71.
PMID: 12838272 [PubMed - indexed for MEDLINE]

 **42:** Shanmugam N, Kim YS, Lanting L, Natarajan R.

[Related Articles](#), [Links](#)




Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products.
J Biol Chem. 2003 Sep 12;278(37):34834-44. Epub 2003 Jun 30.
PMID: 12837757 [PubMed - indexed for MEDLINE]

 **43:** Filippov V, Kronenberg G, Pivneva T, Reuter K, Steiner B, Wang LP, Yamaguchi M, Kettenmann H, Kempermann G.

[Related Articles](#), [Links](#)



Subpopulation of nestin-expressing progenitor cells in the adult murine hippocampus shows electrophysiological and morphological characteristics of astrocytes.
Mol Cell Neurosci. 2003 Jul;23(3):373-82.
PMID: 12837622 [PubMed - indexed for MEDLINE]

 **44:** Schroeter ML, Abdul-Khaliq H, Fruhauf S, Hohne R, Schick G, Diefenbacher A, Blasig IE.

[Related Articles](#), [Links](#)



Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia.
Schizophr Res. 2003 Aug 1;62(3):231-6.
PMID: 12837519 [PubMed - indexed for MEDLINE]

 **45:** Gazzolo D, Kornacka M, Bruschetti M, Lituania M, Giovannini L, Serra G, Majewska U, Michetti F.

[Related Articles](#), [Links](#)

**Maternal glucocorticoid supplementation and S100B protein concentrations in cord blood and urine of preterm infants.**

Clin Chem. 2003 Jul;49(7):1215-8. No abstract available.
PMID: 12816930 [PubMed - indexed for MEDLINE]

☐ **46:** Vihinen PP, Pyrhonen SO, Kahari VM.

[Related Articles, Links](#)

**New prognostic factors and developing therapy of cutaneous melanoma.**

Ann Med. 2003;35(2):66-78. Review.
PMID: 12795336 [PubMed - indexed for MEDLINE]

☐ **47:** Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Ayumar B, Vogelbaum MA, Barnett GH, Janigro D.

[Related Articles, Links](#)

**Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions.**

Cancer. 2003 Jun 1;97(11):2806-13.
PMID: 12767094 [PubMed - indexed for MEDLINE]

☐ **48:** Gazzolo D, Michetti F, Bruschettini M, Marchese N, Lituanica M, Mangraviti S, Pedrazzi E, Bruschettini P.

[Related Articles, Links](#)

**Pediatric concentrations of S100B protein in blood: age- and sex-related changes.**

Clin Chem. 2003 Jun;49(6 Pt 1):967-70. No abstract available.
PMID: 12765999 [PubMed - indexed for MEDLINE]

☐ **49:** Lindberg L, Forsell C, Jogi P, Olsson AK.

[Related Articles, Links](#)

**Effects of dexamethasone on clinical course, C-reactive protein, S100B protein and von Willebrand factor antigen after paediatric cardiac surgery.**

Br J Anaesth. 2003 Jun;90(6):728-32.
PMID: 12765886 [PubMed - indexed for MEDLINE]

☐ **50:** Pelinka LE, Bahrami S, Szalay L, Umar F, Redl H.

[Related Articles, Links](#)

**Hemorrhagic shock induces an S 100 B increase associated with shock severity.**

Shock. 2003 May;19(5):422-6.
PMID: 12744484 [PubMed - indexed for MEDLINE]

☐ **51:** de Baar M, Diephuis JC, Moons KG, Holtkamp J, Hijman R, Kalkman CJ.

[Related Articles, Links](#)

**The effect of zero-balanced ultrafiltration during cardiopulmonary bypass on S100b release and cognitive function.**

Perfusion. 2003 Mar;18(1):9-14.
PMID: 12705644 [PubMed - indexed for MEDLINE]

☐ **52:** Dimopoulou I, Korfias S, Dafni U, Anthi A, Psachoulia C, Jullien G, Sakas DE, Roussos C.

[Related Articles, Links](#)

**Protein S-100b serum levels in trauma-induced brain death.**

Neurology. 2003 Mar 25;60(6):947-51.
PMID: 12654958 [PubMed - indexed for MEDLINE]

☐ **53:** Ishida K, Gohara T, Kawata R, Ohtake K, Morimoto Y, Sakabe T.

[Related Articles, Links](#)

**Are serum S100beta proteins and neuron-specific enolase predictors of cerebral damage in cardiovascular surgery?**

J Cardiothorac Vasc Anesth. 2003 Feb;17(1):4-9.
PMID: 12635053 [PubMed - indexed for MEDLINE]


☐ **54:** Mangano DT.

[Related Articles, Links](#)

**S100beta and NSE: stroke surrogate signals or natal neural noise?**

J Cardiothorac Vasc Anesth. 2003 Feb;17(1):1-3. No abstract available.

PMID: 12635052 [PubMed - indexed for MEDLINE]


-  **55:** Pelinka LE, Toegel E, Mauritz W, Redl H. [Related Articles](#), [Links](#)



Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma.

Shock. 2003 Mar;19(3):195-200.

PMID: 12630517 [PubMed - indexed for MEDLINE]


-  **56:** Spinella PC, Dominguez T, Drott HR, Hub J, McCormick L, Rajendra A, Argon J, McIntosh T, Helfaer M. [Related Articles](#), [Links](#)



S-100beta protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury.

Crit Care Med. 2003 Mar;31(3):939-45.

PMID: 12627009 [PubMed - indexed for MEDLINE]


-  **57:** Foerch C, du Mesnil de Rochemont R, Singer O, Neumann-Haefelin T, Buchkremer M, Zanella FE, Steinmetz H, Sitzer M. [Related Articles](#), [Links](#)



S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion.

J Neurol Neurosurg Psychiatry. 2003 Mar;74(3):322-5.

PMID: 12588916 [PubMed - indexed for MEDLINE]


-  **58:** Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. [Related Articles](#), [Links](#)



Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.

Melanoma Res. 2003 Feb;13(1):45-9.

PMID: 12569284 [PubMed - indexed for MEDLINE]


-  **59:** Gazzolo D, Masetti P, Vinesi P, Meli M, Abella R, Marcelletti C, Michetti F. [Related Articles](#), [Links](#)



S100B blood levels correlate with rewarming time and cerebral Doppler in pediatric open heart surgery.

J Card Surg. 2002 Jul-Aug;17(4):279-84.

PMID: 12546072 [PubMed - indexed for MEDLINE]


-  **60:** Johnsson P, Backstrom M, Bergh C, Jonsson H, Luhrs C, Alling C. [Related Articles](#), [Links](#)



Increased S100B in blood after cardiac surgery is a powerful predictor of late mortality.

Ann Thorac Surg. 2003 Jan;75(1):162-8.

PMID: 12537211 [PubMed - indexed for MEDLINE]


-  **61:** Gazzolo D, Monego G, Corvino V, Bruschettini M, Bruschettini P, Zelano G, Michetti F. [Related Articles](#), [Links](#)



Human milk contains S100B protein.

Biochim Biophys Acta. 2003 Jan 20;1619(2):209-12.

PMID: 12527118 [PubMed - indexed for MEDLINE]


-  **62:** Chatfield DA, Zemlan FP, Day DJ, Menon DK. [Related Articles](#), [Links](#)



Discordant temporal patterns of S100beta and cleaved tau protein elevation after head injury: a pilot study.

Br J Neurosurg. 2002 Oct;16(5):471-6.

PMID: 12498491 [PubMed - indexed for MEDLINE]











-  **63:** Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Kochanek PM. [Related Articles](#), [Links](#)



Serum S100B concentrations are increased after closed head injury in children: a preliminary study.

J Neurotrauma. 2002 Nov;19(11):1405-9.

PMID: 12490005 [PubMed - indexed for MEDLINE]

-  **64:** [Petzold A, Green AJ, Keir G, Fairley S, Kitchen N, Smith M, Thompson EJ.](#) [Related Articles, Links](#)
Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study.
 Crit Care Med. 2002 Dec;30(12):2705-10.
 PMID: 12483062 [PubMed - indexed for MEDLINE]
-  **65:** [Elting JW, Sulter GA, Kaste M, Lees KR, Diener HC, Hommel M, Versavel M, Teelken AW, De Keyser J.](#) [Related Articles, Links](#)
AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels.
 Stroke. 2002 Dec;33(12):2813-8.
 PMID: 12468775 [PubMed - indexed for MEDLINE]
-  **66:** [Michetti F, Gazzolo D.](#) [Related Articles, Links](#)
S100B protein in biological fluids: a tool for perinatal medicine.
 Clin Chem. 2002 Dec;48(12):2097-104. Review.
 PMID: 12446464 [PubMed - indexed for MEDLINE]
-  **67:** [Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL.](#) [Related Articles, Links](#)
Erythropoietin therapy for acute stroke is both safe and beneficial.
 Mol Med. 2002 Aug;8(8):495-505.
 PMID: 12435860 [PubMed - indexed for MEDLINE]
-  **68:** [Gazzolo D, Visser GH, Lituania M, Sarli R, Bruschettini M, Michetti F, Bruschettini PL.](#) [Related Articles, Links](#)
S100B protein cord blood levels and development of fetal behavioral states: a study in normal and small-for-dates fetuses.
 J Matern Fetal Neonatal Med. 2002 Jun;11(6):378-84.
 PMID: 12389652 [PubMed - indexed for MEDLINE]
-  **69:** [Tsoporis JN, Marks A, Van Eldik LJ, O'Hanlon D, Parker TG.](#) [Related Articles, Links](#)
Regulation of the S100B gene by alpha 1-adrenergic stimulation in cardiac myocytes.
 Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H193-203. Epub 2002 Sep 05.
 PMID: 12388300 [PubMed - indexed for MEDLINE]
-  **70:** [Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE.](#) [Related Articles, Links](#)
S100B is increased in mood disorders and may be reduced by antidepressive treatment.
 Neuroreport. 2002 Sep 16;13(13):1675-8.
 PMID: 12352625 [PubMed - indexed for MEDLINE]
-  **71:** [Ozatik MA, Tarcan O, Kale A, Askin GA, Balci M, Undar A, Kucukaksu DS, Sener E, Tasdemir O.](#) [Related Articles, Links](#)
Do S100beta protein level increases due to inflammation during cardiopulmonary bypass occur without any neurological deficit?
 Perfusion. 2002 Sep;17(5):335-8.
 PMID: 12243436 [PubMed - indexed for MEDLINE]
-  **72:** [Ball HJ, McParland B, Driussi C, Hunt NH.](#) [Related Articles, Links](#)
Isolating vessels from the mouse brain for gene expression analysis using laser capture microdissection.
 Brain Res Brain Res Protoc. 2002 Jun;9(3):206-13.
 PMID: 12113780 [PubMed - indexed for MEDLINE]
-  **73:** [Gazzolo D, Di Iorio R, Marinoni E, Masetti P, Serra G, Giovannini](#) [Related Articles, Links](#)

L. Michetti F.



S100B protein is increased in asphyxiated term infants developing intraventricular hemorrhage.

Crit Care Med. 2002 Jun;30(6):1356-60.

PMID: 12072694 [PubMed - indexed for MEDLINE]



74: Tokuno S, Hinokiyama K, Tokuno K, Lowbeer C, Hansson LO, Valen G

[Related Articles](#), [Links](#)



Spontaneous ischemic events in the brain and heart adapt the hearts of severely atherosclerotic mice to ischemia.

Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):995-1001.

PMID: 12067910 [PubMed - indexed for MEDLINE]



75: Portela LV, Tort AB, Schaf DV, Ribeiro L, Nora DB, Walz R, Rotta LN, Silva CT, Busnello JV, Kapczinski F, Goncalves CA, Souza DO.

[Related Articles](#), [Links](#)



The serum S100B concentration is age dependent.

Clin Chem. 2002 Jun;48(6 Pt 1):950-2. No abstract available.

PMID: 12029017 [PubMed - indexed for MEDLINE]



76: Svenmarker S, Sandstrom E, Karlsson T, Aberg T.

[Related Articles](#), [Links](#)



Is there an association between release of protein S100B during cardiopulmonary bypass and memory disturbances?

Scand Cardiovasc J. 2002 Mar;36(2):117-22.

PMID: 12028876 [PubMed - indexed for MEDLINE]



77: Machado-Vieira R, Lara DR, Portela LV, Goncalves CA, Soares JC, Kapczinski F, Souza DO.

[Related Articles](#), [Links](#)



Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study.

Eur Neuropsychopharmacol. 2002 Jun;12(3):269-72.

PMID: 12007679 [PubMed - indexed for MEDLINE]



78: Gazzolo D, Masetti P, Meli M, Grutzfeld D, Michetti F.

[Related Articles](#), [Links](#)



Elevated S100B protein as an early indicator of intracranial haemorrhage in infants subjected to extracorporeal membrane oxygenation.

Acta Paediatr. 2002;91(2):218-21.

PMID: 11952012 [PubMed - indexed for MEDLINE]



79: Saez-Torres I, Brieva L, Espejo C, Barrau MA, Montalban X, Martinez-Caceres EM.

[Related Articles](#), [Links](#)



Specific proliferation towards myelin antigens in patients with multiple sclerosis during a relapse.

Autoimmunity. 2002 Feb;35(1):45-50.

PMID: 11908706 [PubMed - indexed for MEDLINE]



80: Shaaban-Ali M, Harmer M, Vaughan RS, Dunne JA, Latto IP, Haaverstad R, Kulatilake EN, Butchart EG.

[Related Articles](#), [Links](#)



Changes in serum S100beta protein and Mini-Mental State Examination after cold (28 degrees C) and warm (34 degrees C) cardiopulmonary bypass using different blood gas strategies (alpha-stat and pH-stat).

Acta Anaesthesiol Scand. 2002 Jan;46(1):10-6.

PMID: 11903066 [PubMed - indexed for MEDLINE]



81: Djukanovic D, Hofmann U, Sucker A, Schadendorf D.


[Related Articles](#), [Links](#)




Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing.

Br J Dermatol. 2001 Dec;145(6):1030-1. No abstract available.

PMID: 11899133 [PubMed - indexed for MEDLINE]


-  **82:** [Gazzolo D, Marinoni E, di Iorio R, Lituania M, Bruschettini PL, Michetti F.](#) [Related Articles, Links](#)

 **Circulating S100beta protein is increased in intrauterine growth-retarded fetuses.**

Pediatr Res. 2002 Feb;51(2):215-9.


PMID: 11809917 [PubMed - indexed for MEDLINE]


-  **83:** [Mohammed MQ, Abraba HD, Sherwood RA, MacRae K, Retsas S.](#) [Related Articles, Links](#)

 **Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.**

Med Oncol. 2001;18(2):109-20.


PMID: 11778756 [PubMed - indexed for MEDLINE]


-  **84:** [Portela LV, Brenol JC, Walz R, Bianchin M, Tort AB, Canabarro UP, Beheregaray S, Marasca JA, Xavier RM, Neto EC, Goncalves CA, Souza DO.](#) [Related Articles, Links](#)

 **Serum S100B levels in patients with lupus erythematosus: preliminary observation.**

Clin Diagn Lab Immunol. 2002 Jan;9(1):164-6.


PMID: 11777848 [PubMed - indexed for MEDLINE]


-  **85:** [Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, Lejeune F, EORTC Melanoma Group.](#) [Related Articles, Links](#)

 **On the release and half-life of S100B protein in the peripheral blood of melanoma patients.**

Int J Cancer. 2001 Nov15;94(4):586-90.

PMID: 11745448 [PubMed - indexed for MEDLINE]


-  **86:** [Potapov EV, Loebe M, Abdul-Khaliq H, Koster A, Stein J, Sodian R, Kopitz M, Hausmann H, Noon GP, DeBaakey ME, Hetzer R.](#) [Related Articles, Links](#)

 **Postoperative course of S-100B protein and neuron-specific enolase in patients after implantation of continuous and pulsatile flow LVADs.**

J Heart Lung Transplant. 2001 Dec;20(12):1310-6.

PMID: 11744415 [PubMed - indexed for MEDLINE]


-  **87:** [Kunihara T, Shiya N, Yasuda K.](#) [Related Articles, Links](#)

 **Changes in S100beta protein levels in cerebrospinal fluid after thoracoabdominal aortic operations.**

J Thorac Cardiovasc Surg. 2001 Nov;122(5):1019-20. No abstract available.

PMID: 11689809 [PubMed - indexed for MEDLINE]


-  **88:** [Vaage J, Anderson R.](#) [Related Articles, Links](#)

 **Biochemical markers of neurologic injury in cardiac surgery: the rise and fall of S100beta.**

J Thorac Cardiovasc Surg. 2001 Nov;122(5):853-5. No abstract available.


PMID: 11689787 [PubMed - indexed for MEDLINE]


-  **89:** [Manev H, Manev R.](#) [Related Articles, Links](#)

 **S100B: an old neurotrophic factor with putative new roles in psychiatric illnesses.**

J Psychiatr Res. 2001 Nov-Dec;35(6):347-50. No abstract available.

PMID: 11684142 [PubMed - indexed for MEDLINE]


















-  **90:** [Wollina U, Hipler UC, Knoll B, Graefe T, Kaatz M, Kirsch K.](#) [Related Articles, Links](#)

 **Serum matrix metalloproteinase-2 in patients with malignant melanoma.**

J Cancer Res Clin Oncol. 2001 Oct;127(10):631-5.

PMID: 11599800 [PubMed - indexed for MEDLINE]


-  **91:** [Robson MJ, Alston RP, Deary IJ, Andrews PJ, Souter MJ.](#) [Related Articles, Links](#)

-  Jugular bulb oxyhemoglobin desaturation, S100beta, and neurologic and cognitive outcomes after coronary artery surgery.
Anesth Analg. 2001 Oct;93(4):839-45.
PMID: 11574343 [PubMed - indexed for MEDLINE]
-  **92:** Lobsiger CS, Smith PM, Buchstaller J, Schweitzer B, Franklin RJ, Suter U, Taylor V. [Related Articles](#), [Links](#)
-  SpL201: a conditionally immortalized Schwann cell precursor line that generates myelin.
Glia. 2001 Oct;36(1):31-47.
PMID: 11571782 [PubMed - indexed for MEDLINE]
-  **93:** Schmidt M, Scheunert T, Steinbach G, Schirmer U, Marx T, Freitag N, Reinelt H. [Related Articles](#), [Links](#)
-  Hypertension as a risk factor for cerebral injury during cardiopulmonary bypass. Protein S100B and transcranial Doppler findings.
Anaesthesia. 2001 Aug;56(8):733-8.
PMID: 11493235 [PubMed - indexed for MEDLINE]
-  **94:** Mussack T, Biberthaler P, Gippner-Steppert C, Kanz KG, Wiedemann E, Mutschler W, Jochum M. [Related Articles](#), [Links](#)
-  Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisms.
Resuscitation. 2001 May;49(2):193-9.
PMID: 11382526 [PubMed - indexed for MEDLINE]
-  **95:** Deichmann M, Benner A, Kuner N, Wacker J, Waldmann V, Naher H. [Related Articles](#), [Links](#)
-  Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100beta or melanoma inhibitory activity (MIA)?
Melanoma Res. 2001 Jun;11(3):291-6.
PMID: 11468518 [PubMed - indexed for MEDLINE]
-  **96:** Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, Rudolf S, Wandinger KP, Kirchner H. [Related Articles](#), [Links](#)
-  Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology.
Mol Psychiatry. 2001 Jul;6(4):445-9.
PMID: 11443531 [PubMed - indexed for MEDLINE]
-  **97:** Haase CG, Schmidt S. [Related Articles](#), [Links](#)
-  Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica.
Neurosci Lett. 2001 Jul 13;307(2):131-3.
PMID: 11427318 [PubMed - indexed for MEDLINE]
-  **98:** LeMaire SA, Bhama JK, Schmittling ZC, Oberwalder PJ, Koksoy C, Raskin SA, Curling PE, Coselli JS. [Related Articles](#), [Links](#)
-  S100beta correlates with neurologic complications after aortic operation using circulatory arrest.
Ann Thorac Surg. 2001 Jun;71(6):1913-8; discussion 1918-9.
PMID: 11426768 [PubMed - indexed for MEDLINE]
-  **99:** Krahn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU. [Related Articles](#), [Links](#)
-  S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin

and lactate-dehydrogenase.

Anticancer Res. 2001 Mar-Apr;21(2B):1311-6.

PMID: 11396205 [PubMed - indexed for MEDLINE]


-  **100:** Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J. [Related Articles, Links](#)



Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources.

Ann Thorac Surg. 2001 May;71(5):1512-7.

PMID: 11383792 [PubMed - indexed for MEDLINE]


-  **101:** Jonsson H, Johnsson P, Birch-Jensen M, Alling C, Westaby S, Blomquist S. [Related Articles, Links](#)



S100B as a predictor of size and outcome of stroke after cardiac surgery.

Ann Thorac Surg. 2001 May;71(5):1433-7.

PMID: 11383778 [PubMed - indexed for MEDLINE]

-  **102:** Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G. [Related Articles, Links](#)



High serum S100B levels for trauma patients without head injuries.

Neurosurgery. 2001 Jun;48(6):1255-8; discussion 1258-60.

PMID: 11383727 [PubMed - indexed for MEDLINE]


-  **103:** Regner A, Kaufman M, Friedman G, Chemale I. [Related Articles, Links](#)



Increased serum S100beta protein concentrations following severe head injury in humans: a biochemical marker of brain death?

Neuroreport. 2001 Mar 26;12(4):691-4.

PMID: 11277565 [PubMed - indexed for MEDLINE]


-  **104:** Kunzi-Rapp K, Kaskel P, Steiner R, Peter RU, Krahn G. [Related Articles, Links](#)



Increased blood levels of human S100 in melanoma chick embryo xenografts' circulation.

Pigment Cell Res. 2001 Feb;14(1):9-13.

PMID: 11277496 [PubMed - indexed for MEDLINE]


-  **105:** van Passel R, Schlooz WA, Lamers KJ, Lemmens WA, Roiteveel JJ. [Related Articles, Links](#)



S100B protein, glia and Gilles de la Tourette syndrome.

Eur J Paediatr Neurol. 2001;5(1):15-9.

PMID: 11277359 [PubMed - indexed for MEDLINE]


-  **106:** de Kruijk JR, Leffers P, Menheere PP, Meerhoff S, Twijnstra A. [Related Articles, Links](#)



S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with health controls.

Acta Neurol Scand. 2001 Mar;103(3):175-9.

PMID: 11240565 [PubMed - indexed for MEDLINE]


-  **107:** Pokela M, Anttila V, Rimpilainen J, Hirvonen J, Vainionpaa V, Kiviluoma K, Ronsi P, Mennander A, Juvonen T. [Related Articles, Links](#)



Serum S-100beta protein predicts brain injury after hypothermic circulatory arrest in pigs.

Scand Cardiovasc J. 2000 Dec;34(6):570-4.

PMID: 11214009 [PubMed - indexed for MEDLINE]


-  **108:** Johnsson P. [Related Articles, Links](#)



S100-B in blood: a marker of brain damage or simply a covariate?

Scand Cardiovasc J. 2000 Dec;34(6):548-9. No abstract available.

PMID: 11214005 [PubMed - indexed for MEDLINE]

-  **109:** Biberthaler P, Mussack T, Wiedemann E, Kanz KG, Koelsch M. [Related Articles, Links](#)

Gippner-Steppert C, Jochum M.



Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma.

World J Surg. 2001 Jan;25(1):93-7.

PMID: 11213162 [PubMed - indexed for MEDLINE]

☐ **110:** Preston E, Webster J, Small D.

[Related Articles, Links](#)



Characteristics of sustained blood-brain barrier opening and tissue injury in a model for focal trauma in the rat.

J Neurotrauma. 2001 Jan;18(1):83-92.

PMID: 11200252 [PubMed - indexed for MEDLINE]

☐ **111:** Martin JA, Craft DK, Su JH, Kim RC, Cotman CW.

[Related Articles, Links](#)



Astrocytes degenerate in frontotemporal dementia: possible relation to hypoperfusion.

Neurobiol Aging. 2001 Mar-Apr;22(2):195-207.

PMID: 11182469 [PubMed - indexed for MEDLINE]

☐ **112:** Mercier F, Hatton GL.

[Related Articles, Links](#)



Connexin 26 and basic fibroblast growth factor are expressed primarily in the subpial and subependymal layers in adult brain parenchyma: roles in stem cell proliferation and morphological plasticity?

J Comp Neurol. 2001 Feb 26;431(1):88-104.

PMID: 11169992 [PubMed - indexed for MEDLINE]

☐ **113:** McIntyre EA, Abraha HD, Perros P, Sherwood RA.

[Related Articles, Links](#)



Serum S-100beta protein is a potential biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis.

Diabet Med. 2000 Nov;17(11):807-9.

PMID: 11131106 [PubMed - indexed for MEDLINE]

☐ **114:** Schlagenhauff B, Schitteck B, Ellwanger U, Stroebel W, Blum A, Schwarz M, Rassner G, Garbe C.

[Related Articles, Links](#)



Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?

Melanoma Res. 2000 Oct;10(5):451-9.

PMID: 11095406 [PubMed - indexed for MEDLINE]

☐ **115:** Rimpilainen J, Pokela M, Kiviluoma K, Anttila V, Vainionpaa V, Hirvonen J, Ohtonen P, Mennander A, Remes E, Juvonen T.

[Related Articles, Links](#)



Leukocyte filtration improves brain protection after a prolonged period of hypothermic circulatory arrest: A study in a chronic porcine model.

J Thorac Cardiovasc Surg. 2000 Dec;120(6):1131-41.

PMID: 11088037 [PubMed - indexed for MEDLINE]

☐ **116:** de Girolamo P, Arcamone N, Gargiulo G.

[Related Articles, Links](#)



S100-like protein in the goldfish (*Carassius auratus*) kidney. An immunohistochemical study.

Cell Tissue Res. 2000 Oct;302(1):135-8.

PMID: 11079723 [PubMed - indexed for MEDLINE]

☐ **117:** Poletaev AB, Morozov SG, Gnedenko BB, Zlunikin VM, Korzhenevsky DA.




















[Related Articles, Links](#)



Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders.

Autoimmunity. 2000;32(1):33-8.

PMID: 10958173 [PubMed - indexed for MEDLINE]


-  **118:** [Ziagarova GG, Olinevich VB.](#) [Related Articles, Links](#)
-  [Use of S100b protein for optimization of cornea regeneration after surgery]
Izv Akad Nauk Ser Biol. 2000 Jan-Feb;(1):27-32. Russian.
PMID: 10881424 [PubMed - indexed for MEDLINE]
-  **119:** [Gattaz WF, Lara DR, Elkis H, Portela LV, Goncalves CA, Tort AB, Henna J, Souza DO.](#) [Related Articles, Links](#)
-  Decreased S100-beta protein in schizophrenia: preliminary evidence.
Schizophr Res. 2000 Jun 16;43(2-3):91-5.
PMID: 10858627 [PubMed - indexed for MEDLINE]
-  **120:** [Wiltfang J, Nolte W, Otto M, Wildberg J, Bahn E, Figulla HR, Pralle L, Hartmann H, Ruther E, Ramadori G.](#) [Related Articles, Links](#)
-  Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy.
Metab Brain Dis. 1999 Dec;14(4):239-51.
PMID: 10850551 [PubMed - indexed for MEDLINE]
-  **121:** [Walz R, Portela LV, Tort AB, Neto EC, Fernandes LN, Goncalves CA, Souza DO.](#) [Related Articles, Links](#)
-  Serum S100B levels in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.
Neurology. 2000 May 23;54(10):2021-2. No abstract available.
PMID: 10822451 [PubMed - indexed for MEDLINE]
-  **122:** [Mercier F, Hatton GL.](#) [Related Articles, Links](#)
-  Immunocytochemical basis for a meningeo-glial network.
J Comp Neurol. 2000 May 15;420(4):445-65.
PMID: 10805920 [PubMed - indexed for MEDLINE]
-  **123:** [Anderson RE, Hansson LO, Liska J, Settergren G, Vaage J.](#) [Related Articles, Links](#)
-  The effect of cardiectomy suction on the brain injury marker S100beta after cardiopulmonary bypass.
Ann Thorac Surg. 2000 Mar;69(3):847-50.
PMID: 10750771 [PubMed - indexed for MEDLINE]
-  **124:** [Camby I, Lefranc F, Titeca G, Neuci S, Fastrez M, Dedecken L, Schafer BW, Brotchi J, Heizmann CW, Pochet R, Salmon I, Kiss R, Decaestecker C.](#) [Related Articles, Links](#)
-  Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours.
Neuropathol Appl Neurobiol. 2000 Feb;26(1):76-90.
PMID: 10736069 [PubMed - indexed for MEDLINE]
-  **125:** [Brouard M, Quillien V, Ollivier I, Lesimple T, Adamski H, Chevrant-Breton J.](#) [Related Articles, Links](#)
-  [Serum S100B protein and stage of cutaneous melanoma: a prospective study]
Ann Dermatol Venereol. 2000 Jan;127(1):56-9. French.
PMID: 10717564 [PubMed - indexed for MEDLINE]
-  **126:** [Wollina U, Karte K, Hipler UC, Knoll B, Kirsch K, Herold C.](#) [Related Articles, Links](#)
-  Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay.
J Cancer Res Clin Oncol. 2000 Feb;126(2):107-10.
PMID: 10664251 [PubMed - indexed for MEDLINE]
-  **127:** [Jonsson H, Johnsson P, Alling C, Backstrom M, Bergh C, Blomquist S.](#) [Related Articles, Links](#)



S100beta after coronary artery surgery: release pattern, source of contamination, and relation to neuropsychological outcome.

Ann Thorac Surg. 1999 Dec;68(6):2202-8.

PMID: 10617003 [PubMed - indexed for MEDLINE]

-  **128:** [Ettinger A, Laumark AB, Ostroff RM, Brundell J, Baumgartner WA, Razumovsky AY.](#) [Related Articles, Links](#)



A new optical immunoassay for detection of S-100B protein in whole blood.

Ann Thorac Surg. 1999 Dec;68(6):2196-201.

PMID: 10617002 [PubMed - indexed for MEDLINE]


-  **129:** [Muller F, Ngo S, Rebiffe M, Oury JF, Uzan S, Satge D.](#) [Related Articles, Links](#)



Maternal serum s100b protein is ineffective for Down syndrome screening.

Prenat Diagn. 1999 Nov;19(11):1086. No abstract available.

PMID: 10589070 [PubMed - indexed for MEDLINE]


-  **130:** [Flugel A, Labeur MS, Grasbon-Frodl EM, Kreutzberg GW, Graeber MB.](#) [Related Articles, Links](#)



Microglia only weakly present glioma antigen to cytotoxic T cells.

Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):547-56.

PMID: 10571416 [PubMed - indexed for MEDLINE]


-  **131:** [Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H.](#) [Related Articles, Links](#)



S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.

J Clin Oncol. 1999 Jun;17(6):1891-6.

PMID: 10561230 [PubMed - indexed for MEDLINE]


-  **132:** [Bhattacharya K, Westaby S, Pillai R, Standing SJ, Johnsson P, Taggart DP.](#) [Related Articles, Links](#)



Serum S100B and hypothermic circulatory arrest in adults.

Ann Thorac Surg. 1999 Oct;68(4):1225-9.

PMID: 10543483 [PubMed - indexed for MEDLINE]

-  **133:** [Babin-Ebell J, Misoph M, Mullges W, Neukam K, Reese J, Elert O.](#) [Related Articles, Links](#)



Intraoperative embolus formation during cardiopulmonary bypass affects the release of S100B.

Thorac Cardiovasc Surg. 1999 Jun;47(3):166-9.

PMID: 10443518 [PubMed - indexed for MEDLINE]

-  **134:** [Takahashi M, Chamczuk A, Hong Y, Jackowski G.](#) [Related Articles, Links](#)



Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody.

Clin Chem. 1999 Aug;45(8 Pt 1):1307-11. No abstract available.

PMID: 10430807 [PubMed - indexed for MEDLINE]

-  **135:** [Wong CH, Rooney SJ, Bonser RS.](#) [Related Articles, Links](#)



S-100beta release in hypothermic circulatory arrest and coronary artery surgery.

Ann Thorac Surg. 1999 Jun;67(6):1911-4; discussion 1919-21.

PMID: 10391337 [PubMed - indexed for MEDLINE]

-  **136:** [Wiencken AE, Casagrande VA.](#) [Related Articles, Links](#)




Endothelial nitric oxide synthetase (eNOS) in astrocytes: another source of

nitric oxide in neocortex.

Glia. 1999 Jun;26(4):280-90.

PMID: 10383047 [PubMed - indexed for MEDLINE]


-  **137:** [Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E.](#) [Related Articles, Links](#)



Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients.

Melanoma Res. 1999 Apr;9(2):155-61.

PMID: 10380938 [PubMed - indexed for MEDLINE]


-  **138:** [Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E.](#) [Related Articles, Links](#)



S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.

Oncology. 1999;56(4):338-44.

PMID: 10343200 [PubMed - indexed for MEDLINE]


-  **139:** [Kesel AJ, Sonnenbichler I, Polborn K, Gurtler L, Klinkert WE, Modolell M, Nussler AK, Oberthur W.](#) [Related Articles, Links](#)



A new antioxidative vitamin B6 analogue modulates pathophysiological cell proliferation and damage.

Bioorg Med Chem. 1999 Feb;7(2):359-67.

PMID: 10218829 [PubMed - indexed for MEDLINE]

-  **140:** [Atsumi Y, Nozawa-Inoue K, Maeda T, Kurisu K, Wakisaka S.](#) [Related Articles, Links](#)



Immunohistochemical localization of S-100beta in the dental pulp of the rat molar.

Brain Res. 1999 Feb 13;818(2):515-9.

PMID: 10082839 [PubMed - indexed for MEDLINE]


-  **141:** [Yang YH, Kim JK, Oh SH, Kim CK, Kim JY.](#) [Related Articles, Links](#)



Rapid prenatal diagnosis of trisomy 21 by polymerase chain reaction-associated analysis of small tandem repeats and S100B in chromosome 21.

Fetal Diagn Ther. 1998 Nov-Dec;13(6):361-6.

PMID: 9933820 [PubMed - indexed for MEDLINE]


-  **142:** [Ashraf S, Bhattacharya K, Zacharias S, Kaul P, Kay PH, Watterson KG.](#) [Related Articles, Links](#)



Serum S100beta release after coronary artery bypass grafting: roller versus centrifugal pump.

Ann Thorac Surg. 1998 Dec;66(6):1958-62.

PMID: 9930476 [PubMed - indexed for MEDLINE]

-  **143:** [Wimmer-Greinecker G, Matheis G, Brieden M, Dietrich M, Oremek G, Westphal K, Winkelmann BR, Moritz A.](#) [Related Articles, Links](#)



Neuropsychological changes after cardiopulmonary bypass for coronary artery bypass grafting.

Thorac Cardiovasc Surg. 1998 Aug;46(4):207-12.

PMID: 9776494 [PubMed - indexed for MEDLINE]


-  **144:** [Schmidt S.](#) [Related Articles, Links](#)



[S100B: pathogenetic and pathophysiologic significance in neurology]

Nervenarzt. 1998 Aug;69(8):639-46. Review. German.

PMID: 9757414 [PubMed - indexed for MEDLINE]

-  **145:** [Bonfrer JM, Korse CM, Nieweg OE, Rankin EM.](#) [Related Articles, Links](#)




The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma.

Br J Cancer. 1998 Jun;77(12):2210-4.
PMID: 9649135 [PubMed - indexed for MEDLINE]

-  **146:** [Grocott HP, Croughwell ND, Amory DW, White WD, Kirchner JL, Newman MF.](#) [Related Articles, Links](#)




Cerebral emboli and serum S100beta during cardiac operations.
Ann Thorac Surg. 1998 Jun;65(6):1645-9; discussion 1649-50.
PMID: 9647074 [PubMed - indexed for MEDLINE]

-  **147:** [Gruden' MA, Dektiarev DN, Shumova EA, Deev IL, Sherstnev VV.](#) [Related Articles, Links](#)




[Autoantibodies to neurotrophic factors and perinatal brain performance disorders in children]
Vestn Ross Akad Med Nauk. 1998;(2):30-3. Russian. No abstract available.
PMID: 9567716 [PubMed - indexed for MEDLINE]

-  **148:** [Kamell R, von Schoultz E, Hansson LO, Nilsson B, Arstrand K, Kagedal B.](#) [Related Articles, Links](#)




S100B protein, 5-S-cysteinyl-dopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Melanoma Res. 1997 Oct;7(5):393-9.
PMID: 9429222 [PubMed - indexed for MEDLINE]

-  **149:** [Schmidt S, Linington C, Zipp F, Sotgiu S, de Waal Malefyt R, Wekerle H, Hohlfield R.](#) [Related Articles, Links](#)



Multiple sclerosis: comparison of the human T-cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis.
Brain. 1997 Aug;120 (Pt 8):1437-45.
PMID: 9278633 [PubMed - indexed for MEDLINE]

-  **150:** [Hohlfield R, Londei M, Massacesi L, Salvetti M.](#) [Related Articles, Links](#)





T-cell autoimmunity in multiple sclerosis.
Immunol Today. 1995 Jun;16(6):259-61. Review. No abstract available.
PMID: 7544976 [PubMed - indexed for MEDLINE]

Display Show:

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 23 2004 06:26:50



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for S100beta AND serum Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 99 of 99

One page.

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Fujii EY, Kozuki M, Mu J, Ino Y, Ushioda N, Tomimatsu T, Fukuda H, Kanzaki T, Nakayama M, Murata Y.](#) Related Articles, Links

Correlation of neuron-specific enolase and S100B with histological cerebral damage in fetal sheep after severe asphyxia.
Brain Res. 2004 Aug 20;1018(1):136-40.
PMID: 15262215 [PubMed - indexed for MEDLINE]

☐ 2: [Fazio V, Bhudia SK, Marchi N, Aumayr B, Janigro D.](#) Related Articles, Links

Peripheral detection of S100beta during cardiothoracic surgery: what are we really measuring?
Ann Thorac Surg. 2004 Jul;78(1):46-52; discussion 52-3.
PMID: 15223400 [PubMed - in process]

☐ 3: [Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M.](#) Related Articles, Links

Effects of head and extracranial injuries on serum protein S100B levels in trauma patients.
J Trauma. 2004 Jun;56(6):1229-34; discussion 1234.
PMID: 15211130 [PubMed - indexed for MEDLINE]

☐ 4: [Schmidt H, Sorensen BS, Nexø E, von der Maase H.](#) Related Articles, Links

S100beta protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma.
Melanoma Res. 2004 Jun;14(3):211-5.
PMID: 15179191 [PubMed - in process]

☐ 5: [Brvar M, Mozina H, Osredkar J, Mozina M, Noc M, Brucan A, Bunc M.](#) Related Articles, Links

S100B protein in carbon monoxide poisoning: a pilot study.
Resuscitation. 2004 Jun;61(3):357-60.
PMID: 15172716 [PubMed - indexed for MEDLINE]

☐ 6: [Kleindienst A, Harvey HB, Rice AC, Muller C, Hamm RJ, Gaab MR, Bullock MR.](#) Related Articles, Links


Intraventricular infusion of the neurotrophic protein S100B improves cognitive recovery after fluid percussion injury in the rat.
J Neurotrauma. 2004 May;21(5):541-7.
PMID: 15165362 [PubMed - indexed for MEDLINE]


☐ 7: [Hasselblatt M, Mooren FC, von Ahsen N, Keyvani K, Fromme A, Schwarze-Eicker K, Senner V, Paulus W.](#) Related Articles, Links

Serum S100beta increases in marathon runners reflect extracranial release rather than glial damage.
Neurology. 2004 May 11;62(9):1634-6.
PMID: 15136701 [PubMed - indexed for MEDLINE]

☐ 8: [Banfalvi T, Gergye M, Beczassy E, Gilde K, Otto S.](#) Related Articles, Links


[Role of S100B protein in neoplasms and other diseases]
Magy Onkol. 2004;48(1):71-4. Epub 2004 Apr 23. Review. Hungarian.
PMID: 15105899 [PubMed - indexed for MEDLINE]


-  **9:** [Sorci G, Riuzzi F, Agneletti AL, Marchetti C, Donato R.](#) [Related Articles, Links](#)

 **S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner.**

J Cell Physiol. 2004 May;199(2):274-83.


PMID: 15040010 [PubMed - indexed for MEDLINE]


-  **10:** [Scaccianoce S, Del Bianco P, Pannitteri G, Passarelli F.](#) [Related Articles, Links](#)

 **Relationship between stress and circulating levels of S100B protein.**

Brain Res. 2004 Apr 9;1004(1-2):208-11.


PMID: 15033438 [PubMed - indexed for MEDLINE]


-  **11:** [Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D.](#) [Related Articles, Links](#)

 **Peripheral markers of blood-brain barrier damage.**

Clin Chim Acta. 2004 Apr;342(1-2):1-12.


PMID: 15026262 [PubMed - in process]


-  **12:** [Snyder-Ramos SA, Grubke T, Bauer H, Bauer M, Luntz AP, Motsch J, Martin E, Vahl CF, Missler U, Wiesmann M, Bottiger BW.](#) [Related Articles, Links](#)

 **Cerebral and extracerebral release of protein S100B in cardiac surgical patients.**

Anaesthesia. 2004 Apr;59(4):344-9.


PMID: 15023104 [PubMed - indexed for MEDLINE]


-  **13:** [Valencia JV, Mone M, Zhang J, Weetall M, Buxton FP, Hughes TE.](#) [Related Articles, Links](#)

 **Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA.**

Diabetes. 2004 Mar;53(3):743-51.

PMID: 14988260 [PubMed - indexed for MEDLINE]


-  **14:** [Stolz E, Gerriets T, Kluge A, Klovekom WP, Kaps M, Bachmann G.](#) [Related Articles, Links](#)

 **Diffusion-weighted magnetic resonance imaging and neurobiochemical markers after aortic valve replacement: implications for future neuroprotective trials?**

Stroke. 2004 Apr;35(4):888-92. Epub 2004 Feb 19.


PMID: 14976326 [PubMed - indexed for MEDLINE]


-  **15:** [Timar J, Udvarhelyi N, Banfalvi T, Gilde K, Orosz Z.](#) [Related Articles, Links](#)

 **Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies.**

Histopathology. 2004 Feb;44(2):180-4.


PMID: 14764062 [PubMed - indexed for MEDLINE]


-  **16:** [Schmidt AP, Tort AB, Amaral OB, Schmidt AP, Walz R, Vettorazzi-Stuckzynski J, Martins-Costa SH, Ramos JG, Souza DO, Portela LV.](#) [Related Articles, Links](#)

 **Serum S100B in pregnancy-related hypertensive disorders: a case-control study.**

Clin Chem. 2004 Feb;50(2):435-8. No abstract available.

PMID: 14752015 [PubMed - indexed for MEDLINE]

-  **17:** [Di Legge S, Di Piero V, Di Stani F, Perna R, Gattuso R, Reale MG, Benedetti Valentini F, Lenzi GL.](#) [Related Articles, Links](#)

 **Carotid endarterectomy and gliofibrillar S100b protein release.**

Neurol Sci. 2003 Dec;24(5):351-6.

PMID: 14716532 [PubMed - indexed for MEDLINE]

-  **18:** [Dietrich MO, Tort AB, Schaf DV, Farina M, Goncalves CA, Souza](#) [Related Articles, Links](#)

DO, Portela LV.



Increase in serum S100B protein level after a swimming race.

Can J Appl Physiol. 2003 Oct;28(5):710-6.

PMID: 14710522 [PubMed - indexed for MEDLINE]

19:

Dietrich DE, Hauser U, Peters M, Zhang Y, Wiesmann M, Hasselmann M, Rudolf S, Jungling O, Kirchner H, Munte TF, Aroll V, Emrich HM, Johannes S, Rothermundt M.

[Related Articles, Links](#)



Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression.

Neurosci Lett. 2004 Jan 2;354(1):69-73.

PMID: 14698484 [PubMed - indexed for MEDLINE]

20:

Shaaban Ali M, Harmer M, Elliott M, Thomas AL, Kirkham F.

[Related Articles, Links](#)



A pilot study of evaluation of cerebral function by S100beta protein and near-infrared spectroscopy during cold and warm cardiopulmonary bypass in infants and children undergoing open-heart surgery.

Anaesthesia. 2004 Jan;59(1):20-6.

PMID: 14687094 [PubMed - indexed for MEDLINE]

21:

Schulpis KH, Kariyannis C, Papassotiriou I.

[Related Articles, Links](#)



Serum levels of neural protein S-100B in phenylketonuria.

Clin Biochem. 2004 Jan;37(1):76-9.

PMID: 14675567 [PubMed - indexed for MEDLINE]

22:

Sussmuth SD, Tuman H, Ecker D, Ludolph AC.

[Related Articles, Links](#)



Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum.

Neurosci Lett. 2003 Dec 15;353(1):57-60.

PMID: 14642437 [PubMed - indexed for MEDLINE]

23:

Tort AB, Dietrich MO, Goncalves CA, Souza DO, Portela LV.

[Related Articles, Links](#)



Influence of anticoagulants on the measurement of S100B protein in blood.

Clin Biochem. 2003 Nov;36(8):629-32.

PMID: 14636878 [PubMed - indexed for MEDLINE]

24:

Portela LV, Tort AB, Walz R, Bianchin M, Trevisol-Bittencourt PC, Wille PR, Cardoso RC, Ishida MM, vonWangenheim A, Grisard EC, Steindel M, Goncalves CA, Souza DO.

[Related Articles, Links](#)



Interictal serum S100B levels in chronic neurocysticercosis and idiopathic epilepsy.

Acta Neurol Scand. 2003 Dec;108(6):424-7. Erratum in: Acta Neurol Scand. 2004 Jan;109(1):84.

PMID: 14616295 [PubMed - indexed for MEDLINE]

25:

Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC.

[Related Articles, Links](#)



Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study.

Mol Cell Proteomics. 2004 Jan;3(1):66-72. Epub 2003 Oct 26.

PMID: 14581522 [PubMed - indexed for MEDLINE]

26:

Brunet JF, Pellerin L, Magistretti P, Villemure JG.

[Related Articles, Links](#)



Cryopreservation of human brain tissue allowing timely production of viable adult human brain cells for autologous transplantation.




















Cryobiology. 2003 Oct;47(2):179-83.

PMID: 14580852 [PubMed - indexed for MEDLINE]


27:


Anderson RE, Winnerkvist A, Hansson LO, Nilsson O, Rosengren L, Settergren G, Vaage J.

[Related Articles, Links](#)


-  **Biochemical markers of cerebrospinal ischemia after repair of aneurysms of the descending and thoracoabdominal aorta.**
J Cardiothorac Vasc Anesth. 2003 Oct;17(5):598-603.
PMID: 14579213 [PubMed - indexed for MEDLINE]
-  **28: Jonsson H.** Related Articles, Links
 **S100B and cardiac surgery: possibilities and limitations.**
Restor Neurol Neurosci. 2003;21(3-4):151-7. Review.
PMID: 14530577 [PubMed - indexed for MEDLINE]
-  **29: Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, Kanner A, Ayumar B, Albensi B, Cavaglia M, Janigro D.** Related Articles, Links
 **Peripheral markers of brain damage and blood-brain barrier dysfunction.**
Restor Neurol Neurosci. 2003;21(3-4):109-21. Review.
PMID: 14530574 [PubMed - indexed for MEDLINE]
-  **30: Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, Kirchner H, Rothermundt M.** Related Articles, Links
 **S100B and response to treatment in major depression: a pilot study.**
Eur Neuropsychopharmacol. 2003 Aug;13(4):235-9.
PMID: 12888182 [PubMed - indexed for MEDLINE]
-  **31: Vaquero J, Jordano Q, Lee WM, Blei AT, US Acute Liver Failure Study Group.** Related Articles, Links
 **Serum protein S-100b in acute liver failure: Results of the US Acute Liver Failure Study group.**
Liver Transpl. 2003 Aug;9(8):887-8. No abstract available.
PMID: 12884207 [PubMed - indexed for MEDLINE]
-  **32: Schroeter ML, Abdul-Khaliq H, Fruhauf S, Hohne R, Schick G, Diefenbacher A, Blasig IE.** Related Articles, Links
 **Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia.**
Schizophr Res. 2003 Aug 1;62(3):231-6.
PMID: 12837519 [PubMed - indexed for MEDLINE]
-  **33: Sorci G, Riuzzi F, Agneletti AL, Marchetti C, Donato R.** Related Articles, Links
 **S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner.**
Mol Cell Biol. 2003 Jul;23(14):4870-81.
PMID: 12832473 [PubMed - indexed for MEDLINE]
-  **34: Vibinen PP, Pyrhonen SO, Kabari VM.** Related Articles, Links
 **New prognostic factors and developing therapy of cutaneous melanoma.**
Ann Med. 2003;35(2):66-78. Review.
PMID: 12795336 [PubMed - indexed for MEDLINE]
-  **35: Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Ayumar B, Vogelbaum MA, Barnett GH, Janigro D.** Related Articles, Links
 **Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions.**
Cancer. 2003 Jun 1;97(11):2806-13.
PMID: 12767094 [PubMed - indexed for MEDLINE]
-  **36: de Baar M, Diephuis JC, Moons KG, Holtkamp J, Hijman R, Kalkman CJ.** Related Articles, Links
 **The effect of zero-balanced ultrafiltration during cardiopulmonary bypass on S100b release and cognitive function.**
Perfusion. 2003 Mar;18(1):9-14.

PMID: 12705644 [PubMed - indexed for MEDLINE]


-  **37:** Dimopoulou I, Korfiatis S, Dafni U, Anthi A, Psachoulia C, Jullien G, Sakas DE, Roussos C. [Related Articles](#), [Links](#)


 **Protein S-100b serum levels in trauma-induced brain death.**
Neurology. 2003 Mar 25;60(6):947-51.
PMID: 12654958 [PubMed - indexed for MEDLINE]


-  **38:** Ishida K, Gohara T, Kawata R, Ohtake K, Morimoto Y, Sakabe T. [Related Articles](#), [Links](#)

 **Are serum S100beta proteins and neuron-specific enolase predictors of cerebral damage in cardiovascular surgery?**
J Cardiothorac Vasc Anesth. 2003 Feb;17(1):4-9.
PMID: 12635053 [PubMed - indexed for MEDLINE]


-  **39:** Pelinka LE, Toegel E, Mauritz W, Redl H. [Related Articles](#), [Links](#)


 **Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma.**
Shock. 2003 Mar;19(3):195-200.
PMID: 12630517 [PubMed - indexed for MEDLINE]


-  **40:** Spinella PC, Dominguez T, Drott HR, Huh J, McCormick L, Rajendra A, Argon J, McIntosh T, Helfaer M. [Related Articles](#), [Links](#)

 **S-100beta protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury.**
Crit Care Med. 2003 Mar;31(3):939-45.
PMID: 12627009 [PubMed - indexed for MEDLINE]


-  **41:** Kay A, Petzold A, Kerr M, Keir G, Thompson E, Nicoll J. [Related Articles](#), [Links](#)


 **Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: correlation with injury severity and clinical outcome.**
Stroke. 2003 Mar;34(3):637-42. Epub 2003 Feb 13.
PMID: 12624284 [PubMed - indexed for MEDLINE]


-  **42:** Foerch C, du Mesnil de Rochemont R, Singer O, Neumann-Haefelin T, Buchkremer M, Zanella FE, Steinmetz H, Sitzer M. [Related Articles](#), [Links](#)


 **S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion.**
J Neurol Neurosurg Psychiatry. 2003 Mar;74(3):322-5.
PMID: 12588916 [PubMed - indexed for MEDLINE]


-  **43:** Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. [Related Articles](#), [Links](#)


 **Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.**
Melanoma Res. 2003 Feb;13(1):45-9.
PMID: 12569284 [PubMed - indexed for MEDLINE]


-  **44:** Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Kochanek PM. [Related Articles](#), [Links](#)


 **Serum S100B concentrations are increased after closed head injury in children: a preliminary study.**
J Neurotrauma. 2002 Nov;19(11):1405-9.
PMID: 12490005 [PubMed - indexed for MEDLINE]


-  **45:** Petzold A, Green AJ, Keir G, Fairley S, Kitchen N, Smith M, Thompson EJ. [Related Articles](#), [Links](#)


 **Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study.**
Crit Care Med. 2002 Dec;30(12):2705-10.
PMID: 12483062 [PubMed - indexed for MEDLINE]


-  **46:** Elting JW, Sulter GA, Kaste M, Lees KR, Diener HC, Hommel M, Versavel M, Teelken AW, De Keyser J. [Related Articles](#), [Links](#)

 **AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels.**
Stroke. 2002 Dec;33(12):2813-8.
PMID: 12468775 [PubMed - indexed for MEDLINE]


-  **47:** Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL. [Related Articles](#), [Links](#)


 **Erythropoietin therapy for acute stroke is both safe and beneficial.**
Mol Med. 2002 Aug;8(8):495-505.
PMID: 12435860 [PubMed - indexed for MEDLINE]


-  **48:** Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE. [Related Articles](#), [Links](#)


 **S100B is increased in mood disorders and may be reduced by antidepressive treatment.**
Neuroreport. 2002 Sep 16;13(13):1675-8.
PMID: 12352625 [PubMed - indexed for MEDLINE]


-  **49:** Ozatik MA, Tarcan O, Kale A, Askin GA, Balci M, Undar A, Kucukaksu DS, Sener E, Tasdemir O. [Related Articles](#), [Links](#)


 **Do S100beta protein level increases due to inflammation during cardiopulmonary bypass occur without any neurological deficit?**
Perfusion. 2002 Sep;17(5):335-8.
PMID: 12243436 [PubMed - indexed for MEDLINE]


-  **50:** Goncalves D, Karl J, Leite M, Rotta L, Salbego C, Rocha E, Wofchuk S, Goncalves CA. [Related Articles](#), [Links](#)

 **High glutamate decreases S100B secretion stimulated by serum deprivation in astrocytes.**
Neuroreport. 2002 Aug 27;13(12):1533-5.
PMID: 12218700 [PubMed - indexed for MEDLINE]


-  **51:** Tokuno S, Hinokiyama K, Tokuno K, Lowbeer C, Hansson LO, Valen G. [Related Articles](#), [Links](#)


 **Spontaneous ischemic events in the brain and heart adapt the hearts of severely atherosclerotic mice to ischemia.**
Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):995-1001.
PMID: 12067910 [PubMed - indexed for MEDLINE]


-  **52:** Portela LV, Tort AB, Schaf DV, Ribeiro L, Nora DB, Walz R, Rotta LN, Silva CT, Busnello JV, Kapczinski F, Goncalves CA, Souza DO. [Related Articles](#), [Links](#)

 **The serum S100B concentration is age dependent.**
Clin Chem. 2002 Jun;48(6 Pt 1):950-2. No abstract available.
PMID: 12029017 [PubMed - indexed for MEDLINE]


-  **53:** Svenmarker S, Sandstrom E, Karlsson T, Aberg T. [Related Articles](#), [Links](#)


 **Is there an association between release of protein S100B during cardiopulmonary bypass and memory disturbances?**
Scand Cardiovasc J. 2002 Mar;36(2):117-22.
PMID: 12028876 [PubMed - indexed for MEDLINE]

-  **54:** Machado-Vieira R, Lara DR, Portela LV, Goncalves CA, Soares JC, Kapczinski F, Souza DO. [Related Articles](#), [Links](#)


 **Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study.**
Eur Neuropsychopharmacol. 2002 Jun;12(3):269-72.


PMID: 12007679 [PubMed - indexed for MEDLINE]


-  **55:** [Shaaban-Ali M, Harner M, Vaughan RS, Dunne JA, Latto IP, Haaverstad R, Kulatilake EN, Butchart EG.](#) [Related Articles, Links](#)

 **Changes in serum S100beta protein and Mini-Mental State Examination after cold (28 degrees C) and warm (34 degrees C) cardiopulmonary bypass using different blood gas strategies (alpha-stat and pH-stat).**
Acta Anaesthesiol Scand. 2002 Jan;46(1):10-6.
PMID: 11903066 [PubMed - indexed for MEDLINE]


-  **56:** [Djukanovic D, Hofmann U, Sucker A, Schadendorf D.](#) [Related Articles, Links](#)


 **Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing.**
Br J Dermatol. 2001 Dec;145(6):1030-1. No abstract available.
PMID: 11899133 [PubMed - indexed for MEDLINE]


-  **57:** [Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, Kochanek PM.](#) [Related Articles, Links](#)


 **Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children.**
Pediatrics. 2002 Feb;109(2):E31.
PMID: 11826241 [PubMed - indexed for MEDLINE]


-  **58:** [Mohammed MQ, Abraha HD, Sherwood RA, MacRae K, Retsas S.](#) [Related Articles, Links](#)


 **Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.**
Med Oncol. 2001;18(2):109-20.
PMID: 11778756 [PubMed - indexed for MEDLINE]


-  **59:** [Portela LV, Brenol JC, Walz R, Bianchin M, Tort AB, Canabarro UP, Beheregaray S, Marasca JA, Xavier RM, Neto EC, Goncalves CA, Souza DO.](#) [Related Articles, Links](#)

 **Serum S100B levels in patients with lupus erythematosus: preliminary observation.**
Clin Diagn Lab Immunol. 2002 Jan;9(1):164-6.
PMID: 11777848 [PubMed - indexed for MEDLINE]


-  **60:** [Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, Lejeune F; EORTC Melanoma Group.](#) [Related Articles, Links](#)


 **On the release and half-life of S100B protein in the peripheral blood of melanoma patients.**
Int J Cancer. 2001 Nov15;94(4):586-90.
PMID: 11745448 [PubMed - indexed for MEDLINE]


-  **61:** [Potapov EV, Loebe M, Abdul-Khalig H, Koster A, Stein J, Sodian R, Kopitz M, Hausmann H, Noon GP, DeBaakey ME, Hetzer R.](#) [Related Articles, Links](#)

 **Postoperative course of S-100B protein and neuron-specific enolase in patients after implantation of continuous and pulsatile flow LVADs.**
J Heart Lung Transplant. 2001 Dec;20(12):1310-6.
PMID: 11744415 [PubMed - indexed for MEDLINE]


-  **62:** [Wollina U, Hipler UC, Knoll B, Graefe T, Kaatz M, Kirsch K.](#) [Related Articles, Links](#)


 **Serum matrix metalloproteinase-2 in patients with malignant melanoma.**
J Cancer Res Clin Oncol. 2001 Oct;127(10):631-5.
PMID: 11599800 [PubMed - indexed for MEDLINE]


-  **63:** [Schmidt M, Scheunert T, Steinbach G, Schirmer U, Marx T, Freitag N, Reinelt H.](#) [Related Articles, Links](#)


 **Hypertension as a risk factor for cerebral injury during cardiopulmonary bypass. Protein S100B and transcranial Doppler findings.**


Anaesthesia. 2001 Aug;56(8):733-8.
PMID: 11493235 [PubMed - indexed for MEDLINE]


-  **64:** Mussack T, Biberthaler P, Gippner-Steppert C, Kanz KG, Wiedemann E, Mutschler W, Jochum M. [Related Articles, Links](#)


 **Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisms.**
Resuscitation. 2001 May;49(2):193-9.
PMID: 11382526 [PubMed - indexed for MEDLINE]


-  **65:** Deichmann M, Benner A, Kuner N, Wacker J, Waldmann V, Naher H. [Related Articles, Links](#)

 **Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100beta or melanoma inhibitory activity (MIA)?**
Melanoma Res. 2001 Jun;11(3):291-6.
PMID: 11468518 [PubMed - indexed for MEDLINE]


-  **66:** LeMaire SA, Bhama JK, Schmittling ZC, Oberwalder PJ, Koksoy C, Raskin SA, Curling PE, Coselli JS. [Related Articles, Links](#)


 **S100beta correlates with neurologic complications after aortic operation using circulatory arrest.**
Ann Thorac Surg. 2001 Jun;71(6):1913-8; discussion 1918-9.
PMID: 11426768 [PubMed - indexed for MEDLINE]


-  **67:** Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J. [Related Articles, Links](#)


 **Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources.**
Ann Thorac Surg. 2001 May;71(5):1512-7.
PMID: 11383792 [PubMed - indexed for MEDLINE]


-  **68:** Anderson RE, Hansson LO, Nilsson O, Djilali-Merzoug R, Settergren G. [Related Articles, Links](#)


 **High serum S100B levels for trauma patients without head injuries.**
Neurosurgery. 2001 Jun;48(6):1255-8; discussion 1258-60.
PMID: 11383727 [PubMed - indexed for MEDLINE]


-  **69:** Regner A, Kaufman M, Friedman G, Chemale I. [Related Articles, Links](#)


 **Increased serum S100beta protein concentrations following severe head injury in humans: a biochemical marker of brain death?**
Neuroreport. 2001 Mar 26;12(4):691-4.
PMID: 11277565 [PubMed - indexed for MEDLINE]


-  **70:** van Passel R, Schlooz WA, Lamers KJ, Lemmens WA, Rotteveel JJ. [Related Articles, Links](#)

 **S100B protein, glia and Gilles de la Tourette syndrome.**
Eur J Paediatr Neurol. 2001;5(1):15-9.
PMID: 11277359 [PubMed - indexed for MEDLINE]

-  **71:** de Kruijk JR, Leffers P, Menheere PP, Meerhoff S, Twijnstra A. [Related Articles, Links](#)

 **S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with health controls.**
Acta Neurol Scand. 2001 Mar;103(3):175-9.
PMID: 11240565 [PubMed - indexed for MEDLINE]

-  **72:** Pokela M, Anttila V, Rimpilainen J, Hirvonen J, Vainionpää V, Kiviluoma K, Ronsi P, Mennander A, Juvonen T. [Related Articles, Links](#)

 **Serum S-100beta protein predicts brain injury after hypothermic circulatory**

arrest in pigs.

Scand Cardiovasc J. 2000 Dec;34(6):570-4.

PMID: 11214009 [PubMed - indexed for MEDLINE]


-  **73:** Biberthaler P, Mussack T, Wiedemann E, Kanz KG, Koelsch M, Gippner-Steppert C, Jochum M. [Related Articles, Links](#)



Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma.

World J Surg. 2001 Jan;25(1):93-7.

PMID: 11213162 [PubMed - indexed for MEDLINE]


-  **74:** McIntyre EA, Abraha HD, Perros P, Sherwood RA. [Related Articles, Links](#)



Serum S-100beta protein is a potential biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis.

Diabet Med. 2000 Nov;17(11):807-9.

PMID: 11131106 [PubMed - indexed for MEDLINE]


-  **75:** Pinto SS, Gottfried C, Mendez A, Goncalves D, Karl J, Goncalves CA, Wofchuk S, Rodnight R. [Related Articles, Links](#)



Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology.

FEBS Lett. 2000 Dec 15;486(3):203-7.

PMID: 11119704 [PubMed - indexed for MEDLINE]


-  **76:** Schlagenhauff B, Schittek B, Ellwanger U, Stroebe W, Blum A, Schwarz M, Rassner G, Garbe C. [Related Articles, Links](#)



Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?

Melanoma Res. 2000 Oct;10(5):451-9.

PMID: 11095406 [PubMed - indexed for MEDLINE]


-  **77:** Poletaev AB, Morozov SG, Gnedenko BB, Zlunikin VM, Korzhenevsky DA. [Related Articles, Links](#)



Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders.

Autoimmunity. 2000;32(1):33-8.

PMID: 10958173 [PubMed - indexed for MEDLINE]

-  **78:** Wiltfang J, Nolte W, Otto M, Wildberg J, Bahn E, Figulla HR, Pralle L, Hartmann H, Ruther E, Ramadori G. [Related Articles, Links](#)



Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy.

Metab Brain Dis. 1999 Dec;14(4):239-51.

PMID: 10850551 [PubMed - indexed for MEDLINE]


-  **79:** Nishi M, Kawata M, Azmitia EC. [Related Articles, Links](#)



Trophic interactions between brain-derived neurotrophic factor and s100beta on cultured serotonergic neurons.

Brain Res. 2000 Jun 16;868(1):113-8.

PMID: 10841894 [PubMed - indexed for MEDLINE]

-  **80:** Walz R, Portela LV, Tort AB, Neto EC, Fernandes LN, Goncalves CA, Souza DO. [Related Articles, Links](#)




Serum S100B levels in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.

Neurology. 2000 May 23;54(10):2021-2. No abstract available.


PMID: 10822451 [PubMed - indexed for MEDLINE]

-  **81:** Anderson RE, Hansson LO, Liska J, Settergren G, Vaage J. [Related Articles, Links](#)


 The effect of cardiotomy suction on the brain injury marker S100beta after cardiopulmonary bypass.

Ann Thorac Surg. 2000 Mar;69(3):847-50.

PMID: 10750771 [PubMed - indexed for MEDLINE]


 **82:** Brouard M, Quillien V, Olivier I, Lesimple T, Adamski H, Chevrant-Breton J.

[Related Articles](#), [Links](#)


 [Serum S100B protein and stage of cutaneous melanoma: a prospective study]

Ann Dermatol Venereol. 2000 Jan;127(1):56-9. French.

PMID: 10717564 [PubMed - indexed for MEDLINE]


 **83:** Wollina U, Karte K, Hipler UC, Knoll B, Kirsch K, Herold C.

[Related Articles](#), [Links](#)


 Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay.

J Cancer Res Clin Oncol. 2000 Feb;126(2):107-10.

PMID: 10664251 [PubMed - indexed for MEDLINE]


 **84:** Jonsson H, Johnsson P, Alling C, Backstrom M, Bergh C, Blomquist S.

[Related Articles](#), [Links](#)


 S100beta after coronary artery surgery: release pattern, source of contamination, and relation to neuropsychological outcome.

Ann Thorac Surg. 1999 Dec;68(6):2202-8.

PMID: 10617003 [PubMed - indexed for MEDLINE]

 **85:** Ettinger A, Laumark AB, Ostroff RM, Brundell J, Baumgartner WA, Razumovsky AY.

[Related Articles](#), [Links](#)


 A new optical immunoassay for detection of S-100B protein in whole blood.

Ann Thorac Surg. 1999 Dec;68(6):2196-201.

PMID: 10617002 [PubMed - indexed for MEDLINE]

 **86:** Muller F, Ngo S, Rebiffe M, Oury JF, Uzan S, Satge D.

[Related Articles](#), [Links](#)


 Maternal serum s100b protein is ineffective for Down syndrome screening.

Prenat Diagn. 1999 Nov;19(11):1086. No abstract available.

PMID: 10589070 [PubMed - indexed for MEDLINE]


 **87:** Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H.

[Related Articles](#), [Links](#)


 S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.

J Clin Oncol. 1999 Jun;17(6):1891-6.

PMID: 10561230 [PubMed - indexed for MEDLINE]


 **88:** Bhattacharya K, Westaby S, Pillai R, Standing SJ, Johnsson P, Taggart DP.

[Related Articles](#), [Links](#)


 Serum S100B and hypothermic circulatory arrest in adults.

Ann Thorac Surg. 1999 Oct;68(4):1225-9.

PMID: 10543483 [PubMed - indexed for MEDLINE]

 **89:** Takahashi M, Chamczuk A, Hong Y, Jackowski G.

[Related Articles](#), [Links](#)


 Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody.

Clin Chem. 1999 Aug;45(8 Pt 1):1307-11. No abstract available.

PMID: 10430807 [PubMed - indexed for MEDLINE]

 **90:** Wong CH, Rooney SJ, Bonser RS.


[Related Articles](#), [Links](#)

 S-100beta release in hypothermic circulatory arrest and coronary artery

surgery.

Ann Thorac Surg. 1999 Jun;67(6):1911-4; discussion 1919-21.

PMID: 10391337 [PubMed - indexed for MEDLINE]


-  **91:** Wang S, Rosengren LE, Franlund M, Hamberger A, Haglid KG. [Related Articles, Links](#)



Bcl-2 expression regulates cell sensitivity to S100beta-mediated apoptosis.

Brain Res Mol Brain Res. 1999 Jun 18;70(1):167-76.

PMID: 10381557 [PubMed - indexed for MEDLINE]


-  **92:** Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E. [Related Articles, Links](#)



Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients.

Melanoma Res. 1999 Apr;9(2):155-61.

PMID: 10380938 [PubMed - indexed for MEDLINE]


-  **93:** Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E. [Related Articles, Links](#)



S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.

Oncology. 1999;56(4):338-44.

PMID: 10343200 [PubMed - indexed for MEDLINE]

-  **94:** Ashraf S, Bhattacharya K, Zacharias S, Kaul P, Kay PH, Watterson KG. [Related Articles, Links](#)



Serum S100beta release after coronary artery bypass grafting: roller versus centrifugal pump.

Ann Thorac Surg. 1998 Dec;66(6):1958-62.

PMID: 9930476 [PubMed - indexed for MEDLINE]

-  **95:** Mi H, Barres BA. [Related Articles, Links](#)



Purification and characterization of astrocyte precursor cells in the developing rat optic nerve.

J Neurosci. 1999 Feb 1;19(3):1049-61.

PMID: 9920668 [PubMed - indexed for MEDLINE]


-  **96:** Bonfrer JM, Korse CM, Nieweg OE, Rankin EM. [Related Articles, Links](#)



The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma.

Br J Cancer. 1998 Jun;77(12):2210-4.

PMID: 9649135 [PubMed - indexed for MEDLINE]


-  **97:** Grocott HP, Croughwell ND, Amory DW, White WD, Kirchner JL, Newman MF. [Related Articles, Links](#)



Cerebral emboli and serum S100beta during cardiac operations.

Ann Thorac Surg. 1998 Jun;65(6):1645-9; discussion 1649-50.

PMID: 9647074 [PubMed - indexed for MEDLINE]

-  **98:** Karnell R, von Schoultz E, Hansson LO, Nilsson B, Arstrand K, Kagedal B. [Related Articles, Links](#)



S100B protein, 5-S-cysteinyl-dopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.

Melanoma Res. 1997 Oct;7(5):393-9.

PMID: 9429222 [PubMed - indexed for MEDLINE]

-  **99:** Pena LA, Brecher CW, Marshak DR. [Related Articles, Links](#)



beta-Amyloid regulates gene expression of glial trophic substance S100 beta in C6 glioma and primary astrocyte cultures.

Brain Res Mol Brain Res. 1995 Dec 1;34(1):118-26.
PMID: 8750867 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 23 2004 06:26:30

Connecting via winsock to STN
Welcome to STN International! Enter x:x
* * * * * Welcome to STN International * * * * *
* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:05:16 ON 01 DEC 2004

=> FILE BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 11:05:27 ON 01 DEC 2004

FILE 'ANABSTR' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 11:05:27 ON 01 DEC 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 11:05:27 ON 01 DEC 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 11:05:27 ON 01 DEC 2004

FILE 'CAPLUS' ENTERED AT 11:05:27 ON 01 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (c) 2004 DECHEMA ev

FILE 'CEN' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 11:05:27 ON 01 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Proquest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 11:05:27 ON 01 DEC 2004

FILE 'FOMAD' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 11:05:27 ON 01 DEC 2004

FILE 'HEALSAFE' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 11:05:27 ON 01 DEC 2004

FILE 'NIOSHTIC' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 11:05:27 ON 01 DEC 2004

Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.

All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 11:05:27 ON 01 DEC 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 11:05:27 ON 01 DEC 2004

Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 11:05:27 ON 01 DEC 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'PS' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 11:05:27 ON 01 DEC 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 11:05:27 ON 01 DEC 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:05:27 ON 01 DEC 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 11:05:27 ON 01 DEC 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 11:05:27 ON 01 DEC 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s s100b OR s100beta

51 FILES SEARCHED...

L1 4579 S100B OR S100BETA

=> s blood OR serum

15 FILES SEARCHED...

31 FILES SEARCHED...

48 FILES SEARCHED...

65 FILES SEARCHED...

L2 17380596 BLOOD OR SERUM

=> s L1 AND L2

46 FILES SEARCHED...

L3 1522 L1 AND L2

=> DUP REM L3

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING IS APPROXIMATELY 52% COMPLETE FOR L3

PROCESSING COMPLETED FOR L3

L4 665 DUP REM L3 (857 DUPLICATES REMOVED)

=> s L4 AND blood brain barrier

17 FILES SEARCHED...

31 FILES SEARCHED...

50 FILES SEARCHED...

65 FILES SEARCHED...

L5 79 L4 AND BLOOD BRAIN BARRIER

=> D L5 1-79

L5 ANSWER 1 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN

AN 2004:439308 BIOSIS

DN PREV200400438352

TI Peripheral markers of ***blood*** - ***brain*** ***barrier***
damage.

AU Marchi, Nicola; Cavaglia, Marco; Fazio, Vincent; Bhudia, Sunil; Hallene,
Kerri; Janigro, Damir [Reprint Author]

CS Cerebrovasc Res CtrDept Neurol surg, Cleveland Clin Fdn, 9500 Euclid
Ave,NB20, Cleveland, OH, 44195, USA
janigrd@ccf.org

SO Clinica Chimica Acta, (April 2004) vol. 342, No. 1-2, pp. 1-12. print.
ISSN: 0009-8981 (ISSN print).

DT Article
General Review; (Literature Review)

LA English

ED Entered STN: 17 Nov 2004

Last Updated on STN: 17 Nov 2004

L5 ANSWER 2 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN

AN 2004:302423 BIOSIS

DN PREV200400302879

TI Intraventricular infusion of the neurotrophic protein ***s100b***
improves cognitive recovery after fluid percussion injury in the rat.

AU Kleindienst, Andrea [Reprint Author]; Harvey, Harlan B.; Rice, Ann C.;
Mueller, Christian; Hamm, Robert J.; Gaab, Michael R.; Bullock, M. Ross

CS Med Coll VirginiaDept Neurosurg, Virginia Commonwealth Univ, 1101 E
Marshall St,Box 980508, Richmond, VA, 23298, USA
akleindienst@vcu.edu

SO Journal of Neurotrauma, (May 2004) vol. 21, No. 5, pp. 541-547. print.
ISSN: 0897-7151 (ISSN print).

DT Article

LA English

ED Entered STN: 30 Jun 2004

Last Updated on STN: 30 Jun 2004

L5 ANSWER 3 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2004:273640 BIOSIS
DN PREV200400273979
TI Relationship between stress and circulating levels of ***s100B***
protein.
AU Scaccianoce, Sergio [Reprint Author]; Del Bianco, Paola; Pannitteri,
Gaetano; Passarelli, Francesca
CS Dept Human Physiol & Pharmacol Vittorio Erspamer, Univ Rome La Sapienza,
Piazzale Aldo Moro 5, I-00185, Rome, Italy
sergio.scaccianoce@uniroma1.it
SO Brain Research, (April 9 2004) Vol. 1004, No. 1-2, pp. 208-211. print.
ISSN: 0006-8993 (ISSN print).
DT Article
LA English
ED Entered STN: 2 Jun 2004
Last Updated on STN: 2 Jun 2004

L5 ANSWER 4 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:377358 BIOSIS
DN PREV200300377358
TI ***Serum*** ***s100B*** is increased during early treatment with
antipsychotics and in deficit schizophrenia.
AU Schroeter, Matthias L. [Reprint Author]; Abdul-Khalig, Hashim; Fruehauf,
Stephan; Hoehne, Ruth; Schick, Gabi; Diefenbacher, Albert; Blasig, Ingolf
E.
CS Max-Planck-Institute of Cognitive Neuroscience, Stephanstr. 1A, 04103,
Leipzig, Germany
schroet@cns.mpg.de
SO Schizophrenia Research, (1 August 2003) Vol. 62, No. 3, pp. 231-236.
print.
ISSN: 0920-9964.
DT Article
LA English
ED Entered STN: 13 Aug 2003
Last Updated on STN: 13 Aug 2003

L5 ANSWER 5 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:348858 BIOSIS
DN PREV200300348858
TI ***Serum*** ***s100beta*** : A noninvasive marker of ***blood***
- ***brain*** ***barrier*** function and brain lesions.
AU Kanner, Andrew A.; Marchi, Nicola; Fazio, Vincent; Mayberg, Marc R.;
Koltz, Michael T.; Siomin, Vitaly; Stevens, Glen H. J.; Masaryk, Thomas;
Ayumar, Barbara; Vogelbaum, Michael A.; Barnett, Gene H.; Janigro, Damir
[Reprint Author]
CS Department of Neurosurgery, Cleveland Clinic Foundation, 9500 Euclid
Avenue, c/o Martha Tobin, Editorial Services Manager, S-80, Cleveland, OH,
44195, USA
janigrd@ccf.org
SO Cancer, (June 1 2003) Vol. 97, No. 11, pp. 2806-2813. print.
ISSN: 0008-543X (ISSN print).
DT Article
LA English
ED Entered STN: 30 Jul 2003
Last Updated on STN: 30 Jul 2003

L5 ANSWER 6 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:325895 BIOSIS
DN PREV200300325895
TI ***SERUM*** ***s100B*** IS RELATED TO EARLY TREATMENT WITH TYPICAL
ANTIPSYCHOTICS, DEFICIT SYNDROME AND THOUGHT DISTURBANCE IN SCHIZOPHRENIA.
AU Schroeter, M. L. [Reprint Author]; Abdul-Khalig, H.; Diefenbacher, A.;
Blasig, I. E.
CS Max Planck Inst of Cog Neurosci, Leipzig, Germany
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)
Vol. 2002, pp. Abstract No. 706.8. <http://sfn.scholarone.com>. cd-rom.
Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience.
Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)

LA English
ED Entered STN: 16 Jul 2003
Last Updated on STN: 16 Jul 2003

L5 ANSWER 7 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:324622 BIOSIS
DN PREV200300324622
TI MARKERS OF BBB DAMAGE AND INFLAMMATORY PROCESS.
AU Janigro, D. [Reprint Author]; Fazio, V. [Reprint Author]; Cucullo, L.
[Reprint Author]; Marchi, N. [Reprint Author]
CS Neurosurgery, Cleveland Clinic, Cleveland, OH, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)
Vol. 2002, pp. Abstract No. 580.9. <http://sfn.scholarone.com>. cd-rom.
Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience.
Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)

LA English
ED Entered STN: 16 Jul 2003
Last Updated on STN: 16 Jul 2003

L5 ANSWER 8 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:108486 BIOSIS
DN PREV200300108486
TI ***S100B*** and NSE Levels from the Jugular Bulb during CEA: The
Possibility of Distinct Roles in Monitoring.
AU Sahlein, Daniel H. [Reprint Author]; Heyer, Eric J. [Reprint Author];
Rampersad, Anita [Reprint Author]; Mocco, J. [Reprint Author]; Connolly,
E. Sander [Reprint Author]
CS Anesthesiology, Columbia Presbyterian Medical Center, New York, NY, USA
SO Anesthesiology Abstracts of Scientific Papers Annual Meeting, (2002) No.
2002, pp. Abstract No. A-314. <http://www.asa-abstracts.com>. cd-rom.
Meeting Info.: 2002 Annual Meeting of the American Society of
Anesthesiologists. Orlando, FL, USA. October 12-16, 2002. American Society
of Anesthesiologists Inc.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Feb 2003
Last Updated on STN: 26 Feb 2003

L5 ANSWER 9 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2002:204644 BIOSIS
DN PREV200200204644
TI New antidepressant drugs that do not cross the ***blood*** -
brain ***barrier***
AU Manev, H. [Reprint author]; Manev, R.
CS Psychiatric Institute, Department of Psychiatry, University of Illinois at
Chicago, 1601 West Taylor Street, M/C912, Chicago, IL, 60612, USA
hmanev@psych.uic.edu
SO Medical Hypotheses, (January, 2002) Vol. 58, No. 1, pp. 83-84. print.
CODEN: MEHYDY. ISSN: 0306-9877.
DT Article
LA English
ED Entered STN: 20 Mar 2002
Last Updated on STN: 20 Mar 2002

L5 ANSWER 10 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2002:144439 BIOSIS
DN PREV200200144439
TI Leukocyte-mediated cerebral disorders during and after cardiac surgery.
AU Scholz, Martin [Reprint author]; Wimmer-Greinecker, Gerhard; Matheis,
Georg
CS Department of Thoracic and Cardiovascular Surgery, J. W. Goethe
University, Theodor-Stern-Kai 7, D-60590, Frankfurt, Germany
m.scholz@em.uni-frankfurt.de
SO Matheis, Georg [Editor]; Moritz, Anton [Editor]; Scholz, Martin [Editor].
(2002) pp. 13-15. Leukocyte depletion in cardiac surgery and cardiology.
print.
Publisher: S. Karger Publishers Inc., 26 West Avon Road, Farmington, CT,
06085, USA; S. Karger AG, CH-4009, Basel, Switzerland.

ISBN: 3-8055-7281-6 (cloth).

DT Book
Book; (Book Chapter)

LA English

ED Entered STN: 14 Feb 2002
Last Updated on STN: 26 Feb 2002

L5 ANSWER 11 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 2001:509040 BIOSIS

DN PREV200100509040

TI S-100b is a ***serum*** marker of ***blood*** -brain disruption.

AU Kapural, M. [Reprint author]; Barnett, G. [Reprint author]; Krizanac-Bengez, L. [Reprint author]; Apollo, D. [Reprint author]; Perl, J. [Reprint author]; Mayberg, M. R. [Reprint author]; Masarik, T. [Reprint author]; Janigro, D. [Reprint author]

CS Cerebrovascular Research, Cleveland Clinic, Cleveland, OH, USA

SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 578. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 31 Oct 2001
Last Updated on STN: 23 Feb 2002

L5 ANSWER 12 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 2001:481306 BIOSIS

DN PREV200100481306

TI A role of autoimmune mechanisms in ischemic brain damage.

AU Skvortsova, V. I.; Sherstnev, V. V.; Gruden, M. A.; Myasoedov, N. F.; Stakhovskaya, L. V.; Efremova, N. M.; Hadzhieva, M. Kh.; Grivennikov, I. A.; Klyushnik, T. P.; Chaschikhina, E. V.; Kuzhilina, V. B.

SO Zhurnal Nevrologii i Psikhiiatrii Imeni S. S. Korsakova, (2001) No. Supplement 1, pp. 46-54. print.

DT Article

LA Russian

ED Entered STN: 17 Oct 2001
Last Updated on STN: 23 Feb 2002

L5 ANSWER 13 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 2001:77273 BIOSIS

DN PREV200100077273

TI Characteristics of sustained ***blood*** - ***brain***
barrier opening and tissue injury in a model for focal trauma in the rat.

AU Preston, Edward [Reprint author]; Webster, Jacqueline; Small, Daniel

CS Institute for Biological Sciences, National Research Council of Canada, M54 Montreal Rd, Ottawa, Ontario, K1A 0R6, Canada
ed.preston@nrc.ca

SO Journal of Neurotrauma, (January, 2001) vol. 18, No. 1, pp. 83-92. print.
ISSN: 0897-7151.

DT Article

LA English

ED Entered STN: 7 Feb 2001
Last Updated on STN: 12 Feb 2002

L5 ANSWER 14 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

AN 2001:76102 BIOSIS

DN PREV200100076102

TI ***Serum*** concentrations of S100 beta protein are correlated with severity of depression as rated by Hamilton depression scale.

AU Schroeter, M. L. [Reprint author]; Abdul-Khaliq, H.; Fuhrhans, C. J.; Blasig, I. E.; Diefenbacher, A.

CS Forschungsinstitut Molekul Pharmakol, Berlin, Germany

SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-127.7. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LA English
ED Entered STN: 7 Feb 2001
Last Updated on STN: 12 Feb 2002

L5 ANSWER 15 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2000:210323 BIOSIS
DN PREV200000210323
TI ***Serum*** concentrations of ***S100beta*** protein are increased
in patients with affective psychiatric disorders.
AU Schroeter, M. L. [Reprint author]; Fruhauf, S. [Reprint author]; Hoehne,
R. [Reprint author]; Fuhrhans, C. J. [Reprint author]; Blasig, I. E.;
Diefenbacher, A. [Reprint author]
CS Koenigin-Elisabeth-Hospital, Abteilung Psychiatrie, Herzbergstr. 79,
10362, Berlin, Germany
SO Society for Neuroscience Abstracts, (1999) Vol. 25, No. 1-2, pp. 1756.
print.
Meeting Info.: 29th Annual Meeting of the Society for Neuroscience. Miami
Beach, Florida, USA. October 23-28, 1999. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 24 May 2000
Last Updated on STN: 5 Jan 2002

L5 ANSWER 16 OF 79 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1999:330358 BIOSIS
DN PREV199900330358
TI S-100beta release in hypothermic circulatory arrest and coronary artery
surgery.
AU Wong, Carl H.; Rooney, Stephen J.; Bonser, Robert S. [Reprint author]
CS Cardiothoracic Surgical Unit, University Hospital Birmingham, Queen
Elizabeth Medical Centre, Edgbaston, Birmingham, B15 2TH, UK
SO Annals of Thoracic Surgery, (June, 1999) Vol. 67, No. 6, pp. 1911-1914.
print.
ISSN: 0003-4975.
DT Article
LA English
ED Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999

L5 ANSWER 17 OF 79 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2003:37330254 BIOTECHNO
TI Release patterns of astrocytic and neuronal biochemical markers in
serum during and after experimental settings of cardiac surgery
AU Abdul-Khaliq H.; Schubert S.; Stoltenburg-Didinger G.; Huebler M.;
Troitzsch D.; Wehsack A.; Boettcher W.; Schwaller B.; Crausaz M.; Celio
M.; Schroter M.L.; Blasig I.E.; Hetzer R.; Lange P.E.
CS Dr. H. Abdul-Khaliq, Clin. Congenital Heart Dis. P., Deutsches
Herzzentrum Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany.
E-mail: abdul-khaliq@dhzb.de
SO Restorative Neurology and Neuroscience, (2003), 21/3-4 (141-150), 61
reference(s)
CODEN: RNNEEL ISSN: 0922-6028
DT Journal; Conference Article
CY Ireland
LA English
SL English

L5 ANSWER 18 OF 79 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2003:37266121 BIOTECHNO
TI Impairment of ***blood*** - ***brain*** ***barrier*** integrity
during carotid surgery as assessed by ***serum*** S-100B protein
concentrations
AU Jaranyi Z.; Szekely M.; Bobek I.; Galfy I.; Geller L.; Selmei L.
CS Prof. L. Selmei, Department of Cardiovascular Surgery, Central
Laboratory, Semmelweis Univ. Faculty of Medicine, Varosmajor u. 68, 1122
Budapest, Hungary.
E-mail: laszlo.selmei@mailexcite.com
SO Clinical Chemistry and Laboratory Medicine, (2003), 41/10 (1320-1322), 16
reference(s)
CODEN: CCLMFW ISSN: 1434-6621
DT Journal; Article
CY Germany, Federal Republic of

LA English
SL English

L5 ANSWER 19 OF 79 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2003:36974961 BIOTECHNO
TI ***Serum*** protein S-100b in acute liver failure: Results of the US
Acute Liver Failure Study Group
AU Vaquero J.; Jordano Q.; Lee W.M.; Blei A.T.
CS J. Vaquero, Hepatology-Department of Medicine, Northwestern Feinberg
Medical School, Northwestern University, Chicago, IL, United States.
SO Liver Transplantation, (01 AUG 2003), 9/8 (887-888), 8 reference(s)
CODEN: LITRFO ISSN: 1527-6465
DT Journal; Letter
CY United States
LA English

L5 ANSWER 20 OF 79 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:810281 CAPLUS
DN 141:329890
TI Astrocytic and neuronal biochemical markers in the ***sera*** of
subjects with diabetes mellitus
AU Hovsepian, Meri R.; Haas, Michael J.; Boyajyan, Anna S.; Guevorkyan,
Astghik A.; Mamikonyan, Ashot A.; Myers, Susan E.; Mooradian, Arshag D.
CS Department of Internal Medicine, Saint Louis University Medical School,
Saint Louis, MO, USA
SO Neuroscience Letters (2004), 369(3), 224-227
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Ltd.
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 79 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:382768 CAPLUS
DN 141:171928
TI Increased ***S100B*** in cerebrospinal fluid of infants with bacterial
meningitis: Relationship to brain damage and routine cerebrospinal fluid
findings
AU Gazzolo, Diego; Grutzfeld, Dariusz; Michetti, Fabrizio; Toesca, Amelia;
Lituanica, Mario; Bruschetti, Matteo; Dobrzanska, Anna; Bruschetti,
Pierluigi
CS Department of Pediatrics and Obstetrics and Gynecology, Giannina Gaslini
Children's University Hospital, Genoa, Italy
SO Clinical Chemistry (Washington, DC, United States) (2004), 50(5), 941-944
CODEN: CLCHAU; ISSN: 0009-9147
PB American Association for Clinical Chemistry
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 79 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:380263 CAPLUS
DN 137:167213
TI ***Serum*** S-100. beta. as a possible marker of ***blood*** -
brain ***barrier*** disruption
AU Kapural, M.; Krizanac-Bengez, Lj.; Barnett, G.; Perl, J.; Masaryk, T.;
Apollo, D.; Rasmussen, P.; Mayberg, M. R.; Janigro, D.
CS Cleveland Clinic Foundation NB-20, Department of Neurological Surgery,
NB2-137, Cleveland, OH, 44195, USA
SO Brain Research (2002), 940(1,2), 102-104
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 79 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:549918 CAPLUS
DN 135:299838
TI Influence of alcohol exposure on S-100b ***serum*** levels
AU Biberthaler, P.; Mussack, T.; Wiedemann, E.; Kanz, K. G.; Gilg, T.;
Gippner-Steppert, C.; Jochum, M.
CS Chirurgische Klinik, Kliniken Innenstadt, Ludwig-Maximilians-Universitat,

Munchen, Germany
SO Brain Edema XI, Proceedings of the International Symposium, 11th,
Newcastle-upon-Tyne, United Kingdom, June 6-10, 1999 (2000), Meeting Date
1999, 177-179. Editor(s): Mendelow, A. David. Publisher: Springer-Verlag
Wien, Wien, Austria.
CODEN: 69BOY6
DT Conference
LA English
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 79 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:417666 CAPLUS
DN 135:135849
TI Protein S-100B: a ***serum*** marker for ischemic and infectious
injury of cerebral tissue
AU Bertsch, Thomas; Casarin, Wendy; Kretschmar, Marianne; Zimmer, Wilma;
Walter, Silke; Sommer, Clemens; Muehlhauser, Frank; Ragoschke, Andreas;
Kuehl, Sandra; Schmidt, Roland; Pohlmann-Eden, Bernd; Nassabi, Claudius;
Nichterlein, Thomas; Fassbender, Klaus
CS Department of Clinical Chemistry, Clinic Mannheim, University of
Heidelberg, Mannheim, Germany
SO Clinical Chemistry and Laboratory Medicine (2001), 39(4), 319-323
CODEN: CCLMFW; ISSN: 1434-6621
PB Walter de Gruyter GmbH & Co. KG
DT Journal
LA English
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 79 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:76425 CAPLUS
DN 134:264372
TI Protein S-100.beta. in brain and ***serum*** after deep hypothermic
circulatory arrest in rabbits: relationship to perivascular astrocytic
swelling
AU Abdul-Khaliq, Hashim; Schubert, Stephan; Stoltenburg-Didinger, Gisella;
Troitzsch, Dirk; Bottcher, Wolfgang; Hubler, Michael; Meissler, Michael;
Grosse-Siestrop, Christian; Alexi-Meskishvili, Vladimir; Hetzer, Roland;
Lange, Peter E.
CS Deutsches Herzzentrum Berlin, Klinikum Benjamin Franklin, Freie
Universitat Berlin, Berlin, Germany
SO Clinical Chemistry and Laboratory Medicine (2000), 38(11), 1169-1172
CODEN: CCLMFW; ISSN: 1434-6621
PB Walter de Gruyter GmbH & Co. KG
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 2004455621 EMBASE
TI [***Serum*** S-100.beta. protein and postoperative neurological
dysfunction - Ready for prime time?].
LA PROTEINE SERIQUE S-100.beta. ET LA DYSFONCTION NEUROLOGIQUE
POSTOPERATOIRE - CORRELATION PRETE POUR UNE LARGE DIFFUSION?.
AU Hall R.I.
CS Dr. R.I. Hall, Department of Anesthesia, Halifax Infirmary, Queen
Elizabeth II Sciences Centre, 1796 Summer Street, Halifax, NS B3H 3A7,
Canada. rihall@dal.ca
SO Canadian Journal of Anesthesia, (2004) 51/7 (645-648).
Refs: 19
ISSN: 0832-610X CODEN: CJOAEP
CY Canada
DT Journal; Editorial
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
024 Anesthesiology
029 Clinical Biochemistry
037 Drug Literature Index
LA English; French

L5 ANSWER 27 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 2004337681 EMBASE

TI Neurofilament light protein and glial fibrillary acidic protein as
 biological markers in MS [5] (multiple letters).
 AU Avasarala J.R.; Lycke J.N.; Malmstrom C.; Haghighi S.; Rosengren L.;
 Andersen O.
 CS United States
 SO Neurology, (10 Aug 2004) 63/3 (599).
 ISSN: 0028-3878 CODEN: NEURAI
 CY United States
 DT Journal; Letter
 FS 008 Neurology and Neurosurgery
 029 Clinical Biochemistry
 LA English

L5 ANSWER 28 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2004063147 EMBASE
 TI Acute Neurovascular Syndromes: Hurry Up, Please, It's Time.
 AU Kennedy J.; Buchan A.M.
 CS Dr. A.M. Buchan, Stroke Research Office, Foothills Medical Centre, 1403
 29th St NW, Calgary, Alta. T2N 2T9, Canada. abuchan@ucalgary.ca
 SO Stroke, (2004) 35/2 (360-362).
 Refs: 33
 ISSN: 0039-2499 CODEN: SJCCA7
 CY United States
 DT Journal; (Short survey)
 FS 006 Internal Medicine
 008 Neurology and Neurosurgery
 014 Radiology
 036 Health Policy, Economics and Management
 037 Drug Literature Index
 LA English

L5 ANSWER 29 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2003438695 EMBASE
 TI Peripheral markers of brain damage and ***blood*** - ***brain***
 barrier dysfunction.
 AU Marchi N.; Rasmussen P.; Kapural M.; Fazio V.; Kight K.; Mayberg M.R.;
 Kanner A.; Ayumar B.; Albensi B.; Cavaglia M.; Janigro D.
 CS Dr. D. Janigro, Cerebrovascular Research, Cleveland Clinic Foundation
 NB20, 9500 Euclid Avenue, Cleveland, OH 44195, United States.
 janigrd@ccf.org
 SO Restorative Neurology and Neuroscience, (2003) 21/3-4 (109-121).
 Refs: 84
 ISSN: 0922-6028 CODEN: RNNEEL
 CY Ireland
 DT Journal; Conference Article
 FS 008 Neurology and Neurosurgery
 LA English
 SL English

L5 ANSWER 30 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2003438692 EMBASE
 TI Molecular markers of brain damage: Current state and future perspectives.
 AU Herrmann M.; Johnsson P.; Romner B.
 CS Dr. M. Herrmann, Center for Advanced Imaging, Dept. Neuropsychol. Behav.
 Neurobio., University of Bremen, Grazer Strasse 6, D-28359 Bremen, Germany.
 manfred.herrmann@uni-bremen.de
 SO Restorative Neurology and Neuroscience, (2003) 21/3-4 (75-77).
 ISSN: 0922-6028 CODEN: RNNEEL
 CY Ireland
 DT Journal; Conference Article
 FS 008 Neurology and Neurosurgery
 LA English

L5 ANSWER 31 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2003369597 EMBASE
 TI ***Serum*** interleukin-8 as a predictive marker for a comparative
 neurologic outcome analysis of patients resuscitated after cardiopulmonary
 arrest [3] (multiple letters).
 AU Ito T.; Saitoh D.; Takasu A.; Norio H.; Kiyozumi T.; Sakamoto T.; Okada
 Y.; Mussack T.; Biberthaler P.; Mutschler W.; Jochum M.
 CS T. Ito, Dept. Traumatology/Critical Care M., National Defense Medical
 College, Saitama, Japan

SO Critical Care Medicine, (1 Sep 2003) 31/9 (2415-2417).
 ISSN: 0090-3493 CODEN: CCMDC7
 CY United States
 DT Journal; Letter
 FS 008 Neurology and Neurosurgery
 018 Cardiovascular Diseases and Cardiovascular surgery
 024 Anesthesiology
 029 Clinical Biochemistry
 LA English

L5 ANSWER 32 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2003308188 EMBASE
 TI Assessment of early brain damage in carotid endarterectomy: Evaluation of
 S-100B ***serum*** levels and somatosensory evoked potentials in a
 pilot study.
 AU Mussack T.; Biberthaler P.; Geisenberger T.; Gippner-Steppert C.;
 Steckmeier B.; Mutschler W.; Jochum M.
 CS Dr. T. Mussack, Department of Surgery Innenstadt, Klinikum der Universitat
 Munchen, Nussbaumstrasse 20, D-80336 Munchen, Germany.
 tmussack@helios.med.uni-muenchen.de
 SO World Journal of Surgery, (2002) 26/10 (1251-1255).
 Refs: 27
 ISSN: 0364-2313 CODEN: WJSUDI
 CY United States
 DT Journal; Conference Article
 FS 006 Internal Medicine
 008 Neurology and Neurosurgery
 009 Surgery
 029 Clinical Biochemistry
 LA English
 SL English; French; Spanish

L5 ANSWER 33 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2003261139 EMBASE
 TI What is a glial cell?.
 AU Barres B.A.
 CS Dr. B.A. Barres, Stanford Univ. School of Medicine, Department of
 Neurobiology, 299 Campus Drive, Stanford, CA 94305-5125, United States.
 barres@stanford.edu
 SO GLIA, (1 Jul 2003) 43/1 (4-5).
 ISSN: 0894-1491 CODEN: GLIAEJ
 CY United States
 DT Journal; Editorial
 FS 002 Physiology
 008 Neurology and Neurosurgery
 021 Developmental Biology and Teratology
 029 Clinical Biochemistry
 LA English

L5 ANSWER 34 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2003228120 EMBASE
 TI Invited commentary.
 AU Jonsson H.
 CS Dr. H. Jonsson, Department of Cardiothoracic Surgery, University Hospital
 Lund, Lund SE-225 85, Sweden. henrikjonsson@thorax.lu.se
 SO Annals of Thoracic Surgery, (1 Jun 2003) 75/6 (1897-1898).
 Refs: 2
 ISSN: 0003-4975 CODEN: ATHSAK
 PUI S 0003-4975(03)00359-X
 CY United States
 DT Journal; Note
 FS 008 Neurology and Neurosurgery
 018 Cardiovascular Diseases and Cardiovascular surgery
 029 Clinical Biochemistry
 LA English

L5 ANSWER 35 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN
 AN 2003113861 EMBASE
 TI ***Serum*** transthyretin monomer as a possible marker of
 blood -to-CSF barrier disruption.
 AU Marchi N.; Fazio V.; Cucullo L.; Kight K.; Masaryk T.; Barnett G.;
 Volgelbaum M.; Kinter M.; Rasmussen P.; Mayberg M.R.; Janigro D.

CS Dr. D. Janigro, Cerebrovascular Research, NB-20 Lerner Research Institute,
Cleveland Clinic Foundation, 9600 Eudid Avenue, Cleveland, OH 44196,
United States. janigrd@ccf.org
SO Journal of Neuroscience, (1 Mar 2003) 23/5 (1949-1955).
Refs: 38
ISSN: 0270-6474 CODEN: JNRSDS
CY United States
DT Journal; Article
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English

L5 ANSWER 36 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 2003036379 EMBASE
TI Increased ***S100B*** in ***blood*** after cardiac surgery is a
powerful predictor of late mortality.
AU Johnsson P.; Backstrom M.; Bergh C.; Jonsson H.; Luhrs C.; Alling C.
CS Dr. P. Johnsson, Dept. of Coronary Artery Disease, Center of Heart and
Lung Disease, Lund University Hospital, SE 221 85 Lund, Sweden.
pelle.johnsson@skane.se
SO Annals of Thoracic Surgery, (1 Jan 2003) 75/1 (162-168).
Refs: 21
ISSN: 0003-4975 CODEN: ATHSAK
PUI S 0003-4975(02)04318-7
CY United States
DT Journal; Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
029 Clinical Biochemistry
LA English
SL English

L5 ANSWER 37 OF 79 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN
AN 2002204339 EMBASE
TI Shunts in unexplained psychotic reactions and encephalopathy [2].
AU Kroll J.
CS J. Kroll, Department of Clinical Chemistry, Blekinge County Hospital,
Karlskrona, Sweden. krollj@danbbs.dk
SO Lancet, (18 May 2002) 359/9319 (1776).
Refs: 5
ISSN: 0140-6736 CODEN: LANCAO
CY United Kingdom
DT Journal; Letter
FS 006 Internal Medicine
008 Neurology and Neurosurgery
032 Psychiatry
048 Gastroenterology
LA English

L5 ANSWER 38 OF 79 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:211571 FEDRIP
NR CRISP 2R01NS020618-20
TI Brain Vascularity in Cardiac Surgery & Neurodegeneration
SF Principal Investigator: MOODY, DIXON M; DMMOODY@WFUBMC.EDU, WAKE FOREST
UNIV SCHOOL OF MED, MEDICAL CENTER BLVD, WINSTON-SALEM, NC 27157
CSP WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NORTH CAROLINA
CSS Supported By: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
DB 2004 (/01/84)
FYR 2003
DE 2006 (/30/08)
FU Competing Continuation (Type 2)
FS National Institutes of Health

L5 ANSWER 39 OF 79 MEDLINE on STN
AN 2004207791 MEDLINE
DN PubMed ID: 15105899
TI [Role of ***S100B*** protein in neoplasms and other diseases].
Az ***S100B*** protein marker szerepe daganatokban es mas korkepekben.
AU Banfalvi Teodora; Gergye Maria; Beczassy Eniko; Gilde Katalin; Otto
Szabolcs
CS Borgyogyszati Osztaly, Orszagos Onkologiai Intezet, Budapest 1122,
Hungary.. banfalvi@oncol.hu
SO Magyar onkologia, (2004) 48 (1) 71-4. Ref: 39
Journal code: 9313833. ISSN: 0025-0244.

CY Hungary
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA Hungarian
 FS Priority Journals
 EM 200407
 ED Entered STN: 20040424
 Last Updated on STN: 20040707
 Entered Medline: 20040706

L5 ANSWER 40 OF 79 MEDLINE on STN
 AN 2002369790 MEDLINE
 DN PubMed ID: 12113780
 TI Isolating vessels from the mouse brain for gene expression analysis using
 laser capture microdissection.
 AU Ball Helen J; McParland Brent; Driussi Catherine; Hunt Nicholas H
 CS Department of Pathology, Blackburn Bldg. D06, University of Sydney,
 Camperdown N.S.W. 2006, Australia.. helenb@med.usyd.edu.au
 SO Brain research. Brain research protocols, (2002 Jun) 9 (3) 206-13.
 Journal code: 9716650. ISSN: 1385-299X.
 CY Netherlands
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200209
 ED Entered STN: 20020713
 Last Updated on STN: 20020928
 Entered Medline: 20020927

L5 ANSWER 41 OF 79 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2003:327808 PROMT
 TITLE: Work of Cleveland Clinic Researchers May Lead to a
 Blood Test for Brain Tumor Diagnosis.
 SOURCE: PR Newswire, (2 Jun 2003) pp. CLM00602062003.
 PUBLISHER: PR Newswire Association, Inc.
 DOCUMENT TYPE: Newsletter
 LANGUAGE: English
 WORD COUNT: 494
 FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 42 OF 79 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
 on STN
 AN 2003:787276 SCISEARCH
 GA The Genuine Article (R) Number: 718TA
 TI Both aging and chronic fluoxetine increase ****s100B*** content in the
 mouse hippocampus
 AU Akhisaroglu M; Manev R; Akhisaroglu E; Uz T; Manev H (Reprint)
 CS Univ Illinois, Dept Psychiat, Inst Psychiat, 1601 W Taylor St, MC912,
 Chicago, IL 60612 USA (Reprint); Univ Illinois, Dept Psychiat, Inst
 Psychiat, Chicago, IL 60612 USA
 CYA USA
 SO NEUROREPORT, (6 AUG 2003) Vol. 14, No. 11, pp. 1471-1473.
 Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA
 19106-3621 USA.
 ISSN: 0959-4965.
 DT Article; Journal
 LA English
 REC Reference Count: 24
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 43 OF 79 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
 on STN
 AN 2000:36629 SCISEARCH
 GA The Genuine Article (R) Number: 270XY
 TI Breaking down the ***blood*** - ***brain*** ***barrier***
 AU Bokesch P M (Reprint)
 CS CLEVELAND CLIN FDN, DEPT CARDIOTHORAC ANESTHESIA, 9500 EUCLID AVE,
 CLEVELAND, OH 44195 (Reprint)
 CYA USA
 SO ANNALS OF THORACIC SURGERY, (DEC 1999) Vol. 68, No. 6, pp. 2013-2014.
 Publisher: ELSEVIER SCIENCE INC, 655 AVENUE OF THE AMERICAS, NEW YORK, NY
 10010.
 ISSN: 0003-4975.
 DT Editorial; Journal

FS LIFE; CLIN
LA English
REC Reference Count: 16

L5 ANSWER 44 OF 79 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN
AN 93:463333 SCISEARCH
GA The Genuine Article (R) Number: LN610
TI BIOLOGICAL STUDIES OF A PUTATIVE AVIAN MUSCLE-DERIVED NEUROTROPHIC FACTOR
THAT PREVENTS NATURALLY-OCCURRING MOTONEURON DEATH IN-VIVO
AU OPPENHEIM R W (Reprint); PREVETTE D; HAVERKAMP L J; HOUENOU L; YIN Q W;
MCMANAMAN J
CS WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT NEUROBIOL & ANAT, WINSTON
SALEM, NC, 27157 (Reprint); BAYLOR COLL MED, DEPT NEUROL, HOUSTON, TX,
77030; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, NEUROSCI PROGRAM, WINSTON
SALEM, NC, 27157
CYA USA
SO JOURNAL OF NEUROBIOLOGY, (AUG 1993) vol. 24, No. 8, pp. 1065-1079.
ISSN: 0022-3034.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 83
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 45 OF 79 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2002:560265 TOXCENTER
DN CRISP-2000-GM45455-090007
TI GROWTH FACTOR EFFECTS ON SEPTAL CHOLINERGIC NEURONS
AU MUDD L M
CS BARRY UNIVERSITY, 11300 NE 2ND AVE, MIAMI SHORES, FL 33161:FLORIDA
CSS U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE; NATIONAL
INSTITUTES OF HEALTH, NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
SO Crisp Data Base National Institutes of Health.
DT (Research)
FS CRISP
LA English
ED Entered STN: 20021200
Last Updated on STN: 20021200

L5 ANSWER 46 OF 79 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2002:554718 TOXCENTER
DN CRISP-1999-GM45455-08A10007
TI GROWTH FACTOR EFFECTS ON SEPTAL CHOLINERGIC NEURONS
AU MUDD L M
CS BARRY UNIVERSITY, 11300 NE 2ND AVE, MIAMI SHORES, FL 33161:FLORIDA
CSS U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE; NATIONAL
INSTITUTES OF HEALTH, NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
SO Crisp Data Base National Institutes of Health.
DT (Research)
FS CRISP
LA English
ED Entered STN: 20021200
Last Updated on STN: 20021200

L5 ANSWER 47 OF 79 USPATFULL on STN
AN 2004:267766 USPATFULL
TI Diagnostic markers of stroke and cerebral injury and methods of use
thereof
IN Valkirs, Gunars, Escondido, CA, UNITED STATES
Dahlen, Jeffrey, San Diego, CA, UNITED STATES
Kirchick, Howard, San Diego, CA, UNITED STATES
Buechler, Kenneth F., San Diego, CA, UNITED STATES
PA Biosite Incorporated (U.S. corporation)
PI US 2004209307 A1 20041021
AI US 2003-673077 A1 20030926 (10)
RLI Continuation-in-part of Ser. No. US 2003-371149, filed on 20 Feb 2003,
PENDING Continuation-in-part of Ser. No. WO 2002-US26604, filed on 20
Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-225082, filed
on 20 Aug 2002, PENDING
PRAI US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)
US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)

DT Utility
FS APPLICATION
LN.CNT 5149
INCL INCLM: 435/007.100
NCL NCLM: 435/007.100
IC [7]
ICM: G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 48 OF 79 USPATFULL on STN
AN 2004:261857 USPATFULL
TI Methods and compositions in treating pain and painful disorders using
16386,15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063,
57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816,
17827 or 32620
IN Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
Karicheti, Venkateswarlu, Chapel Hill, NC, UNITED STATES
Eliasof, Scott D., Lexington, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004204359 A1 20041014
AI US 2004-768158 A1 20040130 (10)
PRAI US 2003-444781P 20030204 (60)
US 2003-452291P 20030305 (60)
US 2003-454540P 20030313 (60)
US 2003-478805P 20030616 (60)
US 2003-491048P 20030730 (60)

DT Utility
FS APPLICATION
LN.CNT 10616
INCL INCLM: 514/012.000
INCLS: 435/007.100; 424/143.100
NCL NCLM: 514/012.000
NCLS: 435/007.100; 424/143.100
IC [7]
ICM: G01N033-53
ICS: A61K038-17; A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 49 OF 79 USPATFULL on STN
AN 2004:158573 USPATFULL
TI Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof
IN Schmidt, Ann Marie, Franklin Lakes, NJ, UNITED STATES
Stern, David, Great Neck, NY, UNITED STATES
PA The Trustees of Columbia University in the City of New York (U.S.
corporation)
PI US 2004121372 A1 20040624
AI US 2003-665867 A1 20030919 (10)
RLI Continuation of Ser. No. US 2001-826589, filed on 5 Apr 2001, GRANTED,
Pat. No. US 6670136 Continuation of Ser. No. WO 1999-US23303, filed on 6
Oct 1999, PENDING Continuation-in-part of Ser. No. US 1999-263312, filed
on 5 Mar 1999, GRANTED, Pat. No. US 6555340 Continuation-in-part of Ser.
No. US 1998-167705, filed on 6 Oct 1998, PENDING

DT Utility
FS APPLICATION
LN.CNT 2855
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/252.300; 435/325.000; 530/350.000;
536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/252.300; 435/325.000; 530/350.000;
536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-705

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 50 OF 79 USPATFULL on STN
AN 2004:138995 USPATFULL
TI System and method for neuronal network analysis
IN Evans, Daron G., Dallas, TX, UNITED STATES
PI US 2004106168 A1 20040603
AI US 2003-370786 A1 20030220 (10)
PRAI US 2002-430409P 20021202 (60)
DT Utility
FS APPLICATION
LN.CNT 1747

INCL INCLM: 435/040.500
INCLS: 435/029.000; 435/283.100
NCL NCLM: 435/040.500
NCLS: 435/029.000; 435/283.100
IC [7]
ICM: G01N033-48
ICS: C12M001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 51 OF 79 USPATFULL on STN
AN 2004:108140 USPATFULL
TI Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
IN Mjalli, Adnan M.M., Jamestown, NC, UNITED STATES
Andrews, Robert C., Jamestown, NC, UNITED STATES
Gopalaswamy, Ramesh, Jamestown, NC, UNITED STATES
Hari, Anitha, High Point, NC, UNITED STATES
Avor, Kwasi S., High Point, NC, UNITED STATES
Qabaja, Ghassan, High Point, NC, UNITED STATES
Guo, Xiao-Chuan, High Point, NC, UNITED STATES
Gupta, Suparna, Greensboro, NC, UNITED STATES
Jones, David R., Asheboro, NC, UNITED STATES
Chen, Xin, High Point, NC, UNITED STATES
PI US 2004082542 A1 20040429
AI US 2003-382203 A1 20030305 (10)
PRAI US 2002-361983P 20020305 (60)
DT Utility
FS APPLICATION
LN.CNT 15091
INCL INCLM: 514/063.000
INCLS: 514/310.000; 514/314.000; 514/365.000; 514/374.000; 514/400.000;
514/266.200; 514/266.230; 544/284.000; 546/148.000; 548/110.000;
548/190.000; 548/222.000; 548/326.500; 514/264.100; 544/279.000
NCL NCLM: 514/063.000
NCLS: 514/310.000; 514/314.000; 514/365.000; 514/374.000; 514/400.000;
514/266.200; 514/266.230; 544/284.000; 546/148.000; 548/110.000;
548/190.000; 548/222.000; 548/326.500; 514/264.100; 544/279.000
IC [7]
ICM: A61K031-695
ICS: A61K031-4709; A61K031-517; A61K031-519; A61K031-426; A61K031-422;
A61K031-4162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 52 OF 79 USPATFULL on STN
AN 2004:95541 USPATFULL
TI Therapeutic polypeptides, nucleic acids encoding same, and methods of use
IN Alsobrook, John P., II, Madison, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Furtak, Katarzyna, Ansonia, CT, UNITED STATES
Gangolli, Esha A., Cambridge, MA, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gilbert, Jennifer A., Madison, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Mishra, Vishnu, Gainesville, FL, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES

Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
PI US 2004072997 A1 20040415
AI US 2003-336603 A1 20030103 (10)
RLI Continuation-in-part of Ser. No. US 2000-746491, filed on 20 Dec 2000,
PENDING Continuation-in-part of Ser. No. US 2001-55569, filed on 26 Oct
2001, PENDING
PRAI US 2002-345222P 20020104 (60)
US 2002-348693P 20020114 (60)
US 2002-349182P 20020116 (60)
US 2002-349733P 20020117 (60)
US 2002-350263P 20020118 (60)
US 2002-351977P 20020124 (60)
US 2002-383758P 20020528 (60)
US 2002-385969P 20020605 (60)
US 2002-387834P 20020611 (60)
US 2002-396407P 20020717 (60)
US 2002-415115P 20020930 (60)
DT Utility
FS APPLICATION
LN.CNT 22075
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500; 530/388.220
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500; 530/388.220
IC [7]
ICM: C07K014-705
ICS: C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 53 OF 79 USPATFULL on STN
AN 2004:95290 USPATFULL
TI Synthetic peptide as treatment for down's syndrome and schizophrenia
IN Lipps, Binie V., Bellaire, TX, UNITED STATES
Lipps, Frederick W., Bellaire, TX, UNITED STATES
PI US 2004072744 A1 20040415
AI US 2002-242175 A1 20020912 (10)
DT Utility
FS APPLICATION
LN.CNT 606
INCL INCLM: 514/012.000
INCLS: 514/014.000; 514/015.000
NCL NCLM: 514/012.000
NCLS: 514/014.000; 514/015.000
IC [7]
ICM: A61K038-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 54 OF 79 USPATFULL on STN
AN 2004:94708 USPATFULL
TI Molecular toxicology modeling
IN Mendrick, Donna, Gaithersburg, MD, UNITED STATES
Porter, Mark, Gaithersburg, MD, UNITED STATES
Johnson, Kory, Gaithersburg, MD, UNITED STATES
Higgs, Brandon, Gaithersburg, MD, UNITED STATES
Castle, Arthur, Gaithersburg, MD, UNITED STATES
Elashoff, Michael, Gaithersburg, MD, UNITED STATES
PI US 2004072160 A1 20040415
AI US 2002-152319 A1 20020522 (10)
PRAI US 2001-292335P 20010522 (60)
US 2001-297523P 20010613 (60)
US 2001-298925P 20010619 (60)
US 2001-303810P 20010710 (60)
US 2001-303807P 20010710 (60)
US 2001-303808P 20010710 (60)
US 2001-315047P 20010828 (60)
US 2001-324928P 20010927 (60)
US 2001-330867P 20011101 (60)
US 2001-330462P 20011022 (60)
US 2001-331805P 20011121 (60)
US 2001-336144P 20011206 (60)
US 2001-340873P 20011219 (60)
US 2002-357843P 20020221 (60)
US 2002-357842P 20020221 (60)
US 2002-357844P 20020221 (60)
US 2002-364134P 20020315 (60)

US 2002-370206P 20020408 (60)
US 2002-370247P 20020408 (60)
US 2002-370144P 20020408 (60)
US 2002-371679P 20020412 (60)
US 2002-372794P 20020417 (60)

DT Utility
FS APPLICATION
LN.CNT 27909

INCL INCLM: 435/006.000
INCLS: 435/091.200; 436/084.000
NCL NCLM: 435/006.000
NCLS: 435/091.200; 436/084.000

IC [7]
ICM: C12Q001-68
ICS: C12P019-34; G01N033-20

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 55 OF 79 USPATFULL on STN
AN 2004:7343 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S.
corporation)
PI US 2004005577 A1 20040108
AI US 2002-242747 A1 20020913 (10)
RLI Continuation of ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING
PRAI US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)

US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)

US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)
DT Utility
FS APPLICATION
LN.CNT 27694
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 56 OF 79 USPATFULL on STN
AN 2004:2561 USPATFULL
TI Proteins, polynucleotides encoding them and methods of using the same
IN Pena, Carol E. A., New Haven, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Furtak, Katarzyna, Ansonia, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Baumgartner, Jason C., New Haven, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES

PI US 2004002584 A1 20040101
AI US 2002-80334 A1 20020221 (10)
PRAI US 2001-270523P 20010221 (60)
US 2001-322712P 20010917 (60)
US 2001-311980P 20010813 (60)
US 2001-330307P 20011018 (60)
US 2001-278796P 20010326 (60)
US 2001-281521P 20010404 (60)
US 2001-276677P 20010316 (60)
US 2001-311595P 20010810 (60)
US 2001-270220P 20010221 (60)
US 2001-274295P 20010308 (60)
US 2001-318526P 20010910 (60)
US 2001-286548P 20010425 (60)
US 2001-291765P 20010517 (60)
US 2001-270797P 20010223 (60)
US 2001-276400P 20010316 (60)
US 2001-270810P 20010223 (60)

DT Utility
FS APPLICATION
LN.CNT 20544
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K001-00
ICS: C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 57 OF 79 USPATFULL on STN
 AN 2004:2099 USPATFULL
 TI Therapeutic polypeptides, nucleic acids encoding same, and methods of
 use
 IN Kekuda, Ramesh, Danbury, CT, UNITED STATES
 Tchernev, Velizar T., Branford, CT, UNITED STATES
 Liu, Xiaohong, Branford, CT, UNITED STATES
 Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Patturajan, Meera, Branford, CT, UNITED STATES
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES
 Vernet, Corine A.M., Branford, CT, UNITED STATES
 Li, Li, Branford, CT, UNITED STATES
 Gorman, Linda, Branford, CT, UNITED STATES
 Malyankar, Uriel M., Branford, CT, UNITED STATES
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
 Shenoy, Suresh G., Branford, CT, UNITED STATES
 Padigar, Muralidhara, Branford, CT, UNITED STATES
 Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
 Miller, Charles E., Guilford, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Pena, Carol E. A., New Haven, CT, UNITED STATES
 Gangolli, Esha A., Madison, CT, UNITED STATES
 Gusev, Vladimir Y., Madison, CT, UNITED STATES
 Smithson, Glenda, Guilford, CT, UNITED STATES
 Zerhusen, Bryan D., Branford, CT, UNITED STATES
 Gerlach, Valerie, Branford, CT, UNITED STATES
 Pochart, Pascale F-J, Madison, CT, UNITED STATES
 Fernandes, Elma R., Branford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Rastelli, Luca, Guilford, CT, UNITED STATES
 Spaderna, Steven K., Berlin, CT, UNITED STATES
 LaRoche, William J., Madison, CT, UNITED STATES
 Zhong, Mei, Branford, CT, UNITED STATES
 Khramtsov, Nikolai V., Branford, CT, UNITED STATES
 Voss, Edward Z., Wallingford, CT, UNITED STATES
 Herrmann, John L., Guilford, CT, UNITED STATES
 PI US 2004002120 A1 20040101
 AI US 2002-94886 A1 20020307 (10)
 PRAI US 2001-274322P 20010308 (60)
 US 2001-313182P 20010817 (60)
 US 2001-288052P 20010502 (60)
 US 2001-318510P 20010910 (60)
 US 2001-274281P 20010308 (60)
 US 2001-314018P 20010821 (60)
 US 2001-274194P 20010308 (60)
 US 2001-274849P 20010309 (60)
 US 2001-296693P 20010607 (60)
 US 2001-313626P 20010820 (60)
 US 2001-332486P 20011109 (60)
 US 2001-275235P 20010312 (60)
 US 2001-275578P 20010313 (60)
 US 2001-288228P 20010502 (60)
 US 2001-275579P 20010313 (60)
 US 2001-312916P 20010816 (60)
 US 2001-275601P 20010313 (60)
 US 2001-311978P 20010813 (60)
 US 2001-276000P 20010314 (60)
 US 2001-276776P 20010316 (60)
 US 2001-296856P 20010608 (60)
 US 2001-276994P 20010319 (60)
 US 2001-291766P 20010517 (60)
 US 2001-277338P 20010320 (60)
 US 2001-288066P 20010502 (60)
 US 2001-277239P 20010320 (60)
 US 2001-315227P 20010827 (60)
 US 2001-318403P 20010910 (60)
 US 2001-277327P 20010320 (60)
 US 2001-277791P 20010321 (60)
 US 2001-325378P 20010927 (60)
 US 2001-277833P 20010322 (60)
 US 2001-278152P 20010323 (60)
 US 2001-310913P 20010808 (60)
 US 2001-303237P 20010705 (60)
 US 2001-278894P 20010326 (60)

US 2001-322360P 20010914 (60)
US 2001-279036P 20010327 (60)
US 2001-312191P 20010814 (60)
US 2001-278999P 20010327 (60)
US 2001-280233P 20010330 (60)
US 2001-303230P 20010705 (60)
US 2001-345399P 20011109 (60)
US 2001-322296P 20010914 (60)
US 2001-280802P 20010402 (60)

DT Utility
FS APPLICATION
LN.CNT 21071

INCL INCLM: 435/007.200
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
514/012.000
NCL NCLM: 435/007.200
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
514/012.000

IC [7]
ICM: G01N033-53
ICS: G01N033-567; A61K038-17; C12P021-02; C12N005-06; C07K014-705;
C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 58 OF 79 USPATFULL on STN
AN 2003:282657 USPATFULL
TI Diagnostic markers of stroke and cerebral injury and methods of use
thereof
IN Valkirs, Gunars E., Escondido, CA, UNITED STATES
Dahlen, Jeffery, San Diego, CA, UNITED STATES
Kirchick, Howard J., San Diego, CA, UNITED STATES
Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED STATES
PI US 2003199000 A1 20031023
AI US 2003-371149 A1 20030220 (10)
RLI Continuation-in-part of Ser. No. US 2002-225082, filed on 20 Aug 2002,
PENDING Continuation-in-part of Ser. No. WO 2002-US26604, filed on 20
Aug 2002, PENDING
PRAI US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)

DT Utility
FS APPLICATION
LN.CNT 4629

INCL INCLM: 435/007.100
INCLS: 435/287.200
NCL NCLM: 435/007.100
NCLS: 435/287.200

IC [7]
ICM: G01N033-53
ICS: C12M001-34

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 59 OF 79 USPATFULL on STN
AN 2003:225742 USPATFULL
TI Protein-protein complexes and methods of using same
IN Giot, Loic, Madison, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Lewin, David A., New Haven, CT, UNITED STATES
PI US 2003157554 A1 20030821
AI US 2001-4083 A1 20011030 (10)
PRAI US 2000-244236P 20001030 (60)

DT Utility
FS APPLICATION
LN.CNT 5186

INCL INCLM: 435/007.100
INCLS: 435/226.000; 435/023.000
NCL NCLM: 435/007.100
NCLS: 435/226.000; 435/023.000

IC [7]
ICM: G01N033-53
ICS: C12Q001-37; C12N009-64

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 60 OF 79 USPATFULL on STN
AN 2003:219280 USPATFULL
TI Method for retarding or precluding alzheimer's dementia

IN Jackowski, George, Kettelby, CANADA
Furesz, Shirley, Cambridge, CANADA
PI US 2003152570 A1 20030814
AI US 2002-334701 A1 20021230 (10)
RLI Continuation-in-part of Ser. No. US 2001-859559, filed on 16 May 2001,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 549
INCL INCLM: 424/140.100
NCL NCLM: 424/140.100
IC [7]
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 61 OF 79 USPATFULL on STN
AN 2003:201372 USPATFULL
TI Novel human proteins, polynucleotides encoding them and methods of using
the same
IN Spytek, Kimberly A., New Haven, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Smithson, Glenda, Branford, CT, UNITED STATES
PI US 2003139358 A1 20030724
AI US 2001-849138 A1 20010504 (9)
PRAI US 2000-201951P 20000505 (60)
US 2000-215857P 20000703 (60)
US 2001-265162P 20010130 (60)
US 2000-203109P 20000508 (60)
US 2000-203295P 20000511 (60)
US 2000-210055P 20000607 (60)
US 2000-204064P 20000512 (60)
US 2000-204063P 20000512 (60)
US 2000-204062P 20000512 (60)
US 2000-203838P 20000512 (60)
US 2000-203839P 20000512 (60)
US 2000-204089P 20000515 (60)
US 2000-204276P 20000516 (60)

DT Utility
FS APPLICATION
LN.CNT 8381
INCL INCLM: 514/044.000
INCLS: 514/012.000; 435/006.000; 435/007.100; 435/069.100; 435/183.000;
435/320.100; 536/023.200
NCL NCLM: 514/044.000
NCLS: 514/012.000; 435/006.000; 435/007.100; 435/069.100; 435/183.000;
435/320.100; 536/023.200
IC [7]

ICM: A61K048-00
ICS: A61K038-17; C12Q001-68; G01N033-53; C07H021-04; C12P021-02;
C12N009-00; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 62 OF 79 USPATFULL on STN
AN 2003:187348 USPATFULL
TI Method of monitoring neuroprotective treatment
IN Chenard, Bertrand L., Waterford, CT, UNITED STATES
Friedman, David L., Madison, CT, UNITED STATES
Kimmel, Lida, Chester, CT, UNITED STATES
Nelms, Linda F., Gales Ferry, CT, UNITED STATES
Silber, B. Michael, Madison, CT, UNITED STATES
Soares, Holly D., Noank, CT, UNITED STATES
Frost White, Walter, JR., Ledyard, CT, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2003129134 A1 20030710
AI US 2002-268465 A1 20021010 (10)
PRAI US 2001-328890P 20011012 (60)
DT Utility
FS APPLICATION
LN.CNT 1218
INCL INCLM: 424/009.300
INCLS: 435/007.920

NCL NCLM: 424/009.300
NCLS: 435/007.920
IC [7]
ICM: G01N033-53
ICS: G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 63 OF 79 USPATFULL on STN
AN 2003:173220 USPATFULL
TI Diagnostic markers of stroke and cerebral injury and methods of use thereof
IN Valkirs, Gunars E., Escondido, CA, UNITED STATES
Dahlen, Jeffrey R., San Diego, CA, UNITED STATES
Kirchick, Howard J., San Diego, CA, UNITED STATES
Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED STATES
PI US 2003119064 A1 20030626
AI US 2002-225082 A1 20020820 (10)
PRAI US 2002-346485P 20020102 (60)
US 2001-334964P 20011130 (60)
US 2001-313775P 20010820 (60)
DT Utility
FS APPLICATION
LN.CNT 3467
INCL INCLM: 435/007.100
INCLS: 435/007.200
NCL NCLM: 435/007.100
NCLS: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 64 OF 79 USPATFULL on STN
AN 2003:146756 USPATFULL
TI Neurogenic compositions and methods
IN Lukanidin, Eugene, Copenhagen, DENMARK
Bock, Elisabeth Marianne, Charlottenlund, DENMARK
Berezin, Vladimir, Copenhagen N., DENMARK
PI US 2003100503 A1 20030529
AI US 2002-269643 A1 20021011 (10)
RLI Division of Ser. No. US 2001-781509, filed on 12 Feb 2001, PENDING
Division of Ser. No. US 1999-393433, filed on 10 Sep 1999, PENDING
DT Utility
FS APPLICATION
LN.CNT 1029
INCL INCLM: 514/012.000
INCLS: 530/350.000
NCL NCLM: 514/012.000
NCLS: 530/350.000
IC [7]
ICM: A61K038-18
ICS: C07K014-475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 65 OF 79 USPATFULL on STN
AN 2003:134004 USPATFULL
TI Method for diagnosing multiple sclerosis and an assay therefore
IN Moscarello, Mario Anthony, Toronto, CANADA
Chamczuk, Andrea, Toronto, CANADA
PI US 2003092089 A1 20030515
AI US 2001-992174 A1 20011114 (9)
DT Utility
FS APPLICATION
LN.CNT 1205
INCL INCLM: 435/007.920
NCL NCLM: 435/007.920
IC [7]
ICM: G01N033-53
ICS: G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 66 OF 79 USPATFULL on STN
AN 2003:45351 USPATFULL
TI Benzimidazole derivatives as therapeutic agents
IN M. Mjalli, Adnan M., Jamestown, NC, UNITED STATES
Gopalswamy, Ramesh, Jamestown, NC, UNITED STATES

PI US 2003032663 A1 20030213
AI US 2002-91609 A1 20020305 (10)
PRAI US 2001-273377P 20010305 (60)
DT Utility
FS APPLICATION
LN.CNT 1998
INCL INCLM: 514/394.000
INCLS: 548/304.400
NCL NCLM: 514/394.000
NCLS: 548/304.400
IC [7]
ICM: C07D235-08
ICS: A61K031-4184

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 67 OF 79 USPATFULL on STN
AN 2002:338064 USPATFULL
TI Carboxamide derivatives as therapeutic agents
IN Mjalli, Adnan M. M., Jamestown, NC, UNITED STATES
Andrews, Robert C., Jamestown, NC, UNITED STATES
Gopalaswamy, Ramesh, Jamestown, NC, UNITED STATES
Wysong, Chris, Winston-Salem, NC, UNITED STATES

PI US 2002193432 A1 20021219
AI US 2002-91759 A1 20020305 (10)
PRAI US 2001-273454P 20010305 (60)
US 2001-273445P 20010305 (60)
US 2001-273429P 20010305 (60)
US 2001-273455P 20010305 (60)
US 2001-273446P 20010305 (60)
US 2001-273404P 20010305 (60)
US 2001-273403P 20010305 (60)

DT Utility
FS APPLICATION

LN.CNT 2769

INCL INCLM: 514/478.000
INCLS: 514/617.000; 514/626.000; 564/161.000; 560/159.000
NCL NCLM: 514/478.000
NCLS: 514/617.000; 514/626.000; 564/161.000; 560/159.000
IC [7]

ICM: A61K031-325
ICS: A61K031-165; C07C271-08; C07C233-07

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 68 OF 79 USPATFULL on STN
AN 2002:336863 USPATFULL
TI Methods for regulation of immune responses to conditions involving
mediator-induced pathology
IN Calandra, Thierry, Lausanne, SWITZERLAND
Roger, Thierry, Lausanne, SWITZERLAND
Glauser, Michel P., Lausanne, SWITZERLAND

PI US 2002192217 A1 20021219
AI US 2002-94732 A1 20020307 (10)
PRAI US 2001-274004P 20010307 (60)

DT Utility
FS APPLICATION

LN.CNT 2979

INCL INCLM: 424/145.100
INCLS: 514/044.000
NCL NCLM: 424/145.100
NCLS: 514/044.000
IC [7]

ICM: A61K039-395
ICS: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 69 OF 79 USPATFULL on STN
AN 2002:307557 USPATFULL
TI Method of treatment of alzheimer's disease and device therefor
IN Jackowski, George, Kettleby, CANADA
Furesz, Shirley, Cambridge, CANADA

PI US 2002172676 A1 20021121
AI US 2001-859559 A1 20010516 (9)

DT Utility
FS APPLICATION

LN.CNT 487

INCL INCLM: 424/140.100

NCL INCLS: 604/005.020
NCLM: 424/140.100
NCLS: 604/005.020
IC [7]
ICM: A61K039-395
ICS: A61M037-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 70 OF 79 USPATFULL on STN
AN 2002:287558 USPATFULL
TI Method for monitoring and validating stress induction of disease state
IN Jackowski, George, Kettleby, CANADA
Stanton, Eric B., Burlington, CANADA
PI US 2002160421 A1 20021031
AI US 2001-846341 A1 20010430 (9)
DT Utility
FS APPLICATION
LN.CNT 704
INCL INCLM: 435/007.100
INCLS: 435/006.000; 702/019.000; 702/020.000
NCL NCLM: 435/007.100
NCLS: 435/006.000; 702/019.000; 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G06F019-00; G01N033-48; G01N033-50

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 71 OF 79 USPATFULL on STN
AN 2002:186089 USPATFULL
TI Neurogenic compositions and methods
IN Lukanidin, Eugene, Copenhagen, DENMARK
Bock, Elisabeth Marianne, Charlottenlund, DENMARK
Berezin, Vladimir, Copenhagen N., DENMARK
PI US 2002099010 A1 20020725
AI US 2001-781509 A1 20010212 (9)
RLI Division of Ser. No. US 1999-393433, filed on 10 Sep 1999, PENDING
DT Utility
FS APPLICATION
LN.CNT 1029
INCL INCLM: 514/012.000
INCLS: 435/183.000; 435/069.100; 435/320.100; 435/368.000
NCL NCLM: 514/012.000
NCLS: 435/183.000; 435/069.100; 435/320.100; 435/368.000
IC [7]
ICM: A61K038-17
ICS: C12N009-00; C12N005-08; C12P021-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 72 OF 79 USPATFULL on STN
AN 2002:165192 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002086821 A1 20020704
US 2003125246 A9 20030703
AI US 2001-764881 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LN.CNT 27531
INCL INCLM: 514/012.000
INCLS: 536/023.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 536/023.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 73 OF 79 USPATFULL on STN
AN 2002:57592 USPATFULL
TI DNA for expression under control of a cell cycle-dependent promoter
IN Sedlacek, Hans-Harald, Marburg, GERMANY, FEDERAL REPUBLIC OF
Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF
PA Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF

(non-U.S. corporation)
PI US 6358732 B1 20020319
WO 9606939 19960307
AI US 1997-793110 19970425 (8)
WO 1995-EP3369 19950825
19970425 PCT 371 date
PRAI GB 1994-17366 19940826
GB 1995-6466 19950329
DT Utility
FS GRANTED
LN.CNT 779
INCL INCLM: 435/320.100
INCLS: 424/093.200; 435/375.000; 435/455.000; 514/044.000; 536/023.100;
536/023.500; 536/024.100
NCL NCLM: 435/320.100
NCLS: 424/093.200; 435/375.000; 435/455.000; 514/044.000; 536/023.100;
536/023.500; 536/024.100
IC [7]
ICM: C12N015-85
ICS: C12N015-86; C07H021-04; A61K048-00
EXF 514/44; 435/320.1; 435/375; 435/172.3; 435/455; 424/93.2; 536/23.1;
536/23.5; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 74 OF 79 USPATFULL on STN
AN 2002:12575 USPATFULL
TI Method for the synthesis of compounds of formula I and their uses
thereof
IN Mjalli, Adnan M.M., Jamestown, NC, UNITED STATES
Gopalaswamy, Ramesh, Greensboro, NC, UNITED STATES
Avor, Kwasi S., High Point, NC, UNITED STATES
Wysong, Christopher L., Winston-Salem, NC, UNITED STATES
Patron, Andrew, San Diego, CA, UNITED STATES
PI US 2002006957 A1 20020117
US 6613801 B2 20030902
AI US 2001-799317 A1 20010305 (9)
PRAI US 2000-207343P 20000530 (60)
DT Utility
FS APPLICATION
LN.CNT 2005
INCL INCLM: 514/510.000
INCLS: 514/514.000; 568/024.000; 568/048.000
NCL NCLM: 514/514.000
NCLS: 514/516.000; 564/155.000
IC [7]
ICM: A61K031-21
ICS: A61K031-26; C07C321-00; C07C323-00; C07C381-00; C07C319-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 75 OF 79 USPATFULL on STN
AN 2001:123618 USPATFULL
TI NEUROGENIC COMPOSITIONS AND METHODS
IN BOCK, ELISABETH MARIANNE, CHARLOTTENLUND, Denmark
BEREZIN, VLADIMIR, COPENHAGEN, Denmark
LUKANIDIN, EUGENE, COPENHAGEN, Denmark
PI US 2001011126 A1 20010802
AI US 1999-393433 A1 19990910 (9)
DT Utility
FS APPLICATION
LN.CNT 1005
INCL INCLM: 530/839.000
INCLS: 530/350.000; 530/324.000; 514/002.000
NCL NCLM: 530/839.000
NCLS: 530/350.000; 530/324.000; 514/002.000
IC [7]
ICM: A01N037-18
ICS: A61K038-00; C07K005-00; C07K007-00; C07K016-00; C07K017-00;
C07K001-00; C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 76 OF 79 USPATFULL on STN
AN 1998:104754 USPATFULL
TI Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
IN Glasky, Alvin J., 12231 Pevero, Tustin, CA, United States 92680
Rathbone, Michel P., 40 Spadine Avenue, Hamilton, Ontario, Canada L8M 2
x1

PI US 5801184 19980901
AI US 1995-488976 19950608 (8)
RLI Continuation-in-part of Ser. No. US 1994-280719, filed on 25 Jul 1994,
now patented, Pat. No. US 5447939
DT Utility
FS Granted
LN.CNT 1987
INCL INCLM: 514/310.000
INCLS: 514/262.000; 544/265.000; 544/276.000
NCL NCLM: 514/310.000
NCLS: 514/263.380; 544/265.000; 544/276.000
IC [6]
ICM: A01N043-42
ICS: A01N043-90; C07D473-00
EXF 514/310; 514/262; 544/265; 544/276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 77 OF 79 USPATFULL on STN
AN 97:38390 USPATFULL
TI Astrocyte-specific transcription of human genes
IN Brenner, Michael, Gaithersburg, MD, United States
Besnard, Francois, Rockville, MD, United States
Nakatani, Yoshihiro, Bethesda, MD, United States
PA United States of America Department of Health and Human Services,
Washington, DC, United States (U.S. corporation)
PI US 5627047 19970506
AI US 1994-197463 19940216 (8)
RLI Continuation of Ser. No. US 1991-769626, filed on 4 Oct 1991, now
abandoned
DT Utility
FS Granted
LN.CNT 1071
INCL INCLM: 435/069.100
INCLS: 435/069.700; 435/320.100; 435/368.000; 435/354.000; 435/325.000;
536/023.400; 536/023.500; 536/024.100
NCL NCLM: 435/069.100
NCLS: 435/069.700; 435/320.100; 435/325.000; 435/354.000; 435/368.000;
536/023.400; 536/023.500; 536/024.100
IC [6]
ICM: C12N015-85
ICS: C12N015-62; C12N015-10
EXF 435/69.1; 435/69.7; 435/240.2; 435/320.1; 536/23.5; 536/23.4; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 78 OF 79 USPATFULL on STN
AN 95:80308 USPATFULL
TI Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
IN Glasky, Alvin J., 12231 Pevero, Tustin, CA, United States 92680
Rathbone, Michael P., 40 Spadina Avenue, Hamilton, Ontario, Canada L8M
2X1
PI US 5447939 19950905
AI US 1994-280719 19940725 (8)
DT Utility
FS Granted
LN.CNT 1990
INCL INCLM: 514/310.000
INCLS: 514/262.000; 544/265.000; 544/276.000
NCL NCLM: 514/310.000
NCLS: 514/263.370; 514/263.380; 544/265.000; 544/276.000
IC [6]
ICM: A61K031-52
EXF 514/310; 514/262; 544/265; 544/276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 79 OF 79 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2004-069019 [07] WPIDS
CR 2004-098607 [10]
DNN N2004-055498 DNC C2004-028545
TI Detection of ***blood*** ***brain*** ***barrier***
permeability for diagnosing e.g. neuronal distress, comprises detecting
levels of S100 beta protein in ***blood*** samples and comparing the
result to a control.
DC B04 D16 S03
IN BARNETT, G; JANIGRO, D; MAYBERG, M
PA (BARN-I) BARNETT G; (JANI-I) JANIGRO D; (MAYB-I) MAYBERG M
CYC 1

PI US 2003170747 A1 20030911 (200407)* 18 G01N033-53
ADT US 2003170747 A1 US 2001-891023 20010625
PRAI US 2001-891023 20010625
IC ICM G01N033-53
ICS G01N033-542; G01N033-567
STN INTERNATIONAL LOGOFF AT 11:14:16 ON 01 DEC 2004